WO2009066060A2 - 4-substituted-6-isopropyl-benzene-1,3-diol compounds and their use - Google Patents
4-substituted-6-isopropyl-benzene-1,3-diol compounds and their use Download PDFInfo
- Publication number
- WO2009066060A2 WO2009066060A2 PCT/GB2008/003871 GB2008003871W WO2009066060A2 WO 2009066060 A2 WO2009066060 A2 WO 2009066060A2 GB 2008003871 W GB2008003871 W GB 2008003871W WO 2009066060 A2 WO2009066060 A2 WO 2009066060A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- independently
- compound according
- present
- optionally substituted
- diyl
- Prior art date
Links
- -1 4-substituted-6-isopropyl-benzene-1,3-diol compounds Chemical class 0.000 title claims abstract description 179
- 150000001875 compounds Chemical class 0.000 claims abstract description 631
- 238000011282 treatment Methods 0.000 claims abstract description 97
- 101710113864 Heat shock protein 90 Proteins 0.000 claims abstract description 78
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 32
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 31
- 201000010099 disease Diseases 0.000 claims abstract description 22
- 230000005764 inhibitory process Effects 0.000 claims abstract description 21
- 201000011510 cancer Diseases 0.000 claims abstract description 19
- 238000000338 in vitro Methods 0.000 claims abstract description 15
- 238000001727 in vivo Methods 0.000 claims abstract description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 15
- 230000002062 proliferating effect Effects 0.000 claims abstract description 12
- 230000001404 mediated effect Effects 0.000 claims abstract description 10
- 230000001668 ameliorated effect Effects 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims description 217
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 59
- 150000003839 salts Chemical class 0.000 claims description 43
- 239000012453 solvate Substances 0.000 claims description 38
- 150000004677 hydrates Chemical class 0.000 claims description 34
- 125000001424 substituent group Chemical group 0.000 claims description 34
- 125000001931 aliphatic group Chemical group 0.000 claims description 30
- 239000003814 drug Substances 0.000 claims description 22
- 238000002560 therapeutic procedure Methods 0.000 claims description 21
- 125000005842 heteroatom Chemical group 0.000 claims description 16
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 15
- 230000002401 inhibitory effect Effects 0.000 claims description 14
- 230000004663 cell proliferation Effects 0.000 claims description 12
- 239000003085 diluting agent Substances 0.000 claims description 12
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 12
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 11
- 239000003937 drug carrier Substances 0.000 claims description 8
- 125000002541 furyl group Chemical group 0.000 claims description 8
- 125000004076 pyridyl group Chemical group 0.000 claims description 8
- 125000000335 thiazolyl group Chemical group 0.000 claims description 8
- 229920006395 saturated elastomer Polymers 0.000 claims description 7
- HGHDIUFFBHTMQV-UHFFFAOYSA-N [4-[2,6-bis(4-aminophenyl)thiopyran-4-ylidene]cyclohexa-2,5-dien-1-ylidene]-dimethylazanium;chloride Chemical compound [Cl-].C1=CC(=[N+](C)C)C=CC1=C1C=C(C=2C=CC(N)=CC=2)SC(C=2C=CC(N)=CC=2)=C1 HGHDIUFFBHTMQV-UHFFFAOYSA-N 0.000 claims description 6
- 230000006907 apoptotic process Effects 0.000 claims description 6
- 125000001634 furandiyl group Chemical group O1C(=C(C=C1)*)* 0.000 claims description 6
- 125000002883 imidazolyl group Chemical group 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 5
- 230000006369 cell cycle progression Effects 0.000 claims description 5
- 239000003112 inhibitor Substances 0.000 claims description 5
- BIAQHGJHCDEDSE-UHFFFAOYSA-N 1,2,3,4-tetrahydropyrimidin-2-amine Chemical class NC1NCC=CN1 BIAQHGJHCDEDSE-UHFFFAOYSA-N 0.000 claims description 4
- NDOVLWQBFFJETK-UHFFFAOYSA-N 1,4-thiazinane 1,1-dioxide Chemical compound O=S1(=O)CCNCC1 NDOVLWQBFFJETK-UHFFFAOYSA-N 0.000 claims description 4
- OMGVAGCHEBFMSI-UHFFFAOYSA-N 3-morpholin-4-yl-3-piperazin-1-yl-2-piperidin-1-yl-4-thiomorpholin-4-yl-1,4-thiazinane 1,1-dioxide Chemical compound N1(CCCCC1)C1C(N(CCS1(=O)=O)N1CCSCC1)(N1CCOCC1)N1CCNCC1 OMGVAGCHEBFMSI-UHFFFAOYSA-N 0.000 claims description 4
- 125000000532 dioxanyl group Chemical group 0.000 claims description 4
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 4
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 4
- 125000002757 morpholinyl group Chemical group 0.000 claims description 4
- 125000001624 naphthyl group Chemical group 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- 125000006574 non-aromatic ring group Chemical group 0.000 claims description 4
- 125000004193 piperazinyl group Chemical group 0.000 claims description 4
- 125000003386 piperidinyl group Chemical group 0.000 claims description 4
- 230000001737 promoting effect Effects 0.000 claims description 4
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 4
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 4
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 4
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 4
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 4
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 4
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 4
- 125000001544 thienyl group Chemical group 0.000 claims description 4
- 125000001425 triazolyl group Chemical group 0.000 claims description 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 3
- RKFDMXZZBHOLQJ-UHFFFAOYSA-N 1h-1,2,4-triazin-6-one Chemical compound O=C1C=NC=NN1 RKFDMXZZBHOLQJ-UHFFFAOYSA-N 0.000 claims description 3
- QGKGASXQTBQINX-UHFFFAOYSA-N 3,4-dihydro-1h-pyrimidin-2-one Chemical class O=C1NCC=CN1 QGKGASXQTBQINX-UHFFFAOYSA-N 0.000 claims description 3
- 125000002971 oxazolyl group Chemical group 0.000 claims description 3
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 3
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 3
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims description 2
- ITWVAIXIUIRPSW-UHFFFAOYSA-N 1h-1,2,4-triazine-6-thione Chemical class S=C1C=NC=NN1 ITWVAIXIUIRPSW-UHFFFAOYSA-N 0.000 claims description 2
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 125000002785 azepinyl group Chemical group 0.000 claims description 2
- 125000002393 azetidinyl group Chemical group 0.000 claims description 2
- 125000002576 diazepinyl group Chemical group N1N=C(C=CC=C1)* 0.000 claims description 2
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 claims description 2
- 125000002632 imidazolidinyl group Chemical group 0.000 claims description 2
- 125000004531 indol-5-yl group Chemical group [H]N1C([H])=C([H])C2=C([H])C(*)=C([H])C([H])=C12 0.000 claims description 2
- 125000001041 indolyl group Chemical group 0.000 claims description 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 2
- 125000003072 pyrazolidinyl group Chemical group 0.000 claims description 2
- 125000004550 quinolin-6-yl group Chemical group N1=CC=CC2=CC(=CC=C12)* 0.000 claims description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000004495 thiazol-4-yl group Chemical group S1C=NC(=C1)* 0.000 claims description 2
- SKQBSXLTQMLZNH-UHFFFAOYSA-N (2,4-dihydroxy-5-propan-2-ylphenyl)-phenylmethanone Chemical compound C1=C(O)C(C(C)C)=CC(C(=O)C=2C=CC=CC=2)=C1O SKQBSXLTQMLZNH-UHFFFAOYSA-N 0.000 claims 1
- STPMBIGMWBHRHI-UHFFFAOYSA-N 4-(2,4-dihydroxy-5-propan-2-ylphenyl)-3-methyl-6-propan-2-ylcyclohexa-3,5-diene-1,2-dione Chemical compound O=C1C(=O)C(C(C)C)=CC(C=2C(=CC(O)=C(C(C)C)C=2)O)=C1C STPMBIGMWBHRHI-UHFFFAOYSA-N 0.000 claims 1
- BASGYKYURJIXRG-UHFFFAOYSA-N 4-[1-(3-bromophenyl)ethyl]-6-propan-2-ylbenzene-1,3-diol Chemical compound C1=C(O)C(C(C)C)=CC(C(C)C=2C=C(Br)C=CC=2)=C1O BASGYKYURJIXRG-UHFFFAOYSA-N 0.000 claims 1
- 241001061127 Thione Species 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 96
- 230000001225 therapeutic effect Effects 0.000 abstract description 6
- 230000015572 biosynthetic process Effects 0.000 description 200
- 238000003786 synthesis reaction Methods 0.000 description 200
- 239000007858 starting material Substances 0.000 description 192
- 238000005160 1H NMR spectroscopy Methods 0.000 description 179
- 239000000047 product Substances 0.000 description 62
- 239000000243 solution Substances 0.000 description 50
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 47
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 46
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 46
- 238000000746 purification Methods 0.000 description 43
- 210000004027 cell Anatomy 0.000 description 42
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 38
- 239000000463 material Substances 0.000 description 37
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 36
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
- 238000004458 analytical method Methods 0.000 description 33
- 238000006243 chemical reaction Methods 0.000 description 32
- 238000009472 formulation Methods 0.000 description 30
- QSRRZKPKHJHIRB-UHFFFAOYSA-N methyl 4-[(2,5-dichloro-4-methylthiophen-3-yl)sulfonylamino]-2-hydroxybenzoate Chemical compound C1=C(O)C(C(=O)OC)=CC=C1NS(=O)(=O)C1=C(Cl)SC(Cl)=C1C QSRRZKPKHJHIRB-UHFFFAOYSA-N 0.000 description 29
- 239000002904 solvent Substances 0.000 description 28
- KOTOWWSVJRSQIH-UHFFFAOYSA-N 1-bromo-2,4-dimethoxy-5-propan-2-ylbenzene Chemical compound COC1=CC(OC)=C(C(C)C)C=C1Br KOTOWWSVJRSQIH-UHFFFAOYSA-N 0.000 description 26
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 26
- 230000000694 effects Effects 0.000 description 26
- 239000012074 organic phase Substances 0.000 description 26
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 26
- YGDGZDGRCWHDOU-UHFFFAOYSA-N methyl 4-[[5-chloro-4-(2-hydroxyphenyl)thiophen-2-yl]sulfonylamino]-2-hydroxybenzoate Chemical compound C1=C(O)C(C(=O)OC)=CC=C1NS(=O)(=O)C1=CC(C=2C(=CC=CC=2)O)=C(Cl)S1 YGDGZDGRCWHDOU-UHFFFAOYSA-N 0.000 description 25
- JGSZWSXRFVPVHJ-UHFFFAOYSA-N 1-ethynyl-2,4-dimethoxy-5-propan-2-ylbenzene Chemical compound COC1=CC(OC)=C(C(C)C)C=C1C#C JGSZWSXRFVPVHJ-UHFFFAOYSA-N 0.000 description 24
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 24
- 229960001755 resorcinol Drugs 0.000 description 24
- 239000003921 oil Substances 0.000 description 23
- 235000019439 ethyl acetate Nutrition 0.000 description 22
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 20
- YCIMNLLNPGFGHC-UHFFFAOYSA-N o-dihydroxy-benzene Natural products OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 20
- 239000011541 reaction mixture Substances 0.000 description 20
- 235000019198 oils Nutrition 0.000 description 19
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 18
- 239000000725 suspension Substances 0.000 description 18
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 17
- 239000003795 chemical substances by application Substances 0.000 description 16
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 16
- 238000003756 stirring Methods 0.000 description 16
- 239000007788 liquid Substances 0.000 description 15
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 14
- 239000011734 sodium Substances 0.000 description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
- 239000012267 brine Substances 0.000 description 13
- 125000001246 bromo group Chemical group Br* 0.000 description 13
- 150000002148 esters Chemical class 0.000 description 13
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 13
- MXNFUCNDPLBTMF-UHFFFAOYSA-N 1,3-oxazole-5-carboxamide Chemical compound NC(=O)C1=CN=CO1 MXNFUCNDPLBTMF-UHFFFAOYSA-N 0.000 description 12
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 12
- 238000003556 assay Methods 0.000 description 12
- 238000003818 flash chromatography Methods 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 11
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 11
- 125000000524 functional group Chemical group 0.000 description 11
- HNQIVZYLYMDVSB-NJFSPNSNSA-N methanesulfonamide Chemical compound [14CH3]S(N)(=O)=O HNQIVZYLYMDVSB-NJFSPNSNSA-N 0.000 description 11
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 11
- 239000007787 solid Substances 0.000 description 11
- 239000012043 crude product Substances 0.000 description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- 239000003826 tablet Substances 0.000 description 10
- ZSRHOISGDCJOAT-UHFFFAOYSA-N 2,4-dimethoxy-1-propan-2-ylbenzene Chemical compound COC1=CC=C(C(C)C)C(OC)=C1 ZSRHOISGDCJOAT-UHFFFAOYSA-N 0.000 description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 9
- 238000004440 column chromatography Methods 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 9
- 239000000651 prodrug Substances 0.000 description 9
- 229940002612 prodrug Drugs 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- 239000006071 cream Substances 0.000 description 8
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- 239000002244 precipitate Substances 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 238000010992 reflux Methods 0.000 description 8
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 7
- 101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 description 7
- 239000000969 carrier Substances 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- YMWNTYRZPGVQOX-UHFFFAOYSA-N 1-[isocyano-(4-methylphenyl)sulfonylmethyl]-2,4-dimethoxy-5-propan-2-ylbenzene Chemical compound C1=C(C(C)C)C(OC)=CC(OC)=C1C([N+]#[C-])S(=O)(=O)C1=CC=C(C)C=C1 YMWNTYRZPGVQOX-UHFFFAOYSA-N 0.000 description 6
- RBTJPCKRYLUPEK-UHFFFAOYSA-N 2-(2,4-dimethoxy-5-propan-2-ylphenyl)aniline Chemical compound C1=C(C(C)C)C(OC)=CC(OC)=C1C1=CC=CC=C1N RBTJPCKRYLUPEK-UHFFFAOYSA-N 0.000 description 6
- FXJVNINSOKCNJP-UHFFFAOYSA-N 4-methylbenzenesulfinic acid Chemical compound CC1=CC=C(S(O)=O)C=C1 FXJVNINSOKCNJP-UHFFFAOYSA-N 0.000 description 6
- 206010006187 Breast cancer Diseases 0.000 description 6
- 208000026310 Breast neoplasm Diseases 0.000 description 6
- 206010009944 Colon cancer Diseases 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- 239000007832 Na2SO4 Substances 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 6
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 6
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 239000003925 fat Substances 0.000 description 6
- 235000019197 fats Nutrition 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 229960001866 silicon dioxide Drugs 0.000 description 6
- 229910052938 sodium sulfate Inorganic materials 0.000 description 6
- ZRSNZINYAWTAHE-UHFFFAOYSA-N Anisaldehyde Natural products COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 5
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 206010018338 Glioma Diseases 0.000 description 5
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 5
- 239000000853 adhesive Substances 0.000 description 5
- 230000001070 adhesive effect Effects 0.000 description 5
- 150000001408 amides Chemical class 0.000 description 5
- 239000008346 aqueous phase Substances 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000000356 contaminant Substances 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 239000003480 eluent Substances 0.000 description 5
- 239000003995 emulsifying agent Substances 0.000 description 5
- 238000001704 evaporation Methods 0.000 description 5
- 230000008020 evaporation Effects 0.000 description 5
- 201000001441 melanoma Diseases 0.000 description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 5
- 239000012299 nitrogen atmosphere Substances 0.000 description 5
- 235000010603 pastilles Nutrition 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- 239000003381 stabilizer Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- PRVOOBNOHIXRII-GOBOWQCMSA-N (2s)-4-[(13s)-13-hydroxy-14-[2-[(2s)-2-hydroxydodecoxy]ethoxy]tetradecyl]-2-methyl-2h-furan-5-one Chemical compound CCCCCCCCCC[C@H](O)COCCOC[C@@H](O)CCCCCCCCCCCCC1=C[C@H](C)OC1=O PRVOOBNOHIXRII-GOBOWQCMSA-N 0.000 description 4
- QCGMEWVZBGQOFN-UHFFFAOYSA-N 1,3-oxazole-5-carboxylic acid Chemical compound OC(=O)C1=CN=CO1 QCGMEWVZBGQOFN-UHFFFAOYSA-N 0.000 description 4
- DKNBFMRTFISQTL-UHFFFAOYSA-N 2,4-dimethoxy-5-propan-2-ylbenzaldehyde Chemical compound COC1=CC(OC)=C(C(C)C)C=C1C=O DKNBFMRTFISQTL-UHFFFAOYSA-N 0.000 description 4
- UVNZZNMEBPUOQC-UHFFFAOYSA-N 3-(2,4-dimethoxy-5-propan-2-ylphenyl)aniline Chemical compound C1=C(C(C)C)C(OC)=CC(OC)=C1C1=CC=CC(N)=C1 UVNZZNMEBPUOQC-UHFFFAOYSA-N 0.000 description 4
- 0 CC(C)c(cc(**)c(O)c1)c1O Chemical compound CC(C)c(cc(**)c(O)c1)c1O 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 description 4
- 208000032612 Glial tumor Diseases 0.000 description 4
- MCAHMSDENAOJFZ-UHFFFAOYSA-N Herbimycin A Natural products N1C(=O)C(C)=CC=CC(OC)C(OC(N)=O)C(C)=CC(C)C(OC)C(OC)CC(C)C(OC)C2=CC(=O)C=C1C2=O MCAHMSDENAOJFZ-UHFFFAOYSA-N 0.000 description 4
- 101150028525 Hsp83 gene Proteins 0.000 description 4
- 206010025323 Lymphomas Diseases 0.000 description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 4
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 239000012317 TBTU Substances 0.000 description 4
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 4
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 229940125782 compound 2 Drugs 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 229960004132 diethyl ether Drugs 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- MCAHMSDENAOJFZ-BVXDHVRPSA-N herbimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](OC)[C@@H](OC)C[C@H](C)[C@@H](OC)C2=CC(=O)C=C1C2=O MCAHMSDENAOJFZ-BVXDHVRPSA-N 0.000 description 4
- 230000000155 isotopic effect Effects 0.000 description 4
- FDZZZRQASAIRJF-UHFFFAOYSA-M malachite green Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](C)C)C=C1 FDZZZRQASAIRJF-UHFFFAOYSA-M 0.000 description 4
- 229940107698 malachite green Drugs 0.000 description 4
- 239000002324 mouth wash Substances 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 239000006072 paste Substances 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 150000003852 triazoles Chemical class 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- LRKKZPSFFYQQMA-UHFFFAOYSA-N (2,4-dihydroxy-5-propan-2-ylphenyl)-(3,4-dimethoxyphenyl)methanone Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)C1=CC(C(C)C)=C(O)C=C1O LRKKZPSFFYQQMA-UHFFFAOYSA-N 0.000 description 3
- WLUQWJWTALOWNZ-UHFFFAOYSA-N (2,4-dimethoxy-5-propan-2-ylphenyl)boronic acid Chemical compound COC1=CC(OC)=C(C(C)C)C=C1B(O)O WLUQWJWTALOWNZ-UHFFFAOYSA-N 0.000 description 3
- DBJRPJSDYFDWPV-UHFFFAOYSA-N (4-chlorophenyl)methanesulfonyl chloride Chemical compound ClC1=CC=C(CS(Cl)(=O)=O)C=C1 DBJRPJSDYFDWPV-UHFFFAOYSA-N 0.000 description 3
- FDGCNGPUZIIRQI-UHFFFAOYSA-N (4-methoxyphenyl)methanone Chemical compound O(C1=CC=C([C-]=O)C=C1)C FDGCNGPUZIIRQI-UHFFFAOYSA-N 0.000 description 3
- ABSDMLCOPRVKRL-UHFFFAOYSA-N 1-(4-chlorophenyl)-2,4-dimethoxy-5-propan-2-ylbenzene Chemical group C1=C(C(C)C)C(OC)=CC(OC)=C1C1=CC=C(Cl)C=C1 ABSDMLCOPRVKRL-UHFFFAOYSA-N 0.000 description 3
- JTAWTUNIEMRVMJ-UHFFFAOYSA-N 1-(4-fluoro-2-methylphenyl)-2,4-dimethoxy-5-propan-2-ylbenzene Chemical group C1=C(C(C)C)C(OC)=CC(OC)=C1C1=CC=C(F)C=C1C JTAWTUNIEMRVMJ-UHFFFAOYSA-N 0.000 description 3
- USCPUVDSXRLPGU-UHFFFAOYSA-N 1-[(4-ethylphenyl)-isocyanomethyl]sulfonyl-4-methylbenzene Chemical compound C1=CC(CC)=CC=C1C([N+]#[C-])S(=O)(=O)C1=CC=C(C)C=C1 USCPUVDSXRLPGU-UHFFFAOYSA-N 0.000 description 3
- FYUABHFDUHJWOZ-UHFFFAOYSA-N 1-[2,4-bis(phenylmethoxy)phenyl]ethanone Chemical compound C1=C(OCC=2C=CC=CC=2)C(C(=O)C)=CC=C1OCC1=CC=CC=C1 FYUABHFDUHJWOZ-UHFFFAOYSA-N 0.000 description 3
- SYOANZBNGDEJFH-UHFFFAOYSA-N 2,5-dihydro-1h-triazole Chemical compound C1NNN=C1 SYOANZBNGDEJFH-UHFFFAOYSA-N 0.000 description 3
- UIZLCCRFEHERAA-UHFFFAOYSA-N 4-(4-fluoro-2-methylphenyl)-6-propan-2-ylbenzene-1,3-diol Chemical compound C1=C(O)C(C(C)C)=CC(C=2C(=CC(F)=CC=2)C)=C1O UIZLCCRFEHERAA-UHFFFAOYSA-N 0.000 description 3
- GNSJVLLMEANYSC-UHFFFAOYSA-N 4-[2,4-bis(phenylmethoxy)-5-propan-2-ylphenyl]-5-(2-ethylphenyl)-1,3-oxazole Chemical compound CCC1=CC=CC=C1C1=C(C=2C(=CC(OCC=3C=CC=CC=3)=C(C(C)C)C=2)OCC=2C=CC=CC=2)N=CO1 GNSJVLLMEANYSC-UHFFFAOYSA-N 0.000 description 3
- OQUYWGGWXRMELH-UHFFFAOYSA-N 4-[2,4-bis(phenylmethoxy)-5-propan-2-ylphenyl]-5-[3-(1,2,4-triazol-1-ylmethyl)phenyl]-1,3-oxazole Chemical compound C=1C=CC=CC=1COC=1C=C(OCC=2C=CC=CC=2)C(C(C)C)=CC=1C=1N=COC=1C(C=1)=CC=CC=1CN1C=NC=N1 OQUYWGGWXRMELH-UHFFFAOYSA-N 0.000 description 3
- DQPXRIILOWSSLK-UHFFFAOYSA-N 4-[2,4-bis(phenylmethoxy)-5-propan-2-ylphenyl]-5-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]-1,3-oxazole Chemical compound C=1C=CC=CC=1COC=1C=C(OCC=2C=CC=CC=2)C(C(C)C)=CC=1C=1N=COC=1C(C=C1)=CC=C1CN1CCN(C)CC1 DQPXRIILOWSSLK-UHFFFAOYSA-N 0.000 description 3
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- 108091006112 ATPases Proteins 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 3
- 229910015845 BBr3 Inorganic materials 0.000 description 3
- 102000001301 EGF receptor Human genes 0.000 description 3
- 108060006698 EGF receptor Proteins 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- UDLLFLQFQMACJB-UHFFFAOYSA-N azidomethylbenzene Chemical compound [N-]=[N+]=NCC1=CC=CC=C1 UDLLFLQFQMACJB-UHFFFAOYSA-N 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 3
- 235000010290 biphenyl Nutrition 0.000 description 3
- 239000004305 biphenyl Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- WMSPXQIQBQAWLL-UHFFFAOYSA-N cyclopropanesulfonamide Chemical compound NS(=O)(=O)C1CC1 WMSPXQIQBQAWLL-UHFFFAOYSA-N 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- RSOJSFYJLQADDM-UHFFFAOYSA-N ethanesulfonamide Chemical compound [CH2]CS(N)(=O)=O RSOJSFYJLQADDM-UHFFFAOYSA-N 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 238000010914 gene-directed enzyme pro-drug therapy Methods 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 208000014829 head and neck neoplasm Diseases 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 125000000468 ketone group Chemical group 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 230000000873 masking effect Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- CKJNUZNMWOVDFN-UHFFFAOYSA-N methanone Chemical compound O=[CH-] CKJNUZNMWOVDFN-UHFFFAOYSA-N 0.000 description 3
- GGNLNCSXHXUJOT-UHFFFAOYSA-N methyl 4-[2,4-bis(phenylmethoxy)-5-propan-2-ylphenyl]-1,3-oxazole-5-carboxylate Chemical compound O1C=NC(C=2C(=CC(OCC=3C=CC=CC=3)=C(C(C)C)C=2)OCC=2C=CC=CC=2)=C1C(=O)OC GGNLNCSXHXUJOT-UHFFFAOYSA-N 0.000 description 3
- 239000002808 molecular sieve Substances 0.000 description 3
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 3
- SWBLLSQMOMPTMC-UHFFFAOYSA-N naphthalene-2-sulfonamide Chemical compound C1=CC=CC2=CC(S(=O)(=O)N)=CC=C21 SWBLLSQMOMPTMC-UHFFFAOYSA-N 0.000 description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
- 201000008968 osteosarcoma Diseases 0.000 description 3
- 125000004304 oxazol-5-yl group Chemical group O1C=NC=C1* 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 239000011505 plaster Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- UCQHWQIQCCNKTE-UHFFFAOYSA-N propane-1-sulfonamide Chemical compound [CH2]CCS(N)(=O)=O UCQHWQIQCCNKTE-UHFFFAOYSA-N 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 3
- 239000012047 saturated solution Substances 0.000 description 3
- 238000002805 secondary assay Methods 0.000 description 3
- 208000000587 small cell lung carcinoma Diseases 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 229940124530 sulfonamide Drugs 0.000 description 3
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 3
- AYUNIORJHRXIBJ-TXHRRWQRSA-N tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 description 3
- 229950007866 tanespimycin Drugs 0.000 description 3
- CFOAUYCPAUGDFF-UHFFFAOYSA-N tosmic Chemical compound CC1=CC=C(S(=O)(=O)C[N+]#[C-])C=C1 CFOAUYCPAUGDFF-UHFFFAOYSA-N 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- CEGVSMPQMHZTOQ-UHFFFAOYSA-N (2,4-dihydroxy-5-propan-2-ylphenyl)-(3-hydroxyphenyl)methanone Chemical compound C1=C(O)C(C(C)C)=CC(C(=O)C=2C=C(O)C=CC=2)=C1O CEGVSMPQMHZTOQ-UHFFFAOYSA-N 0.000 description 2
- PUGIKXZHUAGIIL-UHFFFAOYSA-N (2,4-dihydroxy-5-propan-2-ylphenyl)-(4-hydroxyphenyl)methanone Chemical compound C1=C(O)C(C(C)C)=CC(C(=O)C=2C=CC(O)=CC=2)=C1O PUGIKXZHUAGIIL-UHFFFAOYSA-N 0.000 description 2
- JGGSZRUCFDROOQ-UHFFFAOYSA-N (2,6-dichlorophenyl)-(2,4-dihydroxy-5-propan-2-ylphenyl)methanone Chemical compound C1=C(O)C(C(C)C)=CC(C(=O)C=2C(=CC=CC=2Cl)Cl)=C1O JGGSZRUCFDROOQ-UHFFFAOYSA-N 0.000 description 2
- DPMHOKBEIAAJGX-UHFFFAOYSA-N (4-chlorophenyl)-(2,4-dihydroxy-5-propan-2-ylphenyl)methanone Chemical compound C1=C(O)C(C(C)C)=CC(C(=O)C=2C=CC(Cl)=CC=2)=C1O DPMHOKBEIAAJGX-UHFFFAOYSA-N 0.000 description 2
- IDTWRXVGBVZQHB-UHFFFAOYSA-N (4-chlorophenyl)methanone Chemical compound ClC1=CC=C([C+]=O)C=C1 IDTWRXVGBVZQHB-UHFFFAOYSA-N 0.000 description 2
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 description 2
- XKWPEJAXRJQKPL-UHFFFAOYSA-N 1-(3,4-difluorophenyl)-2,4-dimethoxy-5-propan-2-ylbenzene Chemical group C1=C(C(C)C)C(OC)=CC(OC)=C1C1=CC=C(F)C(F)=C1 XKWPEJAXRJQKPL-UHFFFAOYSA-N 0.000 description 2
- YOMCDOHEMZFLNF-UHFFFAOYSA-N 1-(3-fluoro-4-methoxyphenyl)-2,4-dimethoxy-5-propan-2-ylbenzene Chemical group C1=C(F)C(OC)=CC=C1C1=CC(C(C)C)=C(OC)C=C1OC YOMCDOHEMZFLNF-UHFFFAOYSA-N 0.000 description 2
- RPRBQFUYSVMDHB-UHFFFAOYSA-N 1-(4-fluoro-2-propan-2-yloxyphenyl)-2,4-dimethoxy-5-propan-2-ylbenzene Chemical group C1=C(C(C)C)C(OC)=CC(OC)=C1C1=CC=C(F)C=C1OC(C)C RPRBQFUYSVMDHB-UHFFFAOYSA-N 0.000 description 2
- XBPUPLUOBPCECH-UHFFFAOYSA-N 1-(4-fluorophenyl)-2,4-dimethoxy-5-propan-2-ylbenzene Chemical group C1=C(C(C)C)C(OC)=CC(OC)=C1C1=CC=C(F)C=C1 XBPUPLUOBPCECH-UHFFFAOYSA-N 0.000 description 2
- JMTPIENQTKMREN-UHFFFAOYSA-N 1-(azidomethyl)-4-chlorobenzene Chemical compound ClC1=CC=C(CN=[N+]=[N-])C=C1 JMTPIENQTKMREN-UHFFFAOYSA-N 0.000 description 2
- ZFNRVJFYENTFFD-UHFFFAOYSA-N 1-[(4-chlorophenyl)methyl]-4-(2,4-dimethoxy-5-propan-2-ylphenyl)triazole Chemical compound C1=C(C(C)C)C(OC)=CC(OC)=C1C(N=N1)=CN1CC1=CC=C(Cl)C=C1 ZFNRVJFYENTFFD-UHFFFAOYSA-N 0.000 description 2
- NGHULORTTGVRJZ-UHFFFAOYSA-N 1-[(4-chlorophenyl)methyl]-5-(2,4-dimethoxy-5-propan-2-ylphenyl)triazole Chemical compound C1=C(C(C)C)C(OC)=CC(OC)=C1C1=CN=NN1CC1=CC=C(Cl)C=C1 NGHULORTTGVRJZ-UHFFFAOYSA-N 0.000 description 2
- UXCQPEDHCCJBNL-UHFFFAOYSA-N 1-[(4-fluorophenyl)-isocyanomethyl]sulfonyl-4-methylbenzene Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C([N+]#[C-])C1=CC=C(F)C=C1 UXCQPEDHCCJBNL-UHFFFAOYSA-N 0.000 description 2
- KIJCBVOPJSHLBI-UHFFFAOYSA-N 1-[isocyano(phenyl)methyl]sulfonyl-4-methylbenzene Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C([N+]#[C-])C1=CC=CC=C1 KIJCBVOPJSHLBI-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- SULYEHHGGXARJS-UHFFFAOYSA-N 2',4'-dihydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1O SULYEHHGGXARJS-UHFFFAOYSA-N 0.000 description 2
- VQTDPCRSXHFMOL-UHFFFAOYSA-N 2,4-Dimethoxyacetophenone Chemical compound COC1=CC=C(C(C)=O)C(OC)=C1 VQTDPCRSXHFMOL-UHFFFAOYSA-N 0.000 description 2
- SPNCDKLGLPWEGP-UHFFFAOYSA-N 2,4-bis(phenylmethoxy)-5-propan-2-ylbenzaldehyde Chemical compound C1=C(OCC=2C=CC=CC=2)C(C(C)C)=CC(C=O)=C1OCC1=CC=CC=C1 SPNCDKLGLPWEGP-UHFFFAOYSA-N 0.000 description 2
- FXKKJKXHKNPZTP-UHFFFAOYSA-N 2,4-dimethoxy-1-prop-1-en-2-ylbenzene Chemical compound COC1=CC=C(C(C)=C)C(OC)=C1 FXKKJKXHKNPZTP-UHFFFAOYSA-N 0.000 description 2
- DMIYKWPEFRFTPY-UHFFFAOYSA-N 2,6-dichlorobenzaldehyde Chemical compound ClC1=CC=CC(Cl)=C1C=O DMIYKWPEFRFTPY-UHFFFAOYSA-N 0.000 description 2
- RRMCISXMKPFTRH-UHFFFAOYSA-N 2-(2,4-dimethoxy-5-propan-2-ylphenyl)-5-fluoroaniline Chemical compound C1=C(C(C)C)C(OC)=CC(OC)=C1C1=CC=C(F)C=C1N RRMCISXMKPFTRH-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- DOCGBVWUOFIWAQ-UHFFFAOYSA-N 2-[2,4-bis(phenylmethoxy)phenyl]propan-2-ol Chemical compound C1=C(OCC=2C=CC=CC=2)C(C(C)(O)C)=CC=C1OCC1=CC=CC=C1 DOCGBVWUOFIWAQ-UHFFFAOYSA-N 0.000 description 2
- SITOSHURCPNUOI-UHFFFAOYSA-N 2-[4-(2,4-dihydroxy-5-propan-2-ylphenyl)-1,3-oxazol-5-yl]benzonitrile Chemical compound C1=C(O)C(C(C)C)=CC(C2=C(OC=N2)C=2C(=CC=CC=2)C#N)=C1O SITOSHURCPNUOI-UHFFFAOYSA-N 0.000 description 2
- SMYFNASAUIXJGG-UHFFFAOYSA-N 2-[4-[2,4-bis(phenylmethoxy)-5-propan-2-ylphenyl]-1,3-oxazol-5-yl]benzonitrile Chemical compound C=1C=CC=CC=1COC=1C=C(OCC=2C=CC=CC=2)C(C(C)C)=CC=1C=1N=COC=1C1=CC=CC=C1C#N SMYFNASAUIXJGG-UHFFFAOYSA-N 0.000 description 2
- UPXZHXVOMCGZDS-UHFFFAOYSA-N 2-phenylbenzene-1,3-diol Chemical class OC1=CC=CC(O)=C1C1=CC=CC=C1 UPXZHXVOMCGZDS-UHFFFAOYSA-N 0.000 description 2
- FJVYQKQMCUJQOO-UHFFFAOYSA-N 4-(2,4-dihydroxy-5-propan-2-ylphenyl)-1,3-oxazole-5-carboxylic acid Chemical compound C1=C(O)C(C(C)C)=CC(C2=C(OC=N2)C(O)=O)=C1O FJVYQKQMCUJQOO-UHFFFAOYSA-N 0.000 description 2
- AGLQEYVGVMEKHI-UHFFFAOYSA-N 4-(2,4-dihydroxy-5-propan-2-ylphenyl)-n-[[4-(1-hydroxyethyl)phenyl]methyl]-1,3-oxazole-5-carboxamide Chemical compound C1=C(O)C(C(C)C)=CC(C2=C(OC=N2)C(=O)NCC=2C=CC(=CC=2)C(C)O)=C1O AGLQEYVGVMEKHI-UHFFFAOYSA-N 0.000 description 2
- VLSZJCAPAMVSNB-UHFFFAOYSA-N 4-(2,4-dimethoxy-5-propan-2-ylphenyl)-1-[(2-fluorophenyl)methyl]triazole Chemical compound C1=C(C(C)C)C(OC)=CC(OC)=C1C(N=N1)=CN1CC1=CC=CC=C1F VLSZJCAPAMVSNB-UHFFFAOYSA-N 0.000 description 2
- TVCWFYHEZCHSDG-UHFFFAOYSA-N 4-(2,4-dimethoxy-5-propan-2-ylphenyl)-1-[(4-fluorophenyl)methyl]triazole Chemical compound C1=C(C(C)C)C(OC)=CC(OC)=C1C(N=N1)=CN1CC1=CC=C(F)C=C1 TVCWFYHEZCHSDG-UHFFFAOYSA-N 0.000 description 2
- LRVZLCQBSAQIHG-UHFFFAOYSA-N 4-(2,4-dimethoxy-5-propan-2-ylphenyl)-5-(4-ethylphenyl)-1,3-oxazole Chemical compound C1=CC(CC)=CC=C1C1=C(C=2C(=CC(OC)=C(C(C)C)C=2)OC)N=CO1 LRVZLCQBSAQIHG-UHFFFAOYSA-N 0.000 description 2
- VIVKYJPEUHFVLV-UHFFFAOYSA-N 4-(2-morpholin-4-ylethylamino)benzaldehyde Chemical compound C1=CC(C=O)=CC=C1NCCN1CCOCC1 VIVKYJPEUHFVLV-UHFFFAOYSA-N 0.000 description 2
- WUQAHEHDQAKSGM-UHFFFAOYSA-N 4-(3,4-difluorophenyl)-6-propan-2-ylbenzene-1,3-diol Chemical compound C1=C(O)C(C(C)C)=CC(C=2C=C(F)C(F)=CC=2)=C1O WUQAHEHDQAKSGM-UHFFFAOYSA-N 0.000 description 2
- PXNCIHNRNFWDDV-UHFFFAOYSA-N 4-(3-aminophenyl)-6-propan-2-ylbenzene-1,3-diol Chemical compound C1=C(O)C(C(C)C)=CC(C=2C=C(N)C=CC=2)=C1O PXNCIHNRNFWDDV-UHFFFAOYSA-N 0.000 description 2
- ZYTQNCRZTOGVEI-UHFFFAOYSA-N 4-(3-benzyltriazol-4-yl)-6-propan-2-ylbenzene-1,3-diol Chemical compound CC(C)c1cc(-c2cnnn2Cc2ccccc2)c(O)cc1O ZYTQNCRZTOGVEI-UHFFFAOYSA-N 0.000 description 2
- ZZCWCJTVJSYJPE-UHFFFAOYSA-N 4-(4-chlorophenyl)-6-propan-2-ylbenzene-1,3-diol Chemical compound C1=C(O)C(C(C)C)=CC(C=2C=CC(Cl)=CC=2)=C1O ZZCWCJTVJSYJPE-UHFFFAOYSA-N 0.000 description 2
- PYKFODIVBUQZIS-UHFFFAOYSA-N 4-(4-fluoro-3-methylphenyl)-6-propan-2-ylbenzene-1,3-diol Chemical compound C1=C(O)C(C(C)C)=CC(C=2C=C(C)C(F)=CC=2)=C1O PYKFODIVBUQZIS-UHFFFAOYSA-N 0.000 description 2
- ZXRZLWCYYUTNCQ-UHFFFAOYSA-N 4-(4-fluorophenyl)-6-propan-2-ylbenzene-1,3-diol Chemical compound C1=C(O)C(C(C)C)=CC(C=2C=CC(F)=CC=2)=C1O ZXRZLWCYYUTNCQ-UHFFFAOYSA-N 0.000 description 2
- GDVRLYQTEMVEPN-UHFFFAOYSA-N 4-[1-(3,4-dihydroxyphenyl)triazol-4-yl]-6-propan-2-ylbenzene-1,3-diol Chemical compound CC(C)c1cc(-c2cn(nn2)-c2ccc(O)c(O)c2)c(O)cc1O GDVRLYQTEMVEPN-UHFFFAOYSA-N 0.000 description 2
- HDFIWCFHYNTYJW-UHFFFAOYSA-N 4-[2,4-bis(phenylmethoxy)-5-propan-2-ylphenyl]-5-(3,4-dimethoxyphenyl)-1,3-oxazole Chemical compound C1=C(OC)C(OC)=CC=C1C1=C(C=2C(=CC(OCC=3C=CC=CC=3)=C(C(C)C)C=2)OCC=2C=CC=CC=2)N=CO1 HDFIWCFHYNTYJW-UHFFFAOYSA-N 0.000 description 2
- QJYZAVJVAXOKIG-UHFFFAOYSA-N 4-[2,4-bis(phenylmethoxy)-5-propan-2-ylphenyl]-5-(3-pyridin-3-ylphenyl)-1,3-oxazole Chemical compound C=1C=CC=CC=1COC=1C=C(OCC=2C=CC=CC=2)C(C(C)C)=CC=1C=1N=COC=1C(C=1)=CC=CC=1C1=CC=CN=C1 QJYZAVJVAXOKIG-UHFFFAOYSA-N 0.000 description 2
- QYEYIELPGDYAGM-UHFFFAOYSA-N 4-[2,4-bis(phenylmethoxy)-5-propan-2-ylphenyl]-5-[3-(pyrrolidin-1-ylmethyl)phenyl]-1,3-oxazole Chemical compound C=1C=CC=CC=1COC=1C=C(OCC=2C=CC=CC=2)C(C(C)C)=CC=1C=1N=COC=1C(C=1)=CC=CC=1CN1CCCC1 QYEYIELPGDYAGM-UHFFFAOYSA-N 0.000 description 2
- WKFFJPYRCCEEBA-UHFFFAOYSA-N 4-[2,4-bis(phenylmethoxy)-5-propan-2-ylphenyl]-5-[3-[(4-methylpiperazin-1-yl)methyl]phenyl]-1,3-oxazole Chemical compound C=1C=CC=CC=1COC=1C=C(OCC=2C=CC=CC=2)C(C(C)C)=CC=1C=1N=COC=1C(C=1)=CC=CC=1CN1CCN(C)CC1 WKFFJPYRCCEEBA-UHFFFAOYSA-N 0.000 description 2
- ZGIXRUPGYKCUBC-UHFFFAOYSA-N 4-[2,4-bis(phenylmethoxy)-5-propan-2-ylphenyl]-5-[4-(piperidin-1-ylmethyl)phenyl]-1,3-oxazole Chemical compound C=1C=CC=CC=1COC=1C=C(OCC=2C=CC=CC=2)C(C(C)C)=CC=1C=1N=COC=1C(C=C1)=CC=C1CN1CCCCC1 ZGIXRUPGYKCUBC-UHFFFAOYSA-N 0.000 description 2
- JNUOGJDWMQVPPQ-UHFFFAOYSA-N 4-[2,4-bis(phenylmethoxy)-5-propan-2-ylphenyl]-5-[4-(pyrrolidin-1-ylmethyl)phenyl]-1,3-oxazole Chemical compound C=1C=CC=CC=1COC=1C=C(OCC=2C=CC=CC=2)C(C(C)C)=CC=1C=1N=COC=1C(C=C1)=CC=C1CN1CCCC1 JNUOGJDWMQVPPQ-UHFFFAOYSA-N 0.000 description 2
- QFYLIJTYODAJHG-UHFFFAOYSA-N 4-[2,4-bis(phenylmethoxy)-5-propan-2-ylphenyl]-5-phenyl-1,3-oxazole Chemical compound C=1C=CC=CC=1COC=1C=C(OCC=2C=CC=CC=2)C(C(C)C)=CC=1C=1N=COC=1C1=CC=CC=C1 QFYLIJTYODAJHG-UHFFFAOYSA-N 0.000 description 2
- CNZGDKQUUYDDIQ-UHFFFAOYSA-N 4-[4-(4-fluorophenyl)-1,3-oxazol-5-yl]-6-propan-2-ylbenzene-1,3-diol Chemical compound C1=C(O)C(C(C)C)=CC(C2=C(N=CO2)C=2C=CC(F)=CC=2)=C1O CNZGDKQUUYDDIQ-UHFFFAOYSA-N 0.000 description 2
- NJXIOGGENMVXRZ-UHFFFAOYSA-N 4-[4-[2,4-bis(phenylmethoxy)-5-propan-2-ylphenyl]-1,3-oxazol-5-yl]-n-(2-morpholin-4-ylethyl)aniline Chemical compound C=1C=CC=CC=1COC=1C=C(OCC=2C=CC=CC=2)C(C(C)C)=CC=1C=1N=COC=1C(C=C1)=CC=C1NCCN1CCOCC1 NJXIOGGENMVXRZ-UHFFFAOYSA-N 0.000 description 2
- HLHUMUPRPSURTL-UHFFFAOYSA-N 4-[5-(2-ethylphenyl)-1,3-oxazol-4-yl]-6-propan-2-ylbenzene-1,3-diol Chemical compound CCC1=CC=CC=C1C1=C(C=2C(=CC(O)=C(C(C)C)C=2)O)N=CO1 HLHUMUPRPSURTL-UHFFFAOYSA-N 0.000 description 2
- PUFFUMWLXVZWNQ-UHFFFAOYSA-N 4-[5-(4-fluorophenyl)-1,3-oxazol-4-yl]-6-propan-2-ylbenzene-1,3-diol Chemical compound C1=C(O)C(C(C)C)=CC(C2=C(OC=N2)C=2C=CC(F)=CC=2)=C1O PUFFUMWLXVZWNQ-UHFFFAOYSA-N 0.000 description 2
- UOQXIWFBQSVDPP-UHFFFAOYSA-N 4-fluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1 UOQXIWFBQSVDPP-UHFFFAOYSA-N 0.000 description 2
- OYMKLQVAUQHWPG-UHFFFAOYSA-N 5-(1,3-benzodioxol-5-yl)-4-[2,4-bis(phenylmethoxy)-5-propan-2-ylphenyl]-1,3-oxazole Chemical compound C1=C(OCC=2C=CC=CC=2)C(C(C)C)=CC(C2=C(OC=N2)C=2C=C3OCOC3=CC=2)=C1OCC1=CC=CC=C1 OYMKLQVAUQHWPG-UHFFFAOYSA-N 0.000 description 2
- JDDZNAXVTHKQMJ-UHFFFAOYSA-N 5-(2,4-dihydroxy-5-propan-2-ylphenyl)-2-fluoro-n-phenylbenzamide Chemical compound C1=C(O)C(C(C)C)=CC(C=2C=C(C(F)=CC=2)C(=O)NC=2C=CC=CC=2)=C1O JDDZNAXVTHKQMJ-UHFFFAOYSA-N 0.000 description 2
- QOAJSZRJZMGRIW-UHFFFAOYSA-N 5-(2,4-dihydroxy-5-propan-2-ylphenyl)-2-fluorobenzoic acid Chemical compound C1=C(O)C(C(C)C)=CC(C=2C=C(C(F)=CC=2)C(O)=O)=C1O QOAJSZRJZMGRIW-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 206010003571 Astrocytoma Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 2
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 101150029707 ERBB2 gene Proteins 0.000 description 2
- 241000792859 Enema Species 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 description 2
- 229930194542 Keto Natural products 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- 108010006519 Molecular Chaperones Proteins 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- PXJSQKRFSPUUEX-UHFFFAOYSA-N OC1C=CC=C(O)C1=O Chemical class OC1C=CC=C(O)C1=O PXJSQKRFSPUUEX-UHFFFAOYSA-N 0.000 description 2
- 108010058765 Oncogene Protein pp60(v-src) Proteins 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 206010039710 Scleroderma Diseases 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 102100023038 WD and tetratricopeptide repeats protein 1 Human genes 0.000 description 2
- WBRGWURMIYKCOL-UHFFFAOYSA-N [4-(dimethylamino)phenyl]-(2-hydroxy-4-methoxy-5-propan-2-ylphenyl)methanone Chemical compound C1=C(C(C)C)C(OC)=CC(O)=C1C(=O)C1=CC=C(N(C)C)C=C1 WBRGWURMIYKCOL-UHFFFAOYSA-N 0.000 description 2
- JTIGKAWLJXAWEM-UHFFFAOYSA-N [5-(2,4-dimethoxy-5-propan-2-ylphenyl)-2-fluorophenyl]-morpholin-4-ylmethanone Chemical compound C1=C(C(C)C)C(OC)=CC(OC)=C1C1=CC=C(F)C(C(=O)N2CCOCC2)=C1 JTIGKAWLJXAWEM-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 2
- 239000012346 acetyl chloride Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 150000001409 amidines Chemical class 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 238000010913 antigen-directed enzyme pro-drug therapy Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 150000007514 bases Chemical class 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- LUFPJJNWMYZRQE-UHFFFAOYSA-N benzylsulfanylmethylbenzene Chemical compound C=1C=CC=CC=1CSCC1=CC=CC=C1 LUFPJJNWMYZRQE-UHFFFAOYSA-N 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 125000002843 carboxylic acid group Chemical group 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 230000017858 demethylation Effects 0.000 description 2
- 238000010520 demethylation reaction Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000007920 enema Substances 0.000 description 2
- 229940095399 enema Drugs 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 125000002587 enol group Chemical group 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000003352 fibrogenic effect Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 201000006334 interstitial nephritis Diseases 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- MGJXBDMLVWIYOQ-UHFFFAOYSA-N methylazanide Chemical compound [NH-]C MGJXBDMLVWIYOQ-UHFFFAOYSA-N 0.000 description 2
- VYGYNVZNSSTDLJ-HKCOAVLJSA-N monorden Natural products CC1CC2OC2C=C/C=C/C(=O)CC3C(C(=CC(=C3Cl)O)O)C(=O)O1 VYGYNVZNSSTDLJ-HKCOAVLJSA-N 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 229940097496 nasal spray Drugs 0.000 description 2
- 239000007922 nasal spray Substances 0.000 description 2
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 2
- 239000003883 ointment base Substances 0.000 description 2
- 150000002891 organic anions Chemical class 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- CTRLRINCMYICJO-UHFFFAOYSA-N phenyl azide Chemical compound [N-]=[N+]=NC1=CC=CC=C1 CTRLRINCMYICJO-UHFFFAOYSA-N 0.000 description 2
- OAHKWDDSKCRNFE-UHFFFAOYSA-N phenylmethanesulfonyl chloride Chemical compound ClS(=O)(=O)CC1=CC=CC=C1 OAHKWDDSKCRNFE-UHFFFAOYSA-N 0.000 description 2
- 238000002428 photodynamic therapy Methods 0.000 description 2
- SATCULPHIDQDRE-UHFFFAOYSA-N piperonal Chemical compound O=CC1=CC=C2OCOC2=C1 SATCULPHIDQDRE-UHFFFAOYSA-N 0.000 description 2
- 208000005987 polymyositis Diseases 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000002810 primary assay Methods 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- AECPBJMOGBFQDN-YMYQVXQQSA-N radicicol Chemical compound C1CCCC(=O)C[C@H]2[C@H](Cl)C(=O)CC(=O)[C@H]2C(=O)O[C@H](C)C[C@H]2O[C@@H]21 AECPBJMOGBFQDN-YMYQVXQQSA-N 0.000 description 2
- 229930192524 radicicol Natural products 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- ATEBXHFBFRCZMA-VXTBVIBXSA-N rifabutin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC(=C2N3)C(=O)C=4C(O)=C5C)C)OC)C5=C1C=4C2=NC13CCN(CC(C)C)CC1 ATEBXHFBFRCZMA-VXTBVIBXSA-N 0.000 description 2
- 229960000885 rifabutin Drugs 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- KFZUDNZQQCWGKF-UHFFFAOYSA-M sodium;4-methylbenzenesulfinate Chemical compound [Na+].CC1=CC=C(S([O-])=O)C=C1 KFZUDNZQQCWGKF-UHFFFAOYSA-M 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
- 229930192474 thiophene Natural products 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- PQDJYEQOELDLCP-UHFFFAOYSA-N trimethylsilane Chemical compound C[SiH](C)C PQDJYEQOELDLCP-UHFFFAOYSA-N 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- WJUFSDZVCOTFON-UHFFFAOYSA-N veratraldehyde Chemical compound COC1=CC=C(C=O)C=C1OC WJUFSDZVCOTFON-UHFFFAOYSA-N 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 1
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- QHZXHFVIYQCUEF-UHFFFAOYSA-N (2,4-dihydroxy-5-propan-2-ylphenyl)-[4-(dimethylamino)phenyl]methanone Chemical compound C1=C(O)C(C(C)C)=CC(C(=O)C=2C=CC(=CC=2)N(C)C)=C1O QHZXHFVIYQCUEF-UHFFFAOYSA-N 0.000 description 1
- PYEDYJJGEREHLN-UHFFFAOYSA-N (2-amino-4-fluorophenyl)boronic acid Chemical compound NC1=CC(F)=CC=C1B(O)O PYEDYJJGEREHLN-UHFFFAOYSA-N 0.000 description 1
- DIRRKLFMHQUJCM-UHFFFAOYSA-N (2-aminophenyl)boronic acid Chemical compound NC1=CC=CC=C1B(O)O DIRRKLFMHQUJCM-UHFFFAOYSA-N 0.000 description 1
- AVOWPOFIQZSVGV-UHFFFAOYSA-N (2-phenoxyphenyl)boronic acid Chemical compound OB(O)C1=CC=CC=C1OC1=CC=CC=C1 AVOWPOFIQZSVGV-UHFFFAOYSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- GCTFTMWXZFLTRR-GFCCVEGCSA-N (2r)-2-amino-n-[3-(difluoromethoxy)-4-(1,3-oxazol-5-yl)phenyl]-4-methylpentanamide Chemical compound FC(F)OC1=CC(NC(=O)[C@H](N)CC(C)C)=CC=C1C1=CN=CO1 GCTFTMWXZFLTRR-GFCCVEGCSA-N 0.000 description 1
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 1
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 1
- ITOFPJRDSCGOSA-KZLRUDJFSA-N (2s)-2-[[(4r)-4-[(3r,5r,8r,9s,10s,13r,14s,17r)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H](CC[C@]13C)[C@@H]2[C@@H]3CC[C@@H]1[C@H](C)CCC(=O)N[C@H](C(O)=O)CC1=CNC2=CC=CC=C12 ITOFPJRDSCGOSA-KZLRUDJFSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 1
- RMGYQBHKEWWTOY-UHFFFAOYSA-N (3,4-difluorophenyl)boronic acid Chemical compound OB(O)C1=CC=C(F)C(F)=C1 RMGYQBHKEWWTOY-UHFFFAOYSA-N 0.000 description 1
- QBMHZZHJIBUPOX-UHFFFAOYSA-N (3-aminophenyl)boronic acid;hydron;chloride Chemical compound Cl.NC1=CC=CC(B(O)O)=C1 QBMHZZHJIBUPOX-UHFFFAOYSA-N 0.000 description 1
- IILGLPAJXQMKGQ-UHFFFAOYSA-N (3-fluoro-4-methoxyphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C=C1F IILGLPAJXQMKGQ-UHFFFAOYSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
- OOKAZRDERJMRCJ-KOUAFAAESA-N (3r)-7-[(1s,2s,4ar,6s,8s)-2,6-dimethyl-8-[(2s)-2-methylbutanoyl]oxy-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]-3-hydroxy-5-oxoheptanoic acid Chemical compound C1=C[C@H](C)[C@H](CCC(=O)C[C@@H](O)CC(O)=O)C2[C@@H](OC(=O)[C@@H](C)CC)C[C@@H](C)C[C@@H]21 OOKAZRDERJMRCJ-KOUAFAAESA-N 0.000 description 1
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
- OMBVEVHRIQULKW-DNQXCXABSA-M (3r,5r)-7-[3-(4-fluorophenyl)-8-oxo-7-phenyl-1-propan-2-yl-5,6-dihydro-4h-pyrrolo[2,3-c]azepin-2-yl]-3,5-dihydroxyheptanoate Chemical compound O=C1C=2N(C(C)C)C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C(C=3C=CC(F)=CC=3)C=2CCCN1C1=CC=CC=C1 OMBVEVHRIQULKW-DNQXCXABSA-M 0.000 description 1
- DXYUAQQPCWNJQX-UHFFFAOYSA-N (4-butoxy-2,3,5,6-tetrafluorophenyl)boronic acid Chemical compound CCCCOC1=C(F)C(F)=C(B(O)O)C(F)=C1F DXYUAQQPCWNJQX-UHFFFAOYSA-N 0.000 description 1
- CAYQIZIAYYNFCS-UHFFFAOYSA-N (4-chlorophenyl)boronic acid Chemical compound OB(O)C1=CC=C(Cl)C=C1 CAYQIZIAYYNFCS-UHFFFAOYSA-N 0.000 description 1
- IQMLIVUHMSIOQP-UHFFFAOYSA-N (4-fluoro-2-methylphenyl)boronic acid Chemical compound CC1=CC(F)=CC=C1B(O)O IQMLIVUHMSIOQP-UHFFFAOYSA-N 0.000 description 1
- RSEFJQODCQCGRB-UHFFFAOYSA-N (4-fluoro-2-propan-2-yloxyphenyl)boronic acid Chemical compound CC(C)OC1=CC(F)=CC=C1B(O)O RSEFJQODCQCGRB-UHFFFAOYSA-N 0.000 description 1
- JCIJCHSRVPSOML-UHFFFAOYSA-N (4-fluoro-3-methylphenyl)boronic acid Chemical compound CC1=CC(B(O)O)=CC=C1F JCIJCHSRVPSOML-UHFFFAOYSA-N 0.000 description 1
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 1
- SRKGZXIJDGWVAI-GVAVTCRGSA-M (e,3r)-7-[6-tert-butyl-4-(4-fluorophenyl)-2-propan-2-ylpyridin-3-yl]-3,5-dihydroxyhept-6-enoate Chemical compound CC(C)C1=NC(C(C)(C)C)=CC(C=2C=CC(F)=CC=2)=C1\C=C\C(O)C[C@@H](O)CC([O-])=O SRKGZXIJDGWVAI-GVAVTCRGSA-M 0.000 description 1
- ZYZCALPXKGUGJI-DDVDASKDSA-M (e,3r,5s)-7-[3-(4-fluorophenyl)-2-phenyl-5-propan-2-ylimidazol-4-yl]-3,5-dihydroxyhept-6-enoate Chemical compound C=1C=C(F)C=CC=1N1C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C(C(C)C)N=C1C1=CC=CC=C1 ZYZCALPXKGUGJI-DDVDASKDSA-M 0.000 description 1
- DEVSOMFAQLZNKR-RJRFIUFISA-N (z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-n'-pyrazin-2-ylprop-2-enehydrazide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C2=NN(\C=C/C(=O)NNC=3N=CC=NC=3)C=N2)=C1 DEVSOMFAQLZNKR-RJRFIUFISA-N 0.000 description 1
- QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 1
- 125000003626 1,2,4-triazol-1-yl group Chemical group [*]N1N=C([H])N=C1[H] 0.000 description 1
- CMHPUBKZZPSUIQ-UHFFFAOYSA-N 1,3-benzodioxol-5-ylboronic acid Chemical compound OB(O)C1=CC=C2OCOC2=C1 CMHPUBKZZPSUIQ-UHFFFAOYSA-N 0.000 description 1
- KKHFRAFPESRGGD-UHFFFAOYSA-N 1,3-dimethyl-7-[3-(n-methylanilino)propyl]purine-2,6-dione Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCCN(C)C1=CC=CC=C1 KKHFRAFPESRGGD-UHFFFAOYSA-N 0.000 description 1
- AMRDNIIPWHNQOD-UHFFFAOYSA-N 1-(2,4-dihydroxy-5-propan-2-ylphenyl)-2-phenylethanone Chemical compound C1=C(O)C(C(C)C)=CC(C(=O)CC=2C=CC=CC=2)=C1O AMRDNIIPWHNQOD-UHFFFAOYSA-N 0.000 description 1
- IKDXLKIVIWTKFR-UHFFFAOYSA-N 1-(4-chlorophenyl)-n-[2-(2,4-dimethoxy-5-propan-2-ylphenyl)phenyl]methanesulfonamide Chemical compound C1=C(C(C)C)C(OC)=CC(OC)=C1C1=CC=CC=C1NS(=O)(=O)CC1=CC=C(Cl)C=C1 IKDXLKIVIWTKFR-UHFFFAOYSA-N 0.000 description 1
- QNSNRRPTJZXLLE-UHFFFAOYSA-N 1-(4-fluoro-3-methylphenyl)-2,4-dimethoxy-5-propan-2-ylbenzene Chemical group C1=C(C(C)C)C(OC)=CC(OC)=C1C1=CC=C(F)C(C)=C1 QNSNRRPTJZXLLE-UHFFFAOYSA-N 0.000 description 1
- MHSLDASSAFCCDO-UHFFFAOYSA-N 1-(5-tert-butyl-2-methylpyrazol-3-yl)-3-(4-pyridin-4-yloxyphenyl)urea Chemical compound CN1N=C(C(C)(C)C)C=C1NC(=O)NC(C=C1)=CC=C1OC1=CC=NC=C1 MHSLDASSAFCCDO-UHFFFAOYSA-N 0.000 description 1
- SELQEFVDUSTTJB-UHFFFAOYSA-N 1-(azidomethyl)-2-chloro-4-fluorobenzene Chemical compound FC1=CC=C(CN=[N+]=[N-])C(Cl)=C1 SELQEFVDUSTTJB-UHFFFAOYSA-N 0.000 description 1
- BOSNISRGGXSMHE-UHFFFAOYSA-N 1-(azidomethyl)-2-chlorobenzene Chemical compound ClC1=CC=CC=C1CN=[N+]=[N-] BOSNISRGGXSMHE-UHFFFAOYSA-N 0.000 description 1
- WJSUIHLKOGPGRY-UHFFFAOYSA-N 1-(azidomethyl)-2-fluorobenzene Chemical compound FC1=CC=CC=C1CN=[N+]=[N-] WJSUIHLKOGPGRY-UHFFFAOYSA-N 0.000 description 1
- TWZXVFYNRLIXRY-UHFFFAOYSA-N 1-(azidomethyl)-2-methylbenzene Chemical compound CC1=CC=CC=C1CN=[N+]=[N-] TWZXVFYNRLIXRY-UHFFFAOYSA-N 0.000 description 1
- WYFWUPTWYUKGQM-UHFFFAOYSA-N 1-(azidomethyl)-3-chlorobenzene Chemical compound ClC1=CC=CC(CN=[N+]=[N-])=C1 WYFWUPTWYUKGQM-UHFFFAOYSA-N 0.000 description 1
- UEQMFQIPTDUPPJ-UHFFFAOYSA-N 1-(azidomethyl)-4-fluorobenzene Chemical compound FC1=CC=C(CN=[N+]=[N-])C=C1 UEQMFQIPTDUPPJ-UHFFFAOYSA-N 0.000 description 1
- NBXGSUCKCKGTCH-UHFFFAOYSA-N 1-(azidomethyl)-4-methylbenzene Chemical compound CC1=CC=C(CN=[N+]=[N-])C=C1 NBXGSUCKCKGTCH-UHFFFAOYSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
- ICFMDEAXZQNLTF-UHFFFAOYSA-N 1-[(2-chlorophenyl)methyl]-4-(2,4-dimethoxy-5-propan-2-ylphenyl)triazole Chemical compound C1=C(C(C)C)C(OC)=CC(OC)=C1C(N=N1)=CN1CC1=CC=CC=C1Cl ICFMDEAXZQNLTF-UHFFFAOYSA-N 0.000 description 1
- DENUTDCUFYRJIA-UHFFFAOYSA-N 1-[(3-chlorophenyl)methyl]-4-(2,4-dimethoxy-5-propan-2-ylphenyl)triazole Chemical compound C1=C(C(C)C)C(OC)=CC(OC)=C1C(N=N1)=CN1CC1=CC=CC(Cl)=C1 DENUTDCUFYRJIA-UHFFFAOYSA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- XBXJQBGKICADKR-UHFFFAOYSA-N 1-azido-2-methoxybenzene Chemical compound COC1=CC=CC=C1N=[N+]=[N-] XBXJQBGKICADKR-UHFFFAOYSA-N 0.000 description 1
- HVKZQLYQRLHTTQ-UHFFFAOYSA-N 1-azido-3-methoxybenzene Chemical compound COC1=CC=CC(N=[N+]=[N-])=C1 HVKZQLYQRLHTTQ-UHFFFAOYSA-N 0.000 description 1
- FREBDBVIKOZLKJ-UHFFFAOYSA-N 1-benzyl-5-(2,4-dimethoxy-5-propan-2-ylphenyl)triazole Chemical compound C1=C(C(C)C)C(OC)=CC(OC)=C1C1=CN=NN1CC1=CC=CC=C1 FREBDBVIKOZLKJ-UHFFFAOYSA-N 0.000 description 1
- QBTLWHYKYLZHKG-UHFFFAOYSA-N 1-iodo-2,4-dimethoxy-5-propan-2-ylbenzene Chemical compound COC1=CC(OC)=C(C(C)C)C=C1I QBTLWHYKYLZHKG-UHFFFAOYSA-N 0.000 description 1
- PGNPSNXWEGBATM-UHFFFAOYSA-N 1-methoxy-4-(1-methoxycyclohexa-2,4-dien-1-yl)benzene Chemical group COC1(CC=CC=C1)C1=CC=C(C=C1)OC PGNPSNXWEGBATM-UHFFFAOYSA-N 0.000 description 1
- LGEZTMRIZWCDLW-UHFFFAOYSA-N 14-methylpentadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C LGEZTMRIZWCDLW-UHFFFAOYSA-N 0.000 description 1
- UAYYSAPJTRVEQA-UHFFFAOYSA-N 1h-indol-5-ylmethanamine Chemical compound NCC1=CC=C2NC=CC2=C1 UAYYSAPJTRVEQA-UHFFFAOYSA-N 0.000 description 1
- BESOQRFWCAJXLE-UHFFFAOYSA-N 2,3-bis(bromomethyl)-1,4-dimethoxybenzene Chemical compound COC1=CC=C(OC)C(CBr)=C1CBr BESOQRFWCAJXLE-UHFFFAOYSA-N 0.000 description 1
- VHRXVQAJXHNNHS-UHFFFAOYSA-N 2,4-bis(phenylmethoxy)-1-propan-2-ylbenzene Chemical compound C1=C(OCC=2C=CC=CC=2)C(C(C)C)=CC=C1OCC1=CC=CC=C1 VHRXVQAJXHNNHS-UHFFFAOYSA-N 0.000 description 1
- SVYBNGHBLSAQGA-UHFFFAOYSA-N 2,4-dimethoxy-1-(1-propan-2-ylcyclohexa-2,4-dien-1-yl)benzene Chemical group C(C)(C)C1(CC=CC=C1)C1=C(C=C(C=C1)OC)OC SVYBNGHBLSAQGA-UHFFFAOYSA-N 0.000 description 1
- JBLIDPPHFGWTKU-UHFFFAOYSA-N 2,6-dichlorobenzoyl chloride Chemical compound ClC(=O)C1=C(Cl)C=CC=C1Cl JBLIDPPHFGWTKU-UHFFFAOYSA-N 0.000 description 1
- WGFNXGPBPIJYLI-UHFFFAOYSA-N 2,6-difluoro-3-[(3-fluorophenyl)sulfonylamino]-n-(3-methoxy-1h-pyrazolo[3,4-b]pyridin-5-yl)benzamide Chemical compound C1=C2C(OC)=NNC2=NC=C1NC(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=CC(F)=C1 WGFNXGPBPIJYLI-UHFFFAOYSA-N 0.000 description 1
- NYTIHVYONFLHSE-UHFFFAOYSA-N 2-(1,3-oxazol-2-yl)-4-phenylbenzene-1,3-diol Chemical class Oc1ccc(-c2ccccc2)c(O)c1-c1ncco1 NYTIHVYONFLHSE-UHFFFAOYSA-N 0.000 description 1
- FQMZXMVHHKXGTM-UHFFFAOYSA-N 2-(1-adamantyl)-n-[2-[2-(2-hydroxyethylamino)ethylamino]quinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC2=NC(NCCNCCO)=CC=C21 FQMZXMVHHKXGTM-UHFFFAOYSA-N 0.000 description 1
- VCUXVXLUOHDHKK-UHFFFAOYSA-N 2-(2-aminopyrimidin-4-yl)-4-(2-chloro-4-methoxyphenyl)-1,3-thiazole-5-carboxamide Chemical compound ClC1=CC(OC)=CC=C1C1=C(C(N)=O)SC(C=2N=C(N)N=CC=2)=N1 VCUXVXLUOHDHKK-UHFFFAOYSA-N 0.000 description 1
- QEBYEVQKHRUYPE-UHFFFAOYSA-N 2-(2-chlorophenyl)-5-[(1-methylpyrazol-3-yl)methyl]-4-[[methyl(pyridin-3-ylmethyl)amino]methyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C1=CN(C)N=C1CN1C(=O)C=C2NN(C=3C(=CC=CC=3)Cl)C(=O)C2=C1CN(C)CC1=CC=CN=C1 QEBYEVQKHRUYPE-UHFFFAOYSA-N 0.000 description 1
- CIOQUUUMMYPGKD-UHFFFAOYSA-N 2-(4-propan-2-ylphenyl)isoindole-1,3-dione Chemical compound C1=CC(C(C)C)=CC=C1N1C(=O)C2=CC=CC=C2C1=O CIOQUUUMMYPGKD-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- KQGHTOZUPICELS-UHFFFAOYSA-N 2-[4-(dimethylamino)phenyl]acetic acid Chemical compound CN(C)C1=CC=C(CC(O)=O)C=C1 KQGHTOZUPICELS-UHFFFAOYSA-N 0.000 description 1
- WVAKRQOMAINQPU-UHFFFAOYSA-N 2-[4-[2-[5-(2,2-dimethylbutyl)-1h-imidazol-2-yl]ethyl]phenyl]pyridine Chemical compound N1C(CC(C)(C)CC)=CN=C1CCC1=CC=C(C=2N=CC=CC=2)C=C1 WVAKRQOMAINQPU-UHFFFAOYSA-N 0.000 description 1
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 1
- FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 description 1
- VVCMGAUPZIKYTH-VGHSCWAPSA-N 2-acetyloxybenzoic acid;[(2s,3r)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate;1,3,7-trimethylpurine-2,6-dione Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C.C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 VVCMGAUPZIKYTH-VGHSCWAPSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- NPRYCHLHHVWLQZ-TURQNECASA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynylpurin-8-one Chemical compound NC1=NC=C2N(C(N(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C NPRYCHLHHVWLQZ-TURQNECASA-N 0.000 description 1
- IMRWILPUOVGIMU-UHFFFAOYSA-N 2-bromopyridine Chemical compound BrC1=CC=CC=N1 IMRWILPUOVGIMU-UHFFFAOYSA-N 0.000 description 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
- NTWBHJYRDKBGBR-UHFFFAOYSA-N 2-ethylbenzaldehyde Chemical compound CCC1=CC=CC=C1C=O NTWBHJYRDKBGBR-UHFFFAOYSA-N 0.000 description 1
- SFAAOBGYWOUHLU-UHFFFAOYSA-N 2-ethylhexyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(CC)CCCC SFAAOBGYWOUHLU-UHFFFAOYSA-N 0.000 description 1
- QVTPWONEVZJCCS-UHFFFAOYSA-N 2-formylbenzonitrile Chemical compound O=CC1=CC=CC=C1C#N QVTPWONEVZJCCS-UHFFFAOYSA-N 0.000 description 1
- UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 1
- PJKVFARRVXDXAD-UHFFFAOYSA-N 2-naphthaldehyde Chemical compound C1=CC=CC2=CC(C=O)=CC=C21 PJKVFARRVXDXAD-UHFFFAOYSA-N 0.000 description 1
- TYEYBOSBBBHJIV-UHFFFAOYSA-M 2-oxobutanoate Chemical compound CCC(=O)C([O-])=O TYEYBOSBBBHJIV-UHFFFAOYSA-M 0.000 description 1
- VMZCDNSFRSVYKQ-UHFFFAOYSA-N 2-phenylacetyl chloride Chemical compound ClC(=O)CC1=CC=CC=C1 VMZCDNSFRSVYKQ-UHFFFAOYSA-N 0.000 description 1
- VIOBGCWEHLRBEP-UHFFFAOYSA-N 3,4-dimethoxybenzoyl chloride Chemical compound COC1=CC=C(C(Cl)=O)C=C1OC VIOBGCWEHLRBEP-UHFFFAOYSA-N 0.000 description 1
- DFRAKBCRUYUFNT-UHFFFAOYSA-N 3,8-dicyclohexyl-2,4,7,9-tetrahydro-[1,3]oxazino[5,6-h][1,3]benzoxazine Chemical compound C1CCCCC1N1CC(C=CC2=C3OCN(C2)C2CCCCC2)=C3OC1 DFRAKBCRUYUFNT-UHFFFAOYSA-N 0.000 description 1
- IBVURYHFXBPNCW-UHFFFAOYSA-N 3-(1,2,4-triazol-1-ylmethyl)benzaldehyde Chemical compound O=CC1=CC=CC(CN2N=CN=C2)=C1 IBVURYHFXBPNCW-UHFFFAOYSA-N 0.000 description 1
- JAHMUNMGBWWUDQ-UHFFFAOYSA-N 3-(2,4-dimethoxy-5-propan-2-ylphenyl)pyridine Chemical compound C1=C(C(C)C)C(OC)=CC(OC)=C1C1=CC=CN=C1 JAHMUNMGBWWUDQ-UHFFFAOYSA-N 0.000 description 1
- JMKQKKQFLYPQDD-UHFFFAOYSA-N 3-(imidazol-1-ylmethyl)benzaldehyde Chemical compound O=CC1=CC=CC(CN2C=NC=C2)=C1 JMKQKKQFLYPQDD-UHFFFAOYSA-N 0.000 description 1
- XHHOLQHPKIDQEM-UHFFFAOYSA-N 3-(pyrrolidin-1-ylmethyl)benzaldehyde Chemical compound O=CC1=CC=CC(CN2CCCC2)=C1 XHHOLQHPKIDQEM-UHFFFAOYSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- WFOVEDJTASPCIR-UHFFFAOYSA-N 3-[(4-methyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)methylamino]-n-[[2-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound N=1N=C(C=2C=CN=CC=2)N(C)C=1CNC(C=1)=CC=CC=1C(=O)NCC1=CC=CC=C1C(F)(F)F WFOVEDJTASPCIR-UHFFFAOYSA-N 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- WMPDAIZRQDCGFH-UHFFFAOYSA-N 3-methoxybenzaldehyde Chemical compound COC1=CC=CC(C=O)=C1 WMPDAIZRQDCGFH-UHFFFAOYSA-N 0.000 description 1
- RUQIUASLAXJZIE-UHFFFAOYSA-N 3-methoxybenzoyl chloride Chemical compound COC1=CC=CC(C(Cl)=O)=C1 RUQIUASLAXJZIE-UHFFFAOYSA-N 0.000 description 1
- UJPFNRWGFPAZMO-UHFFFAOYSA-N 3-pyridin-3-ylbenzaldehyde Chemical compound O=CC1=CC=CC(C=2C=NC=CC=2)=C1 UJPFNRWGFPAZMO-UHFFFAOYSA-N 0.000 description 1
- IYQQHEUFQZMAMW-UHFFFAOYSA-N 4-(2,4-dimethoxy-5-propan-2-ylphenyl)-1-[(2-methylphenyl)methyl]triazole Chemical compound C1=C(C(C)C)C(OC)=CC(OC)=C1C(N=N1)=CN1CC1=CC=CC=C1C IYQQHEUFQZMAMW-UHFFFAOYSA-N 0.000 description 1
- ANNVEWDFEUPFJV-UHFFFAOYSA-N 4-(2,4-dimethoxy-5-propan-2-ylphenyl)-1-[(4-propan-2-ylphenyl)methyl]triazole Chemical compound C1=C(C(C)C)C(OC)=CC(OC)=C1C(N=N1)=CN1CC1=CC=C(C(C)C)C=C1 ANNVEWDFEUPFJV-UHFFFAOYSA-N 0.000 description 1
- FGLXMUOMJOHGKH-UHFFFAOYSA-N 4-(2-morpholin-4-ylethoxy)benzaldehyde Chemical compound C1=CC(C=O)=CC=C1OCCN1CCOCC1 FGLXMUOMJOHGKH-UHFFFAOYSA-N 0.000 description 1
- TVZXAVGWNACMQS-UHFFFAOYSA-N 4-(azidomethyl)-1,2-dichlorobenzene Chemical compound ClC1=CC=C(CN=[N+]=[N-])C=C1Cl TVZXAVGWNACMQS-UHFFFAOYSA-N 0.000 description 1
- WULHNUGSMDNQSA-UHFFFAOYSA-N 4-(azidomethyl)-1,2-difluorobenzene Chemical compound FC1=CC=C(CN=[N+]=[N-])C=C1F WULHNUGSMDNQSA-UHFFFAOYSA-N 0.000 description 1
- UGJDXRVQCYBXAJ-UHFFFAOYSA-N 4-(dimethylamino)benzoyl chloride Chemical compound CN(C)C1=CC=C(C(Cl)=O)C=C1 UGJDXRVQCYBXAJ-UHFFFAOYSA-N 0.000 description 1
- PYVCQHSLEIAQET-UHFFFAOYSA-N 4-(imidazol-1-ylmethyl)benzaldehyde Chemical compound C1=CC(C=O)=CC=C1CN1C=NC=C1 PYVCQHSLEIAQET-UHFFFAOYSA-N 0.000 description 1
- KMAHWHPUXGNVBN-UHFFFAOYSA-N 4-(morpholin-4-ylmethyl)benzaldehyde Chemical compound C1=CC(C=O)=CC=C1CN1CCOCC1 KMAHWHPUXGNVBN-UHFFFAOYSA-N 0.000 description 1
- WWBOSCKXPMBVLG-UHFFFAOYSA-N 4-(piperidin-1-ylmethyl)benzaldehyde Chemical compound C1=CC(C=O)=CC=C1CN1CCCCC1 WWBOSCKXPMBVLG-UHFFFAOYSA-N 0.000 description 1
- MTBYCACQSYAYCC-UHFFFAOYSA-N 4-(pyrrolidin-1-ylmethyl)benzaldehyde Chemical compound C1=CC(C=O)=CC=C1CN1CCCC1 MTBYCACQSYAYCC-UHFFFAOYSA-N 0.000 description 1
- UTLCKVHOCBVCMX-UHFFFAOYSA-N 4-[1-(2-hydroxyphenyl)triazol-4-yl]-6-propan-2-ylbenzene-1,3-diol Chemical compound C1=C(O)C(C(C)C)=CC(C=2N=NN(C=2)C=2C(=CC=CC=2)O)=C1O UTLCKVHOCBVCMX-UHFFFAOYSA-N 0.000 description 1
- SFNPGSJIPZQMQS-UHFFFAOYSA-N 4-[1-(3-hydroxyphenyl)triazol-4-yl]-6-propan-2-ylbenzene-1,3-diol Chemical compound C1=C(O)C(C(C)C)=CC(C=2N=NN(C=2)C=2C=C(O)C=CC=2)=C1O SFNPGSJIPZQMQS-UHFFFAOYSA-N 0.000 description 1
- GPOOQYKUAHXTGC-UHFFFAOYSA-N 4-[1-[(2-chlorophenyl)methyl]triazol-4-yl]-6-propan-2-ylbenzene-1,3-diol Chemical compound C1=C(O)C(C(C)C)=CC(C=2N=NN(CC=3C(=CC=CC=3)Cl)C=2)=C1O GPOOQYKUAHXTGC-UHFFFAOYSA-N 0.000 description 1
- BLEVBSZKFOMEDE-UHFFFAOYSA-N 4-[1-[(2-fluorophenyl)methyl]triazol-4-yl]-6-propan-2-ylbenzene-1,3-diol Chemical compound C1=C(O)C(C(C)C)=CC(C=2N=NN(CC=3C(=CC=CC=3)F)C=2)=C1O BLEVBSZKFOMEDE-UHFFFAOYSA-N 0.000 description 1
- ZHLCMIDBCJJKIT-UHFFFAOYSA-N 4-[1-[(3-chlorophenyl)methyl]triazol-4-yl]-6-propan-2-ylbenzene-1,3-diol Chemical compound C1=C(O)C(C(C)C)=CC(C=2N=NN(CC=3C=C(Cl)C=CC=3)C=2)=C1O ZHLCMIDBCJJKIT-UHFFFAOYSA-N 0.000 description 1
- XSAWHMNOXWRCLB-UHFFFAOYSA-N 4-[1-[(4-chlorophenyl)methyl]triazol-4-yl]-6-propan-2-ylbenzene-1,3-diol Chemical compound C1=C(O)C(C(C)C)=CC(C=2N=NN(CC=3C=CC(Cl)=CC=3)C=2)=C1O XSAWHMNOXWRCLB-UHFFFAOYSA-N 0.000 description 1
- LJODSOMXNIJIGZ-UHFFFAOYSA-N 4-[1-[(4-fluorophenyl)methyl]triazol-4-yl]-6-propan-2-ylbenzene-1,3-diol Chemical compound C1=C(O)C(C(C)C)=CC(C=2N=NN(CC=3C=CC(F)=CC=3)C=2)=C1O LJODSOMXNIJIGZ-UHFFFAOYSA-N 0.000 description 1
- UFCPFQYHUIZZEH-UHFFFAOYSA-N 4-[1-[(4-methylphenyl)methyl]triazol-4-yl]-6-propan-2-ylbenzene-1,3-diol Chemical compound C1=C(O)C(C(C)C)=CC(C=2N=NN(CC=3C=CC(C)=CC=3)C=2)=C1O UFCPFQYHUIZZEH-UHFFFAOYSA-N 0.000 description 1
- OZRSDZMMSHMTQL-UHFFFAOYSA-N 4-[2,4-bis(phenylmethoxy)-5-propan-2-ylphenyl]-5-(4-methoxyphenyl)-1,3-oxazole Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C(=CC(OCC=3C=CC=CC=3)=C(C(C)C)C=2)OCC=2C=CC=CC=2)N=CO1 OZRSDZMMSHMTQL-UHFFFAOYSA-N 0.000 description 1
- NGVAWFUWDGWYRC-UHFFFAOYSA-N 4-[2,4-bis(phenylmethoxy)-5-propan-2-ylphenyl]-5-[4-[(4-methyl-1,4-diazepan-1-yl)methyl]phenyl]-1,3-oxazole Chemical compound C=1C=CC=CC=1COC=1C=C(OCC=2C=CC=CC=2)C(C(C)C)=CC=1C=1N=COC=1C(C=C1)=CC=C1CN1CCCN(C)CC1 NGVAWFUWDGWYRC-UHFFFAOYSA-N 0.000 description 1
- PNRATVNNAWGNIX-UHFFFAOYSA-N 4-[2-[4-[4-[2,4-bis(phenylmethoxy)-5-propan-2-ylphenyl]-1,3-oxazol-5-yl]phenoxy]ethyl]morpholine Chemical compound C=1C=CC=CC=1COC=1C=C(OCC=2C=CC=CC=2)C(C(C)C)=CC=1C=1N=COC=1C(C=C1)=CC=C1OCCN1CCOCC1 PNRATVNNAWGNIX-UHFFFAOYSA-N 0.000 description 1
- YILOHLZFZBFXIX-UHFFFAOYSA-N 4-[3-[(4-chlorophenyl)methyl]triazol-4-yl]-6-propan-2-ylbenzene-1,3-diol Chemical compound CC(C)c1cc(-c2cnnn2Cc2ccc(Cl)cc2)c(O)cc1O YILOHLZFZBFXIX-UHFFFAOYSA-N 0.000 description 1
- QSJKPMIWDYHOOX-UHFFFAOYSA-N 4-[4-(4-ethylphenyl)-1,3-oxazol-5-yl]-6-propan-2-ylbenzene-1,3-diol Chemical compound C1=CC(CC)=CC=C1C1=C(C=2C(=CC(O)=C(C(C)C)C=2)O)OC=N1 QSJKPMIWDYHOOX-UHFFFAOYSA-N 0.000 description 1
- BVKCBXCYDBECPD-UHFFFAOYSA-N 4-[5-(1,3-benzodioxol-5-yl)-1,3-oxazol-4-yl]-6-propan-2-ylbenzene-1,3-diol Chemical compound C1=C(O)C(C(C)C)=CC(C2=C(OC=N2)C=2C=C3OCOC3=CC=2)=C1O BVKCBXCYDBECPD-UHFFFAOYSA-N 0.000 description 1
- FIQZEKYNMYOFIR-UHFFFAOYSA-N 4-[5-(3,4-dimethoxyphenyl)-1,3-oxazol-4-yl]-6-propan-2-ylbenzene-1,3-diol Chemical compound C1=C(OC)C(OC)=CC=C1C1=C(C=2C(=CC(O)=C(C(C)C)C=2)O)N=CO1 FIQZEKYNMYOFIR-UHFFFAOYSA-N 0.000 description 1
- HFLHRKRENOEYST-UHFFFAOYSA-N 4-[5-(4-ethylphenyl)-1,3-oxazol-4-yl]-6-propan-2-ylbenzene-1,3-diol Chemical compound C1=CC(CC)=CC=C1C1=C(C=2C(=CC(O)=C(C(C)C)C=2)O)N=CO1 HFLHRKRENOEYST-UHFFFAOYSA-N 0.000 description 1
- OBDCNVKXVVDHQW-UHFFFAOYSA-N 4-[5-[4-(morpholin-4-ylmethyl)phenyl]-1,3-oxazol-4-yl]-6-propan-2-ylbenzene-1,3-diol Chemical compound C1=C(O)C(C(C)C)=CC(C2=C(OC=N2)C=2C=CC(CN3CCOCC3)=CC=2)=C1O OBDCNVKXVVDHQW-UHFFFAOYSA-N 0.000 description 1
- WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 description 1
- MPMKMQHJHDHPBE-RUZDIDTESA-N 4-[[(2r)-1-(1-benzothiophene-3-carbonyl)-2-methylazetidine-2-carbonyl]-[(3-chlorophenyl)methyl]amino]butanoic acid Chemical compound O=C([C@@]1(N(CC1)C(=O)C=1C2=CC=CC=C2SC=1)C)N(CCCC(O)=O)CC1=CC=CC(Cl)=C1 MPMKMQHJHDHPBE-RUZDIDTESA-N 0.000 description 1
- UKFVEWCKADJREX-UHFFFAOYSA-N 4-[[4-[4-[2,4-bis(phenylmethoxy)-5-propan-2-ylphenyl]-1,3-oxazol-5-yl]phenyl]methyl]morpholine Chemical compound C=1C=CC=CC=1COC=1C=C(OCC=2C=CC=CC=2)C(C(C)C)=CC=1C=1N=COC=1C(C=C1)=CC=C1CN1CCOCC1 UKFVEWCKADJREX-UHFFFAOYSA-N 0.000 description 1
- AYAUGIRPNJJDLZ-UHFFFAOYSA-N 4-azido-1,2-dimethoxybenzene Chemical compound COC1=CC=C(N=[N+]=[N-])C=C1OC AYAUGIRPNJJDLZ-UHFFFAOYSA-N 0.000 description 1
- HQIVRLMDLMDRHW-UHFFFAOYSA-N 4-benzyl-2-(2H-triazol-4-yl)benzene-1,3-diol Chemical class C(C1=CC=CC=C1)C1=C(C(=C(O)C=C1)C=1N=NNC=1)O HQIVRLMDLMDRHW-UHFFFAOYSA-N 0.000 description 1
- RKIDDEGICSMIJA-UHFFFAOYSA-N 4-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(Cl)C=C1 RKIDDEGICSMIJA-UHFFFAOYSA-N 0.000 description 1
- DQAZPZIYEOGZAF-UHFFFAOYSA-N 4-ethyl-n-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]piperazine-1-carboxamide Chemical compound C1CN(CC)CCN1C(=O)NC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=CC(C#C)=C1 DQAZPZIYEOGZAF-UHFFFAOYSA-N 0.000 description 1
- BFXHJFKKRGVUMU-UHFFFAOYSA-N 4-fluorobenzenesulfonyl chloride Chemical compound FC1=CC=C(S(Cl)(=O)=O)C=C1 BFXHJFKKRGVUMU-UHFFFAOYSA-N 0.000 description 1
- LBUNNMJLXWQQBY-UHFFFAOYSA-N 4-fluorophenylboronic acid Chemical compound OB(O)C1=CC=C(F)C=C1 LBUNNMJLXWQQBY-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- ONIGRCLBUNKKAB-UHFFFAOYSA-N 4-phenyl-2-(2H-triazol-4-yl)benzene-1,3-diol Chemical class C1(=CC=CC=C1)C1=C(C(=C(O)C=C1)C=1N=NNC=1)O ONIGRCLBUNKKAB-UHFFFAOYSA-N 0.000 description 1
- LYXCJGJSIWFKHZ-UHFFFAOYSA-N 4-phenylbenzene-1,3-diol Chemical compound OC1=CC(O)=CC=C1C1=CC=CC=C1 LYXCJGJSIWFKHZ-UHFFFAOYSA-N 0.000 description 1
- BXOYBAOFPIYTAR-UHFFFAOYSA-N 4-propan-2-yl-6-[1-[(4-propan-2-ylphenyl)methyl]triazol-4-yl]benzene-1,3-diol Chemical compound C1=CC(C(C)C)=CC=C1CN1N=NC(C=2C(=CC(O)=C(C(C)C)C=2)O)=C1 BXOYBAOFPIYTAR-UHFFFAOYSA-N 0.000 description 1
- XYXMUORFQOMGHN-UHFFFAOYSA-N 4-propan-2-yl-6-[5-[4-(1,2,4-triazol-1-ylmethyl)phenyl]-1,3-oxazol-4-yl]benzene-1,3-diol Chemical compound C1=C(O)C(C(C)C)=CC(C2=C(OC=N2)C=2C=CC(CN3N=CN=C3)=CC=2)=C1O XYXMUORFQOMGHN-UHFFFAOYSA-N 0.000 description 1
- NREWJOIHGJZGTN-UHFFFAOYSA-N 5-(2,4-dimethoxy-5-propan-2-ylphenyl)-2-fluorobenzoic acid Chemical compound C1=C(C(C)C)C(OC)=CC(OC)=C1C1=CC=C(F)C(C(O)=O)=C1 NREWJOIHGJZGTN-UHFFFAOYSA-N 0.000 description 1
- PPEITNIRHGNDQE-UHFFFAOYSA-N 5-(2,4-dimethoxy-5-propan-2-ylphenyl)-4-(4-ethylphenyl)-1,3-oxazole Chemical compound C1=CC(CC)=CC=C1C1=C(C=2C(=CC(OC)=C(C(C)C)C=2)OC)OC=N1 PPEITNIRHGNDQE-UHFFFAOYSA-N 0.000 description 1
- FDPJXECGDOHTRJ-UHFFFAOYSA-N 5-(2,4-dimethoxy-5-propan-2-ylphenyl)-4-(4-fluorophenyl)-1,3-oxazole Chemical compound C1=C(C(C)C)C(OC)=CC(OC)=C1C1=C(C=2C=CC(F)=CC=2)N=CO1 FDPJXECGDOHTRJ-UHFFFAOYSA-N 0.000 description 1
- VKLKXFOZNHEBSW-UHFFFAOYSA-N 5-[[3-[(4-morpholin-4-ylbenzoyl)amino]phenyl]methoxy]pyridine-3-carboxamide Chemical compound O1CCN(CC1)C1=CC=C(C(=O)NC=2C=C(COC=3C=NC=C(C(=O)N)C=3)C=CC=2)C=C1 VKLKXFOZNHEBSW-UHFFFAOYSA-N 0.000 description 1
- DGORTXQWDDXSIQ-UHFFFAOYSA-N 5-borono-2-fluorobenzoic acid Chemical compound OB(O)C1=CC=C(F)C(C(O)=O)=C1 DGORTXQWDDXSIQ-UHFFFAOYSA-N 0.000 description 1
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 1
- KCAGQZRIVPTEQT-UHFFFAOYSA-N 5-ethyl-2,4-dimethoxybenzaldehyde Chemical compound CCC1=CC(C=O)=C(OC)C=C1OC KCAGQZRIVPTEQT-UHFFFAOYSA-N 0.000 description 1
- FMWIBYIITPAELA-UHFFFAOYSA-N 5-methoxy-5-(4-methoxyphenyl)cyclohexa-1,3-diene-1-carboxamide Chemical compound COC1(CC(=CC=C1)C(=O)N)C1=CC=C(C=C1)OC FMWIBYIITPAELA-UHFFFAOYSA-N 0.000 description 1
- UZBJUMPCDFLNSS-UHFFFAOYSA-N 6-(2,4-dimethoxyphenyl)-6-propan-2-ylcyclohexa-2,4-dien-1-amine Chemical compound C(C)(C)C1(C(C=CC=C1)N)C1=C(C=C(C=C1)OC)OC UZBJUMPCDFLNSS-UHFFFAOYSA-N 0.000 description 1
- RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 description 1
- GDUANFXPOZTYKS-UHFFFAOYSA-N 6-bromo-8-[(2,6-difluoro-4-methoxybenzoyl)amino]-4-oxochromene-2-carboxylic acid Chemical compound FC1=CC(OC)=CC(F)=C1C(=O)NC1=CC(Br)=CC2=C1OC(C(O)=O)=CC2=O GDUANFXPOZTYKS-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- XASOHFCUIQARJT-UHFFFAOYSA-N 8-methoxy-6-[7-(2-morpholin-4-ylethoxy)imidazo[1,2-a]pyridin-3-yl]-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinolin-1-one Chemical compound C(N1C(=O)C2=C(OC)C=C(C=3N4C(=NC=3)C=C(C=C4)OCCN3CCOCC3)C=C2CC1)C(F)(F)F XASOHFCUIQARJT-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 101150033765 BAG1 gene Proteins 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- IYHHRZBKXXKDDY-UHFFFAOYSA-N BI-605906 Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(C(F)(F)CC)=CC=1N1CCC(S(C)(=O)=O)CC1 IYHHRZBKXXKDDY-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 208000003508 Botulism Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 239000004358 Butane-1, 3-diol Substances 0.000 description 1
- JQUCWIWWWKZNCS-LESHARBVSA-N C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F Chemical compound C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F JQUCWIWWWKZNCS-LESHARBVSA-N 0.000 description 1
- ISMDILRWKSYCOD-GNKBHMEESA-N C(C1=CC=CC=C1)[C@@H]1NC(OCCCCCCCCCCCNC([C@@H](NC(C[C@@H]1O)=O)C(C)C)=O)=O Chemical compound C(C1=CC=CC=C1)[C@@H]1NC(OCCCCCCCCCCCNC([C@@H](NC(C[C@@H]1O)=O)C(C)C)=O)=O ISMDILRWKSYCOD-GNKBHMEESA-N 0.000 description 1
- QULQYCYQLKISBY-UHFFFAOYSA-N C1(O)=CC(O)=CC=C1.O1C=NC=C1 Chemical class C1(O)=CC(O)=CC=C1.O1C=NC=C1 QULQYCYQLKISBY-UHFFFAOYSA-N 0.000 description 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 1
- XSZDEFPXYMEAHD-UHFFFAOYSA-N CC(C)c(c(O)c1)cc(-c2c(-c(cc3)ccc3NCCN3CCOCC3)[o]cn2)c1O Chemical compound CC(C)c(c(O)c1)cc(-c2c(-c(cc3)ccc3NCCN3CCOCC3)[o]cn2)c1O XSZDEFPXYMEAHD-UHFFFAOYSA-N 0.000 description 1
- CUHNRHYHVLUTIT-UHFFFAOYSA-N CC(C)c(c(O)c1)cc(-c2c[n](Cc3ccccc3)nn2)c1O Chemical compound CC(C)c(c(O)c1)cc(-c2c[n](Cc3ccccc3)nn2)c1O CUHNRHYHVLUTIT-UHFFFAOYSA-N 0.000 description 1
- VMVRPSRCMOCRNP-UHFFFAOYSA-N CC(C)c(c(O)c1)cc(-c2cccc(NCc3ccc(C[n]4ncnc4)cc3)c2)c1O Chemical compound CC(C)c(c(O)c1)cc(-c2cccc(NCc3ccc(C[n]4ncnc4)cc3)c2)c1O VMVRPSRCMOCRNP-UHFFFAOYSA-N 0.000 description 1
- OAPFJIDJEPWYPA-UHFFFAOYSA-N CC(C)c(c(O)c1)cc(-c2ncccc2)c1O Chemical compound CC(C)c(c(O)c1)cc(-c2ncccc2)c1O OAPFJIDJEPWYPA-UHFFFAOYSA-N 0.000 description 1
- CTUUUHBYJHOFHP-UHFFFAOYSA-N CC(C)c(c(OC)c1)cc(-c(c(NS(c2ccc(C)cc2)(=O)=O)c2)ccc2F)c1OC Chemical compound CC(C)c(c(OC)c1)cc(-c(c(NS(c2ccc(C)cc2)(=O)=O)c2)ccc2F)c1OC CTUUUHBYJHOFHP-UHFFFAOYSA-N 0.000 description 1
- MRWIFCHZXKCLQJ-UHFFFAOYSA-N CC(C)c(c(OC)c1)cc(-c(cccc2)c2NS(c2cc(cccc3)c3cc2)(=O)=O)c1OC Chemical compound CC(C)c(c(OC)c1)cc(-c(cccc2)c2NS(c2cc(cccc3)c3cc2)(=O)=O)c1OC MRWIFCHZXKCLQJ-UHFFFAOYSA-N 0.000 description 1
- BHJITDQESZYRBS-UHFFFAOYSA-N CC(C)c(c(OC)c1)cc(-c2c(-c(cc3)ccc3F)[o]cn2)c1OC Chemical compound CC(C)c(c(OC)c1)cc(-c2c(-c(cc3)ccc3F)[o]cn2)c1OC BHJITDQESZYRBS-UHFFFAOYSA-N 0.000 description 1
- ZFNPWXSFGACMSB-UHFFFAOYSA-N CC(C)c(c(OC)c1)cc(-c2cc(NS(Cc3ccccc3)(=O)=O)ccc2)c1OC Chemical compound CC(C)c(c(OC)c1)cc(-c2cc(NS(Cc3ccccc3)(=O)=O)ccc2)c1OC ZFNPWXSFGACMSB-UHFFFAOYSA-N 0.000 description 1
- ZFMUOBZBOCKOQK-UHFFFAOYSA-N CC(C)c(c(OC)c1)cc(-c2ccc3OCOc3c2)c1OC Chemical compound CC(C)c(c(OC)c1)cc(-c2ccc3OCOc3c2)c1OC ZFMUOBZBOCKOQK-UHFFFAOYSA-N 0.000 description 1
- KUXTVSAQZRLYEM-UHFFFAOYSA-N CC(C)c(c(OC)c1)cc(-c2cnc[o]2)c1OC Chemical compound CC(C)c(c(OC)c1)cc(-c2cnc[o]2)c1OC KUXTVSAQZRLYEM-UHFFFAOYSA-N 0.000 description 1
- SLOUEDHDWAIUBX-UHFFFAOYSA-N CC(C)c(c(OCc1ccccc1)c1)cc(-c2c(C(O)=O)[o]cn2)c1OCc1ccccc1 Chemical compound CC(C)c(c(OCc1ccccc1)c1)cc(-c2c(C(O)=O)[o]cn2)c1OCc1ccccc1 SLOUEDHDWAIUBX-UHFFFAOYSA-N 0.000 description 1
- WCUAXHWTTHUPPC-UHFFFAOYSA-N CC(C)c(cc(-c1c(-c2ccc(C[n]3cncc3)cc2)[o]cn1)c(O)c1)c1O Chemical compound CC(C)c(cc(-c1c(-c2ccc(C[n]3cncc3)cc2)[o]cn1)c(O)c1)c1O WCUAXHWTTHUPPC-UHFFFAOYSA-N 0.000 description 1
- XLTWINYNWRJXQR-UHFFFAOYSA-N CC(C)c(cc(-c1c(-c2cccc(-c3cnccc3)c2)[o]cn1)c(O)c1)c1O Chemical compound CC(C)c(cc(-c1c(-c2cccc(-c3cnccc3)c2)[o]cn1)c(O)c1)c1O XLTWINYNWRJXQR-UHFFFAOYSA-N 0.000 description 1
- XZKGLFINRLZRAZ-UHFFFAOYSA-N CC(C)c(cc(-c1cc(NCc2ccc(C[n]3ncnc3)cc2)ccc1)c(OC)c1)c1OC Chemical compound CC(C)c(cc(-c1cc(NCc2ccc(C[n]3ncnc3)cc2)ccc1)c(OC)c1)c1OC XZKGLFINRLZRAZ-UHFFFAOYSA-N 0.000 description 1
- CHKAKJVXIUBZTF-UHFFFAOYSA-N CC(C)c(cc(C(NC=O)S(c1ccc(C)cc1)(=O)=O)c(OC)c1)c1OC Chemical compound CC(C)c(cc(C(NC=O)S(c1ccc(C)cc1)(=O)=O)c(OC)c1)c1OC CHKAKJVXIUBZTF-UHFFFAOYSA-N 0.000 description 1
- UHNRLQRZRNKOKU-UHFFFAOYSA-N CCN(CC1=NC2=C(N1)C1=CC=C(C=C1N=C2N)C1=NNC=C1)C(C)=O Chemical compound CCN(CC1=NC2=C(N1)C1=CC=C(C=C1N=C2N)C1=NNC=C1)C(C)=O UHNRLQRZRNKOKU-UHFFFAOYSA-N 0.000 description 1
- PKMUHQIDVVOXHQ-HXUWFJFHSA-N C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O Chemical compound C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O PKMUHQIDVVOXHQ-HXUWFJFHSA-N 0.000 description 1
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 101100507655 Canis lupus familiaris HSPA1 gene Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N Cc(cc1)ccc1S(O)(=O)=O Chemical compound Cc(cc1)ccc1S(O)(=O)=O JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000251556 Chordata Species 0.000 description 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010048832 Colon adenoma Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- 229940127007 Compound 39 Drugs 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 229910016374 CuSO45H2O Inorganic materials 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108010054814 DNA Gyrase Proteins 0.000 description 1
- 108020005199 Dehydrogenases Proteins 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 102100020977 DnaJ homolog subfamily A member 1 Human genes 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 102100038595 Estrogen receptor Human genes 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000289695 Eutheria Species 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 108091006057 GST-tagged proteins Proteins 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 108010042283 HSP40 Heat-Shock Proteins Proteins 0.000 description 1
- 102000004447 HSP40 Heat-Shock Proteins Human genes 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000931227 Homo sapiens DnaJ homolog subfamily A member 1 Proteins 0.000 description 1
- 241000282620 Hylobates sp. Species 0.000 description 1
- 102000000521 Immunophilins Human genes 0.000 description 1
- 108010016648 Immunophilins Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000283953 Lagomorpha Species 0.000 description 1
- 241000222722 Leishmania <genus> Species 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000289581 Macropus sp. Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 1
- AVYVHIKSFXVDBG-UHFFFAOYSA-N N-benzyl-N-hydroxy-2,2-dimethylbutanamide Chemical compound C(C1=CC=CC=C1)N(C(C(CC)(C)C)=O)O AVYVHIKSFXVDBG-UHFFFAOYSA-N 0.000 description 1
- POFVJRKJJBFPII-UHFFFAOYSA-N N-cyclopentyl-5-[2-[[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]amino]-5-fluoropyrimidin-4-yl]-4-methyl-1,3-thiazol-2-amine Chemical compound C1(CCCC1)NC=1SC(=C(N=1)C)C1=NC(=NC=C1F)NC1=NC=C(C=C1)CN1CCN(CC1)CC POFVJRKJJBFPII-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- QOVYHDHLFPKQQG-NDEPHWFRSA-N N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O Chemical compound N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O QOVYHDHLFPKQQG-NDEPHWFRSA-N 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- VYEAHXRPWKOEMY-UHFFFAOYSA-N O-(9H-fluoren-9-ylmethyl)hydroxylamine Chemical compound C1=CC=C2C(CON)C3=CC=CC=C3C2=C1 VYEAHXRPWKOEMY-UHFFFAOYSA-N 0.000 description 1
- BHVRCUAHXVLSNX-UHFFFAOYSA-N O-[(4,5-dimethoxy-2-nitrophenyl)methyl]hydroxylamine Chemical compound COC1=CC(CON)=C([N+]([O-])=O)C=C1OC BHVRCUAHXVLSNX-UHFFFAOYSA-N 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033266 Ovarian Hyperstimulation Syndrome Diseases 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 208000009608 Papillomavirus Infections Diseases 0.000 description 1
- 241001504519 Papio ursinus Species 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 1
- 101710141955 RAF proto-oncogene serine/threonine-protein kinase Proteins 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 206010055666 Retinal neovascularisation Diseases 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 201000005485 Toxoplasmosis Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 208000008385 Urogenital Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000289674 Vombatidae Species 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 1
- RPRMOEFOTPSWBO-UHFFFAOYSA-N [2-(methanesulfonamido)phenyl]boronic acid Chemical compound CS(=O)(=O)NC1=CC=CC=C1B(O)O RPRMOEFOTPSWBO-UHFFFAOYSA-N 0.000 description 1
- BLIXUNCSDKZOOX-UHFFFAOYSA-N [3-[(3-methoxyphenyl)methoxy]phenyl]boronic acid Chemical compound COC1=CC=CC(COC=2C=C(C=CC=2)B(O)O)=C1 BLIXUNCSDKZOOX-UHFFFAOYSA-N 0.000 description 1
- DLQOQRNXQBBPSO-UHFFFAOYSA-N [4-fluoro-3-(morpholine-4-carbonyl)phenyl]boronic acid Chemical compound OB(O)C1=CC=C(F)C(C(=O)N2CCOCC2)=C1 DLQOQRNXQBBPSO-UHFFFAOYSA-N 0.000 description 1
- KPQHVEASBVESSL-UHFFFAOYSA-N [4-fluoro-3-(propan-2-ylcarbamoyl)phenyl]boronic acid Chemical compound CC(C)NC(=O)C1=CC(B(O)O)=CC=C1F KPQHVEASBVESSL-UHFFFAOYSA-N 0.000 description 1
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000004015 abortifacient agent Substances 0.000 description 1
- 231100000641 abortifacient agent Toxicity 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- APUPEJJSWDHEBO-UHFFFAOYSA-P ammonium molybdate Chemical compound [NH4+].[NH4+].[O-][Mo]([O-])(=O)=O APUPEJJSWDHEBO-UHFFFAOYSA-P 0.000 description 1
- 239000011609 ammonium molybdate Substances 0.000 description 1
- 235000018660 ammonium molybdate Nutrition 0.000 description 1
- 229940010552 ammonium molybdate Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 239000000538 analytical sample Substances 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 150000001449 anionic compounds Chemical class 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- MXMOTZIXVICDSD-UHFFFAOYSA-N anisoyl chloride Chemical compound COC1=CC=C(C(Cl)=O)C=C1 MXMOTZIXVICDSD-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 150000003934 aromatic aldehydes Chemical class 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- LVKXKLKGQNIPPL-UHFFFAOYSA-N benzene-1,3-diol;2h-triazole Chemical class C1=CNN=N1.OC1=CC=CC(O)=C1 LVKXKLKGQNIPPL-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 125000006269 biphenyl-2-yl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1=C(*)C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 125000005620 boronic acid group Chemical class 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- SKOLWUPSYHWYAM-UHFFFAOYSA-N carbonodithioic O,S-acid Chemical compound SC(S)=O SKOLWUPSYHWYAM-UHFFFAOYSA-N 0.000 description 1
- 150000001728 carbonyl compounds Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 150000001767 cationic compounds Chemical class 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 238000012650 click reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229910052681 coesite Inorganic materials 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125877 compound 31 Drugs 0.000 description 1
- 229940125878 compound 36 Drugs 0.000 description 1
- 229940125807 compound 37 Drugs 0.000 description 1
- 229940127573 compound 38 Drugs 0.000 description 1
- 229940126540 compound 41 Drugs 0.000 description 1
- 229940125936 compound 42 Drugs 0.000 description 1
- 229940125844 compound 46 Drugs 0.000 description 1
- 229940127271 compound 49 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 229940126545 compound 53 Drugs 0.000 description 1
- 229940127113 compound 57 Drugs 0.000 description 1
- 229940125900 compound 59 Drugs 0.000 description 1
- 229940126179 compound 72 Drugs 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229910052906 cristobalite Inorganic materials 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- PFWWSGFPICCWGU-UHFFFAOYSA-N cyclopropanesulfonyl chloride Chemical compound ClS(=O)(=O)C1CC1 PFWWSGFPICCWGU-UHFFFAOYSA-N 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006264 debenzylation reaction Methods 0.000 description 1
- SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 231100000223 dermal penetration Toxicity 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- AQEFLFZSWDEAIP-UHFFFAOYSA-N di-tert-butyl ether Chemical compound CC(C)(C)OC(C)(C)C AQEFLFZSWDEAIP-UHFFFAOYSA-N 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- BJXYHBKEQFQVES-NWDGAFQWSA-N enpatoran Chemical compound N[C@H]1CN(C[C@H](C1)C(F)(F)F)C1=C2C=CC=NC2=C(C=C1)C#N BJXYHBKEQFQVES-NWDGAFQWSA-N 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- FRYHCSODNHYDPU-UHFFFAOYSA-N ethanesulfonyl chloride Chemical compound CCS(Cl)(=O)=O FRYHCSODNHYDPU-UHFFFAOYSA-N 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- RRGZOQKPWJKLOE-UHFFFAOYSA-N ethanone Chemical compound C[C-]=O RRGZOQKPWJKLOE-UHFFFAOYSA-N 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- GWNFQAKCJYEJEW-UHFFFAOYSA-N ethyl 3-[8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]octanoylamino]benzoate Chemical compound CCOC(=O)C1=CC(NC(=O)CCCCCCCSC2=NN=C(CC3=NN(C)C(=O)C4=CC=CC=C34)N2C)=CC=C1 GWNFQAKCJYEJEW-UHFFFAOYSA-N 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 230000000893 fibroproliferative effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 230000002363 herbicidal effect Effects 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- 238000009815 homocoupling reaction Methods 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000008309 hydrophilic cream Substances 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 229910001412 inorganic anion Inorganic materials 0.000 description 1
- 229910001411 inorganic cation Inorganic materials 0.000 description 1
- 229910052816 inorganic phosphate Inorganic materials 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229940078545 isocetyl stearate Drugs 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 208000011379 keloid formation Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 241001515942 marmosets Species 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 201000000022 melorheostosis Diseases 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- PYFSLJVSCGXYAJ-UHFFFAOYSA-N methyl 2-hydroxy-4-[[3-(2-hydroxyphenyl)phenyl]sulfonylamino]benzoate Chemical compound C1=C(O)C(C(=O)OC)=CC=C1NS(=O)(=O)C1=CC=CC(C=2C(=CC=CC=2)O)=C1 PYFSLJVSCGXYAJ-UHFFFAOYSA-N 0.000 description 1
- OYSNGCBXSJRTAE-UHFFFAOYSA-N methyl 4-(2,4-dimethoxy-5-propan-2-ylphenyl)-1,3-oxazole-5-carboxylate Chemical compound O1C=NC(C=2C(=CC(OC)=C(C(C)C)C=2)OC)=C1C(=O)OC OYSNGCBXSJRTAE-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- LSEFCHWGJNHZNT-UHFFFAOYSA-M methyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(C)C1=CC=CC=C1 LSEFCHWGJNHZNT-UHFFFAOYSA-M 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- LCEDQNDDFOCWGG-UHFFFAOYSA-N morpholine-4-carbaldehyde Chemical compound O=CN1CCOCC1 LCEDQNDDFOCWGG-UHFFFAOYSA-N 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 229940043348 myristyl alcohol Drugs 0.000 description 1
- YCJZWBZJSYLMPB-UHFFFAOYSA-N n-(2-chloropyrimidin-4-yl)-2,5-dimethyl-1-phenylimidazole-4-carboxamide Chemical compound CC=1N(C=2C=CC=CC=2)C(C)=NC=1C(=O)NC1=CC=NC(Cl)=N1 YCJZWBZJSYLMPB-UHFFFAOYSA-N 0.000 description 1
- MRHQBBSKCLIMRH-UHFFFAOYSA-N n-(acetamidomethoxymethyl)acetamide Chemical compound CC(=O)NCOCNC(C)=O MRHQBBSKCLIMRH-UHFFFAOYSA-N 0.000 description 1
- YGBMCLDVRUGXOV-UHFFFAOYSA-N n-[6-[6-chloro-5-[(4-fluorophenyl)sulfonylamino]pyridin-3-yl]-1,3-benzothiazol-2-yl]acetamide Chemical compound C1=C2SC(NC(=O)C)=NC2=CC=C1C(C=1)=CN=C(Cl)C=1NS(=O)(=O)C1=CC=C(F)C=C1 YGBMCLDVRUGXOV-UHFFFAOYSA-N 0.000 description 1
- GTWJETSWSUWSEJ-UHFFFAOYSA-N n-benzylaniline Chemical compound C=1C=CC=CC=1CNC1=CC=CC=C1 GTWJETSWSUWSEJ-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- SRZNTYKTEYEUIW-UHFFFAOYSA-N n-pyrrolidin-1-ylbenzenesulfonamide Chemical compound C=1C=CC=CC=1S(=O)(=O)NN1CCCC1 SRZNTYKTEYEUIW-UHFFFAOYSA-N 0.000 description 1
- OPECTNGATDYLSS-UHFFFAOYSA-N naphthalene-2-sulfonyl chloride Chemical compound C1=CC=CC2=CC(S(=O)(=O)Cl)=CC=C21 OPECTNGATDYLSS-UHFFFAOYSA-N 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 230000014399 negative regulation of angiogenesis Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 125000000018 nitroso group Chemical group N(=O)* 0.000 description 1
- GQPLMRYTRLFLPF-UHFFFAOYSA-N nitrous oxide Inorganic materials [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 108091008569 nuclear steroid hormone receptors Proteins 0.000 description 1
- LUHFJLLCZSYACL-UHFFFAOYSA-N o-(2,2,2-trichloroethyl)hydroxylamine Chemical compound NOCC(Cl)(Cl)Cl LUHFJLLCZSYACL-UHFFFAOYSA-N 0.000 description 1
- GWCBVFMHGHMALR-UHFFFAOYSA-N o-(2-trimethylsilylethyl)hydroxylamine Chemical compound C[Si](C)(C)CCON GWCBVFMHGHMALR-UHFFFAOYSA-N 0.000 description 1
- XYEOALKITRFCJJ-UHFFFAOYSA-N o-benzylhydroxylamine Chemical compound NOCC1=CC=CC=C1 XYEOALKITRFCJJ-UHFFFAOYSA-N 0.000 description 1
- UHJWZORSTYATLW-UHFFFAOYSA-N o-biphenylyl phenyl ether Natural products C=1C=CC=C(C=2C=CC=CC=2)C=1OC1=CC=CC=C1 UHJWZORSTYATLW-UHFFFAOYSA-N 0.000 description 1
- KKVUFSINQFSJNK-UHFFFAOYSA-N o-tert-butylhydroxylamine Chemical compound CC(C)(C)ON KKVUFSINQFSJNK-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002892 organic cations Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 208000008798 osteoma Diseases 0.000 description 1
- 229940127084 other anti-cancer agent Drugs 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 150000002916 oxazoles Chemical class 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- KLAKIAVEMQMVBT-UHFFFAOYSA-N p-hydroxy-phenacyl alcohol Natural products OCC(=O)C1=CC=C(O)C=C1 KLAKIAVEMQMVBT-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- RUVINXPYWBROJD-UHFFFAOYSA-N para-methoxyphenyl Natural products COC1=CC=C(C=CC)C=C1 RUVINXPYWBROJD-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 239000008251 pharmaceutical emulsion Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
- 229940081310 piperonal Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- GUUBJKMBDULZTE-UHFFFAOYSA-M potassium;2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid;hydroxide Chemical compound [OH-].[K+].OCCN1CCN(CCS(O)(=O)=O)CC1 GUUBJKMBDULZTE-UHFFFAOYSA-M 0.000 description 1
- VNDUHYWEWRRBFJ-UHFFFAOYSA-N pp-001 Drugs S1C=CC(C(=O)NC=2C(=C(F)C(=C(F)C=2F)C=2C=C(OC(F)(F)F)C=CC=2)F)=C1C(=O)O VNDUHYWEWRRBFJ-UHFFFAOYSA-N 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003138 primary alcohols Chemical class 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- KPBSJEBFALFJTO-UHFFFAOYSA-N propane-1-sulfonyl chloride Chemical compound CCCS(Cl)(=O)=O KPBSJEBFALFJTO-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000030788 protein refolding Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- ABMYEXAYWZJVOV-UHFFFAOYSA-N pyridin-3-ylboronic acid Chemical compound OB(O)C1=CC=CN=C1 ABMYEXAYWZJVOV-UHFFFAOYSA-N 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000025053 regulation of cell proliferation Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- DPZNOMCNRMUKPS-UHFFFAOYSA-N resorcinol dimethyl ether Natural products COC1=CC=CC(OC)=C1 DPZNOMCNRMUKPS-UHFFFAOYSA-N 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 201000004409 schistosomiasis Diseases 0.000 description 1
- 206010039667 schwannoma Diseases 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 108020003113 steroid hormone receptors Proteins 0.000 description 1
- 102000005969 steroid hormone receptors Human genes 0.000 description 1
- 229910052682 stishovite Inorganic materials 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- FGTJJHCZWOVVNH-UHFFFAOYSA-N tert-butyl-[tert-butyl(dimethyl)silyl]oxy-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)O[Si](C)(C)C(C)(C)C FGTJJHCZWOVVNH-UHFFFAOYSA-N 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- SFLXUZPXEWWQNH-UHFFFAOYSA-K tetrabutylazanium;tribromide Chemical compound [Br-].[Br-].[Br-].CCCC[N+](CCCC)(CCCC)CCCC.CCCC[N+](CCCC)(CCCC)CCCC.CCCC[N+](CCCC)(CCCC)CCCC SFLXUZPXEWWQNH-UHFFFAOYSA-K 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- QNMBSXGYAQZCTN-UHFFFAOYSA-N thiophen-3-ylboronic acid Chemical compound OB(O)C=1C=CSC=1 QNMBSXGYAQZCTN-UHFFFAOYSA-N 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 230000036964 tight binding Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 229910052905 tridymite Inorganic materials 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- NHDIQVFFNDKAQU-UHFFFAOYSA-N tripropan-2-yl borate Chemical compound CC(C)OB(OC(C)C)OC(C)C NHDIQVFFNDKAQU-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 201000002311 trypanosomiasis Diseases 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/74—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/78—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
- C07C225/22—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/25—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
- C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C39/12—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings
- C07C39/15—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings with all hydroxy groups on non-condensed rings, e.g. phenylphenol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C39/24—Halogenated derivatives
- C07C39/367—Halogenated derivatives polycyclic non-condensed, containing only six-membered aromatic rings as cyclic parts, e.g. halogenated poly-hydroxyphenylalkanes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
- C07C47/575—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
- C07C49/82—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups
- C07C49/825—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups all hydroxy groups bound to the ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
- C07C49/84—Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
- C07C65/105—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/36—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
Definitions
- the present invention pertains generally to the field of therapeutic compounds, and more specifically to certain 4-substituted-6-isopropyl-benzene-1 ,3-diol compounds (referred to herein as IBD compounds), which, inter alia, inhibit heat shock protein 90 (HSP90) function.
- IBD compounds 4-substituted-6-isopropyl-benzene-1 ,3-diol compounds
- HSP90 heat shock protein 90
- the present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HSP90 function, and in the treatment of diseases and conditions that are mediated by HSP90, that are ameliorated by the inhibition of HSP90 function, etc., including proliferative conditions such as cancer, etc.
- Ranges are often expressed herein as from “about” one particular value, and/or to “about” another particular value. When such a range is expressed, another embodiment includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by the use of the antecedent "about,” it will be understood that the particular value forms another embodiment.
- HSP90s are ubiquitous chaperone proteins that are involved in folding, activation and assembly of a wide range of proteins, including key proteins involved in signal transduction, cell cycle control and transcriptional regulation. It has been reported that HSP90 is associated with important signaling proteins, such as steroid hormone receptors and protein kinases, including, e.g., Raf-1 , EGFR, v-Src family kinases, Cdk4, and ErbB-2 (Buchner 1999; Stepanova et al., 1996,; Dai. et al., 1996).
- certain co-chaperones e.g., Hsp70, p60/Hop/Stil, Hip, Bag1 , HSP40/Hdj2/Hsjl, immunophilins, p23, and p50, may assist HSP90 in its function (Caplan, 1999).
- Ansamycin antibiotics e.g., herbimycin A (HA), geldanamycin (GM), and 17- AAG are thought to exert anticancerous effects by tight binding of the N-terminus binding site of HSP90, thereby destabilizing substrates that normally interact with HSP90 (Stebbins et a/ 1997,).
- This pocket is highly conserved and has weak homology to the ATP-binding site of DNA gyrase (Stebbins. et al. 1997; Grenert et al., 1997). Further, ATP and ADP have both been shown to bind this pocket with low affinity and to have weak ATPase activity (Prodromou eif al., 1997; Panaretou et al., 1998).
- ansamycins and other HSP90 inhibitors alters HSP90 function and inhibits, for example, protein folding and activation.
- ansamycins and other HSP90 inhibitors have been shown to prevent binding of protein substrates to HSP90 (Scheibel et al., 1999, Schulte et al. 1995; Whitesell, et al., 1994).
- Ansamycins have also been demonstrated to inhibit the ATP- dependent release of chaperone-associated protein substrates (Schneider et al., 1996; Sepp-Lorenzino et al., 1995,). In either event, the substrates are degraded by a ubiquitin- dependent process in the proteasome (Schneider, et al., 1996; Sepp-Lorenzino, 1995, Whitesell, etal., 1994).
- HSP90 substrate destabilization occurs in tumour and non-transformed cells alike and has been shown to be especially effective on a subset of signalling regulators, e.g., Raf (Schulte et al., 1997; Schulte et al. 1995), nuclear steroid receptors (Segnitz and Gehring.
- EGF receptor EGFR
- Her2/Neu Hartmann et al., 1997; Miller et a/., 1994; Mimnaugh et a/., 1996; Schnur et al., 1995
- CDK4 mutant p53
- the ansamycin-induced loss of these proteins leads to the selective disruption of certain regulatory pathways and results in growth arrest at specific phases of the cell cycle (Muise-Helmericks, et a/., 1998) and apoptosis, and/or differentiation of cells so treated (Vasilevskaya, et a/., 1999).
- HSP90 inhibitors have also been implicated in a wide variety of other utilities, including use as anti-inflammatory agents, anti-infectious disease agents, agents for treating autoimmunity, agents for treating ischemia, and agents useful in promoting nerve regeneration ('Rosen et al., 2002; Defranco et a/., 1999; Gold, 2001 ).
- fibrogenic disorders including but not limited to scleroderma, polymyositis, systemic lupus, rheumatoid arthritis, liver cirrhosis, keloid formation, interstitial nephritis, and pulmonary fibrosis may also be treatable with HSP90 inhibitors (Strehlow, 2002).
- Ansamycins and other HSP90 inhibitors thus hold great promise for the treatment and/or prevention of many types of disorders.
- their relative insolubility makes them difficult to formulate and administer, and they are not easily synthesized and currently must, at least in part, be generated through fermentation.
- the dose limiting toxicity of ansamyins is hepatic.
- IBD compounds 4-substituted-6-isopropyl-benzene-1 ,3-diol compounds
- compositions e.g., a pharmaceutical composition
- a pharmaceutical composition comprising an IBD compound, as described herein, and a pharmaceutically acceptable carrier or diluent.
- compositions e.g., a pharmaceutical composition
- a composition comprising the step of admixing an IBD compound, as described herein, and a pharmaceutically acceptable carrier or diluent.
- Another aspect of the present invention pertains to a method of inhibiting heat shock protein 90 (HSP90) function in a cell, in vitro or in vivo, comprising contacting the cell with an effective amount of an IBD compound, as described herein (e.g., without a proviso regarding P-O01 through P-003).
- HSP90 heat shock protein 90
- Another aspect of the present invention pertains to a method of regulating (e.g., inhibiting) cell proliferation (e.g., proliferation of a cell), inhibiting cell cycle progression, promoting apoptosis, or a combination of one or more these, in vitro or in vivo, comprising contacting a cell with an effective amount of an IBD compound, as described herein (e.g., without a proviso regarding P-O01 through P-003).
- Another aspect of the present invention pertains to a method of treatment comprising administering to a subject in need of treatment a therapeutically-effective amount of an IBD compound, as described herein (e.g., without a proviso regarding P-001 through P-003), preferably in the form of a pharmaceutical composition.
- a therapeutically-effective amount of an IBD compound as described herein (e.g., without a proviso regarding P-001 through P-003), preferably in the form of a pharmaceutical composition.
- Another aspect of the present invention pertains to an IBD compound, as described herein (e.g., without a proviso regarding P-001 through P-003), for use in a method of treatment of the human or animal body by therapy.
- Another aspect of the present invention pertains to an IBD compound, as described herein (e.g., without a proviso regarding P-001 through P-003), for the use in a method of treatment of the human or animal body by therapy wherein said compound is used in combination with other pharmaceutically active substances
- Another aspect of the present invention pertains to use of an IBD compound, as described herein (e.g., without a proviso regarding P-001 through P-003), in the manufacture of a medicament for use in treatment.
- the treatment is treatment of a disease or condition that is mediated by heat shock protein 90 (HSP90).
- the treatment is treatment of a disease or condition that is ameliorated by the inhibition of heat shock protein 90 (HSP90) function.
- HSP90 heat shock protein 90
- the treatment is treatment of a disease or condition that is known to be treated by HSP90 inhibitors (e.g., 17-AAG, geldanamycin, etc.).
- HSP90 inhibitors e.g., 17-AAG, geldanamycin, etc.
- the treatment is treatment of a proliferative condition.
- the treatment is treatment of cancer.
- kits comprising (a) an IBD compound, as described herein (e.g., without a proviso regarding P-001 through P-003), preferably provided as a pharmaceutical composition and in a suitable container and/or with suitable packaging; and (b) instructions for use, for example, written instructions on how to administer the compound.
- an IBD compound as described herein (e.g., without a proviso regarding P-001 through P-003), preferably provided as a pharmaceutical composition and in a suitable container and/or with suitable packaging; and (b) instructions for use, for example, written instructions on how to administer the compound.
- Another aspect of the present invention pertains to an IBD compound obtainable by a method of synthesis as described herein, or a method comprising a method of synthesis as described herein.
- Another aspect of the present invention pertains to an IBD compound obtained by a method of synthesis as described herein, or a method comprising a method of synthesis as described herein.
- Another aspect of the present invention pertains to novel intermediates, as described herein, which are suitable for use in the methods of synthesis described herein.
- Another aspect of the present invention pertains to the use of such novel intermediates, as described herein, in the methods of synthesis described herein.
- One aspect of the present invention relates to certain 4-substituted-6-isopropyl- benzene-1 ,3-diol compounds (for convenience, collectively referred to herein as "IBD compounds”), which are structurally related to resorcinol.
- IBD compounds 4-substituted-6-isopropyl- benzene-1 ,3-diol compounds
- the compounds are selected from compounds of the following formula, and pharmaceutically acceptable salts, hydrates, and solvates thereof:
- -X 1 - is independently a covalent single bond or -X 1L -;
- -X 2 - is independently a covalent single bond or -X 2L -;
- -A 1 - is independently -A 1A -;
- -A 2 is independently -A 2A , -H, or -F;
- each of -X 1L - and -X 2L - is independently:
- each -R A is independently -R M , -R AB , or -R AC ; each -R ⁇ is independently saturated aliphatic C ⁇ alkyl; each -R AB is independently aliphatic C 2- 6alkenyl; each -R AC is independently saturated C 3 .
- -A 1A - is independently -A 1AC - or -A 1AH -;
- -A 1AG - is independently C 6- iocarboarylene;
- -A 1AH - is independently C 5-12 heteroarylene; and each -A 1AC - and each -A 1AH - is independently unsubstituted or substituted with one or more substituents -Q 1 ;
- -A 2A is independently -A 2AC or -A 2AH ;
- -A 2AC is independently C 6- iocarboaryl;
- -A 2AH is independently C 5- i 2 heteroaryl; and each -A 2AG and each -A 2AH is independently unsubstituted or substituted with one or more substituents -Q 2 ;
- each -Q 1 and each -Q 2 is independently:
- each -L 1A - is independently saturated aliphatic d. 5 alkylene; in each group -NR 1A2 R 1A3 , -R 1A2 and -R 1A3 , taken together with the nitrogen atom to which they are attached, form a A-, 5-, 6-, or 7-membered non-aromatic ring having exactly 1 ring heteroatom or exactly 2 ring heteroatoms, wherein one of said exactly 2 ring heteroatoms is N, and the other of said exactly 2 ring heteroatoms is independently N, O, or S;
- each -R 1A1 is independently:
- each -R 1B1 is independently saturated aliphatic C 1-6 alkyl
- each -R 1B2 is independently aliphatic C 2-6 alkenyl
- each -R 1B3 is independently aliphatic C 2-6 alkynyl
- each -R 1B4 is independently saturated C 3-6 cycloalkyl
- each -R 1B5 is independently C 3 .
- each -R 1D1 is independently saturated aliphatic C 1-4 alkyl, phenyl, or benzyl; each -L 1D - is independently saturated aliphatic Ci -5 alkylene; and in each group -NR 102 R 103 , -R 102 and -R 1D3 , taken together with the nitrogen atom to which they are attached, form a A-, 5-, 6-, or 7-membered non-aromatic ring having exactly 1 ring heteroatom or exactly 2 ring heteroatoms, wherein one of said exactly 2 ring heteroatoms is N, and the other of said exactly 2 ring heteroatoms is independently N, 0, or S;
- two adjacent -Q 1 groups if present, may together form -0-CH 2 -O- or -0-CH 2 CH 2 -O-; and additionally, two adjacent -Q 2 groups, if present, may together form -0-CH 2 -O- or -0-CH 2 CH 2 -O-.
- -X 1 - is a covalent single bond
- -A 1 - is not: 1 ,2,4-triazine-6 ⁇ one, substituted 1,2,4-triazine 6-one, 1 ,2,4-triazine-6-thione, or substituted 1 ,2,4-triazine- ⁇ -thione (see, e.g., WO 2008/118391);
- 2-amino-1 ,2,3,4-tetrahydropyrimidine or substituted 2-amino-1 ,2,3,4- tetrahydropyrimidine see, e.g., WO 2008/118391
- pyrazol-diyl or substituted pyrazol-diyl see, e.g., WO 2007/021966
- the compounds are optionally as defined herein, but with one or more optional provisos, as defined herein.
- the compound is a compound as defined herein, with the proviso that the compound is not a compound selected from P-001 through P-003.
- the compound is a compound as defined herein, with the proviso that the compound is not a compound selected from P-001 through P-003.
- the compound is a compound as defined herein, with the proviso that the compound is not a compound selected from PP-001 through PP-003, and salts, hydrates, and solvates thereof.
- the compounds are optionally as defined herein, but without any of the above provisos, that is, without a proviso regarding P-001 through P-003.
- a reference to a particular group of compounds "without the proviso regarding P-001 through P-003" is intended to be a reference to the compounds as defined, but wherein the definition no longer includes the indicated proviso.
- the definition no longer includes the indicated proviso.
- -X 1 - is independently a covalent single bond or -X 1L - In one embodiment, -X 1 - is independently a covalent single bond. In one embodiment, -X 1 - is independently -X 1L -.
- -X - is independently a covalent single bond or -X -
- -X 2 - is independently a covalent single bond.
- -X 2 - is independently -X 2L -.
- -A 1 - is independently -A 1A -.
- -A 2 is independently -A 2A , -H, or -F. In one embodiment, -A 2 is independently -A M or -H. In one embodiment, -A 2 is independently -A 2A . In one embodiment, -A 2 is independently -H or -F. In one embodiment, -A 2 is independently -H.
- the group -X 1 -A 1 -X 2 -A 2 is independently:
- the group -X 1 -A 1 -X 2 -A 2 is independently:
- the group -X 1 -A 1 -X 2 -A 2 is independently -X 1L -A 1A -H or -X 1L -A 1A -F.
- the group -X 1 -A 1 -X 2 -A 2 is independently -X 1L -A 1A -H.
- the group -X 1 -A 1 -X 2 -A 2 is independently -A 1A -X 2L -A 2A . In one embodiment, the group -X 1 -A 1 -X 2 -A 2 is independently -A ⁇ -A 2 *.
- the group -X 1 -A 1 -X 2 -A 2 is independently -A 1A -H or -A 1A -F.
- the group -X 1 -A 1 -X 2 -A 2 is independently -A 1A -H.
- -X 1L - is independently:
- -X 1L - is independently: -R L -,
- -X 1L - is independently:
- -X 2L - is independently:
- -X 2L - is independently:
- -X 2L - is independently:
- -X 2L - is independently -R L -.
- -X 2L - is independently -R L -O-.
- each -R L - is independently:
- each -R LA is independently saturated aliphatic Ci -6 alkylene
- each -R LB is independently aliphatic C 2- 6alkenylene
- each -R LC is independently saturated C 3 .
- each -R L - is independently -R ⁇ -, -R LB -, or -R LC -. In one embodiment, each -R L -, if present, is independently -R LA -.
- each -R L - is independently unsubstituted.
- each -R LA if present, is independently saturated aliphatic
- each -R LA if present, is independently saturated aliphatic
- each -R LA if present, is independently saturated aliphatic C 1-2 alkylene.
- each -R L - is independently -CH 2 - Or -CH 2 CH 2 -. In one embodiment, each -R L -, if present, is independently -CH 2 -.
- each -R A if present, is independently -R M or -R AB . In one embodiment, each -R A , if present, is independently -R M . In one embodiment, each -R A , if present, is independently saturated aliphatic C 1-4 alkyl. In one embodiment, each -R A , if present, is independently -Me or -Et. In one embodiment, each -R A , if present, is independently -Me.
- -A 1A - is independently -A 1AC - or -A 1AH -, wherein: -A 1AC - is independently C 6- i 0 carboarylene; -A 1AH - is independently C 5-12 heteroarylene; each -A 1AC - and -A 1AH - is independently unsubstituted or substituted with one or more substituents -Q 1 .
- -A 1A - if present, is independently -A 1AC -.
- -A 1AC - is independently phenylene or naphth-diyl, and is optionally substituted.
- -A 1AC - is independently phenylene, and is optionally substituted.
- -A 1AC - is independently phenyl-1 ,2-diyl, and is optionally substituted.
- -A 1AC - is independently phenyl-1 ,3-diyl, and is optionally substituted.
- -A 1AC - is independently phenyl-1 ,4-diyl, and is optionally substituted.
- -A 1AC - is independently naphth-diyl, and is optionally substituted.
- -A 1AC - is independently naphth-1 ,2-diyl, and is optionally substituted.
- -A 1AC - is independently naphth-1 , 4-diyl, and is optionally substituted.
- -A 1A - if present, is independently -A 1 ⁇ H -.
- -A 1AH - is independently C 5-6 heteroarylene, and is optionally substituted. In one embodiment, -A 1AH -, if present, is independently C 7- i 0 heteroarylene, and is optionally substituted.
- -A 1AH - is independently furan-diyl, thien-diyl, pyrrol-diyl, 1 ,2,3-triazol-diyl, tetrazol-diyl, oxazol-diyl, thiazol-diyl, isothiazol-diyl, pyridin-diyl, pyrimidin-diyl, pyrazin-diyl, or pyridazin-diyl, and is optionally substituted.
- -A 1AH - is independently furan-diyl, thien-diyl, 1 ,2,3-triazol-diyl, oxazol-diyl, thiazol-diyl, or pyridin-diyl, and is optionally substituted.
- -A 1AH - is independently triazol-diyl, and is optionally substituted.
- -A 1AH - is independently 1 ,2,3-triazol-diyl, and is optionally substituted.
- -A 1AH - is independently 1 ,2,3-triazol-1 ,4-diyl, and is optionally substituted.
- -A 1AH - is independently 1 ,2,3-triazol-1 ,5-diyl, and is optionally substituted.
- -A 1AH - is independently 1 ,2,3-triazol-1 ,4-diyl, and is optionally substituted, wherein -X 1 - is attached at the 1 -position of the 1 ,2,3-triazol-1 ,4-diyl.
- -A 1AH - is independently 1 ,2,3-triazo]-1 ,4-diyl, and is optionally substituted, wherein -X 1 - is attached at the 4-position of the 1 ,2,3-triazol-1 ,4-diyl.
- -A 1AH - is independently 1 ,2,3-triazol-i ,5-diyl, and is optionally substituted, wherein -X 1 - is attached at the 1-position of the 1 ,2,3-triazol-1 ,4-diyl.
- -A 1AH - is independently 1 ,2,3-triazoM ,5-diyl, and is optionally substituted, wherein -X 1 - is attached at the 5-position of the 1 ,2,3-triazol-1 ,4-diyl.
- -A 1AH - if present, is independently oxazol-diyl, and is optionally substituted. In one embodiment, -A 1AH -, if present, is independently oxazol-4,5-diyl, and is optionally substituted.
- -A 1AH - is independently oxazol-2,4-diyl, and is optionally substituted.
- -A 1AH - is independently oxazol-2,5-diyl, and is optionally substituted.
- -A 1AH - is independently oxazol-4,5-diyl, and is optionally substituted, wherein -X 1 - is attached at the 4-position of the oxazol-4,5-diyl.
- -A 1AH - is independently oxazol-4,5-diyl, and is optionally substituted, wherein -X 1 - is attached at the 5-position of the oxazo!-4,5-diyl.
- -A 1AH - is independently furan-diyl, and is optionally substituted.
- -A 1AH - is independently thien-diyl, and is optionally substituted.
- -A 1AH - is independently pyridin-diyl, and is optionally substituted.
- -A 1AH - is independently quinolin-diyl, and is optionally substituted.
- -A 1AH - is independently isoquinolin-diyl, and is optionally substituted.
- -A 2A if present, is independently -A 2AC or -A 2 ⁇ 1 wherein: -A 2AC is independently C 6- i 0 carboaryl; -A 2AH is independently C 5 . 12 heteroaryl; each -A 2AC and -A 2AH is independently unsubstituted or substituted with one or more substituents -Q 2 .
- -A 2A if present, is independently -A 2AC . In one embodiment, -A 2AC , if present, is independently phenyl or naphthyl, and is optionally substituted.
- -A 2AC if present, is independently phenyl, and is optionally substituted.
- -A 2AG if present, is independently phenyl, and is optionally substituted at the para-position.
- -A 2AC is independently naphthyl, and is optionally substituted.
- -A 2AC is independently naphth-1-yl, and is optionally substituted.
- -A 2AC is independently naphth-2-yl, and is optionally substituted.
- -A 2A if present, is independently -A 2AH .
- -A 2AH if present, is independently C 5 . 6 heteroaryl, and is optionally substituted.
- -A 2AH is independently C 7-10 heteroaryl, and is optionally substituted.
- -A 2AH is independently furanyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, or pyridazinyl, and is optionally substituted.
- -A 2AH if present, is independently pyridinyl, thiazolyl, or furanyl and is optionally substituted.
- -A 2AH if present, is independently pyridinyl, and is optionally substituted.
- -A 2AH if present, is independently pyridin-2-yl, and is optionally substituted.
- -A 2AH if present, is independently pyridin-3-yl, and is optionally substituted. In one embodiment, -A 2AH , if present, is independently pyridin-4-yl, and is optionally substituted.
- -A 2AH if present, is independently thiazolyl, and is optionally substituted.
- -A 2AH if present, is independently thiazol-4-yl, and is optionally substituted.
- -A 2AH if present, is independently furanyl, and is optionally substituted.
- -A 2AH is independently furan-5-yl, and is optionally substituted.
- -A 2AH is independently imidazolyl, and is optionally substituted.
- -A 2AH is independently imidazol-1-yl, and is optionally substituted.
- -A 2AH is independently quinolinyl, and is optionally substituted.
- -A 2AH is independently quinolin-6-yl, and is optionally substituted.
- -A 2AH is independently indolyl, and is optionally substituted.
- -A 2AH is independently indol-5-yl, and is optionally substituted.
- the group -X 1 -A 1 -X 2 -A 2 is independently -A 2A ;
- -A 2A is independently -A 2AC .
- the group -X 1 -A 1 -X 2 -A 2 is independently -A 2A ; and -A 2A is independently -A 2AH .
- the group -X 1 -A 1 -X 2 -A 2 is independently -A 1A -A 2A ; -A 1A - is independently -A 1AC -; and -A 2A is independently -A 2 ⁇ .
- the group -X 1 -A 1 -X 2 -A 2 is independently -A 1A -A 2A ; -A 1A - is independently -A 1AC -; and -A 2A is independently -A 2AH .
- the group -X 1 -A 1 -X 2 -A 2 is independently -A 1A -A 2A ; -A 1A - is independently -A 1AH -; and -A 2A is independently -A 2AG .
- the group -X 1 -A 1 -X 2 -A 2 is independently -A 1A -A 2A ; -A 1A - is independently -A 1AH -; and -A 2A is independently -A 2AH .
- the group -X 1 -A 1 -X 2 -A 2 is independently -A 1A -A 2A ;
- -A 1A - is independently oxazol-4,5-diyl; and -A 2A is independently phenyl, and is optionally substituted.
- the group -X 1 -A 1 -X 2 -A 2 is independently -A 1A -A 2A ;
- -A 1A - is independently oxazol-4,5-diyl; wherein -A 2A - is attached at the 5-position of the oxazol-4,5-diyl; and -A 2A is independently phenyl, and is optionally substituted.
- the compounds are selected from compounds of the following formula, and pharmaceutically acceptable salts, hydrates, and solvates thereof:
- the group -X 1 -A 1 -X 2 -A 2 is independently -A 1A -A 2A ;
- -A 1A - is independently oxazol-4,5-diyl
- -A 2A is independently -A 2 ⁇ ;
- -A 2AH is independently C 5 . 6 heteroaryl, and is optionally substituted.
- the group -X 1 -A 1 -X 2 -A 2 is independently -A 1A -A 2A ;
- -A 1A - is independently oxazol-4,5-diyl; wherein -A 2A - is attached at the 5-position of the oxazol-4,5-diyl; -A 2A is independently -A 2AH ; and
- -A 2AH is independently C 5-6 heteroaryl, and is optionally substituted.
- the group -X 1 -A 1 -X 2 -A 2 is independently -A ⁇ -A ⁇ ; -A 1A - is independently oxazol-2,5-diyl; and
- -A 2A is independently phenyl, and is optionally substituted.
- the group -X 1 -A 1 -X 2 -A 2 is independently -A 1A -A 2A ; -A 1A - is independently oxazol-2,5-diyl; and
- -A 2A is independently -A 2AH ; and -A 2AH is independently C 5-6 heteroaryl, and is optionally substituted.
- the group -X 1 -A 1 -X 2 -A 2 is independently -A 1A -A 2A ; -A 1A - is independently 1 ,2,3-triazol-1 ,4-diyl or 1 ,2,3-triazol-1 ,5-diyl; -A 2A is independently phenyl, and is optionally substituted. In one embodiment: the group -X 1 -A 1 -X 2 -A 2 is independently -A 1A -A 2A ;
- -A 1A - is independently 1,2,3-triazol-1 ,4-diyl
- -A 2A is independently phenyl, and is optionally substituted.
- the group -X 1 -A 1 -X 2 -A 2 is independently -A ⁇ -A ⁇ ;
- -A 1A - is independently 1 ,2,3-triazol-1 ,5-diyl
- -A 2A is independently phenyl, and is optionally substituted.
- -A 1A - is independently phenyl, and is optionally substituted.
- the group -X 1 -A 1 -X 2 -A 2 is independently -X 1L -A 1A -H or -X 1L -A 1A -F;
- the group -X 1 -A 1 -X 2 -A 2 is independently -X 1L -A 1A -H;
- the group -X 1 -A 1 -X 2 -A 2 is independently -X 1L -A 1A -H or -X 1L -A 1A -F;
- the group -X 1 -A 1 -X 2 -A 2 is independently -X 1L -A 1A -H;
- the group -X 1 -A 1 -X 2 -A 2 is independently -A 1A -H; -A 1A - is independently phenyl and bears at least one substituent, -Q 1 , which is independently:
- the group -X 1 -A 1 -X 2 -A 2 is independently -A 1A -H;
- -A 1A - is independently phenyl and bears at least one substituent, -Q 1 , which is independently:
- the group -X 1 -A 1 -X 2 -A 2 is independently -A ⁇ -X ⁇ -A 2 *; -A 1A - is independently 1 ,2,3-triazol-1 ,4-diyl or 1 ,2,3-triazoM ,5-diyl;
- -X 2L - is independently -CH 2 -; and -A 2A is independently phenyl, and is optionally substituted.
- the group -X 1 -A 1 -X 2 -A 2 is independently -A ⁇ -X ⁇ -A ⁇ ;
- -A 1A - is independently 1 ,2,3-triazol-1 ,4-diyl; -X 2L - is independently -CH 2 -; and -A 2A is independently phenyl, and is optionally substituted.
- the group -X 1 -A 1 -X 2 -A 2 is independently -A ⁇ -X ⁇ -A 2 *;
- -A 1A - is independently 1,2,3-triazol-1 ,5-diyl
- -X 2L - is independently -CH 2 -;
- -A ZA is independently phenyl, and is optionally substituted.
- the group -X 1 -A 1 -X 2 -A 2 is independently -A ⁇ -X ⁇ -A 2 *; -A 1A - is independently oxazol-2,5-diyl;
- -X 2L - is independently -CH 2 -; and -A 2A is independently phenyl, and is optionally substituted.
- the group -X 1 -A 1 -X 2 -A 2 is independently -A 2A ;
- -A 2A is independently phenyl, and is optionally substituted.
- each -A 1AC - and -A 1AH - is independently unsubstituted or substituted with one or more substituents -Q 1 .
- each -A 1AC - and -A 1AH -, if present, is independently unsubstituted.
- each -A 1AC - and -A 1AH - is independently substituted with one or more substituents -Q 1 .
- -A 1AG - if present, is independently unsubstituted.
- -A 1AC - if present, is independently substituted with one or more substituents -Q 1 .
- -A 1AH - if present, is independently unsubstituted. In one embodiment, -A 1AH -, if present, is independently substituted with one or more substituents -Q 1 .
- each -Q 1 is independently:
- each -Q 1 is independently: -F, -Cl, -Br, -I, -R 1A1 , -OH, -OR 1A1 ,
- each -Q 1 is independently: -F, -Cl, -Br, -I, -R 1A1 , -OH, or -OR 1A1 .
- each -Q 1 is independently:
- each -Q 1 is independently selected from those substituents exemplified under the headings "Examples of Specific Embodiments” and “Additional Examples of Specific Embodiments”.
- each -A 2AC - and -A 2AH - is independently unsubstituted or substituted with one or more substituents -Q 2 .
- each -A 2AC - and -A 2AH -, if present, is independently unsubstituted.
- each -A 2AC - and -A 2AH - is independently substituted with one or more substituents -Q 2 .
- -A 2AC - if present, is independently unsubstituted. In one embodiment, -A 2AC -, if present, is independently substituted with one or more substituents -Q 2 .
- -A 2AH - if present, is independently unsubstituted. In one embodiment, -A 2AH -, if present, is independently substituted with one or more substituents -Q 2 .
- each -Q 2 is independently:
- each -Q 2 is independently: -F, -Cl, -Br, -I, -R 1A1 , -OH, or -OR 1A1 .
- each -Q 2 is independently:
- each -Q 2 is independently selected from those substituents exemplified under the headings "Examples of Specific Embodiments” and “Additional Examples of Specific Embodiments”. Eleme ⁇ ts of -Q 1 and -Q 2
- each -NR 1A2 R 1A3 is independently azetidino, pyrrolidino, imidazolidino, pyrazoiidino, piperidino, piperazino, morpholino, thiomorpholino, thiomorpholine-1 ,1 -dioxide, azepino, or diazepino, and is optionally substituted, for example, with one or more groups selected from saturated aliphatic Ci -3 alkyl.
- each -NR 1A2 R 1A3 is independently pyrrolidino, piperidino, piperazino, morpholino, thiomorpholino, or thiomorpholine-1, 1 -dioxide, and is optionally substituted, for example, with one or more groups selected from saturated aliphatic Ci -3 alkyl.
- each -R 1A1 is independently:
- each -R 1A1 is independently:
- each -R 1A1 is independently: -L 1B -R 1B6 , -L 18 -R 1B7 , or -L 1B -R 1B8 .
- each -R 1A1 if present, is independently: -L 1B -R 1B6 or -L 1B -R 1B8 .
- each -R 1A1 is independently:
- each -R 1B6 is independently azetidinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidinyl, piperazinyl, morpholinyl, azepinyl, diazepinyl, tetrahydrofuranyl, tetrahydropyranyl.or dioxanyl, and is optionally substituted.
- each -R 186 is independently pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, tetrahydrofuranyl, tetrahydropyranyl, or dioxanyl, and is optionally substituted.
- each -R 1B7 if present, is independently phenyl, and is optionally substituted. In one embodiment, each -R 1B8 , if present, is independently C 5 . 6 heteroaryl, and is optionally substituted.
- each -R 1B8 is independently furanyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridyl, pyrimidinyl, or pyridazinyl, and is optionally substituted.
- each -L 1B - is independently -CH 2 -.
- each -R 1C1 if present, is independently saturated aliphatic C 1-4 alkyl.
- each -R 1C2 is independently:
- each -R 1C2 is independently:
- each -R 101 is independently saturated aliphatic C 1-4 alkyl.
- each -NR 102 R 103 if present, is independently azetidino, pyrrolidino, imidazolidino, pyrazolidino, piperidino, piperazino, morpholino, thiomorpholino, thiomorpholine-1 ,1-dioxide, azepino, or diazepino, and is optionally substituted, for example, with one or more groups selected from saturated aliphatic C 1-3 alkyl.
- each -NR 102 R 103 is independently pyrrolidino, piperidino, piperazino, morpholino, thiomorpholino, or thiomorpholine-1 ,1 -dioxide, and is optionally substituted, for example, with one or more groups selected from saturated aliphatic Ci. 3 alkyl.
- the IBD compound has a molecular weight of from 230 to 1200. In one embodiment, the bottom of the range is from 250, 275, 300, or 350. In one embodiment, the top of the range is 1100, 1000, 900, 800, 700, or 600. In one embodiment, the range is 250 to 600.
- the compounds are selected from compounds of the following formulae and pharmaceutically acceptable salts, hydrates, and solvates thereof:
- the compounds are selected from compounds of the following formulae and pharmaceutically acceptable salts, hydrates, and solvates thereof:
- the compounds are selected from compounds of the following formulae and pharmaceutically acceptable salts, hydrates, and solvates thereof:
- the compounds are selected from compounds of the following formulae and pharmaceutically acceptable salts, hydrates, and solvates thereof:
- the compounds are selected from compounds of the following formulae and pharmaceutically acceptable salts, hydrates, and solvates thereof:
- the compounds are selected from compounds of the following formulae and pharmaceutically acceptable salts, hydrates, and solvates thereof:
- the compounds are selected from compounds of the following formulae and pharmaceutically acceptable salts, hydrates, and solvates thereof:
- the compounds are selected from compounds of the following formulae and pharmaceutically acceptable salts, hydrates, and solvates thereof:
- the compounds are selected from compounds of the following formulae and pharmaceutically acceptable salts, hydrates, and solvates thereof:
- the compounds are selected from compounds of the following formulae and pharmaceutically acceptable salts, hydrates, and solvates thereof:
- the compounds are selected from compounds of the following formulae and pharmaceutically acceptable salts, hydrates, and solvates thereof:
- the compounds are selected from compounds of the following formulae and pharmaceutically acceptable salts, hydrates, and solvates thereof:
- the compounds are selected from compounds of the following formulae and pharmaceutically acceptable salts, hydrates, and solvates thereof:
- the compounds are selected from compounds of the following formulae and pharmaceutically acceptable salts, hydrates, and solvates thereof:
- the compounds are selected from compounds of the following formulae and pharmaceutically acceptable salts, hydrates, and solvates thereof:
- the compounds are selected from compounds of the following formulae and pharmaceutically acceptable salts, hydrates, and solvates thereof:
- the compounds are selected from compounds of the following formulae and pharmaceutically acceptable salts, hydrates, and solvates thereof:
- the compounds are selected from compounds of the following formulae and pharmaceutically acceptable salts, hydrates, and solvates thereof:
- the compounds are selected from compounds of the following formulae and pharmaceutically acceptable salts, hydrates, and solvates thereof:
- the compounds are selected from compounds of the following formulae and pharmaceutically acceptable salts, hydrates, and solvates thereof:
- the compounds are selected from compounds of the following formulae and pharmaceutically acceptable salts, hydrates, and solvates thereof:
- the compounds are selected from compounds of the following formulae and pharmaceutically acceptable salts, hydrates, and solvates thereof:
- -X 2 - is c a covalent single bond
- -A 2 is -H
- One aspect of the present invention pertains to IBD compounds, as described herein, in substantially purified form and/or in a form substantially free from contaminants.
- the substantially purified form is at least 50% by weight, e.g., at least 60% by weight, e.g., at least 70% by weight, e.g., at least 80% by weight, e.g., at least 90% by weight, e.g., at least 95% by weight, e.g., at least 97% by weight, e.g., at least 98% by weight, e.g., at least 99% by weight.
- the substantially purified form refers to the compound in any stereoisomeric or enantiomeric form.
- the substantially purified form refers to a mixture of stereoisomers, i.e., purified with respect to other compounds.
- the substantially purified form refers to one stereoisomer, e.g., optically pure stereoisomer, in one embodiment, the substantially purified form refers to a mixture of enantiomers.
- the substantially purified form refers to a equimolar mixture of enantiomers (i.e., a racemic mixture, a racemate).
- the substantially purified form refers to one enantiomer, e.g., optically pure enantiomer.
- the contaminants represent no more than 50% by weight, e.g., no more than 40% by weight, e.g., no more than 30% by weight, e.g., no more than 20% by weight, e.g., no more than 10% by weight, e.g., no more than 5% by weight, e.g., no more than 3% by weight, e.g., no more than 2% by weight, e.g., no more than 1% by weight.
- the contaminants refer to other compounds, that is, other than stereoisomers or enantiomers. In one embodiment, the contaminants refer to other compounds and other stereoisomers. In one embodiment, the contaminants refer to other compounds and the other enantiomer.
- the substantially purified form is at least 60% optically pure (i.e., 60% of the compound, on a molar basis, is the desired stereoisomer or enantiomer, and 40% is the undesired stereoisomer or enantiomer), e.g., at least 70% optically pure, e.g., at least 80% optically pure, e.g., at least 90% optically pure, e.g., at least 95% optically pure, e.g., at least 97% optically pure, e.g., at least 98% optically pure, e.g., at least 99% optically pure.
- 60% optically pure i.e., 60% of the compound, on a molar basis, is the desired stereoisomer or enantiomer, and 40% is the undesired stereoisomer or enantiomer
- at least 70% optically pure e.g., at least 80% optically pure, e.g., at least 90% optically pure, e
- Certain compounds may exist in one or more particular geometric, optical, enantiomeric, diasteriomeric, epimeric, atropic, stereoisomeric, tautomeric, conformational, or anomeric forms, including but not limited to, cis- and trans-forms; E- and Z-forms; o, t-, and r- forms; endo- and exo-forms; R-, S-, and meso-forms; D- and L-forms; d- and l-forms; (+) and (-) forms; keto-, enol-, and enolate-forms; syn- and anti-forms; synclinal- and anticlinal-forms; ⁇ - and ⁇ -forms; axial and equatorial forms; boat-, chair-, twist-, envelope-, and halfchair-forms; and combinations thereof, hereinafter collectively referred to as "isomers” (or "isomeric forms").
- isomers are structural (or constitutional) isomers (i.e., isomers which differ in the connections between atoms rather than merely by the position of atoms in space).
- a reference to a methoxy group, -OCH 3 is not to be construed as a reference to its structural isomer, a hydroxymethyl group, -CH 2 OH.
- a reference to ortho-chlorophenyl is not to be construed as a reference to its structural isomer, meta-chlorophenyl.
- Ci -7 alkyl includes n-propyl and iso-propyl; butyl includes n-, iso-, sec-, and tert-butyl; methoxyphenyl includes ortho-, meta-, and para-methoxyphenyl).
- keto-, enol-, and enolate-forms as in, for example, the following tautomeric pairs: keto/enol (illustrated below), imine/enamine, amide/imino alcohol, amidine/amidine, nitroso/oxime, thioketone/enethiol, N-nitroso/hydroxyazo, and nitro/aci-nitro.
- keto enol enolate as in, for example, the following tautomeric pairs: keto/enol (illustrated below), imine/enamine, amide/imino alcohol, amidine/amidine, nitroso/oxime, thioketone/enethiol, N-nitroso/hydroxyazo, and nitro/aci-nitro.
- H may be in any isotopic form, including 1 H, 2 H (D), and 3 H (T); C may be in any isotopic form, including 12 C, 13 C, and 14 C; O may be in any isotopic form, including 16 O and 18 O; and the like.
- a reference to a particular compound includes all such isomeric forms, including mixtures (e.g., racemic mixtures) thereof.
- Methods for the preparation e.g., asymmetric synthesis
- separation e.g., fractional crystallisation and chromatographic means
- isomeric forms are either known in the art or are readily obtained by adapting the methods taught herein, or known methods, in a known manner.
- a salt may be formed with a suitable cation.
- suitable inorganic cations include, but are not limited to, alkali metal ions such as Na + and K + , alkaline earth cations such as Ca 2+ and Mg 2+ , and other cations such as Al +3 .
- Suitable organic cations include, but are not limited to, ammonium ion (i.e., NH 4 + ) and substituted ammonium ions (e.g., NH 3 R + , NH 2 R 2 + , NHR 3 + , NR 4 + ).
- suitable substituted ammonium ions are those derived from: ethylamine, diethylamine, dicyclohexylamine, triethylamine, butylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, benzylamine, phenylbenzylamine, choline, meglumine, and trometharnine, as well as amino acids, such as lysine and arginine.
- An example of a common quaternary ammonium ion is N(CH 3 ) 4 + .
- a salt may be formed with a suitable anion.
- suitable inorganic anions include, but are not limited to, those derived from the following inorganic acids: hydrochloric, hydrobromic, hydroiodic, sulfuric, sulfurous, nitric, nitrous, phosphoric, and phosphorous.
- Suitable organic anions include, but are not limited to, those derived from the following organic acids: 2-acetyoxybenzoic, acetic, ascorbic, aspartic, benzoic, camphorsulfonic, cinnamic, citric, edetic, ethanedisulfonic, ethanesulfonic, fumaric, glucheptonic, gluconic, glutamic, glycolic, hydroxymaleic, hydroxynaphthalene carboxylic, isethionic, lactic, lactobionic, lauric, maleic, malic, methanesulfonic, mucic, oleic, oxalic, palmitic, pamoic, pantothenic, phenylacetic, phenylsulfonic, propionic, pyruvic, salicylic, stearic, succinic, sulfanilic, tartaric, toluenesulfonic, and valeric.
- solvate is used herein in the conventional sense to refer to a complex of solute (e.g., compound, salt of compound) and solvent. If the solvent is water, the solvate may be conveniently referred to as a hydrate, for example, a mono-hydrate, a di-hydrate, a tri-hydrate, etc.
- a reference to a particular compound also includes solvate and hydrate forms thereof.
- chemically protected form is used herein in the conventional chemical sense and pertains to a compound in which one or more reactive functional groups are protected from undesirable chemical reactions under specified conditions (e.g., pH, temperature, radiation, solvent, and the like).
- specified conditions e.g., pH, temperature, radiation, solvent, and the like.
- well known chemical methods are employed to reversibly render unreactive a functional group, which otherwise would be reactive, under specified conditions.
- one or more reactive functional groups are in the form of a protected or protecting group (also known as a masked or masking group or a blocked or blocking group).
- the aldehyde or ketone group is readily regenerated by hydrolysis using a large excess of water in the presence of acid.
- an amine group may be protected, for example, as an amide (-NRCO-R) or a urethane (-NRCO-OR), for example, as: a methyl amide (-NHCO-CH 3 ); a benzyloxy amide (-NHCO-OCH 2 C 6 H 5 , -NH-Cbz); as a t-butoxy amide (-NHCO-OC(CH 3 ) 3 , -NH-Boc); a 2-biphenyl-2-propoxy amide (-NHCO-OC(CHs) 2 C 6 H 4 C 6 H 5 , -NH-Bpoc), as a 9- fluorenylmethoxy amide (-NH-Fmoc), as a 6-nitroveratryloxy amide (-NH-Nvoc), as a 2-trimethylsilylethyloxy amide (-NH-Teoc), as a 2,2,2-trichloroethyloxy amide (-NH-Troc), as
- a carboxylic acid group may be protected as an ester for example, as: an C 1-7 alkyl ester (e.g., a methyl ester; a t-butyl ester); a C-i -7 haloalkyl ester (e.g., a Ci -7 trihaloalkyl ester); a triC 1-7 alkylsiiyl-C 1-7 alkyl ester; or a C 5 . 2 oaryl-C 1-7 alkyl ester (e.g., a benzyl ester; a nitrobenzyl ester); or as an amide, for example, as a methyl amide.
- an C 1-7 alkyl ester e.g., a methyl ester; a t-butyl ester
- a C-i -7 haloalkyl ester e.g., a Ci -7 trihaloalkyl ester
- prodrug refers to a compound which, when metabolised (e.g., in vivo), yields the desired active compound.
- the prodrug is inactive, or less active than the desired active compound, but may provide advantageous handling, administration, or metabolic properties.
- prodrugs are activated enzymatically to yield the active compound, or a compound which, upon further chemical reaction, yields the active compound (for example, as in ADEPT, GDEPT, LIDEPT, etc.).
- the prodrug may be a sugar derivative or other glycoside conjugate, or may be an amino acid ester derivative.
- IBD compounds of the present invention are described herein. These and/or other well known methods may be modified and/or adapted in known ways in order to facilitate the synthesis of additional compounds within the scope of the present invention.
- compositions e.g., a pharmaceutical composition
- a pharmaceutical composition comprising an IBD compound, as described herein, and a pharmaceutically acceptable carrier, diluent, or excipient.
- compositions e.g., a pharmaceutical composition
- a pharmaceutical composition comprising admixing an IBD compound, as described herein, and a pharmaceutically acceptable carrier, diluent, or excipient.
- HSP90 heat shock protein 90
- One aspect of the present invention pertains to a method of inhibiting heat shock protein 90 (HSP90) function, in vitro or in vivo, comprising contacting an HSP90 with an effective amount of an IBD compound, as described herein (e.g., without a proviso regarding P-001 through P-003).
- HSP90 heat shock protein 90
- One aspect of the present invention pertains to a method of inhibiting heat shock protein 90 (HSP90) function in a cell, in vitro or in vivo, comprising contacting the cell with an effective amount of an IBD compound, as described herein (e.g., without a proviso regarding P-001 through P-003).
- HSP90 heat shock protein 90
- the method is performed in vitro. In one embodiment, the method is performed in vivo.
- One of ordinary skill in the art is readily able to determine whether or not, and/or the degree to which, a candidate compound inhibits HSP90 function. Suitable assays for determining heat shock protein 90 (HSP90) function inhibition are described herein and/or are known in the art.
- the IBD compounds described herein e.g., without a proviso regarding P-001 through P-003
- regulate e.g., inhibit
- cell cycle progression e.g., inhibit
- promote e.g., promote apoptosis; or (d) a combination of one or more of these.
- One aspect of the present invention pertains to a method of regulating (e.g., inhibiting) cell proliferation (e.g., proliferation of a cell), inhibiting cell cycle progression, promoting apoptosis, or a combination of one or more these, in vitro or in vivo, comprising contacting a cell with an effective amount of an IBD compound, as described herein (e.g., without a proviso regarding P-001 through P-003).
- the method is a method of regulating (e.g., inhibiting) cell proliferation (e.g., proliferation of a cell), in vitro or in vivo, comprising contacting a cell with an effective amount of an IBD compound, as described herein (e.g., without a proviso regarding P-001 through P-003).
- the method is performed in vitro. In one embodiment, the method is performed in vivo.
- the IBD compound is provided in the form of a pharmaceutically acceptable composition.
- Any type of cell may be treated, including but not limited to, lung, gastrointestinal
- a candidate compound regulates (e.g., inhibits) cell proliferation, etc.
- assays which may conveniently be used to assess the activity offered by a particular compound are described herein.
- a sample of cells e.g., from a tumour
- a compound brought into contact with said cells, and the effect of the compound on those cells observed.
- effect the morphological status of the cells (e.g., alive or dead, etc.) may be determined.
- this may be used as a prognostic or diagnostic marker of the efficacy of the compound in methods of treating a patient carrying cells of the same cellular type.
- Another aspect of the present invention pertains to an IBD compound, as described herein (e.g., without a proviso regarding P-001 through P-003), for use in a method of treatment of the human or animal body by therapy.
- Another aspect of the present invention pertains to use of an IBD compound, as described herein (e.g., without a proviso regarding P-001 through P-003), in the manufacture of a medicament for use in treatment.
- the medicament comprises the IBD compound.
- Another aspect of the present invention pertains to a method of treatment comprising administering to a patient in need of treatment a therapeutically effective amount of an IBD compound, as described herein (e.g., without a proviso regarding P-001 through P-003), preferably in the form of a pharmaceutical composition.
- a therapeutically effective amount of an IBD compound as described herein (e.g., without a proviso regarding P-001 through P-003), preferably in the form of a pharmaceutical composition.
- the treatment is treatment of a disease or condition that is mediated by heat shock protein 90 (HSP90).
- HSP90 heat shock protein 90
- a disease or disorder that is mediated by HSP90 is, for example, a disease or disorder in which HSP90 and/or the action of HSP90 is important or necessary, e.g., for the onset, progresssion, expression, etc., of that disease or disorder.
- the treatment is treatment of: a disease or condition that is ameliorated by the inhibition of heat shock protein 90 (HSP90) function.
- HSP90 heat shock protein 90
- the treatment is treatment of: a disease or condition that is known to be treated by HSP90 inhibitors (e.g., 17-AAG, geldanamycin, etc.)
- HSP90 inhibitors e.g., 17-AAG, geldanamycin, etc.
- the treatment is treatment of:
- fibrogenic disorders such as: scleroderma, systemic sclerosis, polymyositis, systemic lupus erythematosus, liver cirrhosis, and keloids;
- disorders involving angiogenesis such as: granuloma, retinal neovascularisation, choroidal neovascularisation, diabetic nephropathy, melorheostosis, asthma, inflammation, synovitis, abortifacients, wound healing, psoriasis, endometriosis, severe ovarian hyperstimulation syndrome, myelodysplasia syndrome, haemorrhagic telengectasia, atherosclerosis, restenosis, thrombosis,
- viral infections such as:
- HPV infection and influenza
- parasitic infections such as: malaria, schistosomiasis, trypanosomiasis, toxoplasmosis, and leishmania;
- the treatment is treatment of: a proliferative condition.
- proliferative condition pertains to an unwanted or uncontrolled cellular proliferation of excessive or abnormal cells which is undesired, such as, neoplastic or hyperplastic growth.
- the treatment is treatment of: a proliferative condition characterised by benign, pre-malignant, or malignant cellular proliferation, including but not limited to, neoplasms, hyperplasias, and tumours (e.g., histocytoma, glioma, astrocyoma, osteoma), cancers (see below), psoriasis, bone diseases, fibroproliferative disorders (e.g., of connective tissues), pulmonary fibrosis, atherosclerosis, smooth muscle cell proliferation in the blood vessels, such as stenosis or restenosis following angioplasty.
- a proliferative condition characterised by benign, pre-malignant, or malignant cellular proliferation, including but not limited to, neoplasms, hyperplasias, and tumours (e.g., histocytoma, glioma, astrocyoma, osteoma), cancers (see below), psoriasis, bone diseases, fibroprolife
- the treatment is treatment of: cancer.
- the treatment is treatment of: lung cancer, small cell lung cancer, non-small cell lung cancer, gastrointestinal cancer, stomach cancer, bowel cancer, colon cancer, rectal cancer, colorectal cancer, thyroid cancer, breast cancer, ovarian cancer, endometrial cancer, prostate cancer, testicular cancer, liver cancer, kidney cancer, renal cell carcinoma, bladder cancer, pancreatic cancer, brain cancer, glioma, sarcoma, osteosarcoma, bone cancer, nasopharyngeal cancer (e.g., head cancer, neck cancer), skin cancer, squamous cancer, Kaposi's sarcoma, melanoma, malignant melanoma, lymphoma, or leukemia.
- lung cancer small cell lung cancer, non-small cell lung cancer, gastrointestinal cancer, stomach cancer, bowel cancer, colon cancer
- rectal cancer colorectal cancer, thyroid cancer, breast cancer, ovarian cancer, endometrial cancer, prostate cancer, testicular cancer, liver cancer, kidney cancer, renal cell carcinoma, bladder
- the treatment is treatment of: a carcinoma, for example a carcinoma of the bladder, breast, colon (e.g., colorectal carcinomas such as colon adenocarcinoma and colon adenoma), kidney, epidermal, liver, lung (e.g., adenocarcinoma, small cell lung cancer and non-small cell lung carcinomas), oesophagus, gall bladder, ovary, pancreas (e.g., exocrine pancreatic carcinoma), stomach, cervix, thyroid, prostate, skin (e.g., squamous cell carcinoma); a hematopoietic tumour of lymphoid lineage, for example leukemia, acute lymphocytic leukemia, B-cell lymphoma, T-cell lymphoma, Hodgkin's lymphoma, non- Hodgkin's lymphoma, hairy cell lymphoma, or Burkett's lymphoma; a hematopoietic tumour of lymph
- the treatment is treatment of solid tumour cancer. In one embodiment, the treatment is treatment of liquid tumour cancer. In one embodiment, the treatment is treatment of hemotaological cancer.
- the treatment is treatment of: skin cancer, melanoma, breast cancer, estrogen receptor-dependent and independent breast cancer, ovarian cancer, prostate cancer, androgen dependent and independent prostate cancer, renal cancer, colon and colorectal cancer, pancreatic cancer, bladder cancer, esophageal cancer, stomach cancer, genitourinary cancer, uterine cancer, astrocytomas, gliomas, basal cancer, squamous cell carcinoma, sarcoma, osteosarcoma, head and neck cancer, lung cancer, small cell lung carcinoma, non-small cell lung carcinoma, leukemia, lymphoma, and other blood cell cancers.
- the treatment is treatment of: lung cancer, breast cancer, ovarian cancer, colorectal cancer, melanoma, or glioma.
- the anti-cancer effect may arise through one or more mechanisms, including but not limited to, the regulation of cell proliferation, the inhibition of cell cycle progression, the inhibition of angiogenesis (the formation of new blood vessels), the inhibition of metastasis (the spread of a tumour from its origin), the inhibition of invasion (the spread of tumour cells into neighbouring normal structures), or the promotion of apoptosis (programmed cell death).
- the compounds of the present invention may be used in the treatment of the cancers described herein, independent of the mechanisms discussed herein.
- treatment refers generally to treatment and therapy, whether of a human or an animal (e.g., in veterinary applications), in which some desired therapeutic effect is achieved, for example, the inhibition of the progress of the condition, and includes a reduction in the rate of progress, a halt in the rate of progress, alleviatiation of symptoms of the condition, amelioration of the condition, and cure of the condition.
- Treatment as a prophylactic measure i.e., prophylaxis
- treatment is also included. For example, use with patients who have not yet developed the condition, but who are at risk of developing the condition, is encompassed by the term "treatment.”
- treatment includes the prophylaxis of cancer, reducing the incidence of cancer, alleviating the symptoms of cancer, etc.
- terapéuticaally-effective amount refers to that amount of a compound, or a material, composition or dosage form comprising a compound, which is effective for producing some desired therapeutic effect, commensurate with a reasonable benefit/risk ratio, when administered in accordance with a desired treatment regimen.
- treatment includes combination treatments and therapies, in which two or more treatments or therapies are combined, for example, sequentially or simultaneously.
- the compounds described herein may also be used in combination therapies, e.g., in conjunction with other agents, for example, cytotoxic agents, anticancer agents, etc.
- treatments and therapies include, but are not limited to, chemotherapy (the administration of active agents, including, e.g., drugs, antibodies (e.g., as in immunotherapy), prodrugs (e.g., as in photodynamic therapy, GDEPT, ADEPT, etc.); surgery; radiation therapy; photodynamic therapy; gene therapy; and controlled diets.
- a compound as described herein may be beneficial to combine treatment with a compound as described herein with one or more other (e.g., 1 , 2, 3, 4) agents or therapies that regulates cell growth or survival or differentiation via a different mechanism, thus treating several characteristic features of cancer development.
- one or more other agents or therapies that regulates cell growth or survival or differentiation via a different mechanism
- One aspect of the present invention pertains to a compound as described herein, in combination with one or more additional therapeutic agents, as described below.
- the agents may be administered simultaneously or sequentially, and may be administered in individually varying dose schedules and via different routes.
- the agents can be administered at closely spaced intervals (e.g., over a period of 5-10 minutes) or at longer intervals (e.g., 1 , 2, 3, 4 or more hours apart, or even longer periods apart where required), the precise dosage regimen being commensurate with the properties of the therapeutic agent(s).
- agents i.e., the compound described here, plus one or more other agents
- the agents may be formulated together in a single dosage form, or alternatively, the individual agents may be formulated separately and presented together in the form of a kit, optionally with instructions for their use.
- the IBD compounds described herein may also be used as cell culture additives to inhibit heat shock protein 90 (HSP90) function, e.g., to inhibit cell proliferation, etc.
- HSP90 heat shock protein 90
- the IBD compounds described herein may also be used as part of an in vitro assay, for example, in order to determine whether a candidate host is likely to benefit from treatment with the compound in question.
- the IBD compounds described herein may also be used as a standard, for example, in an assay, in order to identify other compounds, other heat shock protein 90 (HSP90) function inhibitors, other anti-proliferative agents, other anti-cancer agents, etc.
- HSP90 heat shock protein 90
- the IBD compounds described herein may also be used as a herbicide.
- kits comprising (a) an IBD compound as described herein, or a composition comprising an IBD compound as described herein, e.g., preferably provided in a suitable container and/or with suitable packaging; and (b) instructions for use, e.g., written instructions on how to administer the compound or composition.
- the written instructions may also include a list of indications for which the active ingredient is a suitable treatment.
- the IBD compound or pharmaceutical composition comprising the IBD compound may be administered to a subject by any convenient route of administration, whether systemically/peripherally or topically (i.e., at the site of desired action).
- Routes of administration include, but are not limited to, oral (e.g., by ingestion); buccal; sublingual; transdermal (including, e.g., by a patch, plaster, etc.); transmucosal (including, e.g., by a patch, plaster, etc.); intranasal (e.g., by nasal spray); ocular (e.g., by eyedrops); pulmonary (e.g., by inhalation or insufflation therapy using, e.g., via an aerosol, e.g., through the mouth or nose); rectal (e.g., by suppository or enema); vaginal (e.g., by pessary); parenteral, for example, by injection, including subcutaneous, intradermal, intramuscular, intravenous, intraarterial, intracardiac, intrathecal, intraspinal, intracapsular, subcapsular, intraorbital, intraperitoneal, intratracheal, subcuticular
- the subject/patient may be a chordate, a vertebrate, a mammal, a placental mammal, a marsupial (e.g., kangaroo, wombat), a rodent (e.g., a guinea pig, a hamster, a rat, a mouse), murine (e.g., a mouse), a lagomorph (e.g., a rabbit), avian (e.g., a bird), canine (e.g., a dog), feline (e.g., a cat), equine (e.g., a horse), porcine (e.g., a pig), ovine (e.g., a sheep), bovine (e.g., a cow), a primate, simian (e.g., a monkey or ape), a monkey
- a rodent e.g., a guinea pig, a
- ape e.g., gorilla, chimpanzee, orangutang, gibbon
- a human e.g., gorilla, chimpanzee, orangutang, gibbon
- the subject/patient may be any of its forms of development, for example, a foetus.
- the subject/patient is a human.
- the IBD compound While it is possible for the IBD compound to be administered alone, it is preferable to present it as a pharmaceutical formulation (e.g., composition, preparation, medicament) comprising at least one IBD compound, as described herein, together with one or more other pharmaceutically acceptable ingredients well known to those skilled in the art, including, but not limited to, pharmaceutically acceptable carriers, diluents, excipients, adjuvants, fillers, buffers, preservatives, anti-oxidants, lubricants, stabilisers, solubilisers, surfactants (e.g., wetting agents), masking agents, colouring agents, flavouring agents, and sweetening agents.
- the formulation may further comprise other active agents, for example, other therapeutic or prophylactic agents.
- the present invention further provides pharmaceutical compositions, as defined above, and methods of making a pharmaceutical composition comprising admixing at least one IBD compound, as described herein, together with one or more other pharmaceutically acceptable ingredients well known to those skilled in the art, e.g., carriers, diluents, excipients, etc. If formulated as discrete units (e.g., tablets, etc.), each unit contains a predetermined amount (dosage) of the compound.
- pharmaceutically acceptable pertains to compounds, ingredients, materials, compositions, dosage forms, etc., which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of the subject in question (e.g., human) without excessive toxicity, irritation, allergic response, or other problenn or complication, commensurate with a reasonable benefit/risk ratio.
- Each carrier, diluent, excipient, etc. must also be “acceptable” in the sense of being compatible with the other ingredients of the formulation.
- Suitable carriers, diluents, excipients, etc. can be found in standard pharmaceutical texts, for example, Remington's Pharmaceutical Sciences, 18th edition, Mack Publishing Company, Easton, Pa., 1990; and Handbook of Pharmaceutical Excipients, 5th edition, 2005.
- the formulations may be prepared by any methods well known in the art of pharmacy. Such methods include the step of bringing into association the compound with a carrier which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association the compound with carriers (e.g., liquid carriers, finely divided solid carrier, etc.), and then shaping the product, if necessary.
- carriers e.g., liquid carriers, finely divided solid carrier, etc.
- the formulation may be prepared to provide for rapid or slow release; immediate, delayed, timed, or sustained release; or a combination thereof.
- Formulations may suitably be in the form of liquids, solutions (e.g., aqueous, nonaqueous), suspensions (e.g., aqueous, non-aqueous), emulsions (e.g., oil-in-water, water-in-oil), elixirs, syrups, electuaries, mouthwashes, drops, tablets (including, e.g., coated tablets), granules, powders, losenges, pastilles, capsules (including, e.g., hard and soft gelatin capsules), cachets, pills, ampoules, boluses, suppositories, pessaries, tinctures, gels, pastes, ointments, creams, lotions, oils, foams, sprays, mists, or aerosols.
- solutions e.g., aqueous, nonaqueous
- suspensions e.g., aqueous, non-aqueous
- emulsions
- Formulations may suitably be provided as a patch, adhesive plaster, bandage, dressing, or the like which is impregnated with one or more compounds and optionally one or more other pharmaceutically acceptable ingredients, including, for example, penetration, permeation, and absorption enhancers. Formulations may also suitably be provided in the form of a depot or reservoir.
- the compound may be dissolved in, suspended in, or admixed with one or more other pharmaceutically acceptable ingredients.
- the compound may be presented in a liposome or other microparticulate which is designed to target the compound, for example, to blood components or one or more organs.
- Formulations suitable for oral administration include liquids, solutions (e.g., aqueous, non-aqueous), suspensions (e.g., aqueous, non-aqueous), emulsions (e.g., oil-in-water, water-in-oil), elixirs, syrups, electuaries, tablets, granules, powders, capsules, cachets, pills, ampoules, boluses.
- Formulations suitable for buccal administration include mouthwashes, losenges, pastilles, as well as patches, adhesive plasters, depots, and reservoirs.
- Losenges typically comprise the compound in a flavored basis, usually sucrose and acacia or tragacanth.
- Pastilles typically comprise the compound in an inert matrix, such as gelatin and glycerin, or sucrose and acacia.
- Mouthwashes typically comprise the compound in a suitable liquid carrier.
- Formulations suitable for sublingual administration include tablets, losenges, pastilles, capsules, and pills.
- Formulations suitable for oral transmucosal administration include liquids, solutions (e.g., aqueous, non-aqueous), suspensions (e.g., aqueous, non-aqueous), emulsions (e.g., oil- in-water, water-in-oil), mouthwashes, losenges, pastilles, as well as patches, adhesive plasters, depots, and reservoirs.
- solutions e.g., aqueous, non-aqueous
- suspensions e.g., aqueous, non-aqueous
- emulsions e.g., oil- in-water, water-in-oil
- mouthwashes e.g., gluges, pastilles, as well as patches, adhesive plasters, depots, and reservoirs.
- Formulations suitable for non-oral transmucosal administration include liquids, solutions (e.g., aqueous, non-aqueous), suspensions (e.g., aqueous, non-aqueous), emulsions (e.g., oil-in-water, water-in-oil), suppositories, pessaries, gels, pastes, ointments, creams, lotions, oils, as well as patches, adhesive plasters, depots, and reservoirs.
- solutions e.g., aqueous, non-aqueous
- suspensions e.g., aqueous, non-aqueous
- emulsions e.g., oil-in-water, water-in-oil
- suppositories e.g., pessaries, gels, pastes, ointments, creams, lotions, oils, as well as patches, adhesive plasters, depots, and reservoirs.
- Formulations suitable for transdermal administration include gels, pastes, ointments, creams, lotions, and oils, as well as patches, adhesive plasters, bandages, dressings, depots, and reservoirs.
- Tablets may be made by conventional means, e.g., compression or moulding, optionally with one or more accessory ingredients.
- Compressed tablets may be prepared by compressing in a suitable machine the compound in a free-flowing form such as a powder or granules, optionally mixed with one or more binders (e.g., povidone, gelatin, acacia, sorbitol, tragacanth, hydroxypropylmethyl cellulose); fillers or diluents (e.g., lactose, microcrystalline cellulose, calcium hydrogen phosphate); lubricants (e.g., magnesium stearate, talc, silica); disintegrants (e.g., sodium starch glycolate, cross-linked povidone, cross-linked sodium carboxymethyl cellulose); surface-active or dispersing or wetting agents (e.g., sodium lauryl sulfate); preservatives (e.g., methyl p-hydroxybenzoate, propyl
- Moulded tablets may be made by moulding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
- the tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the compound therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile.
- Tablets may optionally be provided with a coating, for example, to affect release, for example an enteric coating, to provide release in parts of the gut other than the stomach.
- Ointments are typically prepared from the compound and a paraffinic or a water-miscible ointment base.
- Creams are typically prepared from the compound and an oil-in-water cream base.
- the aqueous phase of the cream base may include, for example, at least about 30% w/w of a polyhydric alcohol, i.e., an alcohol having two or more hydroxyl groups such as propylene glycol, butane-1 ,3-diol, mannitol, sorbitol, glycerol and polyethylene glycol and mixtures thereof.
- the topical formulations may desirably include a compound which enhances absorption or penetration of the compound through the skin or other affected areas. Examples of such dermal penetration enhancers include dimethylsulfoxide and related analogues.
- Emulsions are typically prepared from the compound and an oily phase, which may optionally comprise merely an emulsifier (otherwise known as an emulgent), or it may comprises a mixture of at least one emulsifier with a fat or an oil or with both a fat and an oil.
- an emulsifier also known as an emulgent
- a hydrophilic emulsifier is included together with a lipophilic emulsifier which acts as a stabiliser. It is also preferred to include both an oil and a fat.
- the emulsifier(s) with or without stabiliser(s) make up the so-called emulsifying wax
- the wax together with the oil and/or fat make up the so-called emulsifying ointment base which forms the oily dispersed phase of the cream formulations.
- Suitable emulgents and emulsion stabilisers include Tween 60, Span 80, cetostearyl alcohol, myristyl alcohol, glyceryl monostearate and sodium lauryl sulfate.
- suitable oils or fats for the formulation is based on achieving the desired cosmetic properties, since the solubility of the compound in most oils likely to be used in pharmaceutical emulsion formulations may be very low.
- the cream should preferably be a non-greasy, non-staining and washable product with suitable consistency to avoid leakage from tubes or other containers.
- Straight or branched chain, mono- or dibasic alkyl esters such as di-isoadipate, isocetyl stearate, propylene glycol diester of coconut fatty acids, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate or a blend of branched chain esters known as Crodamol CAP may be used, the last three being preferred esters. These may be used alone or in combination depending on the properties required. Alternatively, high melting point lipids such as white soft paraffin and/or liquid paraffin or other mineral oils can be used.
- Formulations suitable for intranasal administration, where the carrier is a liquid include, for example, nasal spray, nasal drops, or by aerosol administration by nebuliser, include aqueous or oily solutions of the compound.
- Formulations suitable for intranasal administration, where the carrier is a solid include, for example, those presented as a coarse powder having a particle size, for example, in the range of about 20 to about 500 microns which is administered in the manner in which snuff is taken, i.e., by rapid inhalation through the nasal passage from a container of the powder held close up to the nose.
- Formulations suitable for pulmonary administration include those presented as an aerosol spray from a pressurised pack, with the use of a suitable propellant, such as dichlorodifluoromethane, trichlorofluoromethane, dichoro-tetrafluoroethane, carbon dioxide, or other suitable gases.
- a suitable propellant such as dichlorodifluoromethane, trichlorofluoromethane, dichoro-tetrafluoroethane, carbon dioxide, or other suitable gases.
- Formulations suitable for ocular administration include eye drops wherein the compound is dissolved or suspended in a suitable carrier, especially an aqueous solvent for the compound.
- Formulations suitable for rectal administration may be presented as a suppository with a suitable base comprising, for example, natural or hardened oils, waxes, fats, semi-liquid or liquid polyols, for example, cocoa butter or a salicylate; or as a solution or suspension for treatment by enema.
- a suitable base comprising, for example, natural or hardened oils, waxes, fats, semi-liquid or liquid polyols, for example, cocoa butter or a salicylate; or as a solution or suspension for treatment by enema.
- Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the compound, such carriers as are known in the art to be appropriate.
- Formulations suitable for parenteral administration include aqueous or non-aqueous, isotonic, pyrogen-free, sterile liquids (e.g., solutions, suspensions), in which the compound is dissolved, suspended, or otherwise provided (e.g., in a liposome or other microparticulate).
- sterile liquids e.g., solutions, suspensions
- Such liquids may additional contain other pharmaceutically acceptable ingredients, such as anti-oxidants, buffers, preservatives, stabilisers, bacteriostats, suspending agents, thickening agents, and solutes which render the formulation isotonic with the blood (or other relevant bodily fluid) of the intended recipient.
- excipients include, for example, water, alcohols, polyols, glycerol, vegetable oils, and the like.
- suitable isotonic carriers for use in such formulations include Sodium Chloride Injection, Ringer's Solution, or Lactated Ringer's Injection.
- the concentration of the compound in the liquid is from about 1 ng/ml to about 10 ⁇ g/ml, for example from about 10 ng/ml to about 1 ⁇ g/ml.
- the formulations may be presented in unit-dose or multi-dose sealed containers, for example, ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules, and tablets.
- appropriate dosages of the IBD compounds, and compositions comprising the IBD compounds can vary from patient to patient. Determining the optimal dosage will generally involve the balancing of the level of therapeutic benefit against any risk or deleterious side effects.
- the selected dosage level will depend on a variety of factors including, but not limited to, the activity of the particular IBD compound, the route of administration, the time of administration, the rate of excretion of the IBD compound, the duration of the treatment, other drugs, compounds, and/or materials used in combination, the severity of the condition, and the species, sex, age, weight, condition, general health, and prior medical history of the patient.
- the amount of IBD compound and route of administration will ultimately be at the discretion of the physician, veterinarian, or clinician, although generally the dosage will be selected to achieve local concentrations at the site of action which achieve the desired effect without causing substantial harmful or deleterious side-effects.
- Administration can be effected in one dose, continuously or intermittently (e.g., in divided doses at appropriate intervals) throughout the course of treatment. Methods of determining the most effective means and dosage of administration are well known to those of skill in the art and will vary with the formulation used for therapy, the purpose of the therapy, the target cell(s) being treated, and the subject being treated. Single or multiple administrations can be carried out with the dose level and pattern being selected by the treating physician, veterinarian, or clinician.
- a suitable dose of the IBD compound is in the range of about 10 ⁇ g to about 250 mg (more typically about 100 ⁇ g to about 25 mg) per kilogram body weight of the subject per day.
- the compound is a salt, an ester, an amide, a prodrug, or the like
- the amount administered is calculated on the basis of the parent compound and so the actual weight to be used is increased proportionately.
- 1 H NMR spectra were recorded at 25°C at 300 MHz on a Bruker Avance 300 system. Chemical shifts are reported in ppm.
- the 1 H NMR spectra are referenced internally as follows: Spectra in CD 3 OD were referenced to CHD 2 OD: 3.33 ppm; CDCI 3 to CHCI 3 : 7.26 ppm, DMSO-Cf 6 to CHD 2 SOCD 3 : 2.50 ppm.
- the protected triazole of the Formula I was dissolved in DCM (15 mL per mmol) under N 2 atmosphere and the solution cooled to -78°C. BBr 3 was added dropwise (1.2 eq. per OMe group). The mixture was stirred at -78°C for 15 minutes, and then at room temperature overnight. The reaction mixture was evaporated to dryness and the residue was purified by column chromatography using appropriate mixtures of MeOH and DCM as eluent, to give the correspoinding triazole of the Formula II.
- the dimethoxy compound of Formula III was dissolved in dry DCM under N 2 and cooled in ice. BBr 3 (1 M in DCM) was added (2 eq. / methoxy group). The red solution was allowed to warm to room temperature and left stirring overnight. The reaction mixture was quenched with ice and the product extracted into EtOAc. For basic compounds, the aqueous phase was adjusted to pH 8-9 before extraction. The organic phase was dried over MgSO 4 or Na 2 SO 4 (basic compounds), evaporated, and the resulting product of Formula IV was purified by flash chromatography on silica gel.
- 2,4-Dihydroxy-acetophenone (15 g, 98.6 mmol) was dissolved in CH 3 CN (200 mL). Dry powdered K 2 CO 3 (40 g, 289 mmol) was added and the suspension stirred. Benzylbromide (26 mL, 218 mmol) was added drop-wise and the resulting mixture was heated to reflux for 5 h and left stirring at room temperature overnight. TLC (EtOAc-Hep 1 :1 ) showed complete reaction. The solvent was evaporated and the residue re- dissolved in CH 2 CI 2 -water. The phases were separated and the aqueous phase was extracted once with CH 2 CI 2 .
- reaction mixture was poured into aqueous NaHCO 3 (saturated, 300 mL) and the phases separated. The aqueous phase was extracted once with CH 2 CI 2 and the combined organic phase was dried over MgSO 4 and evaporated to colorless (light tan) oil (9.1 g , still wet). Purified on Silicagel with EtOAc- Hep (1 :9). The yield of title compound was 6.5 g (97%) of a colorless oil which crystallizes.
- Triisopropyl borate (2.66 ml_, 11.5 mmol) was dissolved in dry THF (20 ml_) in a new three-necked flask under N 2 and cooled to -78°C.
- the cold THF solution of the lithiated reactant was slowly siphoned into the borate solution while stirring and keeping the temperature at -78 0 C.
- the solution was allowed to warm to room temperature giving a colourless "milky" suspension. This was poured into ice/water, the pH was adjusted to 4 with HCI, and the product extracted with ether (3x). The combined organics were washed with brine and dried over MgSO 4 .
- reaction mixture was quenched with 0 0 C NaHCO 3 -solution (to pH 8-9) and the product was extracted four times with PE: EtOAc (4:1). The combined organic phases was evaporated and the crude material was purified by preparative HPLC to yield 29 mg pure material. The product was used without further purification or analysis.
- Step 1 Isolation of p-tolylsulfinic acid: Sodium p-tolylsulfinate (anhydrous) (3.21 g, 18.0 mmol) was suspended in water (25 mL). After stirring for 10 minutes, all was dissolved and £-butylmethylether (TBME) (25 mL) was added. Then, concentrated HCI (aq) (1.6 mL, 1 eq) was added dropwise. After stirring for 20 minutes, the organic phase was separated, diluted with toluene (25 mL), and evaporated in vacuo to remove 70-90% of the solvents.
- TBME £-butylmethylether
- step 2 The crude product from step 2 (1.27 g, 3.36 mmol) was suspended in dry THF (7 mL) at room temperature. To the white suspension was added POCI 3 (0.62 mL) and the resulting greenish suspension was stirred for 5 minutes, after which it was cooled to 0 0 C. Triethylamine (2.8 mL) was added slowly keeping the temperature below 5°C. The mixture was stirred at O 0 C for 45 minutes, after which EtOAc (5 mL) and water (5 mL) were added. The mixture was stirred for 5 minutes and the phases were separated.
- Step 1 Isolation of p-tolylsulfinic acid: Sodium p-tolylsulfinate (anhydrous) (3.21 g, 18.0 mmol) was suspended in water (25 ml_). After stirring for 10 minutes, all was dissolved and f-butylmethylether (TBME) (25 ml_) was added. Then concentrated HCI (aq) (1.6 mL, 1 eq) was added dropwise. After stirring for 20 minutes, the organic phase was separated, diluted with toluene (25 mL), and evaporated in vacuo to remove 70-90% of the solvents.
- TBME f-butylmethylether
- 5-lsopropyl-2,4-dimethoxybenzaldehyde (1.50 g, 7.20 mmol) was dissolved in dry acetonitrile (3 mL) and dry toluene (3 mL). Molecular sieves (4A) were added. Formamide (0.72 mL, 2.5 eq) and TMSCI (1.00 mL, 1.1 eq) were added and the mixture was heated to 5O 0 C for 4 hours under a N 2 atmosphere. The resulting cloudy orange solution was evaporated to semi-dryness. Dry toluene was added and the solvent was re-evaporated.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain 4-substituted-6-isopropyl-benzene 1,3-diol compounds (referred to herein as IBD compounds), which, inter alia, inhibit heat shock protein 90 (HSP90) function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HSP90 function, and in the treatment of diseases and conditions that are mediated by HSP90, that are ameliorated by the inhibition of HSP90 function, etc., including proliferative conditions such as cancer, etc.
Description
4-SUBSTITUTED-6-ISOPROPYL-BENZENE-1.3-DIOL COMPOUNDS AND THEIR USE
RELATED APPLICATIONS
This application is related to: United States patent application number 61/054,953 filed 21 May 2008; United States patent application number 60/988,915 filed 19 November 2007; and United Kingdom patent application number 0722680.6 filed 19 November 2007; the contents of each of which are incorporated herein by reference in their entirety.
TECHNICAL FIELD
The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain 4-substituted-6-isopropyl-benzene-1 ,3-diol compounds (referred to herein as IBD compounds), which, inter alia, inhibit heat shock protein 90 (HSP90) function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HSP90 function, and in the treatment of diseases and conditions that are mediated by HSP90, that are ameliorated by the inhibition of HSP90 function, etc., including proliferative conditions such as cancer, etc.
BACKGROUND
A number of patents and publications are cited herein in order to more fully describe and disclose the invention and the state of the art to which the invention pertains. Each of these references is incorporated herein by reference in its entirety into the present disclosure, to the same extent as if each individual reference was specifically and individually indicated to be incorporated by reference.
Throughout this specification, including the claims which follow, unless the context requires otherwise, the word "comprise," and variations such as "comprises" and
"comprising," will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.
It must be noted that, as used in the specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a pharmaceutical carrier" includes mixtures of two or more such carriers, and the like.
Ranges are often expressed herein as from "about" one particular value, and/or to "about" another particular value. When such a range is expressed, another embodiment includes
from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by the use of the antecedent "about," it will be understood that the particular value forms another embodiment.
This disclosure includes information that may be useful in understanding the present invention. It is not an admission that any of the information provided herein is prior art or relevant to the presently claimed invention, or that any publication specifically or implicitly referenced is prior art.
Heat Shock Protein 90 (HSP90)
HSP90s are ubiquitous chaperone proteins that are involved in folding, activation and assembly of a wide range of proteins, including key proteins involved in signal transduction, cell cycle control and transcriptional regulation. It has been reported that HSP90 is associated with important signaling proteins, such as steroid hormone receptors and protein kinases, including, e.g., Raf-1 , EGFR, v-Src family kinases, Cdk4, and ErbB-2 (Buchner 1999; Stepanova et al., 1996,; Dai. et al., 1996). Furthermore, certain co-chaperones, e.g., Hsp70, p60/Hop/Stil, Hip, Bag1 , HSP40/Hdj2/Hsjl, immunophilins, p23, and p50, may assist HSP90 in its function (Caplan, 1999).
Ansamycin antibiotics, e.g., herbimycin A (HA), geldanamycin (GM), and 17- AAG are thought to exert anticancerous effects by tight binding of the N-terminus binding site of HSP90, thereby destabilizing substrates that normally interact with HSP90 (Stebbins et a/ 1997,). This pocket is highly conserved and has weak homology to the ATP-binding site of DNA gyrase (Stebbins. et al. 1997; Grenert et al., 1997). Further, ATP and ADP have both been shown to bind this pocket with low affinity and to have weak ATPase activity (Prodromou eif al., 1997; Panaretou et al., 1998). In vitro and in vivo studies have demonstrated that occupancy of this N- terminal pocket by ansamycins and other HSP90 inhibitors alters HSP90 function and inhibits, for example, protein folding and activation. At high concentrations, ansamycins and other HSP90 inhibitors have been shown to prevent binding of protein substrates to HSP90 (Scheibel et al., 1999, Schulte et al. 1995; Whitesell, et al., 1994). Ansamycins have also been demonstrated to inhibit the ATP- dependent release of chaperone-associated protein substrates (Schneider et al., 1996; Sepp-Lorenzino et al., 1995,). In either event, the substrates are degraded by a ubiquitin- dependent process in the proteasome (Schneider, et al., 1996; Sepp-Lorenzino, 1995, Whitesell, etal., 1994).
HSP90 substrate destabilization occurs in tumour and non-transformed cells alike and has been shown to be especially effective on a subset of signalling regulators, e.g., Raf (Schulte et al., 1997; Schulte et al. 1995), nuclear steroid receptors (Segnitz and Gehring. 1997; Smith, et al., 1995), v-src (Whitesell et al., 1994) and certain transmembrane
tyrosine kinases (Sepp-Lorenzino et a/., 1995) such as EGF receptor (EGFR) and Her2/Neu (Hartmann et al., 1997; Miller et a/., 1994; Mimnaugh et a/., 1996; Schnur et al., 1995), CDK4, and mutant p53 (Erlichman et al. 2001). The ansamycin-induced loss of these proteins leads to the selective disruption of certain regulatory pathways and results in growth arrest at specific phases of the cell cycle (Muise-Helmericks, et a/., 1998) and apoptosis, and/or differentiation of cells so treated (Vasilevskaya, et a/., 1999).
In addition to anti-cancer and antitumourigenic activity, HSP90 inhibitors have also been implicated in a wide variety of other utilities, including use as anti-inflammatory agents, anti-infectious disease agents, agents for treating autoimmunity, agents for treating ischemia, and agents useful in promoting nerve regeneration ('Rosen et al., 2002; Defranco et a/., 1999; Gold, 2001 ). In addition, fibrogenic disorders including but not limited to scleroderma, polymyositis, systemic lupus, rheumatoid arthritis, liver cirrhosis, keloid formation, interstitial nephritis, and pulmonary fibrosis may also be treatable with HSP90 inhibitors (Strehlow, 2002).
Ansamycins and other HSP90 inhibitors thus hold great promise for the treatment and/or prevention of many types of disorders. However, their relative insolubility makes them difficult to formulate and administer, and they are not easily synthesized and currently must, at least in part, be generated through fermentation. Further, the dose limiting toxicity of ansamyins is hepatic.
SUMMARY OF THE INVENTION
One aspect of the invention pertains to certain 4-substituted-6-isopropyl-benzene-1 ,3-diol compounds (referred to herein as "IBD compounds"), as described herein.
Another aspect of the invention pertains to a composition (e.g., a pharmaceutical composition) comprising an IBD compound, as described herein, and a pharmaceutically acceptable carrier or diluent.
Another aspect of the invention pertains to method of preparing a composition (e.g., a pharmaceutical composition) comprising the step of admixing an IBD compound, as described herein, and a pharmaceutically acceptable carrier or diluent.
Another aspect of the present invention pertains to a method of inhibiting heat shock protein 90 (HSP90) function in a cell, in vitro or in vivo, comprising contacting the cell with an effective amount of an IBD compound, as described herein (e.g., without a proviso regarding P-O01 through P-003).
Another aspect of the present invention pertains to a method of regulating (e.g., inhibiting) cell proliferation (e.g., proliferation of a cell), inhibiting cell cycle progression, promoting apoptosis, or a combination of one or more these, in vitro or in vivo, comprising contacting a cell with an effective amount of an IBD compound, as described herein (e.g., without a proviso regarding P-O01 through P-003).
Another aspect of the present invention pertains to a method of treatment comprising administering to a subject in need of treatment a therapeutically-effective amount of an IBD compound, as described herein (e.g., without a proviso regarding P-001 through P-003), preferably in the form of a pharmaceutical composition.
Another aspect of the present invention pertains to an IBD compound, as described herein (e.g., without a proviso regarding P-001 through P-003), for use in a method of treatment of the human or animal body by therapy.
Another aspect of the present invention pertains to an IBD compound, as described herein (e.g., without a proviso regarding P-001 through P-003), for the use in a method of treatment of the human or animal body by therapy wherein said compound is used in combination with other pharmaceutically active substances
Another aspect of the present invention pertains to use of an IBD compound, as described herein (e.g., without a proviso regarding P-001 through P-003), in the manufacture of a medicament for use in treatment.
In one embodiment, the treatment is treatment of a disease or condition that is mediated by heat shock protein 90 (HSP90).
In one embodiment, the treatment is treatment of a disease or condition that is ameliorated by the inhibition of heat shock protein 90 (HSP90) function.
In one embodiment, the treatment is treatment of a disease or condition that is known to be treated by HSP90 inhibitors (e.g., 17-AAG, geldanamycin, etc.).
In one embodiment, the treatment is treatment of a proliferative condition.
In one embodiment, the treatment is treatment of cancer.
Another aspect of the present invention pertains to a kit comprising (a) an IBD compound, as described herein (e.g., without a proviso regarding P-001 through P-003), preferably provided as a pharmaceutical composition and in a suitable container and/or with suitable packaging; and (b) instructions for use, for example, written instructions on how to administer the compound.
Another aspect of the present invention pertains to an IBD compound obtainable by a method of synthesis as described herein, or a method comprising a method of synthesis as described herein.
Another aspect of the present invention pertains to an IBD compound obtained by a method of synthesis as described herein, or a method comprising a method of synthesis as described herein.
Another aspect of the present invention pertains to novel intermediates, as described herein, which are suitable for use in the methods of synthesis described herein.
Another aspect of the present invention pertains to the use of such novel intermediates, as described herein, in the methods of synthesis described herein.
As will be appreciated by one of skill in the art, features and preferred embodiments of one aspect of the invention will also pertain to other aspect of the invention.
DETAILED DESCRIPTION OF THE INVENTION
Compounds
One aspect of the present invention relates to certain 4-substituted-6-isopropyl- benzene-1 ,3-diol compounds (for convenience, collectively referred to herein as "IBD compounds"), which are structurally related to resorcinol.
4~substituted-6-isopropyl-benzene-1 ,3-diol resorcinol
In one embodiment, the compounds are selected from compounds of the following formula, and pharmaceutically acceptable salts, hydrates, and solvates thereof:
-X1- is independently a covalent single bond or -X1L-; -X2- is independently a covalent single bond or -X2L-;
-A1- is independently -A1A-; -A2 is independently -A2A, -H, or -F;
except that if: -X2- is -X2L-, then: -A2 is -A2A;
each of -X1L- and -X2L- is independently:
-RL-,
-C(=O)-, -RL-C(=O)-, -C(=O)-RL-,
-RL-C(=O)-RL-,
-O-RL-C(=O)-,
-C(=O)-RL-O-,
-C(=O)-RL-S-,
-O-RL-C(=O)-RL-O,"
-NH-S(=O)2-, -NRA-S(=O)2-,
-RL-NH-S(=O)2-, -RL-NRA-S(=O)2-,
-NH-S(=O)2-RL-, -NRA-S(=O)2-RL-,
-RL-NH-S(=O)2-RL-, -RL-NRA-S(=O)2-RL-,
-S(=O)2-NH-, -S(=O)2-NRA-,
-RL-S(=O)2-NH-, -RL-S(=O)2-NRA-,
-C(=O)-NH-RL-, -C(=O)-NRA-RL-,
-RL-S(=O)2-NH-RL-, -RL-S(=O)2-NRA-RL-,
-O-,
-RL-O-,
-O-RL-,
-RL-O-RL-,
-NH-C(=O)-, -NRA-C(=O)-,
-RL-NH-C(=O)-, -RL-NRA-C(=O)-,
-NH-C(=O)-RL-, -NRA-C(=O)-RL-,
-RL-NH-C(=O)-RL-, -RL-NRA-C(=O)-RL-,
-C(=O)-NH-, -C(=O)-NRA-,
-RL-C(=O)-NH-, -RL-C(=O)-NRA-,
-C(=O)-NH-RL-, -C(=O)-NRA-RL-,
-RL-C(=O)-NH-RL-, -RL-C(=O)-NRA-RL-,
-NH-C(=O)-NH-, -NRA-C(=O)-NH-,
-NH-C(=O)-NRA-, -NRA-C(=O)-NRA-,
-RL-NH-C(=O)-NH-, -RL-NRA-C(=O)-NH-, -RL-NH-C(=O)-NRA-, -RL-NRA-C(=O)-NRA-,
-NH-C(=O)-NH-RL-, -NRA-C(=O)-NH-RL-, -NH-C(=O)-NRA-RL-, -NRA-C(=O)-NRA-RL-,
-RL-NH-C(=O)-NH-RL-, -RL-NRA-C(=O)-NH-RL-,
-RL-NH-C(=O)-NRA-RL-, -RL-NRA-C(=O)-NRA-RL-,
-NH-, -NRA-, -RL-NH-, -RL-NRA-, -NH-RL-, -NRA-RL-, -RL-NH-RL-, -RL-NRA-RL-,
-C(=O)-O- -RL-C(=O)-O-, -C(=O)-O-RL-, -RL-C(=O)-O-RL-,
-O-C(=O)-, -RL-O-C(=O)-, -O-C(=O)-RL-, -RL-O-C(=O)-RL-,
-S(=O)-, -RL-S(=O)-, -S(=O)-RL-, -RL-S(=O)-RL-,
except that -X1L- is not:
-C(=O)-NH-, -C(=O)-NRA-, -C(=O)-NH-RL-, or -C(=O)-NRA-RL-; (see, e.g., WO 2006/109075)
wherein:
each -RA is independently -RM, -RAB, or -RAC; each -Rω is independently saturated aliphatic C^alkyl; each -RAB is independently aliphatic C2-6alkenyl; each -RAC is independently saturated C3.δcycloalkyl; and each -RM, -RΛB, and -RAC is independently unsubstituted or substituted with one or more substituents selected from -F, -Cl, -Br, -I, -OH, -OR, -NH2, -NHR, -NR2, -NHC(=O)R, -NRC(=O)R, -C(=O)OR, -OC(=O)R, -C(=O)NH2, -C(=O)NHR, and -C(=O)NR2, wherein each R is independently saturated aliphatic C1-4alkyl, phenyl, or benzyl;
each -RL- is independently -RL\ -RLB-, -RLG-, -R^-R10-, -R^-R^-, or -R^-R^-R^-; each -RLA is independently saturated aliphatic C1-6alkylene; each -RLB is independently aliphatic C2.6alkenylene; each -RLC is independently saturated C3-6cycloalkylene; and each -RLA, -RLB, and -RLC is independently unsubstituted or substituted with one or more substituents selected from -F, -Cl, -Br, -I, -OH, -OR, -NH2, -NHR, -NR2, -NHC(=O)R, -NRC(=O)R, -C(=O)OR, -OC(=O)R, -C(=O)NH2l -C(=O)NHR, and -C(=O)NR2, wherein each R is independently saturated aliphatic C1-4alkyl, phenyl, or benzyl;
and wherein:
-A1A- is independently -A1AC- or -A1AH-; -A1AG- is independently C6-iocarboarylene; -A1AH- is independently C5-12heteroarylene; and each -A1AC- and each -A1AH- is independently unsubstituted or substituted with one or more substituents -Q1;
-A2A is independently -A2AC or -A2AH; -A2AC is independently C6-iocarboaryl; -A2AH is independently C5-i2heteroaryl; and each -A2AG and each -A2AH is independently unsubstituted or substituted with one or more substituents -Q2;
wherein:
each -Q1 and each -Q2 is independently:
-F, -Cl, -Br, -I,
-R1A1, -CF3, -OCF3,
-OH, -L1A-OH, -O-L1A-OH,
-OR1A1, -L1A-OR1A1, -O-L1A-OR1A1,
-SH, -SR1A1,
-CN, -NO2,
-NH2, -NHR1A1, -NR1A1 2, -NR1A2R1A3,
-L1A-NH2, -L1A-NHR1A1, -L1A-NR1A1 2, -L1A-NR1A2R1A3,
-O-L1A-NH2, -O-L1A-NHR1A1, -O-L1A-NR1A1 2, -O-L1A-NR1A2R1A3,
-NH-L1A-NH2, -NH-L1A-NHR1A1, -NH-L1A-NR1A1 2, -NH-L1A-NR1A2R1A3, -NR1A1-L1A-NH2, -NR1A1-L1A-NHR1A1, -NR1A1-L1A-NR1A1 2, -NR1A1-L1A-NR1A2R1A3,
-C(=O)OH, -C(=O)OR1A1, -OC(=O)R1A1,
-C(=O)NH2, -C(=O)NHR1A1, -C(=O)NR1A1 2, -C(=O)NR1A2R1A3,
-NHC(=O)R1A1, -NR1A1C(=O)R1A1,
-C(=O)NHOR1A1, -C(=O)NR1A1OR1A1,
-NHC(=O)R1A1, -NR1A1C(=O)R1A1, -NHC(=O)OR1A1, -NR1A1C(=O)OR1A1,
-OC(=O)NH2, -OC(=O)NHR1A1, -OC(=O)NR1A1 2, -OC(=O)NR1A2R1A3,
-C(=O)R1A1,
-NHC(=O)NH2, -NHC(=O)NHR1A1,
-NHC(=O)NR1A1 2, -NHC(=O)NR1A2R1A3, -NR1A1C(=O)NH2, -NR1A1C(=O)NHR1A1,
-NR1A1C(=O)NR1A1 2, -NR1A1C(=O)NR1A2R1A3,
-NHS(=O)2R1A1 , -NR1A1S(=O)2R1A1,
-S(=O)2NH2l -S(=O)2NHR1A1, -S(=O)2NR1A1 2, -S(=O)2NR1A2R1A3,
-S(=O)R1A1, -S(=O)2R1A1, -OS(=O)2R1A1, or -S(=O)2OR1A1;
wherein:
each -L1A- is independently saturated aliphatic d.5alkylene; in each group -NR1A2R1A3, -R1A2 and -R1A3, taken together with the nitrogen atom to which they are attached, form a A-, 5-, 6-, or 7-membered non-aromatic ring having exactly 1 ring heteroatom or exactly 2 ring heteroatoms, wherein one of said exactly 2 ring heteroatoms is N, and the other of said exactly 2 ring heteroatoms is independently N, O, or S;
each -R1A1 is independently:
R1B1 D1B2 D1B3 D1B4 D1B5 D1B6 D1B7 D1B8 , -K , -K , -K , -K , -K , -K , -K ,
-L1B-R1B4, -L1B-R1B5, -L1B-R1B6, -L1B-R1B7, or -L1B-R1B8; wherein: each -R1B1 is independently saturated aliphatic C1-6alkyl; each -R1B2 is independently aliphatic C2-6alkenyl; each -R1B3 is independently aliphatic C2-6alkynyl; each -R1B4 is independently saturated C3-6cycloalkyl; each -R1B5 is independently C3.6cycloalkenyl; each -R1B6 is independently non-aromatic C3-7heterocyclyl; each -R1B7 is independently C6.i0carboaryl; each -R1BS is independently C5-10heteroaryl; each -L1B- is independently saturated aliphatic C1-3alkylene; and wherein: each -R1B4, -R1B5, -R1B6, -R1B7, and -R1B8 is optionally substituted, for example, with one or more substituents -R1C1 and/or one or more substituents -R1C2, and
each -R1B1, -R182, -R1B3, and -L1B- is optionally substituted, for example, with one or more substituents -R1C2, wherein: each -R1C1 is independently saturated aliphatic C1-4alkyl, phenyl, or benzyl; each -R1C2 is independently:
-F, -Cl, -Br, -I1 -CF3, -OCF3,
-OH, -L1D-OH, -O-L1D-OH, -OR101, -L1D-OR1D1, -O-L1D-OR1D1, -SH1 -SR101,
-CN, -NO2,
-NH2, -NHR1D\ -NR1D1 2, -NR102R103, -L1D-NH2, -L1D-NHR101, -L1D-NR1D1 2, or -L1D-NR1O2R103, -O-L1D-NH2, -O-L1D-NHR1D1, -O-L1D-NR1D1 2, -O-L10-NR1D2R1D3,
-NH-L1D-NH2, -NH-L1D-NHR1D1, -NH-L1D-NR1D1 2, -NH-L1D-NR1D2R103, -NR1D1-L1D-NH2, -NR1D1-L1D-NHR1D1,
-NR1D1-L10-NR1 D1 2, -NR1D1-L1O-NR1D2R1D3, ' -C(=O)OH,
-C(=O)OR1D1, -OC(=O)R1D1, -C(=O)R101,
-C(=O)NH2, -C(=O)NHR1D1, -C(=O)NR1D1 2, -C(=O)NR1D2R103, -NHC(=O)R1D1, -NR1D1C(=O)R1D\
-S(=O)2NH2, -S(=O)2NHR1A1, -S(=O)2NR1A1 2, -S(=O)2NR1A2R1A3, or -S(=O)2R1A1; wherein: each -R1D1 is independently saturated aliphatic C1-4alkyl, phenyl, or benzyl; each -L1D- is independently saturated aliphatic Ci-5alkylene; and in each group -NR102R103, -R102 and -R1D3, taken together with the nitrogen atom to which they are attached, form a A-, 5-, 6-, or 7-membered non-aromatic ring having exactly 1 ring heteroatom or exactly 2 ring heteroatoms, wherein one of said exactly 2 ring heteroatoms is N, and the other of said exactly 2 ring heteroatoms is independently N, 0, or S;
and additionally, two adjacent -Q1 groups, if present, may together form -0-CH2-O- or -0-CH2CH2-O-; and additionally, two adjacent -Q2 groups, if present, may together form -0-CH2-O- or -0-CH2CH2-O-.
except that:
if -X1- is a covalent single bond, then -A1- is not:
1 ,2,4-triazine-6~one, substituted 1,2,4-triazine 6-one, 1 ,2,4-triazine-6-thione, or substituted 1 ,2,4-triazine-β-thione (see, e.g., WO 2008/118391);
2-OXO-1 ,2,3,4-tetrahydropyrimidine or substituted 2-oxo-1 , 2,3,4- tetrahydropyrimidine (see, e.g., WO 2008/118391 );
2-amino-1 ,2,3,4-tetrahydropyrimidine or substituted 2-amino-1 ,2,3,4- tetrahydropyrimidine (see, e.g., WO 2008/118391); pyrazol-diyl or substituted pyrazol-diyl (see, e.g., WO 2007/021966);
1 ,3-dihydro-imidazol-2-one-diyl or substituted 1 ,3-dihydro-imidazol-2-one-diyl (see, e.g., WO 2007/021877);
1 ,3-dihydro-imidazol-2-thione-diyl or substituted 1 ,3-dihydro-imidazol-2-thione-diyl (see, e.g., WO 2007/021877);
1 ,2,4-triazol-diyl or substituted 1 ,2,4-triazol-diyl (see, e.g., WO 2006/095783);
2,4-dihydro-[1,2,4]triazol-3-one-diyl or substituted 2,4-dihydro- [1 ,2,4]triazol-3-one-diyl (see, e.g., WO 2006/055760);
2,4-dihydro-[1 ,2,4]triazol-3-thione-diyl or substituted 2,4-dihydro- [1 ,2,4]triazol-3-thione-diyl (see, e.g., WO 2006/055760); or isoxazol-diyl or substituted isoxazol-diyl (see, e.g., WO 2004/072051).
Optional Provisos
In one or more aspects of the present invention (e.g., compounds, compositions, compounds for use in therapy, use of compounds in the manufacture of a medicament, methods, methods of treatment, etc.), the compounds are optionally as defined herein, but with one or more optional provisos, as defined herein.
In one embodiment, the compound is a compound as defined herein, with the proviso that the compound is not a compound selected from P-001 through P-003.
In one embodiment, the compound is a compound as defined herein, with the proviso that the compound is not a compound selected from P-001 through P-003.
In one embodiment, the compound is a compound as defined herein, with the proviso that the compound is not a compound selected from PP-001 through PP-003, and salts, hydrates, and solvates thereof.
In one or more aspects of the present invention (e.g., compounds for use in therapy, use of compounds in the manufacture of a medicament, methods, methods of treatment, etc.), the compounds are optionally as defined herein, but without any of the above provisos, that is, without a proviso regarding P-001 through P-003.
For example, a reference to a particular group of compounds "without the proviso regarding P-001 through P-003" (e.g., for use in therapy) is intended to be a reference to the compounds as defined, but wherein the definition no longer includes the indicated proviso. In such cases, it is as if the indicated proviso has been deleted from the definition of compounds, and the definition has been expanded to encompass those compounds which otherwise would have been excluded by the indicated proviso.
The Group -X1-
In one embodiment, -X1- is independently a covalent single bond or -X1L- In one embodiment, -X1- is independently a covalent single bond. In one embodiment, -X1- is independently -X1L-.
The Group -X2-
In one embodiment, -X - is independently a covalent single bond or -X - In one embodiment, -X2- is independently a covalent single bond.
In one embodiment, -X2- is independently -X2L-.
The Group -A1-
In one embodiment, -A1- is independently -A1A-.
The Group -A2
In one embodiment, -A2 is independently -A2A, -H, or -F. In one embodiment, -A2 is independently -AM or -H. In one embodiment, -A2 is independently -A2A. In one embodiment, -A2 is independently -H or -F. In one embodiment, -A2 is independently -H.
Combinations of the Group -X1-. -A1-. -X2-, and -A2
In one embodiment, the group -X1-A1-X2-A2 is independently:
-X1L-A1A-X2L-A2A, -χiL_A 1A-A2A,
-A1A-X2L-A2A, -A1A-A2A, -A1A-H, or
-A1A-F.
In one embodiment, the group -X1-A1-X2-A2 is independently:
-A1A-X2L-A2A,
-A1A-A2A,
-A1A-H, or -A1A-F.
In one embodiment, the group -X1-A1-X2-A2 is independently -X1L-A1A-H or -X1L-A1A-F.
In one embodiment, the group -X1-A1-X2-A2 is independently -X1L-A1A-H.
In one embodiment, the group -X1-A1-X2-A2 is independently -A1A-X2L-A2A.
In one embodiment, the group -X1-A1-X2-A2 is independently -A^-A2*.
In one embodiment, the group -X1-A1-X2-A2 is independently -A1A-H or -A1A-F.
In one embodiment, the group -X1-A1-X2-A2 is independently -A1A-H.
The Group -X1L-
In one embodiment, -X1L-, if present, is independently:
-RL-,
-C(=O)-, -RU-C(=O)-,
-C(=O)-RL-, -RL-C(=O)-RL-,
-O-RL-C(=O)-, -C(=O)-RL-O-,
-C(=O)-RL-S-, or -O-RL-C(=O)-RL-O,
In one embodiment, -X1L-, if present, is independently: -RL-,
-C(=O)-,
-C(=O)-RL-,
-C(=O)-RL-O-, or
-C(=O)-RL-S-.
In one embodiment, -X1L-, if present, is independently:
-C(=O)-,
-C(=O)-RL-,
-C(=0)-RL-O, or -C(=O)-RL-S-.
In one embodiment, -X1L-, if present, is independently -C(=O)-.
In one embodiment, -X1L-, if present, is independently -C(=O)-RL-.
In one embodiment, -X1L-, if present, is independently -C(=O)-RL-O-.
In one embodiment, -X1L-, if present, is independently -RL-.
The Group -X2L-
In one embodiment, -X2L-, if present, is independently:
-RL-,
-NH-S(=O)2-, -NRA-S(=O)2-,
-RL-NH-S(=O)2-, -RL-NRA-S(=O)2-, -NH-S(=O)2-RL-, -NRA-S(=O)2-RL-, -RL-NH-S(=O)2-RL-, -RL-NRA-S(=O)2-RL-,
-S(=O)2-NH-, -S(=O)2-NRA-,
-RL-S(=O)2-NH-, -RL-S(=O)2-NRA-, -C(=O)-NH-RL-, -C(=O)-NRA-RL-, -RL-S(=O)2-NH-RL-, -RL-S(=O)2-NRA-RL-,
-O1
-RL-O-, -O-RL-S -RL-O-RL-,
-NH-C(=O)-, -NRA-C(=O)-,
-RL-NH-C(=O)-, -RL-NRA-C(=O)-, -NH-C(=O)-RL-, -NRA-C(=O)-RL-, -RL-NH-C(=O)-RL-, -RL-NRA-C(=O)-RL-,
-C(=O)-NH-, -C(=O)-NRA-,
-RL-C(=O)-NH-, -RL-C(=O)-NRA-, -C(=O)-NH-RL-, -C(=O)-NRA-RL-, -RL-C(=O)-NH-RL-, or -RL-C(=O)-NRA-RL-.
In one embodiment, -X2L-, if present, is independently:
-RL-,
-NH-S(=O)2-, -NRA-S(=O)2-, -RL-NH-S(=O)2-, -RL-NRA-S(=O)2-,
-NH-S(=O)2-RL-, -NRA-S(=O)2-RL-,
-RL-NH-S(=O)2-RL-, -RL-NRA-S(=O)2-RL-,
-O-, -RL-O-, -O-RL-,
-RL-O-RL-,
-C(=O)-NH-, -C(=O)-NRA-, -RL-C(=O)-NH-, -RL-C(=O)-NRA-, -C(=O)-NH-RL-, -C(=O)-NRA-RL-,
-RL-C(=O)-NH-RL-, or -RL-C(=O)-NRA-RL-.
In one embodiment, -X2L-, if present, is independently:
-RL-,
-NH-S(=O)2-, -NRA-S(=O)2-,
-NH-S(=O)2-RL-, -NRA-S(=O)2-RL-,
-RL-O-,
-C(=O)-NH-, -C(=O)-NRA-, -C(=O)-NH-RL-, or -C(=O)-NRA-RL-.
In one embodiment, -X2L-, if present, is independently -RL-.
In one embodiment, -X2L-, if present, is independently -NH-S(=O)2-, -NRA-S(=O)2-, NH-S(=O)2-RL- or -NRA-S(=O)2-RL-.
In one embodiment, -X2L-, if present, is independently -NH-S(=O)2- or -NRA-S(=O)2-.
In one embodiment, -X2L-, if present, is independently -NH-S(=O)2-RL- or -NRA-S(=O)2-RL-.
In one embodiment, -X2L-, if present, is independently -RL-O-.
In one embodiment, -X2L-, if present, is independently -C(=O)-NH- or -C(=O)-NRA-.
In one embodiment, -X2L-, if present, is independently -C(=O)-NH-RL- or -C(=O)-NRA-RL-.
The Group -RL-
In one embodiment, each -RL-, if present, is independently:
-RLA-, -Rl-EL1 .RLC-1
or .R^LC.^
wherein: each -RLA is independently saturated aliphatic Ci-6alkylene; each -RLB is independently aliphatic C2-6alkenylene; each -RLC is independently saturated C3.6cycloalkylene; and each -RLA, -RLB, and -RLC is independently unsubstituted or substituted with one or more substituents selected from -F, -Cl, -Br, -I1 -OH, -OR, -NH2, -NHR, -NR2, -NHC(=O)R, -NRC(=O)R,
-OC(=O)R, -C(=O)NH2, -C(=O)NHR, and -C(=O)NR2, wherein each R is independently saturated aliphatic C1-4alkyl, phenyl, or benzyl.
In one embodiment, each -RL-, if present, is independently -R^-, -RLB-, or -RLC-. In one embodiment, each -RL-, if present, is independently -RLA-.
In one embodiment, each -RL-, if present, is independently unsubstituted.
In one embodiment, each -RLA, if present, is independently saturated aliphatic
C-,.4alkylene.
In one embodiment, each -RLA, if present, is independently saturated aliphatic
Ci.3alkylene.
In one embodiment, each -RLA, if present, is independently saturated aliphatic C1-2alkylene.
In one embodiment, each -RL-, if present, is independently -CH2- Or -CH2CH2-. In one embodiment, each -RL-, if present, is independently -CH2-.
The Group -RA
In one embodiment, each -RA, if present, is independently: -R^ -R^ or -R*0, wherein: each -RM is independently saturated aliphatic C1-6alkyl; each -RAB is independently aliphatic C2-6alkenyl; each -RAC is independently saturated C3-6cycloalkyl; and each -RM, -RAB, and -RAC is independently unsubstituted or substituted with one or more substituents selected from -F, -Cl, -Br, -I1 -OH, -OR, -NH2, -NHR, -NR2, -NHC(=O)R, -NRC(=O)R, -C(=O)OR, -OC(=O)R, -C(=O)NH2, -C(=O)NHR, and -C(=O)NR2, wherein each R is independently saturated aliphatic d^alkyl, phenyl, or benzyl.
In one embodiment, each -RA, if present, is independently -RM or -RAB. In one embodiment, each -RA, if present, is independently -RM. In one embodiment, each -RA, if present, is independently saturated aliphatic C1-4alkyl. In one embodiment, each -RA, if present, is independently -Me or -Et.
In one embodiment, each -RA, if present, is independently -Me.
The Group -A1A-
In one embodiment, -A1A-, if present, is independently -A1AC- or -A1AH-, wherein: -A1AC- is independently C6-i0carboarylene; -A1AH- is independently C5-12heteroarylene; each -A1AC- and -A1AH- is independently unsubstituted or substituted with one or more substituents -Q1.
In one embodiment, -A1A-, if present, is independently -A1AC-.
In one embodiment, -A1AC-, if present, is independently phenylene or naphth-diyl, and is optionally substituted.
In one embodiment, -A1AC-, if present, is independently phenylene, and is optionally substituted.
In one embodiment, -A1AC-, if present, is independently phenyl-1 ,2-diyl, and is optionally substituted.
In one embodiment, -A1AC-, if present, is independently phenyl-1 ,3-diyl, and is optionally substituted.
In one embodiment, -A1AC-, if present, is independently phenyl-1 ,4-diyl, and is optionally substituted.
In one embodiment, -A1AC-, if present, is independently naphth-diyl, and is optionally substituted.
In one embodiment, -A1AC-, if present, is independently naphth-1 ,2-diyl, and is optionally substituted.
In one embodiment, -A1AC-, if present, is independently naphth-1 , 4-diyl, and is optionally substituted.
In one embodiment, -A1A-, if present, is independently -A1ΛH-.
In one embodiment, -A1AH-, if present, is independently C5-6heteroarylene, and is optionally substituted.
In one embodiment, -A1AH-, if present, is independently C7-i0heteroarylene, and is optionally substituted.
In one embodiment, -A1AH-, if present, is independently furan-diyl, thien-diyl, pyrrol-diyl, 1 ,2,3-triazol-diyl, tetrazol-diyl, oxazol-diyl, thiazol-diyl, isothiazol-diyl, pyridin-diyl, pyrimidin-diyl, pyrazin-diyl, or pyridazin-diyl, and is optionally substituted.
In one embodiment, -A1AH-, if present, is independently furan-diyl, thien-diyl, 1 ,2,3-triazol-diyl, oxazol-diyl, thiazol-diyl, or pyridin-diyl, and is optionally substituted.
In one embodiment, -A1AH-, if present, is independently triazol-diyl, and is optionally substituted.
In one embodiment, -A1AH-, if present, is independently 1 ,2,3-triazol-diyl, and is optionally substituted.
In one embodiment, -A1AH-, if present, is independently 1 ,2,3-triazol-1 ,4-diyl, and is optionally substituted.
In one embodiment, -A1AH-, if present, is independently 1 ,2,3-triazol-1 ,5-diyl, and is optionally substituted.
In one embodiment, -A1AH-, if present, is independently 1 ,2,3-triazol-1 ,4-diyl, and is optionally substituted, wherein -X1- is attached at the 1 -position of the 1 ,2,3-triazol-1 ,4-diyl.
In one embodiment, -A1AH-, if present, is independently 1 ,2,3-triazo]-1 ,4-diyl, and is optionally substituted, wherein -X1- is attached at the 4-position of the 1 ,2,3-triazol-1 ,4-diyl.
In one embodiment, -A1AH-, if present, is independently 1 ,2,3-triazol-i ,5-diyl, and is optionally substituted, wherein -X1- is attached at the 1-position of the 1 ,2,3-triazol-1 ,4-diyl.
In one embodiment, -A1AH-, if present, is independently 1 ,2,3-triazoM ,5-diyl, and is optionally substituted, wherein -X1- is attached at the 5-position of the 1 ,2,3-triazol-1 ,4-diyl.
In one embodiment, -A1AH-, if present, is independently oxazol-diyl, and is optionally substituted.
In one embodiment, -A1AH-, if present, is independently oxazol-4,5-diyl, and is optionally substituted.
In one embodiment, -A1AH-, if present, is independently oxazol-2,4-diyl, and is optionally substituted.
In one embodiment, -A1AH-, if present, is independently oxazol-2,5-diyl, and is optionally substituted.
In one embodiment, -A1AH-, if present, is independently oxazol-4,5-diyl, and is optionally substituted, wherein -X1- is attached at the 4-position of the oxazol-4,5-diyl.
In one embodiment, -A1AH-, if present, is independently oxazol-4,5-diyl, and is optionally substituted, wherein -X1- is attached at the 5-position of the oxazo!-4,5-diyl.
In one embodiment, -A1AH-, if present, is independently furan-diyl, and is optionally substituted.
In one embodiment, -A1AH-, if present, is independently thien-diyl, and is optionally substituted.
In one embodiment, -A1AH-, if present, is independently pyridin-diyl, and is optionally substituted.
In one embodiment, -A1AH-, if present, is independently quinolin-diyl, and is optionally substituted.
In one embodiment, -A1AH-, if present, is independently isoquinolin-diyl, and is optionally substituted.
The Group -A2A
In one embodiment, -A2A, if present, is independently -A2AC or -A2^1 wherein: -A2AC is independently C6-i0carboaryl; -A2AH is independently C5.12heteroaryl; each -A2AC and -A2AH is independently unsubstituted or substituted with one or more substituents -Q2.
In one embodiment, -A2A, if present, is independently -A2AC.
In one embodiment, -A2AC, if present, is independently phenyl or naphthyl, and is optionally substituted.
In one embodiment, -A2AC, if present, is independently phenyl, and is optionally substituted.
In one embodiment, -A2AG, if present, is independently phenyl, and is optionally substituted at the para-position.
In one embodiment, -A2AC, if present, is independently naphthyl, and is optionally substituted.
In one embodiment, -A2AC, if present, is independently naphth-1-yl, and is optionally substituted.
In one embodiment, -A2AC, if present, is independently naphth-2-yl, and is optionally substituted.
In one embodiment, -A2A, if present, is independently -A2AH.
In one embodiment, -A2AH, if present, is independently C5.6heteroaryl, and is optionally substituted.
In one embodiment, -A2AH, if present, is independently C7-10heteroaryl, and is optionally substituted.
In one embodiment, -A2AH, if present, is independently furanyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, or pyridazinyl, and is optionally substituted.
In one embodiment, -A2AH, if present, is independently pyridinyl, thiazolyl, or furanyl and is optionally substituted.
In one embodiment, -A2AH, if present, is independently pyridinyl, and is optionally substituted.
In one embodiment, -A2AH, if present, is independently pyridin-2-yl, and is optionally substituted.
In one embodiment, -A2AH, if present, is independently pyridin-3-yl, and is optionally substituted.
In one embodiment, -A2AH, if present, is independently pyridin-4-yl, and is optionally substituted.
In one embodiment, -A2AH, if present, is independently thiazolyl, and is optionally substituted.
In one embodiment, -A2AH, if present, is independently thiazol-4-yl, and is optionally substituted.
In one embodiment, -A2AH, if present, is independently furanyl, and is optionally substituted.
In one embodiment, -A2AH, if present, is independently furan-5-yl, and is optionally substituted.
In one embodiment, -A2AH, if present, is independently imidazolyl, and is optionally substituted.
In one embodiment, -A2AH, if present, is independently imidazol-1-yl, and is optionally substituted.
In one embodiment, -A2AH, if present, is independently quinolinyl, and is optionally substituted.
In one embodiment, -A2AH, if present, is independently quinolin-6-yl, and is optionally substituted.
In one embodiment, -A2AH, if present, is independently indolyl, and is optionally substituted.
In one embodiment, -A2AH, if present, is independently indol-5-yl, and is optionally substituted.
Some Preferred Combinations: Aryl-Resorcinols
In one embodiment: the group -X1-A1-X2-A2 is independently -A2A; and
-A2A is independently -A2AC.
In one embodiment: the group -X1-A1-X2-A2 is independently -A2A; and -A2A is independently -A2AH.
Some Preferred Combinations: Aryl-Aryl-Resorcinols
In one embodiment: the group -X1-A1-X2-A2 is independently -A1A-A2A; -A1A- is independently -A1AC-; and -A2A is independently -A2^.
In one embodiment: the group -X1-A1-X2-A2 is independently -A1A-A2A; -A1A- is independently -A1AC-; and -A2A is independently -A2AH.
In one embodiment: the group -X1-A1-X2-A2 is independently -A1A-A2A; -A1A- is independently -A1AH-; and -A2A is independently -A2AG.
In one embodiment: the group -X1-A1-X2-A2 is independently -A1A-A2A; -A1A- is independently -A1AH-; and -A2A is independently -A2AH.
Some Preferred Combinations: Phenyl-Oxazolyl-Resorcinols
In one embodiment: the group -X1-A1-X2-A2 is independently -A1A-A2A;
-A1A- is independently oxazol-4,5-diyl; and -A2A is independently phenyl, and is optionally substituted.
In one embodiment: the group -X1-A1-X2-A2 is independently -A1A-A2A;
-A1A- is independently oxazol-4,5-diyl; wherein -A2A- is attached at the 5-position of the oxazol-4,5-diyl; and -A2A is independently phenyl, and is optionally substituted.
In one embodiment, the compounds are selected from compounds of the following formula, and pharmaceutically acceptable salts, hydrates, and solvates thereof:
In one embodiment: the group -X1-A1-X2-A2 is independently -A1A-A2A;
-A1A- is independently oxazol-4,5-diyl; and
-A2A is independently -A2^; and
-A2AH is independently C5.6heteroaryl, and is optionally substituted.
In one embodiment: the group -X1-A1-X2-A2 is independently -A1A-A2A;
-A1A- is independently oxazol-4,5-diyl; wherein -A2A- is attached at the 5-position of the oxazol-4,5-diyl; -A2A is independently -A2AH; and
-A2AH is independently C5-6heteroaryl, and is optionally substituted.
In one embodiment: the group -X1-A1-X2-A2 is independently -A^-A^; -A1A- is independently oxazol-2,5-diyl; and
-A2A is independently phenyl, and is optionally substituted.
In one embodiment: the group -X1-A1-X2-A2 is independently -A1A-A2A; -A1A- is independently oxazol-2,5-diyl; and
-A2A is independently -A2AH; and -A2AH is independently C5-6heteroaryl, and is optionally substituted.
Some Preferred Combinations: Phenyl-Triazolyl-Resorcinols
In one embodiment: the group -X1-A1-X2-A2 is independently -A1A-A2A; -A1A- is independently 1 ,2,3-triazol-1 ,4-diyl or 1 ,2,3-triazol-1 ,5-diyl; -A2A is independently phenyl, and is optionally substituted.
In one embodiment: the group -X1-A1-X2-A2 is independently -A1A-A2A;
-A1A- is independently 1,2,3-triazol-1 ,4-diyl; and
-A2A is independently phenyl, and is optionally substituted.
In one embodiment: the group -X1-A1-X2-A2 is independently -A^-A^;
-A1A- is independently 1 ,2,3-triazol-1 ,5-diyl; and
-A2A is independently phenyl, and is optionally substituted.
Some Preferred Combinations: Keto-resorcinols
In one embodiment: the group -X1-A1-X2-A2 is independently -X1L-A1A-H or -X1L-A1A-F; -X1L- is independently -C(=O)-, -C(=O)-CH2-, -C(=O)-CH2-O-, or -C(=O)-CH2-S-; and
-A1A- is independently phenyl, and is optionally substituted.
In one embodiment: the group -X1-A1-X2-A2 is independently -X1L-A1A-H or -X1L-A1A-F;
-X1L- is independently -C(=O)-CH2-; and -A1A- is independently phenyl, and is optionally substituted.
In one embodiment: the group -X1-A1-X2-A2 is independently -X1L-A1A-H;
-X1L- is independently -C(=O)-CH2-; and -A1A- is independently phenyl, and is optionally substituted.
In one embodiment: the group -X1-A1-X2-A2 is independently -X1L-A1A-H or -X1L-A1A-F;
-X1L- is independently -C(=O)-; and -A1A- is independently phenyl, and is optionally substituted.
In one embodiment: the group -X1-A1-X2-A2 is independently -X1L-A1A-H;
-X1L- is independently -C(=O)-; and -A1A- is independently phenyl, and is optionally substituted.
Some Preferred Combinations: Sulfonamide-Phenyl-Resorcinols
In one embodiment: the group -X1-A1-X2-A2 is independently -A1A-H; -A1A- is independently phenyl and bears at least one substituent, -Q1, which is independently:
-NHS(=O)2R1A1, -NR1A1S(=O)2R1A1,
-S(=O)2NH2, -S(=O)2NHR1A1, -S(=O)2NR1A1 2, or -S(=O)2NR1A2R1A3.
In one embodiment: the group -X1-A1-X2-A2 is independently -A1A-H;
-A1A- is independently phenyl and bears at least one substituent, -Q1, which is independently:
-NHS(=O)2R1A1 or -NR1A1S(=O)2R1A1.
Some Preferred Combinations: Benzyl-Triazolyl-Resorcinols
In one embodiment: the group -X1-A1-X2-A2 is independently -A^-X^-A2*; -A1A- is independently 1 ,2,3-triazol-1 ,4-diyl or 1 ,2,3-triazoM ,5-diyl;
-X2L- is independently -CH2-; and -A2A is independently phenyl, and is optionally substituted.
In one embodiment: the group -X1-A1-X2-A2 is independently -A^-X^-A^;
-A1A- is independently 1 ,2,3-triazol-1 ,4-diyl; -X2L- is independently -CH2-; and -A2A is independently phenyl, and is optionally substituted.
In one embodiment: the group -X1-A1-X2-A2 is independently -A^-X^-A2*;
-A1A- is independently 1,2,3-triazol-1 ,5-diyl;
-X2L- is independently -CH2-; and
-AZA is independently phenyl, and is optionally substituted.
Some Preferred Combinations: Benzyl-Qxazolyl-Resorcinols
In one embodiment: the group -X1-A1-X2-A2 is independently -A^-X^-A2*; -A1A- is independently oxazol-2,5-diyl;
-X2L- is independently -CH2-; and -A2A is independently phenyl, and is optionally substituted.
Some Preferred Combinations: Phenyl-Resorcinols
In one embodiment: the group -X1-A1-X2-A2 is independently -A2A; and
-A2A is independently phenyl, and is optionally substituted.
The Optional Substituents -Q1
In one embodiment, each -A1AC- and -A1AH-, if present, is independently unsubstituted or substituted with one or more substituents -Q1.
In one embodiment, each -A1AC- and -A1AH-, if present, is independently unsubstituted.
In one embodiment, each -A1AC- and -A1AH-, if present, is independently substituted with one or more substituents -Q1.
In one embodiment, -A1AG-, if present, is independently unsubstituted.
In one embodiment, -A1AC-, if present, is independently substituted with one or more substituents -Q1.
In one embodiment, -A1AH-, if present, is independently unsubstituted. In one embodiment, -A1AH-, if present, is independently substituted with one or more substituents -Q1.
In one embodiment, each -Q1, if present, is independently:
-F, -Cl, -Br, -I,
-R1A1,
-CF3, -OCF3,
-OH, -L1A-OH, -O-L1A-OH,
-OR1A\ -L1A-OR1A1, -O-L1A-OR1A1, -NO2,
-NH2, -NHR1A1, -NR1A1 2, -NR1A2R1A3,
-C(=O)OH, -C(=O)OR1A1,
-C(=O)NH2, -C(=O)NHR1A1, -C(=O)NR1A1 2, -C(=O)NR1A2R1A3, -NHC(=O)R1A1, -NR1A1C(=O)R1A1, ■ -NHS(=O)2R1A1, -NR1A1S(=O)2R1A1, -S(=O)2NH2l -S(=O)2NHR1A1, -S(=O)2NR1A1 2, or -S(=O)2NR1A2R1A3; and additionally, two adjacent -Q1 groups, if present, may together form -0-CH2-O- or -0-CH2CH2-O-.
In one embodiment, each -Q1, if present, is independently: -F, -Cl, -Br, -I, -R1A1, -OH, -OR1A1,
-NHS(=O)2R1A1, -NR1A1S(=O)2R1A1, -S(=O)2NH2, -S(=O)2NHR1A1, -S(=O)2NR1A1 2, or -S(=O)2NR1A2R1A3.
In one embodiment, each -Q1, if present, is independently: -F, -Cl, -Br, -I, -R1A1, -OH, or -OR1A1.
In one embodiment, each -Q1, if present, is independently:
-R1A1.
In one embodiment, at least one -Q1 is present, and is independently: -NHS(=O)2R1A1, -NR1A1S(=O)2R1A1, -S(=O)2NH2, -S(=O)2NHR1A1, -S(=O)2NR1A1 2, or -S(=O)2NR1A2R1A3.
In one embodiment, at least one -Q1 is present, and is independently: -NHS(=O)2R1A1 or -NR1A1S(=O)2R1A1.
In one embodiment, each -Q1, if present, is independently selected from those substituents exemplified under the headings "Examples of Specific Embodiments" and "Additional Examples of Specific Embodiments".
The Optional Substituents -Q2
In one embodiment, each -A2AC- and -A2AH-, if present, is independently unsubstituted or substituted with one or more substituents -Q2.
In one embodiment, each -A2AC- and -A2AH-, if present, is independently unsubstituted.
In one embodiment, each -A2AC- and -A2AH-, if present, is independently substituted with one or more substituents -Q2.
In one embodiment, -A2AC-, if present, is independently unsubstituted.
In one embodiment, -A2AC-, if present, is independently substituted with one or more substituents -Q2.
In one embodiment, -A2AH-, if present, is independently unsubstituted. In one embodiment, -A2AH-, if present, is independently substituted with one or more substituents -Q2.
In one embodiment, each -Q2, if present, is independently:
-F1 -Cl1 -Br1 -I,
-R1A1,
-CF3, -OCF3,
-OH, -L1A-OH, -O-L1A-OH,
-OR1A1, -L1A-OR1A1, -O-L1A-OR1A1, -NO2,
-NH2, -NHR1A\ -NR1A1 2, -NR1A2R1A3,
-C(=O)OH, -C(=O)OR1A1,
-C(=O)NH2, -C(=O)NHR1A1, -C(=O)NR1A1 2, -C(=O)NR1A2R1A3,
-NHC(=O)R1A1, -NR1A1C(=O)R1A1, -NHS(=O)2R1A1, -NR1A1S(=O)2R1A1,
-S(=O)2NH2, -S(=O)2NHR1A1, -S(=O)2NR1A1 2, or -S(=O)2NR1A2R1A3; and additionally, two adjacent -Q1 groups, if present, may together form -0-CH2-O- or -0-CH2CH2-O-.
In one embodiment, each -Q2, if present, is independently: -F, -Cl1 -Br, -I1 -R1A1, -OH, -0R1A1, -NHS(=O)2R1A1, -NR1A1S(=O)2R1A1, -S(=O)2NH2, -S(=O)2NHR1A\ -S(=O)2NR1A1 2, or -S(=O)2NR1A2R1A3.
In one embodiment, each -Q2, if present, is independently: -F, -Cl, -Br, -I, -R1A1, -OH, or -OR1A1.
In one embodiment, each -Q2, if present, is independently:
-R1A1.
In one embodiment, each -Q2, if present, is independently selected from those substituents exemplified under the headings "Examples of Specific Embodiments" and "Additional Examples of Specific Embodiments".
Elemeπts of -Q1 and -Q2
In one embodiment, each -NR1A2R1A3, if present, is independently azetidino, pyrrolidino, imidazolidino, pyrazoiidino, piperidino, piperazino, morpholino, thiomorpholino, thiomorpholine-1 ,1 -dioxide, azepino, or diazepino, and is optionally substituted, for example, with one or more groups selected from saturated aliphatic Ci-3alkyl.
In one embodiment, each -NR1A2R1A3, if present, is independently pyrrolidino, piperidino, piperazino, morpholino, thiomorpholino, or thiomorpholine-1, 1 -dioxide, and is optionally substituted, for example, with one or more groups selected from saturated aliphatic Ci-3alkyl.
In one embodiment, each -R1A1, if present, is independently:
_p1B1 _D1B4 _p1B6 _p1B7 _p1B8 -L1B-R1B4, -L1B-R1B6, -L1B-R1B7, or -L1B-R1B8.
In one embodiment, each -R1A1, if present, is independently:
_p1B1 _p1B4 _p1B7
-L1B-R1B4, or -L1B-R1B7.
In one embodiment, each -R1A1, if present, is independently: -L1B-R1B6, -L18-R1B7, or -L1B-R1B8.
In one embodiment, each -R1A1, if present, is independently: -L1B-R1B6 or -L1B-R1B8.
In one embodiment, each -R1A1, if present, is independently:
-R1B1.
In one embodiment, each -R1B6, if present, is independently azetidinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidinyl, piperazinyl, morpholinyl, azepinyl, diazepinyl, tetrahydrofuranyl, tetrahydropyranyl.or dioxanyl, and is optionally substituted.
In one embodiment, each -R186, if present, is independently pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, tetrahydrofuranyl, tetrahydropyranyl, or dioxanyl, and is optionally substituted.
In one embodiment, each -R1B7, if present, is independently phenyl, and is optionally substituted.
In one embodiment, each -R1B8, if present, is independently C5.6heteroaryl, and is optionally substituted.
In one embodiment, each -R1B8, if present, is independently furanyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridyl, pyrimidinyl, or pyridazinyl, and is optionally substituted.
In one embodiment, each -L1B-, if present, is independently -CH2-.
In one embodiment, each -R1C1, if present, is independently saturated aliphatic C1-4alkyl.
In one embodiment, each -R1C2, if present, is independently:
-F, -Cl, -Br, -I1
-CF3, -OCF3, -OH,
-OR1D1,
-SH, -SR1D\
-CN,
-NO2, -NH2, -NHR1D1, -NR1D1 2, -NR1D2R1D3,
-C(=O)OH, -C(=O)OR1D\ -OC(=O)R1D1,
-C(=O)R1D1,
-C(=O)NH2, -C(=O)NHR1D1, -C(=O)NR1D1 2, -C(=O)NR1D2R1D3,
-NHC(=O)R1D1, -NR1D1C(=O)R1D1, -S(=O)2NH2, -S(=O)2NHR1A1, -S(=O)2NR1A1 2, -S(=O)2NR1A2R1A3, or
-S(=O)2R1 A1.
In one embodiment, each -R1C2, if present, is independently:
-F, -Cl, -Br, -I1 -CF3, -OCF3,
-OH,
-0R1D1,
-NH2, -NHR1D1, -NR1D1 2, -NR102R103,
-C(=O)OH, -C(=O)OR101, -OC(=O)R1D1, -C(=O)R1D1,
-C(=O)NH2, -C(=O)NHR1D1, -C(=O)NR1D1 2, -C(=O)NR1D2R103,
-NHC(=O)R1D1, -NR1D1C(=O)R1D1,
-SC=O)2NH2, -S(=O)2NHR1A1, -S(=O)2NR1A1 2, or -S(=O)2NR1A2R1A3.
In one embodiment, each -R101, if present, is independently saturated aliphatic C1-4alkyl.
In one embodiment, each -NR102R103, if present, is independently azetidino, pyrrolidino, imidazolidino, pyrazolidino, piperidino, piperazino, morpholino, thiomorpholino, thiomorpholine-1 ,1-dioxide, azepino, or diazepino, and is optionally substituted, for example, with one or more groups selected from saturated aliphatic C1-3alkyl.
In one embodiment, each -NR102R103, if present, is independently pyrrolidino, piperidino, piperazino, morpholino, thiomorpholino, or thiomorpholine-1 ,1 -dioxide, and is optionally substituted, for example, with one or more groups selected from saturated aliphatic Ci.3alkyl.
Combinations
Each and every compatible combination of the embodiments described above is explicitly disclosed herein, as if each and every combination was individually and explicitly recited.
Molecular Weight
In one embodiment, the IBD compound has a molecular weight of from 230 to 1200. In one embodiment, the bottom of the range is from 250, 275, 300, or 350. In one embodiment, the top of the range is 1100, 1000, 900, 800, 700, or 600. In one embodiment, the range is 250 to 600.
Examples of Specific Embodiments
In one embodiment, the compounds are selected from compounds of the following formulae and pharmaceutically acceptable salts, hydrates, and solvates thereof:
In one embodiment, the compounds are selected from compounds of the following formulae and pharmaceutically acceptable salts, hydrates, and solvates thereof:
In one embodiment, the compounds are selected from compounds of the following formulae and pharmaceutically acceptable salts, hydrates, and solvates thereof:
In one embodiment, the compounds are selected from compounds of the following formulae and pharmaceutically acceptable salts, hydrates, and solvates thereof:
In one embodiment, the compounds are selected from compounds of the following formulae and pharmaceutically acceptable salts, hydrates, and solvates thereof:
Additional Examples of Specific Embodiments
Oxazole-Resorcinols
In one embodiment, the compounds are selected from compounds of the following formulae and pharmaceutically acceptable salts, hydrates, and solvates thereof:
In one embodiment, the compounds are selected from compounds of the following formulae and pharmaceutically acceptable salts, hydrates, and solvates thereof:
In one embodiment, the compounds are selected from compounds of the following formulae and pharmaceutically acceptable salts, hydrates, and solvates thereof:
In one embodiment, the compounds are selected from compounds of the following formulae and pharmaceutically acceptable salts, hydrates, and solvates thereof:
In one embodiment, the compounds are selected from compounds of the following formulae and pharmaceutically acceptable salts, hydrates, and solvates thereof:
Triazole-Resorcinols
In one embodiment, the compounds are selected from compounds of the following formulae and pharmaceutically acceptable salts, hydrates, and solvates thereof:
In one embodiment, the compounds are selected from compounds of the following formulae and pharmaceutically acceptable salts, hydrates, and solvates thereof:
In one embodiment, the compounds are selected from compounds of the following formulae and pharmaceutically acceptable salts, hydrates, and solvates thereof:
In one embodiment, the compounds are selected from compounds of the following formulae and pharmaceutically acceptable salts, hydrates, and solvates thereof:
Keto-Resorcinols
In one embodiment, the compounds are selected from compounds of the following formulae and pharmaceutically acceptable salts, hydrates, and solvates thereof:
In one embodiment, the compounds are selected from compounds of the following formulae and pharmaceutically acceptable salts, hydrates, and solvates thereof:
In one embodiment, the compounds are selected from compounds of the following formulae and pharmaceutically acceptable salts, hydrates, and solvates thereof:
Phenyl-Resorcinols
In one embodiment, the compounds are selected from compounds of the following formulae and pharmaceutically acceptable salts, hydrates, and solvates thereof:
In one embodiment, the compounds are selected from compounds of the following formulae and pharmaceutically acceptable salts, hydrates, and solvates thereof:
In one embodiment, the compounds are selected from compounds of the following formulae and pharmaceutically acceptable salts, hydrates, and solvates thereof:
Heteroaryl-Resorcinols
In one embodiment, the compounds are selected from compounds of the following formulae and pharmaceutically acceptable salts, hydrates, and solvates thereof:
Naphthyl-Resorcinols
In one embodiment, the compounds are selected from compounds of the following formulae and pharmaceutically acceptable salts, hydrates, and solvates thereof:
TABLE 17
Compounds where -X1- is a covalent single bond, -A1- is naphth-diyl,
-X2- is c a covalent single bond, and -A 2 is -H
R
HO
Compound R Compound R
17-1
Substantiallv Purified Forms
One aspect of the present invention pertains to IBD compounds, as described herein, in substantially purified form and/or in a form substantially free from contaminants.
In one embodiment, the substantially purified form is at least 50% by weight, e.g., at least 60% by weight, e.g., at least 70% by weight, e.g., at least 80% by weight, e.g., at least 90% by weight, e.g., at least 95% by weight, e.g., at least 97% by weight, e.g., at least 98% by weight, e.g., at least 99% by weight.
Unless specified, the substantially purified form refers to the compound in any stereoisomeric or enantiomeric form. For example, in one embodiment, the substantially purified form refers to a mixture of stereoisomers, i.e., purified with respect to other compounds. In one embodiment, the substantially purified form refers to one stereoisomer, e.g., optically pure stereoisomer, in one embodiment, the substantially purified form refers to a mixture of enantiomers. In one embodiment, the substantially purified form refers to a equimolar mixture of enantiomers (i.e., a racemic mixture, a racemate). In one embodiment, the substantially purified form refers to one enantiomer, e.g., optically pure enantiomer.
In one embodiment, the contaminants represent no more than 50% by weight, e.g., no more than 40% by weight, e.g., no more than 30% by weight, e.g., no more than 20% by weight, e.g., no more than 10% by weight, e.g., no more than 5% by weight, e.g., no more than 3% by weight, e.g., no more than 2% by weight, e.g., no more than 1% by weight.
Unless specified, the contaminants refer to other compounds, that is, other than stereoisomers or enantiomers. In one embodiment, the contaminants refer to other compounds and other stereoisomers. In one embodiment, the contaminants refer to other compounds and the other enantiomer.
In one embodiment, the substantially purified form is at least 60% optically pure (i.e., 60% of the compound, on a molar basis, is the desired stereoisomer or enantiomer, and 40% is the undesired stereoisomer or enantiomer), e.g., at least 70% optically pure, e.g., at least 80% optically pure, e.g., at least 90% optically pure, e.g., at least 95% optically pure, e.g., at least 97% optically pure, e.g., at least 98% optically pure, e.g., at least 99% optically pure.
Isomers
Certain compounds may exist in one or more particular geometric, optical, enantiomeric, diasteriomeric, epimeric, atropic, stereoisomeric, tautomeric, conformational, or anomeric
forms, including but not limited to, cis- and trans-forms; E- and Z-forms; o, t-, and r- forms; endo- and exo-forms; R-, S-, and meso-forms; D- and L-forms; d- and l-forms; (+) and (-) forms; keto-, enol-, and enolate-forms; syn- and anti-forms; synclinal- and anticlinal-forms; α- and β-forms; axial and equatorial forms; boat-, chair-, twist-, envelope-, and halfchair-forms; and combinations thereof, hereinafter collectively referred to as "isomers" (or "isomeric forms").
Note that, except as discussed below for tautomeric forms, specifically excluded from the term "isomers," as used herein, are structural (or constitutional) isomers (i.e., isomers which differ in the connections between atoms rather than merely by the position of atoms in space). For example, a reference to a methoxy group, -OCH3, is not to be construed as a reference to its structural isomer, a hydroxymethyl group, -CH2OH. Similarly, a reference to ortho-chlorophenyl is not to be construed as a reference to its structural isomer, meta-chlorophenyl. However, a reference to a class of structures may well include structurally isomeric forms falling within that class (e.g., Ci-7alkyl includes n-propyl and iso-propyl; butyl includes n-, iso-, sec-, and tert-butyl; methoxyphenyl includes ortho-, meta-, and para-methoxyphenyl).
The above exclusion does not pertain to tautomeric forms, for example, keto-, enol-, and enolate-forms, as in, for example, the following tautomeric pairs: keto/enol (illustrated below), imine/enamine, amide/imino alcohol, amidine/amidine, nitroso/oxime, thioketone/enethiol, N-nitroso/hydroxyazo, and nitro/aci-nitro.
keto enol enolate
Note that specifically included in the term "isomer" are compounds with one or more isotopic substitutions. For example, H may be in any isotopic form, including 1H, 2H (D), and 3H (T); C may be in any isotopic form, including 12C, 13C, and 14C; O may be in any isotopic form, including 16O and 18O; and the like.
Unless otherwise specified, a reference to a particular compound includes all such isomeric forms, including mixtures (e.g., racemic mixtures) thereof. Methods for the preparation (e.g., asymmetric synthesis) and separation (e.g., fractional crystallisation and chromatographic means) of such isomeric forms are either known in the art or are readily obtained by adapting the methods taught herein, or known methods, in a known manner.
Salts
It may be convenient or desirable to prepare, purify, and/or handle a corresponding salt of the compound, for example, a pharmaceutically-acceptable salt. Examples of pharmaceutically acceptable salts are discussed in Berge et al., 1977, "Pharmaceutically Acceptable Salts," J. Pharm. ScL Vol. 66, pp. 1-19.
For example, if the compound is anionic, or has a functional group which may be anionic (e.g., -COOH may be -COO"), then a salt may be formed with a suitable cation. Examples of suitable inorganic cations include, but are not limited to, alkali metal ions such as Na+ and K+, alkaline earth cations such as Ca2+ and Mg2+, and other cations such as Al+3. Examples of suitable organic cations include, but are not limited to, ammonium ion (i.e., NH4 +) and substituted ammonium ions (e.g., NH3R+, NH2R2 +, NHR3 +, NR4 +). Examples of some suitable substituted ammonium ions are those derived from: ethylamine, diethylamine, dicyclohexylamine, triethylamine, butylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, benzylamine, phenylbenzylamine, choline, meglumine, and trometharnine, as well as amino acids, such as lysine and arginine. An example of a common quaternary ammonium ion is N(CH3)4 +.
If the compound is cationic, or has a functional group which may be cationic (e.g., -NH2 may be -NH3 +), then a salt may be formed with a suitable anion. Examples of suitable inorganic anions include, but are not limited to, those derived from the following inorganic acids: hydrochloric, hydrobromic, hydroiodic, sulfuric, sulfurous, nitric, nitrous, phosphoric, and phosphorous.
Examples of suitable organic anions include, but are not limited to, those derived from the following organic acids: 2-acetyoxybenzoic, acetic, ascorbic, aspartic, benzoic, camphorsulfonic, cinnamic, citric, edetic, ethanedisulfonic, ethanesulfonic, fumaric, glucheptonic, gluconic, glutamic, glycolic, hydroxymaleic, hydroxynaphthalene carboxylic, isethionic, lactic, lactobionic, lauric, maleic, malic, methanesulfonic, mucic, oleic, oxalic, palmitic, pamoic, pantothenic, phenylacetic, phenylsulfonic, propionic, pyruvic, salicylic, stearic, succinic, sulfanilic, tartaric, toluenesulfonic, and valeric. Examples of suitable polymeric organic anions include, but are not limited to, those derived from the following polymeric acids: tannic acid, carboxymethyl cellulose.
Unless otherwise specified, a reference to a particular compound also includes salt forms thereof.
Solvates and Hydrates
It may be convenient or desirable to prepare, purify, and/or handle a corresponding solvate of the compound. The term "solvate" is used herein in the conventional sense to refer to a complex of solute (e.g., compound, salt of compound) and solvent. If the solvent is water, the solvate may be conveniently referred to as a hydrate, for example, a mono-hydrate, a di-hydrate, a tri-hydrate, etc.
Unless otherwise specified, a reference to a particular compound also includes solvate and hydrate forms thereof.
Chemically Protected Forms
It may be convenient or desirable to prepare, purify, and/or handle the compound in a chemically protected form. The term "chemically protected form" is used herein in the conventional chemical sense and pertains to a compound in which one or more reactive functional groups are protected from undesirable chemical reactions under specified conditions (e.g., pH, temperature, radiation, solvent, and the like). In practice, well known chemical methods are employed to reversibly render unreactive a functional group, which otherwise would be reactive, under specified conditions. In a chemically protected form, one or more reactive functional groups are in the form of a protected or protecting group (also known as a masked or masking group or a blocked or blocking group). By protecting a reactive functional group, reactions involving other unprotected reactive functional groups can be performed, without affecting the protected group; the protecting group may be removed, usually in a subsequent step, without substantially affecting the remainder of the molecule. See, for example, Protective Groups in Organic Synthesis (T. Green and P. Wuts; 3rd Edition; John Wiley and Sons, 1999).
A wide variety of such "protecting," "blocking," or "masking" methods are widely used and well known in organic synthesis. For example, a compound which has two nonequivalent reactive functional groups, both of which would be reactive under specified conditions, may be derivatized to render one of the functional groups "protected," and therefore unreactive, under the specified conditions; so protected, the compound may be used as a reactant which has effectively only one reactive functional group. After the desired reaction (involving the other functional group) is complete, the protected group may be "deprotected" to return it to its original functionality.
For example, a hydroxy group may be protected as an ether (-OR) or an ester (-OC(=O)R), for example, as: a t-butyl ether; a benzyl, benzhydryl (diphenylmethyl), or trityl (triphenylmethyl) ether; a trimethylsilyl or t-butyldimethylsilyl ether; or an acetyl ester (-OC(=O)CH3l -OAc).
For example, an aldehyde or ketone group may be protected as an acetal (R-CH(OR)2) or ketal (R2C(OR)2), respectively, in which the carbonyl group (>C=O) is converted to a diether (>C(OR)2), by reaction with, for example, a primary alcohol. The aldehyde or ketone group is readily regenerated by hydrolysis using a large excess of water in the presence of acid.
For example, an amine group may be protected, for example, as an amide (-NRCO-R) or a urethane (-NRCO-OR), for example, as: a methyl amide (-NHCO-CH3); a benzyloxy amide (-NHCO-OCH2C6H5, -NH-Cbz); as a t-butoxy amide (-NHCO-OC(CH3)3, -NH-Boc); a 2-biphenyl-2-propoxy amide (-NHCO-OC(CHs)2C6H4C6H5, -NH-Bpoc), as a 9- fluorenylmethoxy amide (-NH-Fmoc), as a 6-nitroveratryloxy amide (-NH-Nvoc), as a 2-trimethylsilylethyloxy amide (-NH-Teoc), as a 2,2,2-trichloroethyloxy amide (-NH-Troc), as an allyloxy amide (-NH-Alloc), as a 2(-phenylsulfonyl)ethyloxy amide (-NH-Psec); or, in suitable cases (e.g., cyclic amines), as a nitroxide radical (>N-O*).
For example, a carboxylic acid group may be protected as an ester for example, as: an C1-7alkyl ester (e.g., a methyl ester; a t-butyl ester); a C-i-7haloalkyl ester (e.g., a Ci-7trihaloalkyl ester); a triC1-7alkylsiiyl-C1-7alkyl ester; or a C5.2oaryl-C1-7alkyl ester (e.g., a benzyl ester; a nitrobenzyl ester); or as an amide, for example, as a methyl amide.
For example, a thiol group may be protected as a thioether (-SR), for example, as: a benzyl thioether; an acetamidomethyl ether (-S-CH2NHC(=O)CH3).
Prodrugs
it may be convenient or desirable to prepare, purify, and/or handle the compound in the form of a prodrug. The term "prodrug," as used herein, pertains to a compound which, when metabolised (e.g., in vivo), yields the desired active compound. Typically, the prodrug is inactive, or less active than the desired active compound, but may provide advantageous handling, administration, or metabolic properties.
For example, some prodrugs are esters of the active compound (e.g., a physiologically acceptable metabolically labile ester). During metabolism, the ester group (-C(=O)OR) is cleaved to yield the active drug. Such esters may be formed by esterification, for example, of any of the carboxylic acid groups (-C(=0)0H) in the parent compound, with, where appropriate, prior protection of any other reactive groups present in the parent compound, followed by deprotection if required.
Also, some prodrugs are activated enzymatically to yield the active compound, or a compound which, upon further chemical reaction, yields the active compound (for
example, as in ADEPT, GDEPT, LIDEPT, etc.). For example, the prodrug may be a sugar derivative or other glycoside conjugate, or may be an amino acid ester derivative.
Chemical Synthesis
Several methods for the chemical synthesis of IBD compounds of the present invention are described herein. These and/or other well known methods may be modified and/or adapted in known ways in order to facilitate the synthesis of additional compounds within the scope of the present invention.
Compositions
One aspect of the present invention pertains to a composition (e.g., a pharmaceutical composition) comprising an IBD compound, as described herein, and a pharmaceutically acceptable carrier, diluent, or excipient.
Another aspect of the present invention pertains to a method of preparing a composition (e.g., a pharmaceutical composition) comprising admixing an IBD compound, as described herein, and a pharmaceutically acceptable carrier, diluent, or excipient.
Uses
The compounds described herein (e.g., without a proviso regarding P-001 through P-003) are useful, for example, in the treatment of diseases and conditions that are ameliorated by the inhibition of heat shock protein 90 (HSP90) function, such as, for example, proliferative conditions, cancer, etc.
Use in Methods of Inhibiting Heat Shock Protein 90 (HSP90) Function
One aspect of the present invention pertains to a method of inhibiting heat shock protein 90 (HSP90) function, in vitro or in vivo, comprising contacting an HSP90 with an effective amount of an IBD compound, as described herein (e.g., without a proviso regarding P-001 through P-003).
One aspect of the present invention pertains to a method of inhibiting heat shock protein 90 (HSP90) function in a cell, in vitro or in vivo, comprising contacting the cell with an effective amount of an IBD compound, as described herein (e.g., without a proviso regarding P-001 through P-003).
In one embodiment, the method is performed in vitro. In one embodiment, the method is performed in vivo.
One of ordinary skill in the art is readily able to determine whether or not, and/or the degree to which, a candidate compound inhibits HSP90 function. Suitable assays for determining heat shock protein 90 (HSP90) function inhibition are described herein and/or are known in the art.
Use in Methods of Inhibiting Cell Proliferation, Etc.
The IBD compounds described herein (e.g., without a proviso regarding P-001 through P-003), e.g., (a) regulate (e.g., inhibit) cell proliferation; (b) inhibit cell cycle progression; (c) promote apoptosis; or (d) a combination of one or more of these.
One aspect of the present invention pertains to a method of regulating (e.g., inhibiting) cell proliferation (e.g., proliferation of a cell), inhibiting cell cycle progression, promoting apoptosis, or a combination of one or more these, in vitro or in vivo, comprising contacting a cell with an effective amount of an IBD compound, as described herein (e.g., without a proviso regarding P-001 through P-003).
In one embodiment, the method is a method of regulating (e.g., inhibiting) cell proliferation (e.g., proliferation of a cell), in vitro or in vivo, comprising contacting a cell with an effective amount of an IBD compound, as described herein (e.g., without a proviso regarding P-001 through P-003).
In one embodiment, the method is performed in vitro. In one embodiment, the method is performed in vivo.
In one embodiment, the IBD compound is provided in the form of a pharmaceutically acceptable composition.
Any type of cell may be treated, including but not limited to, lung, gastrointestinal
(including, e.g., bowel, colon), breast (mammary), ovarian, prostate, liver (hepatic), kidney (renal), bladder, pancreas, brain, and skin.
One of ordinary skill in the art is readily able to determine whether or not a candidate compound regulates (e.g., inhibits) cell proliferation, etc. For example, assays which may conveniently be used to assess the activity offered by a particular compound are described herein.
For example, a sample of cells (e.g., from a tumour) may be grown in vitro and a compound brought into contact with said cells, and the effect of the compound on those cells observed. As an example of "effect," the morphological status of the cells (e.g., alive
or dead, etc.) may be determined. Where the compound is found to exert an influence on the cells, this may be used as a prognostic or diagnostic marker of the efficacy of the compound in methods of treating a patient carrying cells of the same cellular type.
Use in Methods of Therapy
Another aspect of the present invention pertains to an IBD compound, as described herein (e.g., without a proviso regarding P-001 through P-003), for use in a method of treatment of the human or animal body by therapy.
Use in the Manufacture of Medicaments
Another aspect of the present invention pertains to use of an IBD compound, as described herein (e.g., without a proviso regarding P-001 through P-003), in the manufacture of a medicament for use in treatment.
In one embodiment, the medicament comprises the IBD compound.
Methods of Treatment
Another aspect of the present invention pertains to a method of treatment comprising administering to a patient in need of treatment a therapeutically effective amount of an IBD compound, as described herein (e.g., without a proviso regarding P-001 through P-003), preferably in the form of a pharmaceutical composition.
Conditions Treated - Conditions Mediated by Heat Shock Protein 90 (HSP90)
In one embodiment (e.g., of use in methods of therapy, of use in the manufacture of medicaments, of methods of treatment), the treatment is treatment of a disease or condition that is mediated by heat shock protein 90 (HSP90).
A disease or disorder that is mediated by HSP90 is, for example, a disease or disorder in which HSP90 and/or the action of HSP90 is important or necessary, e.g., for the onset, progresssion, expression, etc., of that disease or disorder.
Conditions Treated - Conditions Ameliorated by the Inhibition of Heat Shock Protein 90 (HSP90) Function
In one embodiment (e.g., of use in methods of therapy, of use in the manufacture of medicaments, of methods of treatment), the treatment is treatment of: a disease or condition that is ameliorated by the inhibition of heat shock protein 90 (HSP90) function.
Conditions Treated - Conditions Known to be Treated by Heat Shock Protein 90 (ΗSP9CH Inhibitors
In one embodiment (e.g., of use in methods of therapy, of use in the manufacture of medicaments, of methods of treatment), the treatment is treatment of: a disease or condition that is known to be treated by HSP90 inhibitors (e.g., 17-AAG, geldanamycin, etc.)
Conditions Treated
In one embodiment (e.g., of use in methods of therapy, of use in the manufacture of medicaments, of methods of treatment), the treatment is treatment of:
neurological damage caused by stroke or cardiac arrest;
fibrogenic disorders, such as: scleroderma, systemic sclerosis, polymyositis, systemic lupus erythematosus, liver cirrhosis, and keloids;
interstitial nephritis;
pulmonary fibrosis;
rheumatoid arthritis;
osteoarthritis;
disorders involving angiogenesis, such as: granuloma, retinal neovascularisation, choroidal neovascularisation, diabetic nephropathy, melorheostosis, asthma, inflammation, synovitis,
abortifacients, wound healing, psoriasis, endometriosis, severe ovarian hyperstimulation syndrome, myelodysplasia syndrome, haemorrhagic telengectasia, atherosclerosis, restenosis, thrombosis,
Crohn's disease, inflammatory bowel disease, ulcerative colitis, and macular degeneration;
viral infections, such as:
HPV infection, and influenza;
parasitic infections, such as: malaria, schistosomiasis, trypanosomiasis, toxoplasmosis, and leishmania;
fungal infection;
diseases involving a translocated toxin, such as: Diphtheria, and
Botulism; and
bacterial infection.
Conditions Treated - Proliferative Conditions and Cancer
In one embodiment (e.g., of use in methods of therapy, of use in the manufacture of medicaments, of methods of treatment), the treatment is treatment of: a proliferative condition.
The term "proliferative condition," as used herein, pertains to an unwanted or uncontrolled cellular proliferation of excessive or abnormal cells which is undesired, such as, neoplastic or hyperplastic growth.
In one embodiment, the treatment is treatment of: a proliferative condition characterised by benign, pre-malignant, or malignant cellular proliferation, including but not limited to, neoplasms, hyperplasias, and tumours (e.g., histocytoma, glioma, astrocyoma, osteoma), cancers (see below), psoriasis, bone diseases, fibroproliferative disorders (e.g., of connective tissues), pulmonary fibrosis, atherosclerosis, smooth muscle cell proliferation in the blood vessels, such as stenosis or restenosis following angioplasty.
In one embodiment, the treatment is treatment of: cancer.
In one embodiment, the treatment is treatment of: lung cancer, small cell lung cancer, non-small cell lung cancer, gastrointestinal cancer, stomach cancer, bowel cancer, colon cancer, rectal cancer, colorectal cancer, thyroid cancer, breast cancer, ovarian cancer, endometrial cancer, prostate cancer, testicular cancer, liver cancer, kidney cancer, renal cell carcinoma, bladder cancer, pancreatic cancer, brain cancer, glioma, sarcoma, osteosarcoma, bone cancer, nasopharyngeal cancer (e.g., head cancer, neck cancer), skin cancer, squamous cancer, Kaposi's sarcoma, melanoma, malignant melanoma, lymphoma, or leukemia.
In one embodiment, the treatment is treatment of: a carcinoma, for example a carcinoma of the bladder, breast, colon (e.g., colorectal carcinomas such as colon adenocarcinoma and colon adenoma), kidney, epidermal, liver, lung (e.g., adenocarcinoma, small cell lung cancer and non-small cell lung carcinomas), oesophagus, gall bladder, ovary, pancreas (e.g., exocrine pancreatic carcinoma), stomach, cervix, thyroid, prostate, skin (e.g., squamous cell carcinoma); a hematopoietic tumour of lymphoid lineage, for example leukemia, acute lymphocytic leukemia, B-cell lymphoma, T-cell lymphoma, Hodgkin's lymphoma, non- Hodgkin's lymphoma, hairy cell lymphoma, or Burkett's lymphoma; a hematopoietic tumor of myeloid lineage, for example acute and chronic myelogenous leukemias, myeiodysplastic syndrome, or promyelocytic leukemia; a tumour of mesenchymal origin, for example fibrosarcoma or habdomyosarcoma; a tumor of the central or peripheral nervous system, for example astrocytoma, neuroblastoma, glioma or schwannoma; melanoma; seminoma; teratocarcinoma; osteosarcoma; xenoderoma pigmentoum; keratoctanthoma; thyroid follicular cancer; or Kaposi's sarcoma.
In one embodiment, the treatment is treatment of solid tumour cancer. In one embodiment, the treatment is treatment of liquid tumour cancer.
In one embodiment, the treatment is treatment of hemotaological cancer.
In one embodiment, the treatment is treatment of: skin cancer, melanoma, breast cancer, estrogen receptor-dependent and independent breast cancer, ovarian cancer, prostate cancer, androgen dependent and independent prostate cancer, renal cancer, colon and colorectal cancer, pancreatic cancer, bladder cancer, esophageal cancer, stomach cancer, genitourinary cancer, uterine cancer, astrocytomas, gliomas, basal cancer, squamous cell carcinoma, sarcoma, osteosarcoma, head and neck cancer, lung cancer, small cell lung carcinoma, non-small cell lung carcinoma, leukemia, lymphoma, and other blood cell cancers.
In one embodiment, the treatment is treatment of: lung cancer, breast cancer, ovarian cancer, colorectal cancer, melanoma, or glioma.
The anti-cancer effect may arise through one or more mechanisms, including but not limited to, the regulation of cell proliferation, the inhibition of cell cycle progression, the inhibition of angiogenesis (the formation of new blood vessels), the inhibition of metastasis (the spread of a tumour from its origin), the inhibition of invasion (the spread of tumour cells into neighbouring normal structures), or the promotion of apoptosis (programmed cell death). The compounds of the present invention may be used in the treatment of the cancers described herein, independent of the mechanisms discussed herein.
Treatment
The term "treatment," as used herein in the context of treating a condition, pertains generally to treatment and therapy, whether of a human or an animal (e.g., in veterinary applications), in which some desired therapeutic effect is achieved, for example, the inhibition of the progress of the condition, and includes a reduction in the rate of progress, a halt in the rate of progress, alleviatiation of symptoms of the condition, amelioration of the condition, and cure of the condition. Treatment as a prophylactic measure (i.e., prophylaxis) is also included. For example, use with patients who have not yet developed the condition, but who are at risk of developing the condition, is encompassed by the term "treatment."
For example, treatment includes the prophylaxis of cancer, reducing the incidence of cancer, alleviating the symptoms of cancer, etc.
The term "therapeutically-effective amount," as used herein, pertains to that amount of a compound, or a material, composition or dosage form comprising a compound, which is
effective for producing some desired therapeutic effect, commensurate with a reasonable benefit/risk ratio, when administered in accordance with a desired treatment regimen.
Combination Therapies
The term "treatment" includes combination treatments and therapies, in which two or more treatments or therapies are combined, for example, sequentially or simultaneously. For example, the compounds described herein may also be used in combination therapies, e.g., in conjunction with other agents, for example, cytotoxic agents, anticancer agents, etc. Examples of treatments and therapies include, but are not limited to, chemotherapy (the administration of active agents, including, e.g., drugs, antibodies (e.g., as in immunotherapy), prodrugs (e.g., as in photodynamic therapy, GDEPT, ADEPT, etc.); surgery; radiation therapy; photodynamic therapy; gene therapy; and controlled diets.
For example, it may be beneficial to combine treatment with a compound as described herein with one or more other (e.g., 1 , 2, 3, 4) agents or therapies that regulates cell growth or survival or differentiation via a different mechanism, thus treating several characteristic features of cancer development.
One aspect of the present invention pertains to a compound as described herein, in combination with one or more additional therapeutic agents, as described below.
The particular combination would be at the discretion of the physician who would select dosages using his common general knowledge and dosing regimens known to a skilled practitioner.
The agents (i.e., the compound described herein, plus one or more other agents) may be administered simultaneously or sequentially, and may be administered in individually varying dose schedules and via different routes. For example, when administered sequentially, the agents can be administered at closely spaced intervals (e.g., over a period of 5-10 minutes) or at longer intervals (e.g., 1 , 2, 3, 4 or more hours apart, or even longer periods apart where required), the precise dosage regimen being commensurate with the properties of the therapeutic agent(s).
The agents (i.e., the compound described here, plus one or more other agents) may be formulated together in a single dosage form, or alternatively, the individual agents may be formulated separately and presented together in the form of a kit, optionally with instructions for their use.
Other Uses
The IBD compounds described herein may also be used as cell culture additives to inhibit heat shock protein 90 (HSP90) function, e.g., to inhibit cell proliferation, etc.
The IBD compounds described herein may also be used as part of an in vitro assay, for example, in order to determine whether a candidate host is likely to benefit from treatment with the compound in question.
The IBD compounds described herein may also be used as a standard, for example, in an assay, in order to identify other compounds, other heat shock protein 90 (HSP90) function inhibitors, other anti-proliferative agents, other anti-cancer agents, etc.
The IBD compounds described herein may also be used as a herbicide.
Kits
One aspect of the invention pertains to a kit comprising (a) an IBD compound as described herein, or a composition comprising an IBD compound as described herein, e.g., preferably provided in a suitable container and/or with suitable packaging; and (b) instructions for use, e.g., written instructions on how to administer the compound or composition.
The written instructions may also include a list of indications for which the active ingredient is a suitable treatment.
Routes of Administration
The IBD compound or pharmaceutical composition comprising the IBD compound may be administered to a subject by any convenient route of administration, whether systemically/peripherally or topically (i.e., at the site of desired action).
Routes of administration include, but are not limited to, oral (e.g., by ingestion); buccal; sublingual; transdermal (including, e.g., by a patch, plaster, etc.); transmucosal (including, e.g., by a patch, plaster, etc.); intranasal (e.g., by nasal spray); ocular (e.g., by eyedrops); pulmonary (e.g., by inhalation or insufflation therapy using, e.g., via an aerosol, e.g., through the mouth or nose); rectal (e.g., by suppository or enema); vaginal (e.g., by pessary); parenteral, for example, by injection, including subcutaneous, intradermal, intramuscular, intravenous, intraarterial, intracardiac, intrathecal, intraspinal, intracapsular, subcapsular, intraorbital, intraperitoneal, intratracheal, subcuticular,
intraarticular, subarachnoid, and intrasternal; by implant of a depot or reservoir, for example, subcutaneously or intramuscularly.
The Subject/Patient
The subject/patient may be a chordate, a vertebrate, a mammal, a placental mammal, a marsupial (e.g., kangaroo, wombat), a rodent (e.g., a guinea pig, a hamster, a rat, a mouse), murine (e.g., a mouse), a lagomorph (e.g., a rabbit), avian (e.g., a bird), canine (e.g., a dog), feline (e.g., a cat), equine (e.g., a horse), porcine (e.g., a pig), ovine (e.g., a sheep), bovine (e.g., a cow), a primate, simian (e.g., a monkey or ape), a monkey
(e.g., marmoset, baboon), an ape (e.g., gorilla, chimpanzee, orangutang, gibbon), or a human.
Furthermore, the subject/patient may be any of its forms of development, for example, a foetus.
In one preferred embodiment, the subject/patient is a human.
Formulations
While it is possible for the IBD compound to be administered alone, it is preferable to present it as a pharmaceutical formulation (e.g., composition, preparation, medicament) comprising at least one IBD compound, as described herein, together with one or more other pharmaceutically acceptable ingredients well known to those skilled in the art, including, but not limited to, pharmaceutically acceptable carriers, diluents, excipients, adjuvants, fillers, buffers, preservatives, anti-oxidants, lubricants, stabilisers, solubilisers, surfactants (e.g., wetting agents), masking agents, colouring agents, flavouring agents, and sweetening agents. The formulation may further comprise other active agents, for example, other therapeutic or prophylactic agents.
Thus, the present invention further provides pharmaceutical compositions, as defined above, and methods of making a pharmaceutical composition comprising admixing at least one IBD compound, as described herein, together with one or more other pharmaceutically acceptable ingredients well known to those skilled in the art, e.g., carriers, diluents, excipients, etc. If formulated as discrete units (e.g., tablets, etc.), each unit contains a predetermined amount (dosage) of the compound.
The term "pharmaceutically acceptable," as used herein, pertains to compounds, ingredients, materials, compositions, dosage forms, etc., which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of the subject in question (e.g., human) without excessive toxicity, irritation, allergic response, or other
problenn or complication, commensurate with a reasonable benefit/risk ratio. Each carrier, diluent, excipient, etc. must also be "acceptable" in the sense of being compatible with the other ingredients of the formulation.
Suitable carriers, diluents, excipients, etc. can be found in standard pharmaceutical texts, for example, Remington's Pharmaceutical Sciences, 18th edition, Mack Publishing Company, Easton, Pa., 1990; and Handbook of Pharmaceutical Excipients, 5th edition, 2005.
The formulations may be prepared by any methods well known in the art of pharmacy. Such methods include the step of bringing into association the compound with a carrier which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association the compound with carriers (e.g., liquid carriers, finely divided solid carrier, etc.), and then shaping the product, if necessary.
The formulation may be prepared to provide for rapid or slow release; immediate, delayed, timed, or sustained release; or a combination thereof.
Formulations may suitably be in the form of liquids, solutions (e.g., aqueous, nonaqueous), suspensions (e.g., aqueous, non-aqueous), emulsions (e.g., oil-in-water, water-in-oil), elixirs, syrups, electuaries, mouthwashes, drops, tablets (including, e.g., coated tablets), granules, powders, losenges, pastilles, capsules (including, e.g., hard and soft gelatin capsules), cachets, pills, ampoules, boluses, suppositories, pessaries, tinctures, gels, pastes, ointments, creams, lotions, oils, foams, sprays, mists, or aerosols.
Formulations may suitably be provided as a patch, adhesive plaster, bandage, dressing, or the like which is impregnated with one or more compounds and optionally one or more other pharmaceutically acceptable ingredients, including, for example, penetration, permeation, and absorption enhancers. Formulations may also suitably be provided in the form of a depot or reservoir.
The compound may be dissolved in, suspended in, or admixed with one or more other pharmaceutically acceptable ingredients. The compound may be presented in a liposome or other microparticulate which is designed to target the compound, for example, to blood components or one or more organs.
Formulations suitable for oral administration (e.g., by ingestion) include liquids, solutions (e.g., aqueous, non-aqueous), suspensions (e.g., aqueous, non-aqueous), emulsions (e.g., oil-in-water, water-in-oil), elixirs, syrups, electuaries, tablets, granules, powders, capsules, cachets, pills, ampoules, boluses.
Formulations suitable for buccal administration include mouthwashes, losenges, pastilles, as well as patches, adhesive plasters, depots, and reservoirs. Losenges typically comprise the compound in a flavored basis, usually sucrose and acacia or tragacanth. Pastilles typically comprise the compound in an inert matrix, such as gelatin and glycerin, or sucrose and acacia. Mouthwashes typically comprise the compound in a suitable liquid carrier.
Formulations suitable for sublingual administration include tablets, losenges, pastilles, capsules, and pills.
Formulations suitable for oral transmucosal administration include liquids, solutions (e.g., aqueous, non-aqueous), suspensions (e.g., aqueous, non-aqueous), emulsions (e.g., oil- in-water, water-in-oil), mouthwashes, losenges, pastilles, as well as patches, adhesive plasters, depots, and reservoirs.
Formulations suitable for non-oral transmucosal administration include liquids, solutions (e.g., aqueous, non-aqueous), suspensions (e.g., aqueous, non-aqueous), emulsions (e.g., oil-in-water, water-in-oil), suppositories, pessaries, gels, pastes, ointments, creams, lotions, oils, as well as patches, adhesive plasters, depots, and reservoirs.
Formulations suitable for transdermal administration include gels, pastes, ointments, creams, lotions, and oils, as well as patches, adhesive plasters, bandages, dressings, depots, and reservoirs.
Tablets may be made by conventional means, e.g., compression or moulding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the compound in a free-flowing form such as a powder or granules, optionally mixed with one or more binders (e.g., povidone, gelatin, acacia, sorbitol, tragacanth, hydroxypropylmethyl cellulose); fillers or diluents (e.g., lactose, microcrystalline cellulose, calcium hydrogen phosphate); lubricants (e.g., magnesium stearate, talc, silica); disintegrants (e.g., sodium starch glycolate, cross-linked povidone, cross-linked sodium carboxymethyl cellulose); surface-active or dispersing or wetting agents (e.g., sodium lauryl sulfate); preservatives (e.g., methyl p-hydroxybenzoate, propyl p-hydroxybenzoate, sorbic acid); flavours, flavour enhancing agents, and sweeteners. Moulded tablets may be made by moulding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the compound therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile. Tablets may optionally be provided
with a coating, for example, to affect release, for example an enteric coating, to provide release in parts of the gut other than the stomach.
Ointments are typically prepared from the compound and a paraffinic or a water-miscible ointment base.
Creams are typically prepared from the compound and an oil-in-water cream base. If desired, the aqueous phase of the cream base may include, for example, at least about 30% w/w of a polyhydric alcohol, i.e., an alcohol having two or more hydroxyl groups such as propylene glycol, butane-1 ,3-diol, mannitol, sorbitol, glycerol and polyethylene glycol and mixtures thereof. The topical formulations may desirably include a compound which enhances absorption or penetration of the compound through the skin or other affected areas. Examples of such dermal penetration enhancers include dimethylsulfoxide and related analogues.
Emulsions are typically prepared from the compound and an oily phase, which may optionally comprise merely an emulsifier (otherwise known as an emulgent), or it may comprises a mixture of at least one emulsifier with a fat or an oil or with both a fat and an oil. Preferably, a hydrophilic emulsifier is included together with a lipophilic emulsifier which acts as a stabiliser. It is also preferred to include both an oil and a fat. Together, the emulsifier(s) with or without stabiliser(s) make up the so-called emulsifying wax, and the wax together with the oil and/or fat make up the so-called emulsifying ointment base which forms the oily dispersed phase of the cream formulations.
Suitable emulgents and emulsion stabilisers include Tween 60, Span 80, cetostearyl alcohol, myristyl alcohol, glyceryl monostearate and sodium lauryl sulfate. The choice of suitable oils or fats for the formulation is based on achieving the desired cosmetic properties, since the solubility of the compound in most oils likely to be used in pharmaceutical emulsion formulations may be very low. Thus the cream should preferably be a non-greasy, non-staining and washable product with suitable consistency to avoid leakage from tubes or other containers. Straight or branched chain, mono- or dibasic alkyl esters such as di-isoadipate, isocetyl stearate, propylene glycol diester of coconut fatty acids, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate or a blend of branched chain esters known as Crodamol CAP may be used, the last three being preferred esters. These may be used alone or in combination depending on the properties required. Alternatively, high melting point lipids such as white soft paraffin and/or liquid paraffin or other mineral oils can be used.
Formulations suitable for intranasal administration, where the carrier is a liquid, include, for example, nasal spray, nasal drops, or by aerosol administration by nebuliser, include aqueous or oily solutions of the compound.
Formulations suitable for intranasal administration, where the carrier is a solid, include, for example, those presented as a coarse powder having a particle size, for example, in the range of about 20 to about 500 microns which is administered in the manner in which snuff is taken, i.e., by rapid inhalation through the nasal passage from a container of the powder held close up to the nose.
Formulations suitable for pulmonary administration (e.g., by inhalation or insufflation therapy) include those presented as an aerosol spray from a pressurised pack, with the use of a suitable propellant, such as dichlorodifluoromethane, trichlorofluoromethane, dichoro-tetrafluoroethane, carbon dioxide, or other suitable gases.
Formulations suitable for ocular administration include eye drops wherein the compound is dissolved or suspended in a suitable carrier, especially an aqueous solvent for the compound.
Formulations suitable for rectal administration may be presented as a suppository with a suitable base comprising, for example, natural or hardened oils, waxes, fats, semi-liquid or liquid polyols, for example, cocoa butter or a salicylate; or as a solution or suspension for treatment by enema.
Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the compound, such carriers as are known in the art to be appropriate.
Formulations suitable for parenteral administration (e.g., by injection), include aqueous or non-aqueous, isotonic, pyrogen-free, sterile liquids (e.g., solutions, suspensions), in which the compound is dissolved, suspended, or otherwise provided (e.g., in a liposome or other microparticulate). Such liquids may additional contain other pharmaceutically acceptable ingredients, such as anti-oxidants, buffers, preservatives, stabilisers, bacteriostats, suspending agents, thickening agents, and solutes which render the formulation isotonic with the blood (or other relevant bodily fluid) of the intended recipient. Examples of excipients include, for example, water, alcohols, polyols, glycerol, vegetable oils, and the like. Examples of suitable isotonic carriers for use in such formulations include Sodium Chloride Injection, Ringer's Solution, or Lactated Ringer's Injection.
Typically, the concentration of the compound in the liquid is from about 1 ng/ml to about 10 μg/ml, for example from about 10 ng/ml to about 1 μg/ml. The formulations may be presented in unit-dose or multi-dose sealed containers, for example, ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use.
Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules, and tablets.
Dosage
It will be appreciated by one of skill in the art that appropriate dosages of the IBD compounds, and compositions comprising the IBD compounds, can vary from patient to patient. Determining the optimal dosage will generally involve the balancing of the level of therapeutic benefit against any risk or deleterious side effects. The selected dosage level will depend on a variety of factors including, but not limited to, the activity of the particular IBD compound, the route of administration, the time of administration, the rate of excretion of the IBD compound, the duration of the treatment, other drugs, compounds, and/or materials used in combination, the severity of the condition, and the species, sex, age, weight, condition, general health, and prior medical history of the patient. The amount of IBD compound and route of administration will ultimately be at the discretion of the physician, veterinarian, or clinician, although generally the dosage will be selected to achieve local concentrations at the site of action which achieve the desired effect without causing substantial harmful or deleterious side-effects.
Administration can be effected in one dose, continuously or intermittently (e.g., in divided doses at appropriate intervals) throughout the course of treatment. Methods of determining the most effective means and dosage of administration are well known to those of skill in the art and will vary with the formulation used for therapy, the purpose of the therapy, the target cell(s) being treated, and the subject being treated. Single or multiple administrations can be carried out with the dose level and pattern being selected by the treating physician, veterinarian, or clinician.
In general, a suitable dose of the IBD compound is in the range of about 10 μg to about 250 mg (more typically about 100 μg to about 25 mg) per kilogram body weight of the subject per day. Where the compound is a salt, an ester, an amide, a prodrug, or the like, the amount administered is calculated on the basis of the parent compound and so the actual weight to be used is increased proportionately.
EXAMPLES
The following examples are provided solely to illustrate the present invention and are not intended to limit the scope of the invention, as described herein.
Genera/
1H NMR spectra were recorded at 25°C at 300 MHz on a Bruker Avance 300 system. Chemical shifts are reported in ppm. The 1H NMR spectra are referenced internally as follows: Spectra in CD3OD were referenced to CHD2OD: 3.33 ppm; CDCI3 to CHCI3: 7.26 ppm, DMSO-Cf6 to CHD2SOCD3: 2.50 ppm.
Column chromatograpy was unless otherwise stated performed using flash silicagel (0.040 - 0.063 mm).
Evaporations were performed in vacuo on a rotary evaporator at 40-50 0C.
LC-MS data were obtained on an Agilent 1200/Bruker Esquire 3000+ system.
Materials
All chemicals used were of reagent grade, and all solvents were of HPLC grade.
General Procedure 1
Click reaction between 1-ethynyl-5-isopropyl-2,4-dimethoxybenzene and azides to form triazoles of the Formula I, for example, as illustrated in the following scheme.
Scheme 1
1-Ethynyl-5-isopropyl-2,4-dimethoxybenzene was dissolved in DMF (7 mL pr mmol) and the arylazide or benzylazide was added (1.05 eq.) together with sodium ascorbate (25 mol%) and CuSO45H2O (a few crystals). The mixture was reacted in a microwave oven for 15 minutes at 900C. The mixture was poured over ice-water, extracted with EtOAc (3
times), and the organic phase was dried (MgSO4), filtered, and the solvents were evaporated. The residue was purified by column chromatography using 20:80 EtOAc/heptane yielding the corresponding triazole of the Formula I.
General Procedure 2
De-methylation of compounds of the Formula I to yield compounds of the Formula il, for example, as illustrated in the following scheme.
Scheme 2
The protected triazole of the Formula I was dissolved in DCM (15 mL per mmol) under N2 atmosphere and the solution cooled to -78°C. BBr3 was added dropwise (1.2 eq. per OMe group). The mixture was stirred at -78°C for 15 minutes, and then at room temperature overnight. The reaction mixture was evaporated to dryness and the residue was purified by column chromatography using appropriate mixtures of MeOH and DCM as eluent, to give the correspoinding triazole of the Formula II.
General Procedure 3
Suzuki-type coupling of 1-bromo-5-isopropyl-2,4-dimethoxybenzene with boronic acids to yield compounds of Formula III, for example, as illustrated in the following scheme.
Scheme 3
DME (2.7 mL), K2CO3 (0.7 mL, 2 M, aq) and tetrabutylammonium bromide (TBAB, 0.05 eq.) were mixed in a microwave oven vial and N2 was passed through the solution for a couple of minutes. Pd(PPh3)4 (19.2 μmol) was added followed by 1-bromo-5- isopropyl-2,4-dimethoxybenzene (0.19 mmol) and the appropriate boronic acid (0.38
mmol). The vial was sealed and reacted at 60-1200C until completion of the coupling (40 minutes to 1.5 hours). The reaction mixture was added to EtOAc and water, and the organic phase was separated, washed with brine, and dried over Na2SO4. The resulting crude product of Formula III was purified by flash chromatography.
General Procedure 4
Demethylation of compounds of Formula III to yield compounds of Formula IV, for example, as illustrated in the following scheme.
Scheme 4
The dimethoxy compound of Formula III was dissolved in dry DCM under N2 and cooled in ice. BBr3 (1 M in DCM) was added (2 eq. / methoxy group). The red solution was allowed to warm to room temperature and left stirring overnight. The reaction mixture was quenched with ice and the product extracted into EtOAc. For basic compounds, the aqueous phase was adjusted to pH 8-9 before extraction. The organic phase was dried over MgSO4 or Na2SO4 (basic compounds), evaporated, and the resulting product of Formula IV was purified by flash chromatography on silica gel.
General Procedure 5
Van Leusen-type oxazole synthesis to yield compounds of Formula V, as illustrated in the following scheme.
Scheme 5
Aldehyde (2.5 mmol) and TosMIC (p-toluensulfonylmethylisocyanide) (2.5 mmol) was suspended in dry MeOH (8 ml_). K2CO3 (oven dried and powdered) (2.5 mmol) was
added and the mixture was heated at reflux for 3 hours or until TLC confirmed complete reaction. The reaction mixture was cooled and the solvent was removed in vacuo. The residue was poured into ice-water and extracted with EtOAc (3 times). The organic phase was washed with dilute HC! (aq) (0.1 M), water and brine and dried over MgSO4. The MgSO4 was filtered off and evaporation of the solvent yielded oxazoles of Formula V adequately pure for further reaction (in most cases > 95 % pure). ("Inversed" Procedure 5 means the corresponding reaction between a TosMIC analogue of protected resorcinol with an aromatic aldehyde).
General Procedure 6
Formation of sulfonamides of Formula VII from 5'-isopropyl-2',4'-dimethoxybiphenyl-2- amine, as illustrated in the following scheme.
Scheme 6
5'-lsopropyl-2',4'-dimethoxybiphenyl-2-amine (27 mg, 0.1 mmol) was dissolved in dry pyridine (5 ml_) under a nitrogen atmosphere. The solution was cooled to 00C and the appropriate sulfonyl chloride (1.2 eq.) dissolved in dry CH2CI2 (1.5 mL) was slowly added. After addition, the reaction mixture was allowed to stand at room temperature over night. The completion of the reaction was checked with ninhydrin (if positive, another 0.3 eq. of sulfonyl chloride was added and allowed to react for 3 hours). The solvent was evaporated in vacuo, and then HCI (aq, 0.1 M, 20 mL) was added. The product was extracted into petrolether/ ethylacetate (2:1) (3 x 10 mL). The combined organic phase was washed with water and brine and dried over Na2SO4. The solvent was evaporated and the residue was re-dissolved in MeOH (2 mL) and filtered through an lsolute PE-AX SPE column to remove any unreacted reagent. The sulfonamides thus obtained were adequately pure for use in subsequent reactions.
General Procedure 7
Formation of carbonyl compounds of the Formula VIII by Friedel Craft reaction using 1-isopropyl-2,4-dimethoxybenzene, as illustrated in the following scheme.
Scheme 7
To a solution of 1-isopropyl-2,4-dimethoxybenzene (144 mg, 0.80 mmol) in dry DCM (5 ml_) was added acid chloride (1.0 mmol). The reaction mixture was cooled to 00C and TiCI4 (0.87 mmol) was added dropwise and the reaction stirred at 00C for 30 minutes and then at room temperature for 1 hour. H2O (10 mL) was added and the aqueous layer was extracted with DCM (3 x 5 mL). The organic phase was washed with H2O (10 mL), brine (10 mL), 10% K2CO3 solution, dried (MgSO4), filtered, and the solvent was evaporated. The crude product was dissolved in a small volume of EtOAc, passed through a short pad of SiO2 (rinsing with EtOAc), and the collected organic phase was evaporated to dryness. The product of Formula VIII was purified by column chromatography.
General Procedure 8
Demethylation of compounds of the Formula VIII to yield compounds of the Formula IX, as illustrated in the following scheme.
Scheme 8
To a stirred solution of a compound of the Formula VIII (0.537 mmol) in dry DCM (10 mL) at 00C was added BBr3 (1 M in DCM, 3.2 mL, 3.2 mmol). The mixture was stirred at reflux for 2 days. The reaction mixture was evaporated and the residue dissolved in diethylether and washed with water, dried over MgSO4, filtered, and the solvent evaporated. The residue was purified by column chromatography to give the corresponding compound of Formula IX. For some compounds, reflux might not be necessary and performing the reaction at room temperature may be sufficient.
General Procedure 9
1-Ethynyl-5-isopropyl-2,4-dimethoxybenzene was prepared from 2,4- dimethoxyacetophenone, as shown in the following scheme.
Scheme 9
General Procedure 10
Debenzylation of compounds of Formula X to yield compounds of Formula IV, for example, as illustrated in the following scheme.
To a stirred solution of a compound of the Formula X in EtOH or EtOAc solution is added a catalytic amount of Pd/C (5%) pre-wetted with the solvent. Hydrogen gas is added from balloon until the reaction is complete. In some cases the reaction mixture needs heeting to 400C. After the end of reaction, the Pd/C is filtered off through celite and the solvents removed in vacuo. The residue is purified by flash chromatography or crystallisation.
Synthesis 1 2,4-Dimethoxy-1-(prop-1-en-2-yl)benzene (Compound 1)
To a cooled (O0C) suspension of methyltriphenylphosphoniumbromide (2.08 g, 5.82 mmol) in dry THF (25 ml_) was dropwise added BuLi (1.02 M, 5.7 ml_, 5.82 mmol) and the mixture stirred at 00C for 30 minutes. A solution of 2,4-dimethoxyacetophenone (1.05 g, 5.83 mmol) in dry THF (10 mL) was added dropwise and the mixture was stirred at rt for 4 h. The reaction was quenched with H2O (30 mL) and the aqueous layer was extracted with diethylether (3 x 50 mL), the organic phase was washed with H2O (2 x 50 mL), brine (50 mL), dried (MgSO4), filtered and the solvents evaporated. The resulting residue was purified by flash chromatography using petrol ether/EtOAc (10:1) as eluent. The title compound was isolated as a colorless oil (0.43 g, 41%). An extra purification by column chromatography or treatment with activated charcoal could be necessary for a successful reduction (next step). 1H-NMR (CDCI3): δ 7.03 (m, 1H), 6.39 (m, 2H), 5.05 (m, 2H), 3.74 (s, 6H), 2.02 (s, 3H).
Synthesis 2
1-lsopropyl-2,4-dimethoxybenzene (Compound 2)
A solution of single chromatographed 2,4-dimethoxy-1-(prop-1-en-2-yl)benzene (8.90 g, 50 mmol) in EtOH (200 mL) was treated twice with 1 g activated charcoal with intermediate titrations through celite. The resulting filtered solution was deoxygenated by passing N2 through the solution and 5% Pd/C (500 mg) was added. Hydrogen was added from balloon. Reduction proceeded at room temperature. When HPLC showed complete reaction, the reaction mixture was filtered through a short pad of celite and the solvent was evaporated. The title compound was isolated as a colourless oil which was pure by 1H-NMR and HPLC and could be used without further purification in subsequent steps. The yield was 8.34 g (92%). 1H-NMR (CDCI3): δ 7.10 (d, 1 H), 6.45 (m, 2H), 3.80 (s, 3H), 3.79 (s, 3H), 3.22 (sep, 1H), 1.18 (d, 6H).
Synthesis 3
1-Bromo-5-isopropyl-2,4-dimethoxybenzene (Compound 3)
A solution of 1-isopropyl-2,4-dimethoxybenzene (3.00, 16.6 mmol) in chloroform (70 ml_) was added a solution of tetrabutylammonium tribromide (8.83 g, 18.3 mmol) in chloroform (30 mL). The reaction mixture was stirred at room temperature for 3 hours. The reaction was quenched with a 5% solution of Na2S2O3 and stirred at room temperature for 30 minutes. The organic phase was isolated and washed with 1 M HCI (aq), brine, dried (Na2SO4), and solvents evaporated. The residue was purified by column chromatography using 20:80 EtOAc/heptane. The title compound was isolated as a white solid (3.25 g, 75%). 1H-NMR (DMSO-c/6): δ 7.26 (s, 1 H), 6.71 (s, 1 H)1 3.85 (s, 3H), 3.84 (s, 3H), 3.13 (sep, 1H), 1.12 (d, 6H).
Synthesis 4 1-lodo-5-isopropyl-2,4-dimethoxybenzene (Compound 4)
A solution of 1-bromo-5-isopropyl-2,4-dimethoxybenzene (0.396 g, 1.53 mmol) in dry diethylether (3 mL) was cooled to -78°C. t-Bul\ (1 mL, 1.7 M) was added dropwise and the mixture stirred at -78°C for 45 minutes. A solution of I2 (0.391 g, 1.54 mmol) in ether (3 mL) was added in one portion and the temperature maintained at -780C for 1 hour, and then heated to room temperature. The reaction mixture was washed with a solution of 25% NaS2O3 to remove excess iodine. The organic phase was isolated, dried (MgSO4), and evaporated. The residue was purified by column chromatography using 10% EtOAc in heptane as eluent. The title compound (0.249 g, 53%) was isolated as a white solid. NMR (DMSO-CZ6): δ 7.41 (s, 1 H), 6.64 (s, 1 H), 3.76 (s, 3H), 3.72 (s, 3H), 3.10 (m, 1H), 1.11 (d, 6H).
Synthesis 5
((5-lsopropyl-2,4-dimethoxyphenyl)ethynyl)trimethylsilane (Compound 5)
A suspension of 1-iodo-5-isopropyl-2,4-dimethoxybenzene (344 mg, 1.12 mmol) in freshly distilled Et3N in a screwcap vial was added Pd(PPh3)2CI2 (48 mg), CuI (68 mg, 0.36 mmol), and trimethylsilyiacetylene (0.8 ml, 5.66 mmol). The mixture was stirred at reflux overnight. The vial was then cooled to room temperature and the reaction mixture diluted with diethylether, and the organic phase was washed with a saturated solution of NH4CI and then with a saturated solution of NaHCO3. The organic phase was dried (MgSO4) and evaporated. The residue was purified by column chromatography using 5% EtOAc in petrol ether as eluent. The title compound (219 mg, 70%) was isolated as a solid. NMR (DMSO-c/e): δ 7.09 (s, 1 H), 6.61 (s, 1 H), 3.85 (s, 3H), 3.83 (s, 3H), 3.11 (m, 1 H), 1.11 (d, 6H), 0.198 (s, 9H).
Synthesis 6
1-Ethynyl-5-isopropyl-2,4-dimethoxybenzene (Compound 6)
A solution of ((5-isopropyl-2,4-dimethoxyphenyl)ethynyl)trimethylsilane (0.219 mg, 0.79 mmol) in MeOH (4 mL) and CHCI3 (2 mL) was added a solution of NaOH (2 M, 0.8 mL). The mixture was stirred at room temperature for 2 hours and the mixture was evaporated to remove organic solvents. The resulting residue was re-dissolved in EtOAC and washed with a saturated solution of NaHCO3. The organic phase was dried (MgSO4) and evaporated. The residue was purified by column chromatography using 8% EtOAc in heptane as eluent. The title compound (125 mg, 78%) was obtained as a yellow solid. NMR (DMSO-Cy6): δ 7.13 (s, 1 H), 6.62 (s, 1H), 4.02 (s, 1H), 3.85 (s, 3H), 3.83 (s, 3H), 3.11 (m, 1 H), 1.1 1 (d, 6H).
Synthesis 7 4-(5-lsopropyl-2,4-dimethoxyphenyl)-1 -phenyl-1 H- 1 ,2,3-triazole (Compound 7)
Obtained using General Procedure 1. Starting materials: Azidobenzene and 1 -ethynyl-5- isopropy!-2,4-dimethoxybenzene. 1H-NMR (DMSO-Cf6): δ 8.82 (s, 1H), 7.99 (m, 3H), 7.63 (m, 2H), 7.51 (m, 2H), 3.98 (s, 3H), 3.90 (s, 3H), 3.24 (sep, 1 H), 1.21 (d, 6H).
Synthesis 8
4-(5-lsopropyl-2,4-dimethoxyphenyl)-1 -(2-methoxyphenyl)-1 H- 1 ,2,3-triazole
(Compound 8)
Obtained using General Procedure 1. Starting materials: 2-Methoxyazidobenzene and 1- ethynyl-5-isopropyl-2,4-dimethoxybenzene. 1H-NMR (DMSO-c/6): δ 8.49 (s, 1 H), 7.99 (s, 1 H), 7.65 (m, 1 H), 7.56 (m, 1 H), 7.34 (d, 1 H), 7.17 (m, 1H), 6.74 (s, 1 H)1 3.94 (s, 3H), 3.89 (s, 3H), 3.87 (s, 3H), 3.24 (sep, 1H), 1.21 (d, 6H).
Synthesis 9
4-(5-lsopropyl-2,4-dimethoxyphenyl)-1 -(3-methoxyphenyl)-1 H-1 ,2,3-triazole
(Compound 9)
Obtained using General Procedure 1. Starting materials: 3-Methoxyazidobenzene and 1-ethynyl-5-isopropyl-2,4-dimethoxybenzene. 1H-NMR (DMSO-Cf6): δ 8.83 (s, 1H), 7.98 (s, 1 H), 7.55 (m, 3H), 7.08 (m, 1 H), 6.75 (s, 1 H), 3.98 (s, 3H), 3.90 (s, 3H), 3.88 (s, 3H), 3.23 (sep, 1H), 1.21 (d, 6H).
Synthesis 10
4-(5-lsopropyl-2,4-dimethoxyphenyl)-1 -(3,4-dimethoxyphenyl)-1 H- 1 ,2,3-triazole
(Compound 10)
Obtained using General Procedure 1. Starting materials: 3,4-Dimethoxyazidobenzene and 1-ethynyl-5-isopropyl-2,4-dimethoxybenzene. 1H-NMR (DMSO-Of6): δ 8.73 (s, 1 H), 7.97 (s, 1H), 7.48 (m, 2H), 7.15 (d, 1H), 6.75 (s, 1H), 3.95 (s, 3H), 3.89 (s, 3H), 3.84 (s, 3H), 3.13 (sep, 1 H), 1.21 (d, 6H).
Synthesis 11
4-(5-lsopropyl-2,4-dimethoxyphenyl)-1 -(4-n-butyl-phenyl)-1 H- 1 ,2,3-triazole
(Compound 11 )
Obtained using General Procedure 1. Starting materials: 4-(/?-Butyl)azidobenzene and 1-ethynyl-5-isopropyl-2,4-dimethoxybenzene. 1H-NMR (DMSO-d6): δ 8.76 (s, 1 H), 7.99 (s, 1 H), 7.88 (s, 1 H), 7.85 (s, 1 H), 7.44 (s, 1 H), 7.41 (s, 1 H), 6.75 (s, 1H), 3.98 (s, 3H), 3.90 (s, 3H), 3.23 (sep, 1 H), 2.68 (t, 2H), 1.61 (m, 2H), 1.34 (m, 2H), 1.21 (d, 6H), 0.93 (t, 3H).
Synthesis 12 1 -Benzyl-4-(5-isopropy!-2,4-dimethoxyphenyl)-1 H- 1 ,2,3-triazole (Compound 12)
Obtained using General Procedure 1. Starting materials: Benzylazide and 1-ethynyl-5- isopropyl-2,4-dimethoxybenzene. 1H-NMR (DMSO-c/6): δ 8.32 (s, 1H), 7.94 (s, 1H)1 7.34 (m, 5H), 6.70 (s, 1 H), 5.65 (s, 2H), 3.91 (s, 3H), 3.87 (s, 3H), 3.21 (sep, 1H), 1.18 (d, 6H).
Synthesis 13
1 -(2-Chloro-4-fluorobenzyl)-4-(5-isopropyl-2,4-dimethoxyphenyl)-1 W- 1 ,2,3-triazole
(Compound 13)
Obtained using General Procedure 1. Starting materials: 2-Chloro-4-fluorobenzylazide and 1-ethynyl-5-isopropyl-2,4-dimethoxybenzene. 1H-NMR (DMSO-de): δ 8.31 (s, 1H), 7.94 (s,1H), 7.58-7.53 (m, 1 H), 7.29-7.26 (m, 2H), 6.71 (s, 1 H), 5.74 (s, 2H), 3.91 (s, 3H), 3.87 (s, 3H), 3.21 (sep, 1H), 1.18 (d, 6H).
Synthesis 14
1-(3,4-Difluorobenzyl)-4-(5-isopropyl-2,4-dimethoxyphenyl)-1/-/-1 ,2,3-triazole
(Compound 14)
Obtained using General Procedure 1. Starting materials: 3,4-Difluorobenzylazide and 1- ethynyl-5-isopropyl-2,4-dimethoxybenzene. 1H-NMR (DMSO-Cf6): δ 8.36 (s, 1 H), 7.93 (s, 1 H), 7.50-7.41 (m, 2H), 7.21-7.14 (m, 1 H), 6.71 (s, 1H), 5.65 (s, 2H), 3.92 (s, 3H), 3.87 (s, 3H), 3.21 (sep, 1 H), 1.18 (d, 6H).
Synthesis 15
4-(5-lsopropyl-2,4-dimethoxyphenyl)-1 -(naphthalen-2-ylmethyl)-1 H-λ ,2,3-triazole
(Compound 15)
Obtained using General Procedure 1. Starting materials: 2-Azidomethylnaphthaiene and 1-ethynyl-5-isopropyl-2,4-dimethoxybenzene. 1H-NMR (DMSO-CZ6): δ 8.37 (s, 1 H), 7.96- 7.84 (m, 4H), 7.55-7.44 (m, 2H), 6.70 (s, 1 H), 5.82 (s, 2H), 3.91 (s, 3H), 3.87 (s, 3H), 3.21 (sep, 1 H), 1.18 (d, 6H).
Svnthesis 16
1-(4-Fluorobenzyl)-4-(5-isopropyl-2,4-dimethoxyphenyl)-1H-1 ,2,3-triazole (Compound 16)
Obtained using General Procedure 1. Starting materials: 4-Fluorobenzylazide and 1- ethynyl-5-isopropyl-2,4-dimethoxybenzene. 1H-NMR (DMSO-Cf6): δ 8.33 (s, 1 H), 7.93 (s, 1 H), 7.42-7.37 (m, 2H), 7.25-7.19 (m, 2H), 6.7 (s, 1 H), 5.64 (s, 1H), 3.91 (s, 3H), 3.87 (s, 3H), 3.20 (sep, 1 H), 3.18 (d, 6H).
Synthesis 17 1 -(4-Chlorobenzyl)-4-(5-isopropyl-2,4-dimethoxyphenyl)-1 H- 1 ,2,3-triazole (Compound 17)
Obtained using General Procedure 1. Starting materials: 4-Chlorobenzylazide and 1- ethynyl-5-isopropyl-2,4-dimethoxybenzene. 1H-NMR (DMSO-Cf6): δ 8.34 (s, 1 H), 7.94 (s, 1 H), 7.47-7.44 (m, 2H), 7.36-7.33 (m, 2H), 6.71 (s, 1 H), 5.66 (s, 2H)1 3.92 (s, 3H), 3.87 (s, 3H), 3.21 (sep, 1 H), 3.18 (d, 6H).
Synthesis 18 1-(4-Methylbenzyl)-4-(5-isopropyl-2,4-dimethoxyphenyl)-1/-/-1 ,2,3-triazole (Compound 18)
Obtained using General Procedure 1. Starting materials: 4-Methylbenzylazide and 1- ethynyl-5-isopropyl-2,4-dimethoxybenzene. 1H-NMR (DMSO-c/6): δ 8.27 (s, 1H), 7.93 (s, 1 H), 7.24-7.17 (m, 4H), 6.7 (s, 1 H), 5.59 (s, 2H), 3.91 (s, 3H), 3.87 (s, 3H), 3.20 (sep, 1 H), 2.28 (s, 3H), 1.18 (d, 6H).
Synthesis 19
1 -(3,4-Dichlorobenzyl)-4-(5-isopropy!-2,4-dimethoxyphenyl)-1 HA ,2,3-triazole
(Compound 19)
Obtained using General Procedure 1. Starting materials: 3,4-Dichlorobenzylazide and 1- ethynyl-5-isopropyl-2,4-dimethoxybenzene. 1H-NMR (DMSO-c/6): δ 8.39 (s, 1 H), 7.94 (s, 1 H), 7.67-7.63 (m, 2H), 7.28 (dd, 1H), 6.71 (s, 1 H), 5.68 (s, 2H), 3.92 (s, 3H), 3.87 (s, 3H), 3.21 (sep, 1 H), 1.18 (d, 6H).
Svnthesis 20
1 -(4-lsopropylbenzyl)-4-(5-isopropyl-2,4-dimethoxyphenyl)-1 H- 1 ,2,3-triazole
(Compound 20)
Obtained using General Procedure 1. Starting materials: 4-lsopropylbenzylazide and 1- ethynyl-5-isopropyl-2,4-dimethoxybenzene. 1H-NMR (DMSO-Cf6): δ 8.30 (s, 1H), 7.93 (s, 1 H), 7.25 (m, 4H), 6.70 (s, 1 H), 5.59 (s, 2H), 3.91 (s, 3H), 3.87 (s, 3H), 3.25 (sep, 1 H), 2.87 (sep, 1 H), 1.20-1.17 (m, 12H).
Synthesis 21 1-(3-Chlorobenzyl)-4-(5-isopropyl-2,4-dimethoxyphenyl)-1/-/-1 ,2,3-triazole (Compound 21)
Obtained using General Procedure 1. Starting materials: 3-Chlorobenzylazide and 1- ethynyl-5-isopropyl-2,4-dimethoxybenzene. 1H-NMR (DMSO-Gf6): δ 8.37 (s, 1 H), 7.94 (s, 1 H), 7.42-7.39 (m, 3H), 7.29-7.25 (m, 1 H), 6.71 (s, 1 H), 5.67 (s, 2H), 3.92 (s, 3H), 3.87 (s, 3H), 3.21 (sep, 1 H), 1.18 (d, 6H).
Synthesis 22 1 -(2-Fluorobenzyl)-4-(5-isopropyl-2,4-dimethoxyphenyl)-1 H- 1 ,2,3-triazole (Compound 22)
Obtained using General Procedure 1. Starting materials: 2-Fluorobenzylazide and 1- ethynyl-5-isopropyl~2,4-dimethoxybenzene. 1H-NMR (DMSO-Of6): δ 8.29 (s, 1 H), 7.93 (s, 1 H), 7.42 (m, 1H), 7.35-7.15 (m, 3H), 6.70 (s, 1H), 5.71 (s, 2H), 3.91 (s, 3H), 3.86 (s, 3H), 3.20 (sep, 1 H), 1.17 (d, 6H).
Synthesis 23 1 -(2-Chlorobenzyl)-4-(5-isopropyl-2,4-dimethoxyphenyl)-7H-1 ,2,3-triazole (Compound 23)
Obtained using General Procedure 1. Starting materials: 2-Chlorobenzylazide and 1- ethynyl-5-isopropyl-2,4-dimethoxybenzene. 1H-NMR (DMSO-Cf6): δ 8.31 (s, 1 H), 7.95 (s, 1 H), 7.53 (m, 1 H), 7.44-7.31 (m, 2H), 7.12 (m, 1 H), 6.71 (s, 1 H), 5.75 (s, 2H), 3.90 (s, 3H), 3.86 (s, 3H), 3.21 (sep, 1 H), 1.17 (d, 6H).
Synthesis 24 4-(5-lsopropyl-2,4-dimethoxyphenyl)-1-(2-methylbenzyl)-1/-/-1 ,2,3-triazole (Compound 24)
Obtained using General Procedure 1. Starting materials: 2-Methylbenzylazide and 1- ethynyl-5-isopropyl-2,4-dimethoxybenzene. 1H-NMR (DMSO-CZ6): δ 8.21 (s, 1H), 7.95 (s, 1 H), 7.27-7.14 (m, 3H), 7.00 (m, 1 H), 6.70 (s, 1H), 5.66 (s, 2H), 3.89 (s, 3H), 3.86 (s, 3H), 3.21 (sep, 1 H), 1.17 (d, 6H).
Synthesis 25 1-Benzyl-5-(5-isopropyl-2,4-dimethoxyphenyl)-1/-M ,2,3-triazole (Compound 25)
1-Ethynyl-5-isopropyl-2,4-dimethoxybenzene (Compound 6, 40 mg, 194 mmol) and benzylazide (33 mg, 250 mmol) was dissolved in THF (1 mL) in a microwave vial. Freshly prepared Cp*RuCI(PPh3)2 (catalytic amount from small spatule tip) was added and the vial was sealed. The reaction mixture was heated for 15 min at 1200C. The solvent was evaporated in vacuo and the residue was purified by flash chromatography (7% EtOAc in PE) to give the title compound. Yield 36 mg (55%). 1H-NMR (CDCI3): δ 7.63 (s, 1 H), 7.18 (d, 2H), 6.93 (d, 2H), 6.76 (s, 1H), 6.46 (s, 1 H), 5.36 (s, 2H), 3.89 (s, 3H), 3.67 (s, 3H), 3.20 (sep, 1 H), 1.08 (d, 6H).
Synthesis 26
1 -(4-Chlorobenzyl)-5-(5-isopropyl-2,4-dimethoxyphenyl)-1 H- 1 ,2,3-triazole (Compound 26)
Made analogous to 1~Benzyl-5-(5-isopropyl-2,4-dimethoxyphenyl)-1H-1,2,3-triazole. Starting materials: 1-Ethynyl-5-isopropyl-2,4-dimethoxybenzene and 1-(azidomethyl)-4- chlorobenzene. 1H-NMR (CDCI3): δ 7.64 (s, 1 H), 7.25-7.17 (m, 3H), 7.05-6.96 (m, 2H), 6.77 (s, 1 H), 6.47 (s, 1 H), 5.36 (s, 2H), 3.89 (s, 3H), 3.68 (s, 3H), 3.18 (sep, 1 H), 1.05 (d, 6H).
Svnthesis 27 1 -(5-lsopropyl-2,4-dimethoxyphenyl)-2-phenylethanone (Compound 27)
Obtained using General Procedure 7. Starting materials: 2-Phenylacetyl chloride and 1- isopropyl-2,4-dimethoxybenzene. 1H-NMR (CDCI3): δ 7.73 (s, 1 H), 7.26 (m, 5H), 6.40 (s, 1 H), 4.28 (s, 2H), 3.91 (s, 3H), 3.89 (s, 3H), 3.18 (sep, 1 H), 1.17 (d, 6H).
Synthesis 28 (5-lsopropyl-2,4-dimethoxyphenyl)(4-methoxyphenyl)methanone (Compound 28)
Obtained using General Procedure 7. Starting materials: 4-Methoxybenzoyl chloride and 1-isopropyl-2,4-dimethoxybenzene. 1H-NMR (CDCI3): δ 7.65 (d, 2H), 7.11 (s, 1 H), 7.02 (d, 2H), 6.72 (s, 1 H), 3.92 (s, 3H), 3.84 (s, 3H), 3.69 (s, 3H), 3.19 (sep, 1 H), 1.14 (d, 6H).
Synthesis 29 (5-lsopropyl-2,4-dimethoxyphenyl)(4-chlorophenyl)methanone (Compound 29)
Obtained using General Procedure 7. Starting materials: 4-Chlorobenzoyl chloride and 1- isopropyl-2,4-dimethoxybenzene. 1H-NMR (CDCI3): δ 7.68-7.63 (m, 2H), 7.57-7.52 (m, 2H), 7.22 (S, 1 H), 6.73 (s, 1 H), 3.93 (s, 3H), 3.67 (s, 3H), 3.18 (sep, 1H), 1.15 (d, 6H).
Synthesis 30
(5-lsopropyl-2,4-dimethoxyphenyl)(2,6-dichlorophenyl)methanone (Compound 30)
Obtained using General Procedure 7. Starting materials: 2, 6-Dichlorobenzoyl chloride and 1-isopropyl-2,4-dimethoxybenzene. 1H-NMR (CDCI3): δ 7.72 (s, 1H), 7.52-7.40 (m, 3H), 6.64 (s, 1 H), 3.94 (s, 3H), 3.56 (s, 3H), 3.15 (sep, 1 H), 1.16 (d, 6H).
Synthesis 31
(4-(Dimethylamino)phenyl)(2-hydroxy-5-isopropyl-4-methoxyphenyl)methanone
(Compound 31)
Obtained using General Procedure 7. Starting materials: 4-(Dimethylamino)benzoyl chloride and 1-isopropyl-2,4-dimethoxybenzene. 1H-NMR (DMSO-Cf5): δ 12.12 (s, 1H), 7.63-7.56 (m, 2H), 7.37 (s, 1 H), 6.82-6.75 (m, 2H), 6.56 (s, 1 H), 3.86 (s, 3H), 3.12 (sep, 1 H), 3.04 (s, 6H), 1.10 (s, 6H). The position (2 vs. 4) of the single methoxy group was not verified.
Synthesis 32 (5-lsopropyl-2,4-dimethoxyphenyl)(3-methoxypheny!)methanone (Compound 32)
Obtained using General Procedure 7. Starting materials: 3-Methoxybenzoyl chloride and 1-isopropyl-2,4-dimethoxybenzene. 1H-NMR (CDCI3): δ 7.43-7.34 (m, 1 H), 7.21-7.15 (m, 4H), 6.72 (s, 1 H), 3.92 (s, 3H), 3.78 (s, 3H), 3.67 (s, 3H), 3.18 (sep, 1 H), 1.13 (d, 6H).
Synthesis 33
1-(2,4-Bis(benzyloxy)phenyl)ethanone (Compound 33)
2,4-Dihydroxy-acetophenone (15 g, 98.6 mmol) was dissolved in CH3CN (200 mL). Dry powdered K2CO3 (40 g, 289 mmol) was added and the suspension stirred. Benzylbromide (26 mL, 218 mmol) was added drop-wise and the resulting mixture was heated to reflux for 5 h and left stirring at room temperature overnight. TLC (EtOAc-Hep 1 :1 ) showed complete reaction. The solvent was evaporated and the residue re- dissolved in CH2CI2 -water. The phases were separated and the aqueous phase was extracted once with CH2CI2. The combined organic phase was washed with brine and dried over MgSO4. The organic phase was evaporated to yield a yellowish oil which crystallized upon standing. Heptane was added for complete crystallization and the white crystals were filtered off and washed thoroughly with heptane. Yield after drying was 29.4 g (90%) of 1-(2,4-bis(benzy!oxy)-phenyl)ethanone. 1H-NMR (CDCI3): δ 7.88-7.82 (m, 1H), 7.49-7.30 (m, 11 H), 6.67-6.59 m, 2H), 5.11 (s, 2H), 5.09 (s, 2H), 2.56 (s, 3H).
Synthesis 34 2-(2,4-Bis(benzyloxy)phenyl)propan-2-ol (Compound 34)
1-(2,4-Bis(benzyloxy)-phenyl)ethanone (15.0 g, 45 mmol) was dissolved under N2 in dry THF (250 mL, HPLC grade dried through Alumina Super I). The solution was cooled to O0C and MeMgBr (3 M, 30 mL, 90 mmol) was added drop-wise keeping T < 5 0C. After end addition the solution was left to heat to RT and stirred for 2 h. TLC showed complete reaction (EtOAc-Hep 1 :3). The reaction mixture was poured onto ice/water and extracted into ether. The combined organic phase was washed with water and brine and dried over MgSO4. Evaporation of solvents gave a white solid (16.0 g) which could be re-crystallized from approx. 50 mL of boiling MeOH. After cooling in the freezer the solid was isolated and washed with small portions of ice-cold MeOH. After drying in vacuum the yield of the title compound was 12.3 g (78%). 1H-NMR (CDCI3): δ 7.48-7.30 (m, 10H), 7.24 (masked, 1 H), 6.67 (d, 1 H), 6.55 (dd, 1H), 5.11 (s, 2H), 5.04 (s, 2H), 4.02 (s, 1 H), 1.60 (s, 6H).
Svnthesis 35
4-lsopropyl-1 ,3-dibenzyloxybenzene (Compound 35)
2-(2,4-Bis(benzyloxy)phenyl)propan-2-ol (7.00 g, 20.1 mmol) was dissolved in dry CH2CI2 (140 mL) under N2 and cooled to -78 0C. Et3SiH (4.2 ml_, 26.1 mmol) was added followed by TFA (3.1 mL, 40.2 mmol; added drop-wise over 5-10 min). An orange color appeared and temporarily a precipitate which re-dissolved with more TFA. The mixture was left to slowly heat up to room temperature. The mixture was left stirring overnight. TLC (EtOAc- Hep 2:8) showed complete conversion. The reaction mixture was poured into aqueous NaHCO3 (saturated, 300 mL) and the phases separated. The aqueous phase was extracted once with CH2CI2 and the combined organic phase was dried over MgSO4 and evaporated to colorless (light tan) oil (9.1 g , still wet). Purified on Silicagel with EtOAc- Hep (1 :9). The yield of title compound was 6.5 g (97%) of a colorless oil which crystallizes. 1H-NMR (CDCI3): δ 7.54-7.29 (m, 10H), 1.14 (d, 1 H), 6.66-6.54 (m, 2H), 5,06 (s, 2H), 5.04 (s, 2H), 3.35 (sep, 1 H), 1.23 (d, 6H).
Synthesis 36 2,4-Bis(benzyloxy)-5-isopropylbenzaldehyde (Compound 36)
DMF (20 mL) was placed in a 100 mL 3-necked flask equipped with a reflux condenser and CaCI2 drying tube. After cooling in ice, POCI3 (1.05 mL, 11 mmol) was added dropwise. After stirring at 00C for 10 minutes, 4-lsopropyl-1 ,3-dibenzyloxybenzene (2.50 g, 7.5 mmol) was added dropwise. The resulting solution was heated to 1000C for 2 hours giving a brown solution. TLC indicated complete reaction and the reaction mixture was poured onto 20 mL crushed ice. The pH was adjusted to 6 with 10% NaOAc and the suspension was placed in the fridge over night to crystallize. The precipitate was filtered off and washed with water and dried. 1H NMR confirmed that the product was the desired product. The crude product was further purified (to remove small amounts of Compound 2) by flash chromatography (silica gel, EtOAc-Hep (30:70) to (80:20). The yield of colourless oil, which crystallized on standing, was 2.94 g (85%). 1H-NMR (CDCI3): δ 10.39 (s, 1 H), 7.75 (s, 1H), 7.44-7.31 (m, 10H), 6.51 (s, 1 H), 5.12 (s, 2H), 5.10 (s, 2H), 3.28 (sep, 1 H), 1.22 (s, 6H).
Synthesis 37 2,4-Dimethoxy-5-isopropylphenylboronic acid (Compound 37)
1-Bromo-5-isopropyl-2,4-dimethoxybenzene (1.00 g, 3.84 mmol) was dissolved in dry THF (20 ml_) in a three-necked flask and kept under a N2 atmosphere. The solution was cooled to -78°C and BuLi (2.4 M (titrated before use) in hexanes) was added (1.95 ml_, 1.2 eq). The initial orange colour faded quickly to a colourless clear solution. The mixture was stirred for 1 hour at -78°C. Triisopropyl borate (2.66 ml_, 11.5 mmol) was dissolved in dry THF (20 ml_) in a new three-necked flask under N2 and cooled to -78°C. The cold THF solution of the lithiated reactant was slowly siphoned into the borate solution while stirring and keeping the temperature at -780C. After addition, the solution was allowed to warm to room temperature giving a colourless "milky" suspension. This was poured into ice/water, the pH was adjusted to 4 with HCI, and the product extracted with ether (3x). The combined organics were washed with brine and dried over MgSO4. The filtered ether solution was evaporated to dryness and the residue recrystallized from EtOH-water to yield pure title compound. 1H-NMR (DMSO-Gf6): δ 7.44 (s, 1H), 7.42 (s, 2H), 6.57 (s, 1 H), 3.85 (s, 1 H), 3.84 (s, 3H), 3.13 (sep, 1 H), 1.12 (d, 6H).
Synthesis 38 3-(5-lsopropyl-2,4-dimethoxyphenyl)pyridine (Compound 38)
Obtained using General Procedure 3. Starting materials: Pyridine-3-boronic acid and 1- bromo-5-isopropyl-2,4-dimethoxybenzene. 1H-NMR (CDCI3): δ 8.75 (dd, 1 H), 8.51 (dd, 1 H), 7.83 (dq, 1 H), 7.30 (ddd, 1H), 7.14 (s, 1H), 6.55 (s, 1 H), 3.90 (s, 3H), 3.82 (s, 3H), 3.29 (sep, 1 H) , 1.22 (d, 6H).
Svnthesis 39 Λ/-(5'-lsopropyl-21,4'-dimethoxybiphenyl-2-yl)methanesulfonamide (Compound 39)
Obtained using General Procedure 3. Starting materials: 2-Methylsulfonylamino- phenylboronic acid and 1-bromo-5-isopropyl-2,4-dimethoxybenzene. 1H-NMR (CDCI3): δ 7.62 (d, 1 H), 7.38 (m, 1 H), 7.31 (m, 1 H), 7.28 (d, 1 H), 7.01 (s, 1 H), 6.84 (bs, 1H), 6.56 (s, 1H), 3.92 (s, 3H), 3.83 (s, 3H), 3.28 (sep, 1H), 2.54 (s, 3H), 1.25-1.10 (m, 6H).
Synthesis 40 1 -(5'-lsopropyl-2',4'-dimethoxybiphenyl-2-ylsulfonyl)pyrrolidine (Compound 40)
Obtained using General Procedure 3. Starting materials: Λ/-Pyrrolidinyl-2-boron- benzensulfonamide and 1-bromo-5-isopropyl-2,4-dimethoxybenzene. An impure product was obtained, which may have contained bis(2,2'-pyrrolidinylsulfonamid)biphenyl from homo-coupling of boronic acid. The product was used without further purification in subsequent reactions. 1H-NMR (CDCI3): δ 8.19 (dd, 1 H), 7.60-7.50 (dt, 1 H1 masked), 7.40 (dt, 1H), 7.28 (dd, 1H), 7.09 (s, 1 H), 6.48 (s, 1H), 3.88 (s, 3H), 3.73 (s, 3H), 3.31- 3.21 (m, 1H, masked), 2.96 (m, 2H), 2.76 (m, 2H), 1.76 (m, 2H, masked), 1.65 (m, 2H, masked), 1.20 (d, 3H), 1.17 (d, 3H). Spectrum contains unknown (possible) pyrrolidinyl- phenylsulfonamide component.
Synthesis 41 5'-lsopropyl-2',4'-dimethoxybiphenyl-2-amine (Compound 41)
Obtained using General Procedure 3. Starting materials: 2-Aminophenylboronic acid and 1-bromo-5-isopropyl-2,4-dimethoxybenzene. 1H-NMR (CDCI3): δ 7.20-7.08 (m, 2H), 7.07 (s, 1 H), 6.87-6.73 (m, 2H), 6.54 (s, 1 H), 3.89 (s, 3H), 3.80 (s, 3H), 3.71 (bs, 2H), 3.27 (sep, 1 H), 1.19 (d, 6H). MS: [M+1]+1 = 272.1.
Synthesis 42
A/-(5'-lsopropyl-2',4'-dimethoxybiphenyl-2-yl)-4-methylbenzene-sulfonamide
(Compound 42)
Obtained using General Procedure 6. Starting materials: 4-Methylphenylsulfonyl chloride and 5'-isopropyl-2',4'-dimethoxybiphenyl-2-amine. TLC-pure material was obtained. Product was used without further purification or analysis.
Synthesis 43
4-Fluoro-Λ/-(5'-isopropyl-2',4'-dimethoxybiphenyl-2-yl)benzenesulfonamide
(Compound 43)
Obtained using General Procedure 6. Starting materials: 4-Fluorobenzenesulfonyl chloride and δ'-isopropyl^'^'-dimethoxybiphenyl^-amine. TLC-pure material was obtained. Product was used without further purification or analysis.
Synthesis 44
Λf-(5'-lsopropyl-2',4'-dimethoxybiphenyl-2-yl)-1-phenylnnethane-sulfonamicle
(Compound 44)
Obtained using General Procedure 6. Starting materials: Phenylmethanesulfonyl chloride and 5'-isopropyl-2',41-dimethoxybiphenyl-2-amine. TLC-pure material was obtained. Product was used without further purification or analysis.
Synthesis 45
1-(4-Chlorophenyl)-N-(5'-isopropyl-2',4'-dimethoxybiphenyl-2-yl)methane-sulfonamide
(Compound 45)
Obtained using General Procedure 6. Starting materials: (4-Chlorophenyl)methane- sulfonyl chloride and 5'-isopropyl-2',4'-dimethoxybiphenyl-2-amine. TLC-pure material was obtained. The product was used without further purification or analysis.
Synthesis 46 A/-(5'-lsopropyl-2',4'-dimethoxybiphenyl-2-yl)naphthalene-2-sulfonamide (Compound 46)
Obtained using General Procedure 6. Starting materials: Naphthalene-2-sulfonyl chloride and 5'-isopropyl-2',4'-dimethoxybiphenyl-2-amine. TLC-pure material was obtained. Product was used without further purification or analysis.
Synthesis 47 A/-(5'-lsopropyl-2',4'-dimethoxybiphenyl-2-yl)ethanesulfonamide (Compound 47)
Obtained using General Procedure 6. Starting materials: Ethanesulfonyl chloride and 5'- isopropyl-2',4'-dimethoxybiphenyl-2-amine. TLC-pure material was obtained. Product was used without further purification or analysis.
Synthesis 48 Λ/-(5'-lsopropyl-2',4'-dimethoxybiphenyl-2-yl)propane-1 -sulfonamide (Compound 48)
Obtained using General Procedure 6. Starting materials: Propanesulfonyl chloride and 51- isopropyl-2',4'-dimethoxybiphenyl-2-amine. TLC-pure material was obtained. Product was used without further purification or analysis.
Synthesis 49 A/-(5'-lsopropyl-2',4'-dimethoxybiphenyl-2-yl)cyclopropane-sulfonamide (Compound 49)
Obtained using General Procedure 6. Starting materials: Cyclopropanesulfonyl chloride and 5'-isopropyl-2',4'-dimethoxybiphenyl-2-amine. TLC-pure material was obtained. Product was used without further purification or analysis.
Synthesis 50
3-(5-lsopropyl-2,4-dimethoxyphenyl)thiophene (Compound 50)
Obtained using General Procedure 3. Starting materials: Thiophene-3-boronic acid and 1-bromo-5-isopropyl-2,4-dimethoxybenzene. 1H-NMR (CDCI3): δ 7.49 (dd, J=1.1/3.8 Hz, 1 H), 7.41 (dd, J=1.1/4.9 Hz, 1 H), 7.32 (dd, J=3.8/4.9 Hz, 1H), 7.29 (s, 1H), 6.53 (s, 1H), 3.88 (s, 3H), 3.86 (s, 3H), 3.27 (sep, 1 H), 1.22 (d, 6H).
Synthesis 51 5-(5-lsopropyl-2,4-dimethoxyphenyl)benzo[d][1 ,3]dioxole (Compound 51 )
Obtained using General Procedure 3. Starting materials: 3,4-(Methylenedioxy)- phenylboronic acid and 1-bromo-5-isopropyl-2,4-dimethoxybenzene. 1H-NMR (CDCI3): δ 7.10 (s, 1 H), 7.03 (d, 1 H), 6.95 (dd, 1 H), 6.85 (d, 1H), 6.52 (s, 1 H), 5.97 (s, 2H), 3.88 (s, 3H), 3.81 (s, 3H), 3.27 (sep, 1 H), 1.21 (d, 6H).
Synthesis 52 5'-lsopropyl-2',4'-dimethoxybiphenyl-2-carboxamide (Compound 52)
Obtained using "inversed" General Procedure 3. Starting materials: 2,4-Dimethoxy-5- isopropylphenylboronic acid (100 mg, 0.45 mmol) and 2-bromopyridine. No NMR data recorded. LC-MS confirmed 70% pure (product contains some Ph3PO + unknown). MS+: 258.1 (M+1 ), 537.0 (2M+Na).
Synthesis 53 5-lsopropyl-2,4-dimethoxy-2'-phenoxybiphenyl (Compound 53)
Obtained using General Procedure 3. Starting materials: 1 -Bromo-5-isopropyl-2,4- dimethoxybenzene and 2 phenoxyphenylboronic acid. TLC-pure material was obtained. The product was used without further purification or analysis.
Synthesis 54 /V^δ'-lsopropyl^'^'-dimethoxybiphenyl^-yOacetamide (Compound 54)
Prepared using a method analogous to General Procedure 6, replacing the sulfonyl chloride with acetyl chloride. Starting materials: 5'-lsopropyl-2',4'-dimethoxybiphenyl-2- amine and acetyl chloride. TLC-pure material was obtained. The product was used without further purification or analysis.
Synthesis 55
4'-Fluoro-5-isopropyl-2,4-dimethoxybiphenyl (Compound 55)
Obtained using General Procedure 3. Starting materials: 1-Bromo-5-isopropyl-2,4- dimethoxybenzene and 4-fluorophenylboronic acid. TLC-pure material was obtained. The product was used without further purification or analysis.
Synthes'is 56
4'-Chloro-5-isopropyl-2,4-dimethoxybiphenyl (Compound 56)
Obtained using General Procedure 3. Starting materials: 1-Bromo-5-isopropyl-2,4- dimethoxybenzene and 4-chlorophenylboronic acid. TLC-pure material was obtained. The product was used without further purification or analysis.
Synthesis 57
4'-FIuoro-5-isopropyl-2,4-dimethoxy-3'-methylbiphenyl (Compound 57)
Obtained using General Procedure 3. Starting materials: 1 -Bromo-5-isopropyl-2,4- dimethoxybenzene and 4-fluoro-3-methylphenylboronic acid. TLC-pure material was obtained. The product was used without further purification or analysis.
Synthesis 58
3',4'-Difluoro-5-isopropyl-2,4-dimethoxybiphenyl (Compound 58)
Obtained using General Procedure 3. Starting materials: 1-Bromo-5-isopropyl-2,4- dimethoxybenzene and 3,4-difluorophenylboronic acid. TLC-pure material was obtained. The product was used without further purification or analysis.
Synthesis 59 4'-Fluoro-5-isopropyl-2,4-dimethoxy-2'-methylbiphenyl (Compound 59)
Obtained using General Procedure 3. Starting materials: 1-Bromo-5-isopropyl-2,4- dimethoxybenzene and 4-fluoro-2-methylphenylboronic acid. TLC-pure material was obtained. The product was used without further purification or analysis.
Synthesis 60 5-lsopropyl-2,4-dimethoxy-3'-(3-methoxybenzyloxy)biphenyl (Compound 60)
Obtained using General Procedure 3. Starting materials: 1-Bromo-5-isopropyl-2,4- dimethoxybenzene and 3-(3-methoxybenzyloxy)phenylboronic acid. TLC-pure material was obtained. The product was used without further purification or analysis.
Synthesis 61 3'-Fluoro-5-isopropyl-2,4,4'-trimethoxybiphenyl (Compound 61)
Obtained using General Procedure 3. Starting materials: 1-Bromo-5-isopropyl-2,4- dimethoxybenzene and 3-fluoro-4-methoxyphenylboronic acid. TLC-pure material was obtained. The product was used without further purification or analysis.
Svnthesis 62
4-Butoxy-2,3,5,6-tetrafluoro-51-isopropyl-21,4'-dimethoxybiphenyl (Compound 62)
Obtained using General Procedure 3. Starting materials: 1-Bromo-5-isopropyl-2,4- dimethoxybenzene and 4-butyloxy-2,3,5,6-tetrafluorophenylboronic acid. TLC-pure material was obtained. The product was used without further purification or analysis.
Synthesis 63 4'-Fluoro-2'-isopropoxy-5-isopropyI-2,4-dimethoxybiphenyl (Compound 63)
Obtained using General Procedure 3. Starting materials: 1 -Bromo-5-isopropyl-2,4- dimethoxybenzene and 4-fluoro-2-isopropoxyphenylboronic acid. TLC-pure material was obtained. The product was used without further purification or analysis.
Synthesis 64
4-Fluoro-5'-isopropyl-2',4'-dimethoxybiphenyl-3-carboxylic acid (Compound 64)
Obtained using General Procedure 3. Starting materials: 1-Bromo~5-isopropyl-2,4- dimethoxybenzene and 5-borono-2-fluorobenzoic acid. TLC-pure material was obtained. The product was used without further purification or analysis.
Svnthesis 65
4-Fluoro-Λ/,5'-diisopropyl-21,4'-dimethoxybiphenyl-3-carboxamide (Compound 65)
Obtained using General Procedure 3. Starting materials: 1-Bromo-5-isopropyl-2,4- dimethoxybenzene and 4-fluoro-3-(isopropylcarbamoyl)phenylboronic acid. TLC-pure material was obtained. The product was used without further purification or analysis.
Synthesis 66
(4-Fluoro-5'-isopropyl-2',4'-dimethoxybiphenyl-3-yl)(morpholino)methanone
(Compound 66)
Obtained using General Procedure 3. Starting materials: 1-Bromo-5-isopropyl-2,4- dimethoxybenzene and 4-fluoro-3-(morpholine-4-carbonyl)phenylboronic acid. TLC-pure material was obtained. The product was used without further purification or analysis.
Synthesis 67 4-Fluoro-5'-isopropyl-2',4'-dimethoxy-Λ/-phenylbiphenyl-3-carboxamide (Compound 67)
Obtained using General Procedure 3. Starting materials: 1-Bromo-5-isopropyl-2,4- dimethoxybenzene and 4-fIuoro-3-(phenylcarbamoyl)phenylboronic acid. TLC-pure material was obtained. The product was used without further purification or analysis.
Svnthesis 68
5'-!sopropyl-2',4'-dimethoxybiphenyl-3-amine (Compound 68)
Obtained using General Procedure 3. Starting materials: 1-Bromo-5-isopropyl-2,4- dimethoxybenzene and 3-aminophenylboronic acid hydrochloride. TLC-pure material was obtained. The product was used without further purification or analysis.
Synthesis 69 Λ/-(5'-lsopropyl-2\4'-dimethoxybiphenyl-3-yl)methanesulfonamide (Compound 69)
Obtained using General Procedure 6. Starting materials: Methanesulfonyl chloride and 5'- isopropyl-2',4'-dimethoxybiphenyl-3-amine. TLC-pure material was obtained. The product was used without further purification or analysis.
Synthesis 70
Λ/-(5'-lsopropyl-2',4'-dimethoxybiphenyl-3-yl)-1-phenylmethanesulfonamide
(Compound 70)
Obtained using General Procedure 6. Starting materials: Phenylmethanesulfonyl chloride and 5'-isopropyl-2',4'-dimethoxybiphenyl-3-amine. TLC-pure material was obtained. The product was used without further purification or analysis.
Svnthesis 71
^-(S'-lsopropyl^'^'-dimethoxybiphenyl-S-yO^-methylbenzenesulfonamicie (Compound
71)
Obtained using General Procedure 6. Starting materials: 4-Methylphenylsulfonyl chloride and 5'-isopropyl-2',4'-dimethoxybiphenyl-3-amine. TLC-pure material was obtained. The product was used without further purification or analysis.
Synthesis 72
1-(4-Chlorophenyl)-Λ/-(5'-isopropyl-2',4I-dimethoxybiphenyl-3-yl)methanesulfonamide
(Compound 72)
Obtained using General Procedure 6. Starting materials: (4-Chlorophenyl)methane- sulfonyl chloride and 5'-isopropyl-2',4'-dimethoxybiphenyl-3-amine. TLC-pure material was obtained. The product was used without further purification or analysis.
Synthesis 73
4-Fluoro-5'-isopropyl-2',4'-dimethoxybiphenyl-2-amine (Compound 73)
Obtained using General Procedure 3. Starting materials: 1-Bromo-5-isopropyl-2,4- dimethoxybenzene and 2-amino-4-fluorophenylboronic acid. TLC-pure material was obtained. The product was used without further purification or analysis.
Synthesis 74
Λ/-(4-Fluoro-5I-isopropyl-2',41-dimethoxybiphenyl-2-yl)-4-methylbenzenesulfonamide
(Compound 74)
Obtained using General Procedure 6. Starting materials: 4-Methylphenylsulfonyl chloride and 4-fluoro-5'-isopropyl-2',4t-dimethoxybiphenyl-2-amine. TLC-pure material was obtained. The product was used without further purification or analysis.
Synthesis 75
1-(4-Chlorophenyl)-Λ/-(4-fluoro-5'-isopropyl-2',4'-dimethoxybiphenyl-2- yl)methanesulfonamide (Compound 75)
Obtained using General Procedure 6. Starting materials: 4-Chlorophenylmethanesulfonyl chloride and 4-fluoro-5'-isopropyl-2',4'-dimethoxybiphenyl-2-amine. TLC-pure material was obtained. The product was used without further purification or analysis.
Synthesis 76
2-(4-(Dimethylamino)phenyl)-/V-(5I-isopropyl-2',4'-dimethoxybiphenyl-3-yl)acetamide
(Compound 76)
4-Dimethylaminophenylacetic acid (24.6 mg, 0.14 mmol) was dissolved in dry DMF (5 mL). TBTU (48 mg, 0,19 mmol) and DIPEA (65 μl_, 3 eq) was added and the mixture was stirred for 20 minutes. Then 5'-lsopropyl-2',4'-dimethoxybiphenyl-3-amine (0.25 M in THF,
0.50 mL, 0.125 mmol) was added and the mixture left stirring over night. The solvents were evaporated in vacuo and the ccrude product was purified on preperative HPLC to yield 26.8 mg pure material (HPLC). The product was used without further purification or analysis.
Synthesis 77
Λ/-(4-((1 H- 1 ,2,4-Triazol-1 -yOmethyObenzyO-S'-isopropyl-Z^'-dimethoxybiphenyl-S-amine
(Compound 77)
4-((1/-/-1 ,2,4-Triazol-1-yl)methyl)benzaldehyde (27.3 mg, 0.134 mmol) and δ'-lsopropyl- 2',4'-dimethoxybiphenyl-3-amine (0.25 M in THF, 0.50 mL, 0.125 mmol) was dissolved in 2 mL THF:HOAc (3:1 ). Na2SO4 (50 mg) was added and the mixture was stirred for 1 h. NaBH(OAc)3 (80.1 mg, 3 eq) was added and the mixture was stirred over night. The reaction mixture was quenched with 0 0C NaHCO3-solution (to pH 8-9) and the product was extracted four times with PE: EtOAc (4:1). The combined organic phases was evaporated and the crude material was purified by preparative HPLC to yield 29 mg pure material. The product was used without further purification or analysis.
Synthesis 78
5-lsopropyl-2,4-dimethoxybenzaldehyde (Compound 78)
DMF (15 mL) was placed in a 100 mL 3-necked flask equipped with a reflux condenser and CaCI2 drying tube. After cooling in ice, POCI3 (2.3 mL, 25 mmol) was added dropwise. After stirring at O0C for 10 minutes, Compound 2 (3.00 g, 16.6 mmol) was added dropwise. The resulting green solution was heated to 1000C for 2 hours. TLC indicated complete reaction and the reaction mixture was poured onto 200 mL crushed ice. The pH was adjusted to 6 with 10% NaOAc and the suspension was placed in the fridge over night to crystallize. The precipitate was filtered off and washed with water and dried. 1H NMR confirmed that the product was the desired product. The crude product
was further purified (to remove small amounts of Compound 2) by flash chromatography (silica gel, EtOAc-Hep (30:70) to (80:20). The yield of colourless oil, which crystallized on standing, was 2.94 g (85%). 1H-NMR (CDCI3): δ 10.31 (s, 1H), 7.70 (s, 1H), 6.40 (s, 1H), 3.93 (s, 3H), 3.92 (s, 3H), 3.20 (sep, 1 H), 1.19 (d, 6H).
Synthesis 79 5-(5-lsopropyl-2,4-dimethoxyphenyl)oxazole (Compound 79)
Obtained using General Procedure 5. Starting material: 5-lsopropyl-2,4- dimethoxybenzaldehyde. 1H-NMR (CDCI3): δ 7.87 (s, 1 H), 7.58 (s, 1 H), 7.41 (s, 1 H), 7.51 (s, 1 H), 3.95 (s, 3H), 3.88 (s, 3H), 3.28 (hep, 1 H), 1.23 (d, 6H).
Synthesis 80 1 -Ethyl-5-(isocyano(tosyl)methyl)-2,4-dirnethoxybenzene (Compound 80)
Step 1: Isolation of p-tolylsulfinic acid: Sodium p-tolylsulfinate (anhydrous) (3.21 g, 18.0 mmol) was suspended in water (25 mL). After stirring for 10 minutes, all was dissolved and £-butylmethylether (TBME) (25 mL) was added. Then, concentrated HCI (aq) (1.6 mL, 1 eq) was added dropwise. After stirring for 20 minutes, the organic phase was separated, diluted with toluene (25 mL), and evaporated in vacuo to remove 70-90% of the solvents. Heptane (7 mL) was added to the resulting slurry, and the precipitate was isolated on a glass filter, washed with heptane, and dried in vacuo. The resulting crude p-tolylsulfinic acid was used fresh in the next step without further purification.
Step 2:
Toluene (dry, 3 ml_) and acetonitrile (dry, 3 mL), both dried over 4 A molecular sieve, was placed in a three-necked round bottomed flask. 5-Ethyl-2,4-dimethoxybenzaldehyde (1.25 g, 6.44 mmol) was added followed by molecular sieves (4A, 0.5 g). Formamide (0.64 mL, 16.1 mmol) and TMSCI (0.90 mL, 7.1 mmol) were added and the mixture stirred a 50°C under a nitrogen atmosphere for 4 hours. Precipitation of yellow-green product was observed. Then, freshly prepared p-tolylsulfinic acid (1.51 g, 9.65 mmol) from step 1 was added and stirring at 5O0C was continued for another 4 hours. To the cooled and almost clear reaction mixture was added TBME (5 mL), and after stirring for 5 minutes, all was poured into ice-water. A precipitate was observed in the upper layer. After stirring at O0C for 1 hour, the precipitate was filtered off and washed with TBDE and dried in vacuo. Weight of crude product: 1.28 g (52 %).
Step 3:
The crude product from step 2 (1.27 g, 3.36 mmol) was suspended in dry THF (7 mL) at room temperature. To the white suspension was added POCI3 (0.62 mL) and the resulting greenish suspension was stirred for 5 minutes, after which it was cooled to 00C. Triethylamine (2.8 mL) was added slowly keeping the temperature below 5°C. The mixture was stirred at O0C for 45 minutes, after which EtOAc (5 mL) and water (5 mL) were added. The mixture was stirred for 5 minutes and the phases were separated. The organic phase was washed with water twice, once with saturated NaHCθ3, and with brine, and then dried over MgSO4, filtered, and evaporated to yield 1.2 g of orange-brown oil. 1-Propanol (5 mL) was added and the resulting suspension was evaporated to half volume and cooled in ice for 45 minutes, after which the resulting solid was isolated by filtration and washed with cold 1-propanol. After drying in vacuo, the yield was 521 mg (43%) of a light tan solid. LC-MS and 1H NMR showed the desired Compound 47 as >95% pure. 1H NMR (CD3OD) δ 7.60 (d, 2H), 7.42 (d, 2H), 6.96 (s, 1 H), 6.51 (s, 1H), 6.41 (s, 1H), 3.88 (s, 3H), 3.68 (s, 3H), 2.53 (q, 2H), 2.48 (s, 3H), 1.11 (t, 3H). MS+: 382.0 (M+Na), 740.7 (2M+Na), MS-: 358.2 (M-H).
Synthesis 81 1 -(lsocyano(tosyl)methyi)-5-isopropyl-2,4-dimethoxybenzene (Compound 81 )
Step 1: Isolation of p-tolylsulfinic acid: Sodium p-tolylsulfinate (anhydrous) (3.21 g, 18.0 mmol) was suspended in water (25 ml_). After stirring for 10 minutes, all was dissolved and f-butylmethylether (TBME) (25 ml_) was added. Then concentrated HCI (aq) (1.6 mL, 1 eq) was added dropwise. After stirring for 20 minutes, the organic phase was separated, diluted with toluene (25 mL), and evaporated in vacuo to remove 70-90% of the solvents. Heptane (7 mL) was added to the resulting slurry and the precipitate was isolated on a glass filter, washed with heptane, and dried in vacuo. The resulting crude p-tolylsulfinic acid was used fresh in the next step without further purification.
Step 2:
5-lsopropyl-2,4-dimethoxybenzaldehyde (1.50 g, 7.20 mmol) was dissolved in dry acetonitrile (3 mL) and dry toluene (3 mL). Molecular sieves (4A) were added. Formamide (0.72 mL, 2.5 eq) and TMSCI (1.00 mL, 1.1 eq) were added and the mixture was heated to 5O0C for 4 hours under a N2 atmosphere. The resulting cloudy orange solution was evaporated to semi-dryness. Dry toluene was added and the solvent was re-evaporated. To the residual oil was added acetonitrile (1 mL) and toluene (1 mL) followed by p-tolylsulfinic acid (freshly prepared in step 1) (1.69 g, 2.5 eq). The solution was stirred at 500C for 5 hours and then at room temperature overnight. To the resulting yellow suspension was added TBME (2 mL). After stirring for 5 minutes, water (10 mL) was added after which the precipitate dissolved. The mixture was stirred at 00C for 1 hour. The organic phase was isolated and evaporated in vacuo at 35°C to give a viscous oil (2.4 g). HPLC and LC-MS show mixture of products (possibly due to degradation on the column).
The above raw product (2.4 g) was suspended in dry THF (7 ml) in a two-necked flask equipped with thermometer. POCI3 (1.13 mL, 2 eq) was added and the solution cooled on acetone/ice bath to O0C. Triethylamine (5.1 mL, 6 eq.) was added slowly, keeping the temperature below 5°C. The mixture was stirred at O0C for 45 minutes. To the solution was added EtOAc (5 mL) and H2O (5 mL) and the mixture was stirred for 10 minutes. The organic phase was separated and washed twice with water, twice with saturated NaHCO3, once with brine, and dried over Na2SO4. Evaporation yielded (2.2 g) of a viscous oil. LC-MS showed that it was the desired product; [M-H]"1 = 372.2 and [M+Na]+1 = 396.0. From the UV-trace, the content of the desired compound was estimated to be about 30-40% in mixture with 2 major unidentified by-products. The title product was used as obtained for further reactions. An analytical sample was further purified on silica gel (EtOAc-PE (7:3) ) to give the following NMR data: 1H-NMR (CD3OD): δ 7.58 (d, 2H), 7.42 (d, 2H), 6.95 (s, 1H), 6.52 (s, 1H), 6.42 (s, 1H), 3.89 (s, 3H), 3.71 (s, 3H), 3.19 (sep, 1 H), 2.48 (S1 3H), 1.1 1 (d, 6H).
Synthesis 82 5-(4-Ethylphenyl)-4-(5-isopropyl-2,4-dimethoxyphenyl)oxazole (Compound 82)
Prepared using an "inversed" General Procedure 5. Starting materials: Crude 1-(isocyano(tosyl)methyl)-5-isopropyl-2,4-dimethoxybenzene and 4-ethylbenzaldehyde. The compound was obtained as approximately 70% pure as judged from LC-MS. MS: [M+H]+1 = 352.20. The product was used in subsequent reactions without further purification.
Synthesis 83
5-(4-Fluorophenyl)-4-(5-isopropyl-2,4-dimethoxyphenyl)oxazoIe (Compound 83)
Prepared using an "inversed" General Procedure 5. Starting materials: 1 -(isocyano(tosyl)methyl)-5-isopropyl-2,4-dimethoxybenzene and 4-fluoro-benzaldehyde. The compound was obtained as approximately 50% pure as judged from LC-MS. MS:
[M+H]+1 = 342.10. The product was used in subsequent reactions without further purification.
Synthesis 84 4-(5-lsopropyl-2,4-dimethoxyphenyl)-5-(naphthalen-2-yl)oxazole (Compound 84)
Prepared using an "inversed" General Procedure 5. Starting materials: Crude 1 -(isocyano(tosyl)methyl)-5-isopropyl-2,4-dimethoxybenzene and 2-naphthaldehyde. 1H-NMR (CD3OD): δ 8.35 (s, 1 H)1 8.02 (s, 1 H), 7.88-7.75 (m, 3H), 7.57-7.44 (m, 3H), 7.29 (s, 1 H), 6.71 (s, 1 H), 3.96 (s, 3H), 3.61 (s, 3H), 3.31 (sep, 1H, masked), 1.20 (d, 6H). LC-MS. -90% pure. MS: [M+H]+1 = 374.1.
Synthesis 85 1 -(Isocyano(phenyl)methylsulfonyl)-4-methylbenzene (Compound 85)
Synthesized analogous to 1-(isocyano(tosyi)methyl)-5-isopropyl-2,4-dimethoxybenzene using benzaldehyde as starting material. 1H-NMR (CD3OD): δ 7.67-7.62 (m, 2H), 7.54- 7.34 (m, 7H), 2.49 (s, 3H). MS: [M+H]+1 = 294.0.
Synthesis 86
5-(5-lsopropyl-2,4-dimethoxyphenyl)-4-phenyloxazole (Compound 86)
Prepared using General Procedure 5. Starting materials: 1-(lsocyano(phenyl)- methylsulfonyl)-4-methylbenzene and 5-isopropyl-2,4-dimethoxybenzaldehyde. Crude product -80 % pure. Used as is for subsequent step. 1H-NMR (DMSO-c/6): δ 8.44 (s,
1 H), 7.53-7.47 (m, 2H), 7.36-7.20 (m, 3H), 7.14 (s, 1 H), 6.75 (s, 1 H), 3.91 (s, 3H), 3.67 (s, 3H), 3.18 (sep, 1 H), 1.09 (d, 6H).
Synthesis 87 1-Fluoro-4-(isocyano(tosyl)methyl)benzene (Compound 87)
Synthesized analogous to 1-(isocyano(tosyl)methyl)-5-isopropyl-2,4-dimethoxybenzene using 4-fluorobenzaldehyde as starting material. 1H-NMR (CD3OD): δ 7.68 (d, 2H), 7.47 (d, 2H), 7.46-7.38 (m, 2H), 7.24-7.14 (m, 2H), 2.50 (s, 3H). MS: [M+Na]+1 = 312.1.
Synthesis 88 4-(4-Fluorophenyl)-5-(5-isopropyl-2,4-dimethoxyphenyl)oxazole (Compound 88)
Prepared using General Procedure 5. Starting materials: 1-Fluoro-4- (isocyano(tosyl)methyl)benzene and 5-isopropy!-2,4-dimethoxybenzaldehyde. Crude product -75 % pure. Used as is for subsequent step. 1H-NMR (DMSOd6): δ 8.44 (s, 1 H), 7.50 (m, 2H), 7.22-7.12 (m, 3H), 6.74 (s, 1 H), 3.91 (s, 3H)1 3.66 (s, 3H), 3.18 (sep, 1 H), 1.10 (d, 6H). MS: [M+H]+1 = 342.2.
Synthesis 89 1-Ethyl-4-(isocyano(tosyl)methyl)benzene (Compound 89)
Synthesized analogous to 1-(isocyano(tosyl)methyl)-5-isopropyl-2,4-dimethoxybenzene using 4-ethylbenzaldehyde as starting material. 1H-NMR (CD3OD): δ 7.64 (d, 2H), 7.44 (d, 2H), 7.27 (bs, 4H), 2.70 (q, 2H), 2.50 (s, 3H), 1.26 (t, 3H). MS: [M+Na]+1 = 322.2.
Svnthesis 90 4-(4-Ethylphenyl)-5-(5-isopropyl-2,4-dimethoxyphenyl)oxazo!e (Compound 90)
Prepared using General Procedure 5. Starting materials: 1-Ethyl-4- (isocyano(tosyl)methyl)benzene and 5-isopropyl-2,4-dimethoxybenzaldehyde. Impure. Used as is for subsequent step. 1H-NMR (DMSO-Cf6): δ 8.41 (s, 1 H)1 7.41 (m, 2H), 7.17- 7.1 1 (m, 2H), 7.12 (s, 1 H), 6.74 (s, 1 H), 3.91 (s, 3H), 3.67 (s, 3H), 3.17 (sep, 1H), 2.57 (q, 2H), 1.15 (t, 3H) 1.08 (d, 6H). MS: [M+H]+1 = 352.1.
Synthesis 91 4-(lsocyano(tosyl)methyl)-6-isopropyl-1 ,3-dibenzyloxybenzene (Compound 91)
Synthesized analogous to 1-(isocyano(tosyl)methyl)-5-isopropyl-2,4-dimethoxybenzene using (2,4-bis(benzyloxy)-5-isopropyl-benzaldehyde) as starting material. The product was isolated as a white solid in 18 % overall yield (2 steps). 1H-NMR (CD3OD): δ 7.55- 7.49 (m, 2H), 7.46-7.30 (m, 12H), 7.00 (s, 1 H), 6.66 (s, 1 H), 6.40 (s, <1 H, deut. exchange), 5.12 (s, 2H), 5.05 (d, 1H), 4.9 (masked d, 1H), 3.26 (sep, 1 H), 2.46 (s, 3H), 1.14 (dd, 6H). 1H-NMR (DMSO-Cy6): δ 7.59-7.29 (m, 14H), 6.89 (s, 1 H), 6.84 (s, 1H), 6.68 (1H), 5.18 (s, 2H), 5.13 (d, 1 H), 5.99 (d, 1 H), 3.14 (sep, 1H), 2.41 (s, 3H), 1.04 (dd, 6H). MS: [M+Na]+1 = 548.1.
Synthesis 92 4-(2,4-Bis(benzyloxy)-5-isopropylphenyl)-5-phenyloxazole (Compound 92)
Prepared using an "inversed" General Procedure 5. Starting materials: 4- (lsocyano(tosy[)methyl)-6-isopropyl-1 ,3-dibenzyloxybenzene and benzaldehyde. 1H-NMR
(CD3OD): δ 8.29 (s, 1 H), 7.52-7.13 (arom 14H), 6.96 (m, 2H), 6.81 (s, 1 H), 5.16 (s, 2H), 4.9 (masked, 2H), 3.36 (sep, masked, 1H), 1.23 (d, 6H).
Synthesis 93 4-(2,4-Bis(benzyloxy)-5-isopropylphenyl)-5-(2-ethylphenyl)oxazole (Compound 93)
Prepared using an "inversed" General Procedure 5. Starting materials: 4- (lsocyano(tosyl)methy!)-6-isopropyl-1 ,3-dibenzyloxybenzene and 2-ethylbenzaldehyde. -70 % pure. Used as is for subsequent steps. 1H-NMR (CD3OD): δ 8.34 (s, 1H), 7.51- 7.0 (m, arom. H), 6.59 (s, 1 H), 5.23 (d, 2H), 5.02 (s, 2H), 3.27 (sep, 1H), 2.49 (q, 2H), 1.14 (d, 6H), 1.00 (t, 3H). MS: [M+H]+1 = 504.3.
Synthesis 94 4-(2,4-Bis(benzyloxy)-5-isopropylphenyl)-5-(4-methoxyphenyl)oxazoIe (Compound 94)
Prepared using an "inversed" General Procedure 5. Starting materials: A- (lsocyano(tosyl)methyl)-6-isopropyl-1 ,3-dibenzyloxybenzene and 4-methoxy- benzaldehyde. -85% pure. Used as is for subsequent reaction. 1H-NMR (CD3OD): δ 8.24 (s, 1H), 7.51-7.34 (m, 8H), 7.27 (s, 1 H), 7.22-7.17 (m, 3H)1 7.02-6.96 (m, 2H), 6.91- 6.86 (m, 2H), 6.81 (s, 1 H), 5.25 (d, 1 H), 5.16 (s, 2H), 4.9 (masked d, 1 H), 3.81 (s, 3H), 3.26 (sep, 1 H), 2.46 (s, 3H), 1.22 (d, 6H). MS: [M+H]+1 = 506.3.
Synthesis 95
4-(2,4-Bis(benzyloxy)-5-isopropylphenyl)-5-(3,4-dimethoxyphenyl)oxazole (Compound 95)
Prepared using an "inversed" General Procedure 5. Starting materials: A- (lsocyano(tosyl)methyl)-6-isopropyl-1 ,3-dibenzyloxybenzene and 3,4- dimethoxybenzaldehyde. 1H-NMR (CD3OD): δ 8.25 (s, 1H), 7.49-6.80 (arom, 16H), 5.18 (s, 2H), 4.9 (masked, 2H), 3.85 (s, 3H), 3.48 (s, 3H), 3.26 (sep, 1 H), 1.23 (d, 6H). MS: [M+H]+1 = 536.3.
Synthesis 96
5-(Benzo[d][1 ,3]dioxol-5-yl)-4-(2,4-bis(benzyloxy)-5-isopropylphenyl)oxazole
(Compound 96)
Prepared using an "inversed" General Procedure 5. Starting materials: 4- (lsocyano(tosy!)methyl)-6-isopropyl-1 ,3-dibenzyloxybenzene and piperonal. 1H-NMR (CD3OD): δ 8.23 (s, 1 H), 7.55-6.74 (arom, 16H), 5.96 (s, 2H), 5.17 (s, 2H), 4.9 (masked, 2H), 3.85 (s, 3H), 3.48 (s, 3H), 3.26 (sep, 1 H), 1.23 (d, 6H). MS: [M+H]+1 = 520.3.
Synthesis 97 2-(4-(2,4-Bis(benzyloxy)-5-isopropylphenyl)oxazol-5-yl)benzonitrile (Compound 97)
Prepared using an "inversed" General Procedure 5. Starting materials: 4- (lsocyano(tosyl)methyl)-6-isopropyl-1 ,3-dibenzyloxybenzene and 2-formylbenzonitrile. 1H-NMR (DMSO-de): δ 8.64 (s, 1H), 7.74 (dd, 1H), 7.58 (dt, 1H), 7.50-7.20 (arom, 12H), 6.90-6.84 (m, 3H), 5.16 (s, 2H), 4.77 (s, 2H), 3.24 (sep, 1 H), 1.16 (d, 6H). MS: [M+H]+1 = 501.3; [M+Na]+1 = 523.3.
Synthesis 98 4-(4-(4_(2,4-Bis(benzyloxy)-5-isopropylphenyl)oxazol-5-yl)ben2yl)morpholine
(Compound 98)
Prepared using an "inversed" General Procedure 5. Starting materials: 4- (lsocyano(tosyl)methyl)-6-isopropyl-1 ,3-dibenzyloxybenzene and 4- (morpholinomethyl)benzaldehyde. 1H-NMR (CD3OD): δ 8.35 (s, 1 H), 7.60-6.93 (arom, 16H), 6.85 (s, 1H), 5.19 (s, 2H), 4.9 (masked, 2H), 4.0 (br, 2H), 3.77 (br, 4H), 3.26 (masked sep, 1 H), 2.88 (br, 4H), 1.24 (d, 6H). MS: [M+H]+1 = 575.4.
Synthesis 99
5-(4-((1 H-lmidazol-1-yl)methyl)phenyl)-4-(2,4-bis(benzyloxy)-5-isopropylphenyl)oxazole
(Compound 99)
(lsocyano(tosyl)methyl)-6-isopropyl-1 ,3-dibenzyloxybenzene and 4-((1H-imidazol-1- yl)methyl)benzaldehyde. 1H-NMR (DMSO-c/6): δ 8.44 (s, 1H), 7.72 (s, 1H), 7.54-6.81 (arom, 18H), 5.20(s, 2H), 5.19 (s, 2H), 4.92 (s, 2H), 3.24 (sep, 1H), 1.15 (d, 6H).
Synthesis 100
5-(4-((1 /-/-1 , 2,4-TriazoM -yl)methyl)phenyl)-4-(2,4-bis(benzyloxy)-5- isopropylphenyl)oxazole (Compound 100)
Prepared using an "inversed" General Procedure 5. Starting materials: 4- (lsocyano(tosyl)methyl)-6-isopropyl-1 ,3-dibenzyloxybenzene and 4-((1/7-1 ,2,4-triazol-1- yl)methyl)benzaldehyde. 1H-NMR (DMSO-c/6): δ 8.64 (s, 1H), 8.45 (s, 1H), 7.98 (s, 1H),
7.53-7.06 (arom, 13H), 6.95 (s, 1 H), 6.83 (m, 2H), 5.42 (s, 2H), 5.20 (s, 2H), 4.91 (s, 2H), 3.26 (sep, 1H), 1.15 (s, 6H). MS: [M+H]+1 = 557.3.
Synthesis 101
4-(2,4-Bis(benzyloxy)-5-isopropylphenyl)-5-(4-(piperidin-1-ylmethyl)phenyl)oxazole
(Compound 101)
Prepared using an "inversed" General Procedure 5. Starting materials: 4- (!socyano(tosyl)methy!)-6-isopropyl-1 ,3-dibenzyloxybenzene and 4-(piperidin-1- ylmethyl)benzaldehyde. 1H-NMR (CD3OD): δ 8.30 (s, 1 H), 7.53-7.11 (arom, 13), 6.95 (m, 2H), 6.82 (s, 1 H), 5.18 (s, 2H), 4.9 (masked, 2H), 3.51 (s, 2H), 2.41 (br, 4H), 1.57 (br, 4H), 1.44 (br, 2H), 1.23 (d, 6H). MS: [M+H]+1 = 573.4.
Synthesis 102
4-(2,4-bis(benzyloxy)-5-isopropylphenyl)-5-(4-((4-methylpiperazin-1- yl)methyl)phenyl)oxazole (Compound 102)
Prepared using an "inversed" General Procedure 5. Starting materials: A- (lsocyano(tosyl)methyl)-6-isopropyl-1 ,3-dibenzyloxybenzene and 4-((4-/V- methy!piperazin-1-yl)methyl)benzaldehyde. 90% pure LC-MS. MS: [M+H]+1 = 588.4.
Synthesis 103
4-(2,4-Bis(benzyloxy)-5-isopropylphenyI)-5-(4-((4-methyl-1 ,4-diazepan-1- yl)methyl)phenyi)oxazole (Compound 103)
Prepared using an "inversed" General Procedure 5. Starting materials: A- (lsocyano(tosyl)methyl)-6-isopropyl-1 ,3-dibenzyloxybenzene and 4-((4-Λ/-methyl-1 ,4- diazepan-1-yl)methyl)benzaldehyde. 1H-NMR (CD3OD): δ 8.30 (s, 1H), 7.54-6.91 (arom, 15H), 6.84 (s, 1 H), 5.18 (s, 2H), 4.93 (masked s, 2H), 3.71 (s, 2H), 3.26 (sep, 1H), 3.22 (m, 2H), 3.06 (2H, m), 2.8 (m, 2H), 2.75 (m, 2H), 2.75 (s, 3H), 1.95 (m, 2H), 1.24 (d, 6H). MS: [M+H]+1 = 602.4.
Synthesis 104
4-(2,4-Bis(benzyloxy)-5-isopropylphenyl)-5-(4-(pyrrolidin-1-ylmethyl)phenyl)oxazole (Compound 104)
Prepared using an "inversed" General Procedure 5. Starting materials: A- (lsocyano(tosyl)methyl)-6-isopropyl-1 ,3-dibenzyloxybenzene and 4-(pyrrolidin-1- ylmethyl)benzaldehyde. 1H-NMR (CD3OD): δ 8.30 (s, 1 H), 7.53-7.25 (arom, 10H), 7.18 (m, 3H), 6.96 (m, 2H), 6.82 (s, 1 H), 5.18 (s, 2H), 4.9 (masked s, 2H), 3.66 (s, 2H), 3.26 (masked sep, 1 H), 2.53 (br, 4H), 1.80 (br, 4H), 1.24 (d, 6H). MS: [M+H]+1 = 594.4.
Synthesis 105
4-(4-(2,4-Bis(benzyloxy)-5-isopropylphenyl)oxazol-5-yl)-N-(2-morpholinoethyl)aniline (Compound 105)
Prepared using an "inversed" General Procedure 5. Starting materials: A- (lsocyano(tosyl)methyl)-6-isopropyl-1 ,3-dibenzyloxybenzene and 4-(2- morpholinoethylamino)benzaldehyde. Yield was -25 % (LC-MS). Crude product contained approximately 50% 4-(2-morpholinoethylamino)benzaldehyde. Product confirmed from LC-MS : MS: [M+H]+1 = 604.4. 1H-NMR (CD3OD): δ 8.28 (s, 1 H), 5.19 (s, 2H), 4.98 (s, 2H), 1.14 (d, 6H). Other signals were unconfirmed. The product was used in subsequent reaction without further purification.
Svnthesis 106
5-(3-((1/-/-lmidazol-1-yl)methyl)phenyl)-4-(2,4-bis(ben2yloxy)-5-isopropylphenyl)oxazole
(Compound 106)
(lsocyano(tosyl)methyl)-6-isopropyl-1 ,3-dibenzyloxybenzene and 3-((1H-imidazol-1- yl)methyl)benzaldehyde. 1H-NMR (DMSO-d6): δ 8.46 (s, 1 H), 7.66 (s, 1 H), 7.56-6.78 (arom, 18H), 5.25 (s, 2H), 5.16 (s, 2H), 4.85 (s, 2H), 3.26 (masked sep, 1 H), 1.16 (d, 6H). MS: [M+H]+1 = 556.4.
Synthesis 107
5-(3-((1H-1 ,2,4-Triazol-1-yl)methyl)phenyl)-4-(2,4-bis(benzyloxy)-5-isopropylphenyl)- oxazole (Compound 107)
(lsocyano(tosy!)methyl)-6-isopropyl-1 ,3-dibenzyloxybenzene and 3-((1H-1 ,2,4-triazol-1- yl)methyl)benzaldehyde. 1H-NMR (DMSO-c/6): δ 8.58 (s, 1 H), 8.45 (s, 1H), 7.95 (s, 1H), 7.57- 7.08 (arom, 13H), 6.91 (s, 1 H), 6.82 (d, 2H), 5.40 (s, 2H), 5.25 (s, 2H), 4.86 (s, 2H), 3.26 (masked sep, 1 H), 1.16 (d, 6H). MS: [M+H]+1 = 557.4.
Synthesis 108
4-(2,4-Bis(benzyloxy)-5-isopropylphenyl)-5-(3-((4-methylpiperazin-1-yl)methyl)phenyl)- oxazole (Compound 108)
Prepared using an "inversed" General Procedure 5. Starting materials: A- (lsocyano(tosyl)methyl)-6-isopropyl-1 ,3-dibenzyloxybenzene and 3-((4-/V- methylpiperazin-1-y|)methyl)benzaldehyde. 1H-NMR (DMSO-c/6): δ 8.46 (s, 1 H), 7.54-
7.11 (arom, 13H), 6.96 (s, 1H), 6.90 (d, 2H), 5.21 (s, 2H), 4.96 (s, 2H). Remaining signals were not assigned due to broadening and overlap with DMSO and H2O signals. LC-MS indicated pure compound. MS: [M+H]+1 = 588.5.
Synthesis 109
4-(2,4-bis(benzyloxy)-5-isopropylphenyl)-5-(3-(pyrrolidin-1-ylmethyl)phenyl)oxazole
(Compound 109)
Prepared using an "inversed" General Procedure 5. Starting materials: 4- (lsocyano(tosyl)methyl)-6-isopropyl-1 ,3-dibenzyloxybenzene and 3-(pyrrolidin-1 - ylmethyl)benzaldehyde. 1H-NMR (DMSO-Cf6): δ 8.45 (s, 1H), 7.53-7.11 (arom, 13H), 6.98-6.88 (arom, m, 3H), 5.20 (s, 2H), 4.96 (s, 2H), 3.51 (br.s, 2H), 3.26 (masked sep, 1 H), 2.34 (br, 4H), 1.62 (br, 4H). 1.15 (d, 6H). MS: [M+H]+1 = 559.5.
Synthesis 110
4-(2,4-Bis(benzyloxy)-5-isopropylphenyl)-5-(3-(pyridin-3-yl)phenyl)oxazole
(Compound 110)
Prepared using an "inversed" General Procedure 5. Starting materials: 4- (!socyano(tosyl)methyl)-6-isopropyl-1 ,3-dibenzyloxybenzene and 3-(pyridin-3- yl)benzaldehyde. LC-MS shows pure compound. No NMR spectrum was recorded. MS: [M+H]+1 = 553.4.
Synthesis 111 Methyl 4-(2,4-bis(benzyloxy)-5-isopropylphenyl)oxazole-5-carboxylate (Compound 111)
4-(lsocyano(tosyl)methyl)-6-isopropyl-1,3-dibenzyloxybenzene (600 mg, 1.14 mmol) was suspended in dry MeOH (20 mL). To the suspension was added ethylglyoxylate solution (50% in toluene) folowed by dry K2CO3. The mixture was heated to reflux under N2 for 3 days. LC-MS showed a mixture of products. Solvents were evaporate and the residue partitioned between water and EtOAc. The aqueous phase was extracted twice with
EtOAc and the combined organic phases were washed with 0.1 M HCI (aq), water, brine, and dried over MgSO4. The EtOAc was evaporated and the residue purified by flash chromatography to give 370 mg of methyl 4-(2,4-bis(benzyloxy)-5- isopropylphenyl)oxazole-5-carboxylate. 1H-NMR (DMSO-c/6): δ 8.62 (s, 1H), 7.55-7.23 (arom, 11 H), 6.95 (s, 1 H), 5.21 (s, 2H)1 5.10 (s, 1H), 3.61 (s, 3H), 3.26 (masked sep, 1H), 1.16 (ds, 6H). MS: [M+H]+1 = 458.3.
Synthesis 112 4-(5-lsopropyl-2,4-dimethoxyphenyl)oxazole-5~carboxylic acid (Compound 112)
Methyl 4-(5-isopropyl-2,4-dimethoxyphenyl)oxazole-5-carboxylate (370 mg, 0.81 mmol) was suspended in MeOH (5 mL) and KOH (5 mL, 1 M) was added. The mixture was refluxed for 6 h. MeOH was removed in vacuo and the aqueous solution was acidified (pH = 1) with HCI (2 M) and extracted with EtOAc. The organic phase was washed with brine, dried over MgSO4 and evaporated to dryness. The crude product was purified by ion-exchange chromatography using a lsolute (PE-AX) column eluting bi-products first with CH3CN and the acid with a mixture of CH3CN and 1 M HCI (aq). Evaporation of the eluate gave the free acid (160 mg) as more than 90 % pure (HPLC) which was adequate for use in subsequent steps. 1H-NMR (DMSO-c/6): δ 8.57 (s, 1 H), 7.54-7.29 (arom, 10H), 7.20 (S, 1H), 6.92 (s, 1 H), 5.19 (s, 2H), 5.09 (s, 2H), 3.26 (masked sep, 1H), 1.16 (d, 6H). MS: [M+H]+1 = 444.2.
Synthesis 113 Λ/-Benzyl-4-(5-isopropyl-2,4-dimethoxyphenyl)oxazole-5-carboxamide (Compound 113)
4-(5-lsopropyl-2,4-dimethoxyphenyl)oxazole-5-carboxylic acid (made analogous to the benzylated analogue) (19.3 mg, 66.3 μmol) was dissolved in dry DMF (4 mL). TBTU (18.58 mg, 72.9 μmol) and DIPEA (28.4 μL, 166 μmol) was added and the mixture was stirred for 15 min at RT. Benzylamine (8.7 μL, 80 μmol) was added and stirring was continued for 3 h. TLC showed complete reaction. The solvent was evaporated in vacuo and the residue was purified by flash chromatography (EtOAOHeptane (1 :1 )). The yield of Λ/-Benzyl-4-(5-isopropyl-2,4-dimethoxyphenyl)oxazole-5-carboxamide was 11.5 mg. 1H-NMR (DMSO-c/6): δ 8.49 (s, 1 H), 7.34-7.17 (arom, 6H), 6.63 (s, 1H)1 4.37 (d, 2H), 3.86 (s, 3H), 3.61 (s, 3H), 3.26 (masked sep, 1 H), 1.13 (d, 6H). MS: [M+H]+1 = 381.2.
Synthesis 114
Λ/-((1W-indol-5-yl)methyl)-4-(2,4-bis(benzyloxy)-5-isopropylphenyl)oxazole-5-carboxamide
(Compound 114)
4-(5-lsopropyl-2,4-dimethoxyphenyl)oxazole-5-carboxylic acid (40 mg, 90 //mol) was dissolved in dry DMF (4 mL). TBTU (25.3 mg, 99 μmol) and DIPEA (38.6 //I, 225 μmol) were added and the resulting mixture was stirred for 15 min at RT. Then (1H-indol-5- yl)methanamine (13.2 mg, 90 μmol) was added and the mixture was stirred overnight. The solvent was evaporated in vacuo and the residue was purified by flash chromatography (3% MeOH in CDCI3). The yield Λ/-((1H-indoI-5-yl)methyl)-4-(2,4- bis(benzyloxy)-5-isopropylphenyl)oxazole-5-carboxamide was 21.5 mg. 1H-NMR (CD3OD): δ 11.00 (bs, 1 H), 8.69 (t, 1 H), 8.50 (s, 1 H), 7.52-7.18 (arom, 14 H), 7.00 (d, 1 H), 6.87 (s, 1H), 6.33 (bs, 1H), 5.16 (s, 2H), 5.04 (s, 2H), 4.38 (d, 2H), 3.26 (masked sep, 1H), 1.15 (d, 6H). MS: [M+H]+1 = 572.2.
Svnthesis 115
4-(2,4-bis(benzyloxy)-5-isopropylphenyl)-Λ/-(4-(Λ/,Λ/-dimethylamino)benzyl)oxazole-5- carboxamide (Compound 115)
4-(5-lsopropyl-2,4-dimethoxyphenyl)oxazole-5-carboxylic acid (40 mg, 90 μmol) was dissolved in dry DMF (4 m!_). TBTU (25.3 mg, 99 μmol) and DIPEA (38.6 //I, 225 μmol) were added and the resulting mixture was stirred for 15 min at RT. Then 4-(N1N- dimethylamino)benzylamine bis-hydrochloride (20.1 mg, 90 μmol) was added and the mixture was stirred overnight. The solvent was evaporated in vacuo and the residue was purified by flash chromatography (3% MeOH in CDCI3). The yield of 4-(2,4- bis(benzyloxy)-5-isopropylphenyl)-/V-(4-(/V,/V-dimethylamino)benzyl)oxazole-5- carboxamide was 26.6 mg. 1H-NMR (DMSO-c/6): δ 8.51 (s, 1 H), 7.50-7.26 (arom, 10H), 7.20 (s, 1 H), 7.06 (d, 2H), 6.86 (s, 1 H), 6.60 (d, 2H), 5.16 (s, 2H), 5.03 (s, 2H), 4.20 (d, 2H), 3.22 (sep, 1H), 2.81 (s, 6H), 1.15 (d, 6H). MS: [M+H]+1 = 576.3.
Synthesis 116
/V-(4-(4-(2,4-Bis(benzyloxy)-5-isopropylphenyl)oxazσl-5-yl)phenyl)-Λ/-(2- morpholinoethyl)acetamide (Compound 116)
(lsocyano(tosyl)methyl)-6-isopropyl-1 ,3-dibenzyloxybenzene and /V-(4-formylphenyl)-Λ/- (2-morpholinoethyl)acetamide. 1H-NMR (DMSO-d6): δ 8.55 (s, 1 H), 7.84 (d, 2H), 7.50- 7.26 (arom, 12H), 7.21 (s, 1 H), 6.87 (s, 1 H), 5.16 (s, 2H), 5.04 (s, 2H), 4.37 (d, 2H), 3.22 (sep, 1 H), 2.5 (masked s, 3H)1 1.14 (d, 6H). MS: [M+H]+1 = 575.2.
Synthesis 117
4-(2-(4-(4-(2,4-Bis(benzyloxy)-5-isopropylphenyl)oxazol-5-yl)phenoxy)ethyl)morpholine
(Compound 117)
Prepared using an "inversed" General Procedure 5. Starting materials: 4- (!socyano(tosyl)methyl)-6-isopropyl-1 ,3-dibenzyloxybenzene and 4-(2- morpholinoethoxy)benzaldehyde. No NMR of the free amine was obtained. LC-MS indicated pure compound. MS: [M+H]+1 = 605.4.
Synthesis 118 4-lsopropyl-6-(1 -phenyl-1 H- 1 ,2,3-triazol-4-yl)benzene-1 ,3-diol (Compound DD-001 )
Prepared using General Procedure 2. Starting material: 4-(5-lsopropyl-2,4- dimethoxyphenyl)-1 -phenyl-1 H-1 ,2,3-triazole. 1H-NMR (DMSO-c/6): δ 9.91 (br s, 1H), 9.43 (br s, 1 H), 8.79 (s, 1 H), 7.96 (m, 2H), 7.77 (s, 1 H), 7.62 (m, 2H)1 7.50 (m, 1 H), 6.50 (s, 1 H), 3.16 (sep, 1 H), 1.20 (d, 6H).
Synthesis 119
4-(1-(2-Hydroxyphenyl)-1 H-1 , 2,3-triazol-4-yl)-6-isopropylbenzene-1 ,3-diol
(Compound DD-002)
Prepared using General Procedure 2. Starting material: 4-(5-lsopropyl-2,4- dimethoxyphenyl)-1-(2-methoxyphenyl)-1H-1 ,2,3-triazole. 1H-NMR (DMSO-Qf6): δ 10.51 (bs, 1H), 9.84 (s, 1 H), 9.36 (s, 1 H), 8.60 (s, 1 H), 7.79 (s, 1H), 7.64 (d, 1 H), 7.34 (m, 1H), 7.12 (d, 1 H), 7.00 (m, 1 H), 6.48 (s, 1 H), 3.15 (sep, 1 H), 1.19 (d, 6H).
Synthesis 120
4-(1 -(3-Hydroxyphenyl)-1 H-1 ,2,3-triazol-4-yl)-6-isopropylbenzene-1 ,3-diol
(Compound DD-003)
Prepared using General Procedure 2. Starting material: 4-(5-lsopropyl-2,4- dimethoxyphenyl)-1-(3-methoxyphenyl)-1 H-1 ,2,3-triazole. 1H-NMR (DMSO-Cf6): δ 10.02 (s, 1 H), 9.91 (s, 1 H), 9.43 (s, 1 H), 8.72 (s, 1 H), 7.76 (s, 1 H), 7.35 (m, 3H), 6.88 (m, 1H), 6.49 (s, 1 H), 3.15 (sep, 1 H), 1.19 (d, 6H).
Synthesis 121
4-(1 -(3,4-Dihydroxyphenyl)-1 H-1 ,2,3-triazol-4-yl)-6-isopropylbenzene-1 ,3-diol
(Compound DD-004)
Prepared using General Procedure 2. Starting material: 4-(5-lsopropyl-2,4- dimethoxyphenyl)-1-(3,4-dimethoxyphenyl)-1H-1 ,2,3-triazole. 1H-NMR (DMSO-c/6): δ 9.92 (br s), 9.41 (br s), 8.60 (s, 1H), 7.73 (s, 1H), 7.29 (d, 1H), 7.15 (d, 1H), 6.89 (d, 1H), 6.48 (s, 1H), 3.14 (sep, 1H), 1.19 (d, 6H).
Synthesis 122
4-(1 -(4-n-Butylphenyl)-1 H-1 ,2,3-triazol-4-yl)-6-isopropy!benzene-1 ,3-diol
(Compound DD-005)
Prepared using General Procedure 2. Starting material: 4-(5-lsopropyl-2,4- dimethoxyphenyl)-1-(4-/>butyl-phenyl)-1/-/-1 ,2,3-triazole. 1H-NMR (DMSO-d6): δ 9.91 (s, 1 H), 9.43 (s, 1 H), 8.75 (s, 1 H), 7.85 (s, 1 H), 7.83 (s, 1 H), 7.76 (s, 1 H), 7.44 (s, 1 H)1 7.41 (s, 1 H), 6.50 (S, 1H), 3.15 (sep, 1 H), 2.67 (t, 2H), 1.61 (m, 2H), 1.34 (m, 2H), 1.19 (d, 6H), 0.92 (t, 3H).
Synthesis 123 4-(1-Benzyl-1/-/-1 ,2,3-triazol-4-yl)-6-isopropylbenzene-1 ,3-diol (Compound DD-006)
Prepared using General Procedure 2. Starting material: 1-Benzyl-4-(5-isopropyl-2,4- dimethoxyphenyl)-1W-1 ,2,3-triazole. 1H-NMR (DMSO-Cy6): δ 9.82 (bs, 1H), 9.34 (bs, 1 H), 8.29 (s, 1 H), 7.70 (s, 1 H), 7.34 (m, 5H), 6.43 (s, 1 H), 5.64 (s, 1 H), 5.64 (s, 2H), 3.12 (sep, 1 H), 1.16 (d, 6H).
Svnthesis 124
4-(1-(2-Chloro-4-fluorobenzyl)-1/-/-1,2,3-triazol-4-yl)-6-isopropy!benzene-1 ,3-diol
(Compound DD-007)
Prepared using General Procedure 2. Starting material: 1-(2-Chloro-4-fluorobenzyl)-4-(5- isopropyl-2,4-dimethoxyphenyl)-1W-1 ,2,3-triazole. 1H-NMR (DMSOd6): δ 9.77 (br s, 1H), 9.32 (br s, 1 H), 8.22 (s, 1H), 7.67 (s, 1 H), 7.51 (dd, 1H), 7.31-7.19 (m, 2H), 6.39 (s, 1 H), 5.68 (s, 2H), 3.08 (sep, 1 H), 1.12 (d, 6H).
Synthesis 125
4-(1-(2,4-Difluorobenzyl)-1/-/-1 ,2,3-triazol-4-yl)-6-isopropylbenzene-1 ,3-diol
(Compound DD-008)
Prepared using General Procedure 2. Starting material: 1-(3,4-Difluorobenzyl)-4-(5- isopropyl-2,4-dimethoxyphenyl)-1tf-1 ,2,3-triazole. 1H-NMR (DMSOd6): 6 9.81 (s, 1H), 9.34 (s, 1 H), 8.33 (s, 1 H), 7.70 (s, 1 H), 7.52-7.41 (m, 2H), 7.21-7.17 (m, 1H), 6.44 (s, 1H), 5.64 (s, 1 H), 3.12 (sep, 1H), 1.16 (d, 6H).
Svnthesis 126
4-lsopropyl-6-(1-(naphthalen-2-ylmethyl)-1/-/-1 ,2,3-triazol-4-yl)benzene -1 ,3-diol
(Compound DD-009)
Prepared using General Procedure 2. Starting material: 4-(5-lsopropyl-2,4- dimethoxyphenyl)-1-(naphthalen-2~ylmethyl)-1H-1 ,2,3-triazole. 1H-NMR (DMSO-Cf6): δ 9.82 (s, 1H), 9.33 (s, 1 H), 8.34 (s, 1 H), 7.95-7.85 (m, 4H), 7.71 (s, 1H), 7.57-7.52 (m, 2H), 7.45 (dd, 1 H), 6.43 (s, 1H), 5.82 (s, 2H), 3.12 (sep, 1H), 1.16 (d, 6H).
Synthesis 127
4-(1-(4-Fluorobenzyl)-1H-1 ,2,3-triazol-4-yl)-6-isopropylbenzene-1 ,3-diol
(Compound DD-010)
Prepared using General Procedure 2. Starting material: 1-(4-Fluorobenzyl)-4-(5- isopropyl-2,4-dimethoxyphenyl)-1H-1 ,2,3-triazole. 1H-NMR (DMSO-Cf6): δ 9.82 (s, 1H), 9.34 (s, 1 H), 8.30 (s, 1 H), 7.70 (s, 1 H), 7.42-7.38 (m, 2H), 7.24-7.19 (m, 2H), 6.43 (s, 1 H), 5.63 (s, 2H), 3.12 (sep, 1H), 1.16 (d, 6H).
Svnthesis 128
4-(1 -(4-Chlorobenzyl)-1 H- 1 ,2,3-triazol-4-yl)-6-isopropylbenzene-1 ,3-diol
(Compound DD-011 )
Prepared using General Procedure 2. Starting material: 1 -(4-Chlorobenzyl)-4-(5- isopropyl-2,4-dimethoxyphenyl)-1H-1 ,2,3-triazole. 1H-NMR (DMSO-dβ): δ 9.82 (s, 1H), 9.34 (s, 1 H), 8.31 (s, 1 H), 7.70 (s, 1 H), 7.48-7.43 (m, 2H), 7.36-7.32 (m, 2H), 6.44 (s, 1H), 5.65 (s, 2H), 3.12 (sep, 1 H), 1.16 (d, 6H).
Synthesis 129
4-(1-(4-Methylbenzyl)-1H-1 ,2,3-triazol-4-yl)-6-isopropylbenzene-1 ,3-diol
(Compound DD-012)
Prepared using General Procedure 2. Starting material: 1-(4-Methylbenzyl)-4-(5- isopropyl-2,4-dimethoxyphenyl)-1W-1 ,2,3-triazole. 1H-NMR (DMSO-Cf6): δ 9.82 (s, 1H), 9.33 (s, 1 H), 8.25 (s, 1 H), 7.69 (s, 1H), 7.24-7.17 (m, 4H), 6.43 (s, 1H), 5.58 (s, 2H), 3.12 (sep, 1 H), 2.29 (s, 3H), 1.16 (d, 6H).
Svnthesis 130
4-(1 -(3,4-Dichlorobenzy!)-1 H- 1 ,2,3-triazol-4-yl)-6-isopropylbenzene-1 ,3-diol
(Compound DD-013)
Prepared using General Procedure 2. Starting material: 1-(3,4-Dichlorobenzyl)-4-(5- isopropyl-2,4-dimethoxyphenyl)~1/-/-1 ,2,3-triazole. 1H-NMR (DMSO-cfe): δ 9.82 (s, 1H), 9.35 (s, 1 H), 8.35 (s, 1 H), 7.71-7.63 (m, 3H)1 7.31-7.27 (m, 1 H), 6.44 (s, 1H), 5.67 (s, 2H), 3.12 (sep, 1 H), 1.16 (d, 6H).
Synthesis 131
4-(1 -(4-isopropylbenzyl)-1 H- 1 ,2,3-triazol-4-yl)-6-isopropylbenzene-1 ,3-diol
(Compound DD-014)
Prepared using General Procedure 2. Starting material: 1-(4-isopropylbenzyl)-4-(5- isopropyl-2,4-dimethoxyphenyl)-1 H-1 ,2,3-triazole. 1H-NMR (DMSO-Cf6): δ 9.83 (s, 1H), 9.34 (S, 1 H), 8.28 (s, 1 H), 7.69 (s, 1 H), 7.25 (s, 4H), 6.43 (s, 1 H), 5.59 (s, 2H), 3.12 (sep, 1H), 2.87 (sep, 1 H), 1.18 (d, 6H), 1.15 (d, 6H).
Synthesis 132
4-(1 -(3-Chlorobenzyl)-1 H-1 ,2,3-triazol-4-yl)-6-isopropylbenzene-1 ,3-diol
(Compound DD-015)
Prepared using General Procedure 2. Starting material: 1-(3-Chlorobenzyl)-4-(5- isopropyl-2,4-dimethoxyphenyl)-1H-1 ,2,3-triazole. 1H-NMR (DMSO-Cf6): δ 9.82 (s, 1H), 9.34 (s, 1 H)1 8.34 (s, 1 H), 7.71 (s, 1 H), 7.42-7.39 (m, 3H), 7.30-7.25 (m, 1H), 6.44 (s, 1H), 5.67 (s, 2H), 3.12 (sep, 1 H), 1.16 (d, 6H).
Synthesis 133
4-(1 -(2-Fluorobenzyl)-1 H-1 ,2,3-triazol-4-yl)-6-isopropylbenzene-1 ,3-diol
(Compound D-016)
Prepared using General Procedure 2. Starting material: 1-(2-Fluorobenzyl)-4-(5- isopropyl-2,4-dimethoxyphenyl)-1H-1 ,2,3-triazole. 1H-NMR (DMSO-c/6): δ 9.81 (s, 1 H), 9.33 (s, 1 H), 8.26 (s, 1 H), 7.70 (s, 1 H), 7.49-7.18 (arom, 4H), 6.43 (s, 1 H), 5.70 (s, 2H), 3.11 (sep, 1 H), 1.15 (d, 6H). MS: [M+H]+1 = 328.3.
Synthesis 134
4-(1 -(2-Chlorobenzyl)-1 H- 1 ,2,3-triazol-4-yl)-6-isopropylbenzene-1 ,3-diol
(Compound DD-017)
Prepared using General Procedure 2. Starting material: 1-(2-Chlorobenzyl)-4-(5- isopropyl-2,4-dimethoxyphenyl)-1H-1 ,2,3-triazole. 1H-NMR (DMSO-Cf6): δ 9.81 (s, 1H)1 9.34 (s, 1 H), 8.27 (s, 1 H), 7.71 (s, 1 H), 7.53 (m, 1 H), 7.42-7.31 (m, 2H), 7.18 (s, 1H), 6.43 (s, 1 H), 5.74 (s, 2H), 3.12 (sep, 1 H), 1.16 (d, 6H). MS: [M+H]+1 = 344.2.
Synthesis 135
4-lsopropyl-6-(1 -(2-methylbenzyl)-1 H- 1 ,2,3-triazol-4-yl)benzene-1 ,3-diol
(Compound DD-018)
Prepared using General Procedure 2. Starting material: 1-(2-Methylbenzyl)-4-(5- isopropyl-2,4-dimethoxyphenyl)-1H-1 ,2,3-triazole. 1H-NMR (DMSO-Cf6): 5 9.81 (s, 1H). 9.33 (s, 1 H), 8.18 (s, 1 H), 7.70 (s, 1 H), 7.28-7.14 (m, 3H), 7.06 (d, 1H), 6.42 (s, 1H), 5.65 (s, 2H), 3.12 (sep, 1 H), 2.32 (s, 3H), 1.15 (d, 6H). MS: [M+H]+1 = 324.1.
Synthesis 136 4-(1-Benzyl-1 H-1 ,2,3-triazol-5-yl)-6-isopropylbenzene-1 ,3-diol (Compound DD-019)
Prepared using General Procedure 2. Starting material: 1 -Benzyl-5-(5-isopropyl-2,4- dimethoxyphenyl)-1H-1 ,2,3-triazole. 1H-NMR (CDCI3): δ 7.66 (s, 1H), 7.14 (m, 3H), 6.94 (m, 2H), 6.73 (s, 1 H), 6.57 (s, 1 H), 6.5-5.5 (br., 2H) 5.38 (br. s, 2H), 3.09 (sep, 1H)1 0.99 (d, 6H). MS: [M+H]+1 = 310.1.
Synthesis 137
4-(1 -(4-Chlorobenzyl)-1 H- 1 ,2,3-triazol-5-yl)-6-isopropylbenzene-1 ,3-diol
(Compound DD-020)
Prepared using General Procedure 2. Starting material: 1-(4-Chlorobenzyl)-5-(5- isopropyl-2,4-dimethoxyphenyl)-1H-1 ,2,3-triazole. 1H-NMR (CDCI3): δ 7.66 (s, 1H), 7.15 (d, 2H), 6.92 (d, 2H), 6.61 (s, 1H), 6.60 (s, 1 H), 7.5-6.5 (br., 2H) 5.38 (br. s, 2H), 3.09 (sep, 1 H), 1.07 (d, 6H). MS: [M+H]+1 = 344.2.
Synthesis 138 1 -(2,4-Dihydroxy-5-isopropylphenyl)-2-phenylethanone (Compound BB-001 )
Prepared using General Procedure 8. Starting material: 1-(5-lsopropyl-2,4- dimethoxyphenyl)-2-phenylethanone. 1H-NMR (DMSO-d6): δ 12.34 (s, 1H), 10.64 (s, 1 H), 7.72 (s, 1H), 7.29 (m, 5H), 6.30 (s, 1H), 4.32 (s, 2H), 3.09 (sep, 1 H), 1.16 (d, 6H).
Svnthesis 139
(2,4-Dihydroxy-5-isopropylphenyl)(4-hydroxyphenyl)methanone (Compound BB-002)
Prepared using General Procedure 8. Starting material: (5-lsopropyl-2,4- dimethoxyphenyl)(4-methoxyphenyl)methanone. 1H-NMR (CDCI3): δ 12.31 (s, 1H), 7.55- 7.51 (m, 2H), 7.35 (s, 1 H), 6.86-6.82 (m, 2H), 6.30 (s, 1 H), 5.39 (s, 1H), 5.20 (s, 1 H), 3.02 (sep, 1 H), 1.08 (d, 6H).
Synthesis 140
(2,4-Dihydroxy-5-isopropylphenyl)(4-chlorophenyl)methanone (Compound BB-003)
Prepared using General Procedure 8. Starting material: (5-lsopropyl-2,4- dimethoxyphenyl)(4-chlorophenyl)methanone. 1H-NMR (DMSO-Cf6): δ 11.77 (s, 1H), 10.77 (br s, 1H), 7.68-7.59 (m, 4H), 7.22 (s, 1H), 6.42 (s, 1H), 3.06 (sep, 1H), 1.08 (d, 6H).
Synthesis 141
(2,4-Dihydroxy-5-isopropylphenyl)(2,6-dichlorophenyl)methanone (Compound BB-004)
Prepared using General Procedure 8. Starting material: (5-lsopropyl-2,4- dimethoxyphenyl)(2,6-dichlorophenyl)methanone. 1H-NMR (DMSO-Cf6): δ 11.45 (br s,
1 H), 11.00 (br s, 1 H), 7.64-7.51 (m, 3H), 6.97 (br s, 1H), 6.40 (s, 1 H), 3.01 (sep, 1H), 1.02 (d, 6H).
Synthesis 142
(2,4-Dihydroxy-5-isopropylphenyl)(4-(dimethylamino)phenyl)methanone
(Compound BB-005)
Prepared using General Procedure 8. Starting material: (4-(Dimethylamino)phenyl)(2- hydroxy-5-isopropyl-4-methoxyphenyl)methanone. 1H-NMR (DMSO-Cf6): δ 12.15 (s, 1H), 10.47 (s, 1 H), 7.57 (d, 2H), 7.35 (s, 1 H), 6.78 (d, 2H), 6.38 (s, 1 H), 3.09 (masked sep, 1 H), 3.03 (s, 6H), 1.10 (d, 6H). MS: [M+H]+1 = 300.1.
Synthesis 143 (2,4-Dihydroxy-5-isopropylphenyl)(3-hydroxyphenyl)methanone (Compound BB-006)
Prepared using General Procedure 8. Starting material: (5-lsopropyl-2,4- dimethoxyphenyl)(3-methoxyphenyl)methanone. 1H-NMR (DMSO-c/e): δ 12.10 (s, 1H), 10.75 (s, 1 H), 9.82 (s, 1 H), 7.38- 7.27 (m, 2H), 7.07-6.94 (m, 3H), 6.40 (s, 1 H), 3.05 (sep, 1H), 1.07 (d, 6H). MS: [M+H]+1 = 273.1.
Synthesis 144 (2,4-Dihydroxy-5-isopropylphenyl)(3,4-dimethoxyphenyl)methanone (Compound BB-007)
4-lsopropyl-1 ,3-dibenzyloxybenzene (216 mg, 0.65 mmol) was dissolved in dry CH2CI2 (5 mL) and cooled to 0 0C. 4-Methoxybenzoy! chloride (167 mg, 0.83 mmol) was added
followed by TiCI4 (78 μl_, 1.1 eq) and the resulting mixture was stirred for 1 h at 0 0C. Additional TiCI4 added (143 μL, 2 eq) and the mixture was stirred for another 2 h. The reaction mixture was quenched by addition of H2O and the phases were separated. The organic phase was washed with sat. NaHCO3 and dried over MgSO4. TLC (5% MeOH in CH2CI2) showed one major spot. Purification by flash chromatography yielded 7.7 mg of pure (2,4-Dihydroxy-5-isopropylphenyl)(3,4-dimethoxyphenyl)methanone. 1H NMR (DMSO-CZ6): δ 12.04 (s, 1H), 10.66 (s, 1H), 7.35 (s, 1H), 7.29-7.22 (m, 2H), 7.11 (d, 3JN- H=8.3 Hz, 1 H), 6.41 (s, 1 H), 3.86 (s, 3H), 3.80 (s, 3H), 3.10 (sep, 1 H), 1.09 (d, 6H). MS: [M+H]+1 = 317.2.
Synthesis 145 (2,4-Dihydroxy-5-isopropyiphenyl)(4-methoxyphenyl)methanone (Compound BB-008)
Synthesized analogous to (2,4-Dihydroxy-5-isopropylphenyl)(3,4- dimethoxyphenyi)methanone using 4-isopropyl-1 ,3-dibenzyloxybenzene and 3,4- dimethoxybenzoyl chloride as reactants. 1H NMR (DMSO-d6): δ 12.00 (s, 1H), 10.8-10.4 (br., 1 H), 7.64 (d, 2H), 7.29 (s, 1 H), 7.08 (d, 2H), 6.39 (s, 1 H), 3.86 (s, 3H), 3.07 (sep, 1H), 1.09 (d, 6H). MS: [M+H]+1 = 287.2.
Synthesis 146
4-lsopropyl-6-(pyridin-3-yl)benzene-1 ,3-diol (Compound EE-001)
Prepared using General Procedure 4. Starting material: 3-(5-isopropyl-2,4- dimethoxyphenyl)pyridine. 1H-NMR (DMSO-dβ): δ 9.53 (s, 1 H), 9.48 (s, 1H), 8.79 (bs, 1 H), 8.49 (bs, 1H), 8.11 (d, 1 H), 7.55 (bt, 1 H), 7.05 (s, 1 H), 6.51 (s, 1H), 3.11 (sep, 1H), 1.16 (d, 6H).
Synthesis 147 Λ/-(21,41-Dihydroxy-5'-isopropy!biphenyl-2-yl)methanesulfonamide (Compound CC-002)
Prepared using General Procedure 4. Starting material: A/-(5'-isopropyl-2',4'- dimethoxybiphenyl-2-yl)methanesulfonamide. 1H-NMR (DMSO-Cf6): δ 10.00 (bs, 1H), 9.45 (s, 1 H), 8.31 (s, 1 H), 7.87 (bs, 1 H), 7.40-7.25 (m, 4H), 6.83 (s, 1 H), 6.53 (s, 1H), 3.12 (sep, 1 H), 2.52 (s, 3H), 1.12 (d, 6H).
Synthesis 148 5-lsopropyl-2'-(pyrrolidin-1 -ylsulfonyl)biphenyl-2,4-diol (Compound CC-003)
Prepared using General Procedure 4. Starting material: 1-(5'-lsopropyl-2',4'- dimethoxybiphenyl-2-ylsulfonyl)pyrrolidine. Obtained as 85-90% pure. Contains 10-15% mono-methoxy analog. 1H-NMR (CDCI3): δ 8.16 (dd, 1 H), 7.61 (dt, 1H)1 7.51 (dt, 1H), 7.30 (dd, 1 H), 6.85 (s, 1 H), 6.51 (s, 1 H), 4.95-4.65 (bs, 2H), 3.17 (sep, 1 H), 3.00-2.95 (m, 2H), 2.85-2.75 (m, 2H), 1.75-1.65 (m, 4H), 1.24 (d, 3H), 1.20 (d, 3H).
Synthesis 149
A/-(2',4'-Dihydroxy-5'-isopropylbiphenyl-2-yl)-4-methylbenzene-sulfonamide
(Compound CC-004)
Prepared using General Procedure 4. Starting material: Λ/-(5'-isopropyl-2',4'- dimethoxybiphenyl-2-yl)-4-methylbenzene-sulfonamide. 1H-NMR (DMSO-c/6): δ 10.16 (bs, 1 H)1 9.40 (bs, 1 H), 8.39 (s, 1 H), 7.35 (dd, 1 H), 7.27 (dt, 1H), 7.19 (dt, 1H, masked),
7.18 (d, 2H), 7.10 (dd, 1H, masked), 7.08 (d, 2H), 6.50 (s, 1 H), 6.38 (s, 1H), 3.02 (sep, 1 H), 2.26 (s, 3H), 1.07 (d, 6H).
Synthesis 150
Λ/-(2',4I-Dihydroxy-5'-isopropylbiphenyi-2-yl)-4-f!uorobenzene-sulfonamide
(Compound CC-005)
Prepared using General Procedure 4. Starting material: 4-Fluoro-Λ/-(5'~isopropyl-2',4l- dimethoxybiphenyl-2-yl)benzenesulfonamide. 1H-NMR (DMSO-c/6): δ 10.27 (bs, 1 H), 9.41 (bs, 1 H)1 8.55 (s, 1 H), 7.40-7.20 (m, 5H), 7.15-7.00 (m, 3H), 6.47 (s, 1H), 6.33 (s, 1H)1 3.00 (sep, 1 H), 1.06 (d, 6H).
Synthesis 151
Λ/-(2',4'-Dihydroxy-5'-isopropylbipheny!-2-yl)-1-phenylmethane-sulfonamide
(Compound CC-006)
Prepared using General Procedure 4. Starting material: ΛHS'-lsopropyl^'^1- dimethoxybiphenyl-2-yl)-1-phenylmethane-sulfonamide. 1H-NMR (DMSO-Cf6): δ 9.95 (bs, 1H), 9.45 (bs, 1H), 7.92 (s, 1H), 7.40 (d, 1H), 7.35-7.20 (m, 6H), 7.09 (d, 2H), 6.94 (s, 1 H), 6.52 (s, 1 H), 3.13 (sep, 1 H), 1.13 (d, 6H).
Synthesis 152
1-(4-Chlorophenyl)-N-(2I,4l-dihydroxy-5'-isopropylbiphenyl-2-yl)-methanesulfonamide
(Compound CC-007)
Prepared using General Procedure 4. Starting material: 1-(4-Chlorophenyl)-N-(5'- isopropyl-2',4'-dimethoxybiprienyi-2-yl)methane-sulfonamide. 1H-NMR (DMSO-c/6): δ 9.94 (bs, 1 H), 9.48 (bs, 1 H), 7.95 (s, 1 H), 7.45 (d, 1 H), 7.35-7.22 (m, 6H), 7.08 (d, 2H), 6.94 (s, 1 H), 6.50 (s, 1 H), 3.13 (sep, 1 H), 1.13 (d, 6H).
Synthesis 153
A/-(2f,4'-Dihydroxy-5'-isopropylbiphenyl-2-yl)naphthalene-2-sulfonamide
(Compound CC-008)
Prepared using General Procedure 4. Starting material: Λ/^S'-lsopropyl^1^1- dimethoxybiphenyl-2-yl)naphthalene-2-sulfonamide. 1H-NMR (DMSO-Qf6): δ 10.27 (bs, 1 H), 9.41 (bs, 1 H), 8.65 (s, 1 H), 8.0 (d, 1 H, J = 1.5 Hz), 7.90 (d, 2H), 7.74 (d, 1 H), 7.63 (dt, 1H), 7.57 (dt, 1H), 7.40 (dd, 1 H), 7.28 (dt, 1H), 7.25-7.15 (m, 2H), 7.06 (dd, 1H), 6.52 (s, 1 H), 6.17 (s, 1H), 2.78 (sep, 1 H), 0.78 (d, 6H).
Synthesis 154 /V-(2\4'-Dihydroxy-5'-isopropylbiphenyl-2-y!)ethanesulfonamide (Compound CC-009)
Prepared using General Procedure 4. Starting material: /V-(5'-lsopropyl-2',4'- dimethoxybiphenyl-2-yl)ethanesulfonamide. 1H-NMR (DMSO-Qf6): δ 10.07 (s, 1 H), 9.46 (bs, 1H), 7.82 (s, 1H), 7.43-7.22 (m, 4H), 6.89 (s, 1H), 6.53 (s, 1H), 3.13 (sep, 1H), 2.65 (q, 2H), 1.13 (d, 6H)1 0.73 (t, 3H).
Svnthesis 155 A/-(2',4'-Dihydroxy-5'-isopropylbiphenyl-2-yl)propane-1 -sulfonamide (Compound CC-010)
Prepared using General Procedure 4. Starting material: A/-(5'-lsopropyl-2',4'- dimethoxybiphenyl-2-yl)propane-1-sulfonamide. 1H-NMR (DMSO-Cf6): δ 10.13 (s, 1 H), 9.47 (bs, 1H), 7.92 (s, 1H), 7.42-7.23 (m, 4H), 6.90 (s, 1 H), 6.54 (s, 1 H), 3.12 (sep, 1H), 2,56 (bt, 2H), 1.22 (m, 2H), 1.14 (d, 6H), 0.66 (t, 3H).
Synthesis 156
Λ/-(2',4'-Dihydroxy-51-isopropylbiphenyl-2-yl)cyclopropanesulfonamide
(Compound CC-001 )
Prepared using General Procedure 4. Starting material: Λ/-(5'-lsopropyl-2',4'- dimethoxybiphenyl-2-yl)cyclopropane-sulfonamide. 1H-NMR (DMSO-c/6): δ 10.17 (s, 1H), 9.46 (bs, 1 H), 7.93 (s, 1H), 7.41-7.25 (m, 4H), 6.91 (s, 1H), 6.54 (s, 1H), 3.12 (sep, 1H), 1.94 (m, 1 H)1 1.11 (d, 6H), 0.55 (m, 4H).
Synthesis 157
4-lsopropyl-6-(thiophen-3-yl)benzene-1 ,3-diol (Compound EE-002)
Prepared using General Procedure 4. Starting material: 3-(5-lsopropyl-2,4- dimethoxyphenyl)thiophene. 1H-NMR (DMSO-c/6): δ 9.32 (s, 1 H), 9.19 (s, 1H), 7.60 (dd, 1 H), 7.46 (m, 2H), 7.15 (s, 1 H), 6.44 (s, 1 H), 3.10 (sep, 1 H), 1.15 (d, 2H).
Synthesis 158
5-lsopropylbiphenyl-2,3',4,4'-tetraol (Compound CC-011)
Prepared using General Procedure 4. Starting material: 5-(5-lsopropyl-2,4- dimethoxyphenyl)benzo[d][1 ,3]dioxole. LC-MS of product indicates 85% pure. 1H-NMR (DMSO-CZ6): δ 9.05 (bs, 1 H), 8.88 (bs, 1 H), 9.20-8.20 (vbs, 2H), 6.91 (s, 1H), 6.85 (s, 1H), 6.77-6.50 (m, 2H), 6.39 (s, 1H), 3.10 (sep, 1H), 1.13 (d, 6H).
Synthesis 159 4-lsopropyl-6-(pyridin-2-yI)benzene-1 ,3-diol (Compound EE-003)
Prepared using General Procedure 4. Starting material: 5'-lsopropyl-2',4'- dimethoxybiphenyl-2-carboxamide. 1H-NMR (CDCI3): δ 14.50 (bs, 1H), 8.44 (m, 1H), 7.87-7.74 (m, 2H), 7.59 (s, 1 H), 7.15 (m, 1 H), 6.43 (s, 1 H), 5.3 (bs, 1 H), 3.19 (sep, 1 H), 1.29 (d, 6H).
Synthesis 160 5-lsopropyl-2'-phenoxybiphenyl-2,4-diol (Compound CC-012)
Prepared using General Procedure 4. Starting material: 5-lsopropyl-2,4-dimethoxy-2'- phenoxybiphenyl. 1H-NMR (DMSO-Cf6): δ 9.10 (s, 1 H), 8.93 (s, 1H), 7.36 (dd, 1 H), 7.33- 7.20 (m, 3H), 7.15 (dt, 1H), 7.04-6.82 (m, 4H), 6.80 (s, 1H), 6.36 (s, 1H), 3.01 (sep, 1 H), 0.97 (d, 6H).
Svnthesis 161 A/-(2',4'-Dihydroxy-5'-isopropylbiphenyl-2-yl)acetamicle (Compound CC-013)
Prepared using General Procedure 4. Starting material: Λ/-(5'-lsopropyl-2',4'- dimethoxybiphenyl-2-yl)acetamide. 1H-NMR (DMSO-d6): δ 9.47 (bs, 1H), 9.29 (bs, 1 H), 8.66 (bs, 1 H), 7.63 (d, 1 H), 7.30-7.08 (m, 3H), 7.80 (s, 1 H), 6.49 (s, 1 H), 3.11 (sep, 1H), 1.91 (s, 3H), 1.12 (d, 6H).
Synthesis 162
4'-Fluoro-5-isopropylbiphenyl-2,4-diol (Compound CC-014)
Prepared using General Procedure 4. Starting material: 4'-Fluoro-5-isopropyl-2,4- dimethoxybiphenyl. 1H-NMR (DMSO-c/6): δ 9.23 (s, 1 H), 9.16 (s, 1H), 7.54-7.43 (m, 2H), 7.20-7.09 (m, 2H), 6.92 (s, 1 H), 6.45 (s, 1 H) ,3.10 (sep, 1 H), 1.13 (d, 6H).
Synthesis 163
4'-Chloro-5-isopropylbiphenyl-2,4-diol (Compound CC-015)
Prepared using General Procedure 4. Starting material: 4'-Chloro-5-isopropyl-2,4- dimethoxybiphenyl. 1H-NMR (CDCI3): δ 7.50-7.35 (arom, 4H), 7.01 (s, 1H), 6.41 (s, 1 H), 5.1 (br, 2H), 3.14 (sep, 1H), 1.25 (d, 6H). MS: [M-H]"1 = 261.1.
Svnthesis 164 4'-Fluoro-5-isopropyl-3'-methylbiphenyl-2,4-diol (Compound CC-016)
Prepared using General Procedure 4. Starting material: 4'-Fluoro-5-isopropyl-2,4- dimethoxy-3'-methylbiphenyl. 1H-NMR (CDCI3): δ 7.30-7.03 (arom, 3H), 6.98 (s, 1H), 6.42 (s, 1H), 5.36 (br, 2H), 3.14 (sep, 1 H), 2.33 (d, 3H), 1.25 (d, 6H).
Synthesis 165
3',4'-Difluoro-5-isopropylbiphenyl-2,4-diol (Compound CC-017)
Prepared using General Procedure 4. Starting material: 3',4'-Difluoro-5-isopropyl-2,4- dimethoxybiphenyl. 1H-NMR (CDCI3): δ 7.36-7.12 (arom, 3H), 7.00 (s, 1H), 6.40 (s, 1H), 4.53 (br, 2H), 3.14 (sep, 1 H), 1.25 (d, 6H). MS: [M-H]"1 = 263.0.
Synthesis 166 4'-Fluoro-5-isopropyl-2'-methylbiphenyl-2,4-diol (Compound CC-018)
Prepared using General Procedure 4. Starting material: 4'-Fluoro-5-isopropyl-2,4- dimethoxy-2'-methylbiphenyl. 1H-NMR (CDCI3): δ 7.19 (dd, 1 H)1 7.07-6.91 (m, 2H), 6.86 (s, 1 H), 6.43 (s, 1 H), 5.67 (br, 2H), 3.14 (sep, 1 H), 2.16 (s, 3H), 1.25 (d, 6H).
Svnthesis 167 5-lsopropylbiphenyl-2,3',4-triol (Compound CC-019)
Prepared using General Procedure 4. Starting material: 5-lsopropyl-2,4-dimethoxy-3'-(3- methoxybenzyloxy)biphenyl. 1H-NMR (DMSO-d6): δ 9.5-8.6 (br, 2H), 7.11 (t, 1H), 7.00- 6.83 (arom, 3H), 6.60 (d, 1 H), 6.42 (s, 1 H), 3.10 (sep, 1 H), 1.13 (d, 6H). MS: [M-H]"1 = 243.0.
Synthesis 168
S'-Fluoro-δ-isopropylbiphenyl^^'-triol (Compound CC-020)
Prepared using General Procedure 4. Starting material: 3'-Fluoro-5-isopropyl-2,4,4'- trimethoxybiphenyl. 1H-NMR (DMSO-c/6): δ 9.64 (br, 1H), 9.17 (br. 1H), 9.11 (br, 1H), 7.25 (dd, 1 H), 7.09 (dd, 1H), 6.91 (m, 2H), 6.41 (s, 1 H), 3.09 (sep, 1 H), 1.14 (d, 6H). MS: [M+H]+1 = 263.1.
Synthesis 169 2',3',51,6'-Tetrafluoro-5-isopropylbiphenyl-2,4,4'-triol (Compound CC-021 )
Prepared using General Procedure 4. Starting material: 4-Butoxy-2,3,5,6-tetrafluoro-51- isopropyl-2',4'-dimethoxybiphenyl. 1H-NMR (DMSO-CZ6): δ 9.72 (s, 1H), 9.38 (s, 1H), 7.05 (s, 1 H), 6.54 (br, s, OH), 6.48 (s, 1 H), 3.04 (sep, 1H), 1.09 (d, 6H). MS: [M-H]"1 = 315.0.
Svπthesis 170
4'-Fluoro-5-isopropylbiphenyl-2,2\4-trio! (Compound CC-022)
Prepared using General Procedure 4. Starting material: 4'-Fluoro-2'-isopropoxy-5- isopropyl-2,4-dimethoxybiphenyl. 1H-NMR (CDCI3): δ 7.19 (t, 1 H), 6.99 (s, 1 H), 6.82-6.68 (m, 2H), 6.47 (s, 1H), 6.43 (br. s, 1H), 6.05 (br. s, 1H), 3.15 (sep, 1H), 1.24 (d, 6H). MS: [M+H]+1 = 263.1.
Synthesis 171 4-Fluoro-2',4'-dihydroxy-5'-isopropylbiphenyl-3-carboxylic acid (Compound CC-023)
Prepared using General Procedure 4. Starting material: 4-Fluoro-5'-isopropyl-2',4I- dimethoxybiphenyl-3-carboxylic acid. 1H-NMR (DMSO-Cf6): δ 13.2 (br, 1H), 9.32 (s, 1H), 9.29 (S, 1 H), 7.95 (dd, 1 H), 7.70 (ddd, 1 H), 7.26 (dd, 1 H), 6.95 (s, 1 H), 6.46 (s, 1H), 3.11 (sep, 1H), 1.14 (d, 6H). MS: [M+H]+1 = 291.1.
Synthesis 172
4-Fluoro-2',4'-dihydroxy-/V,51-diisopropylbiphenyl-3-carboxamide (Compound CC-024)
Prepared using General Procedure 4. Starting material: 4-Fluoro-Λ/,5'-diisopropyl-2',4I- dimethoxybiphenyl-3-carboxamide. 1H-NMR (CDCI3): δ 8.34 (dd, NH), 7.55 (ddd, 1H), 7.17 (dd, 1 H), 7.2 (br, 1 H), 6.99 (s, 1 H), 6.75 (dd, 1 H), 6.67 (s, 1H), 6.3 (br. 1H), 4.35 (sep, 1 H), 3.20 (sep, 1 H), 1.26 (d, 6H), 1.24 (d, 6H). MS: [M+H]+1 = 332.2.
Synthesis 173
(4-Fluoro-2',4'-dihydroxy-51-isopropylbiphenyl-3-yl)(morphormo)methanone
(Compound CC-025)
Prepared using General Procedure 4. Starting material: (4-Fluoro-5'-isopropyi-2',4'- dimethoxybiphenyl-3-yl)(morpholino)methanone. 1H-NMR (CDCI3): δ 7.66 (dd, 1H), 7.57 (dd, 1 H), 7.11 (t, 1 H), 6.95 (s, 1 H), 6.25 (s, 1 H), 3.82 (m, 2H), 3.77 (m, 2H), 3.65 (br, 2H), 3.41 (br, 2H), 3.15 (sep, 1 H), 1.19 (d, 6H). MS: [M+H]+1 = 360.2.
Synthesis 174
4-Fluoro-2',4'-dihydroxy-5'-isopropyl-N-phenylbiphenyl-3-carboxamide
(Compound CC-026)
Prepared using General Procedure 4. Starting material: 4-Fluoro-5'-isopropyl-2',4'- dimethoxy-A/-phenylbiphenyl-3-carboxamide. 1H-NMR (DMSO-c/6): δ 10.40 (s, 1H), 9.31 (br, 2H), 7.80-7.60 (arom, 4H), 7.42-7.05 (arom, 4H), 7.00 (s, 1 H), 6.48 (s, 1H), 3.10 (sep, 1H), 1.15 (d, 6H). MS: [M+H]+1 = 366.2.
Synthesis 175
3'-Amino-5-isopropylbiphenyl-2,4-diol (Compound CC-027)
Prepared using General Procedure 4. Starting material: 5'-lsopropyl-2\4'- dimethoxybiphenyl-3-amine. 1H-NMR (DMSO-d6): δ 9.03 (br, 2H), 6.96 (t, 1H), 6.87 (s,
1 H), 6.68 (s, 1H), 6.61 (d, 1 H), 6.41 (masked d, 1H), 6.40 (s, 1H), 4.92 (br, 2H), 3.10 (sep, 1 H), 1.13 (d, 6H). MS: [M+H]+1 = 244.1.
Synthesis 176 Λ/-(2',4'-Dihvdroxy-5'-isopropylbiphenyl-3-yl)methaπesulfonamide (Compound CC-028)
Prepared using General Procedure 4. Starting material: Λ/-(5'-lsopropyl-2'.4'- dimethoxybiphenyl-3-vOmethanesulfonamide. 1H-NMR (DMSO-Cf6): δ 9.63 (s, NH), 9,24 (br, 2H), 7.38 (s, 1 H), 7.27 (t, 1 H), 7.21 (d, 1 H), 7.05 (d, 1 H), 6.92 (s, 1 H), 6.42 (s, 1 H), 3.10 (sep, 1 H), 2.98 (s, 3H), 1.14 (d, 6H). MS: [M+Na]+1 = 344.0.
Synthesis 177
A/-(2',4'-Dihydroxy-5'-isopropylbiphenyl-3-yl)-1-phenylmethanesulfonamide
(Compound CC-029)
Prepared using General Procedure 4. Starting material: /V-(5'-lsopropyl-2',4'- dimethoxybiphenyl-3-yl)-1-phenylmethanesulfonamide. 1H-NMR (DMSOd6): δ 9.77 (s, NH), 9,29 (s, 1 H), 9.22 (s, 1 H) ), 7.46-7.04 (arom, 9H), 6.95 (s, 1 H), 6.48 (s, 1H), 4.46 (s, 2H), 3.10 (sep, 1 H), 1.14 (d, 6H). MS: [M+Na]+1 = 420.1.
Synthesis 178
Λ/-(2',4'-Dihydroxy-5'-isopropylbiphenyl-3-yl)-4-methylbenzenesulfonamide- methylbenzenesulfonamide (Compound CC-030)
Prepared using General Procedure 4. Starting material: Λ/-(5'-lsopropyl-2',4'- dimethoxybiphenyl-3-yl)-4-methylbenzenesulfonamide. 1H-NMR (DMSO-Qf6): δ 9.36 (br, 3H), 7.67 (d, 2H), 7.28 (d, 2H), 7.25-6.80 (arom, 4H), 6.70 (s, 1H), 6.43 (s, 1H), 4.46 (s, 2H), 3.10 (sep, 1 H), 1.14 (d, 6H). MS: [M+Na]+1 = 420.1.
Synthesis 179
1-(4-Chlorophenyl)-Λ/-(2',4'-dihydroxy-5'-isopropylbiphenyl-3-yl)methanesulfonamide
(Compound CC-031)
Prepared using General Procedure 4. Starting material: 1-(4-Chlorophenyl)-Λ/-(4-fluoro- 5'-isopropyl-2',4'-dimethoxybiphenyl-2-yl)methanesulfonamide. 1H-NMR (DMSO-Cf6): δ 9.75 (s, NH), 9.27 (s, 1 H), 9.21 (s, 1H), 7.48-7.04 (arom, 8H), 6.94 (s, 1 H), 6.46 (s, 1H), 4.46 (s, 2H), 3.10 (sep, 1H), 1.14 (d, 6H). MS: [M+Na]+1 = 354.0.
Synthesis 180
Λ/-(4-fIuoro-2',4'-dihydroxy-5'-isopropylbiphenyl-2-yl)-4-methylbenzenesulfonamide
(Compound CC-032)
Prepared using General Procedure 4. Starting material: Λ/-(4-Fluoro-5'-isopropyl-2',4'- dimethoxybiphenyl-2-y!)-4-methylbenzenesulfonamide. 1H-NMR (DMSO-c/6): δ 10.13 (br, 1 H), 9.45 (br, 1 H), 8.54 (s, 1 H), 7.39-6.95 (arom, 7H), 6.49 (s, 1H), 6.39 (s, 1 H), 3.10 (sep, 1 H), 2.28 (s, 3H),1.14 (d, 6H). MS: [M+Na]+1 = 438.0.
Svnthesis 181
1-(4-Chlorophenyl)-/V-(4-fluoro-2l,4'-dihydroxy-5'-isopropylbiphenyl-2- yl)methanesulfonamide (Compound CC-033)
Prepared using General Procedure 4. Starting material: 1-(4-Chlorophenyl)-Λ/-(4-fluoro- 5'-isopropyl-2',4'-dimethoxybiphenyl-2-yl)methanesulfonamide. 1H-NMR (DMSO-Cf6): δ 9.85 (s, 1 H), 9.45 (s, 1 H), 8.03 (s, 1 H), 7.37-6.98 (arom, 7H), 6.88 (s, 1 H), 6.50 (s, 1H). 3.10 (sep, 1 H), 1.14 (d, 6H). MS: [M-H]"1 = 448.1.
Synthesis 182
/V-(2',4'-Dihydroxy-5'-isopropylbiphenyl-3-yl)-2-(4-(dimethylamino)phenyl)acetamide
(Compound CC-034)
Prepared using General Procedure 4. Starting material: 2-(4-(Dimethylamino)phenyl)-Λ/- (5'-isopropyl-2',4'-dimethoxybiphenyl-3-yI)acetamide. 1H-NMR (DMSO-Of6): δ 10.00 (s, 1 H), 9.2 (br, 2H), 7.61 (s, 1 H), 7.54 (d, 1 H), 7.28-7.10 (arom, 4H), 6.90 (s, 1 H), 6.68 (d, 2H), 6.43 (s, 1 H), 3.48 (s, 2H), 3.10 (sep, 1 H), 2.85 (s, 6H),1.14 (d, 6H). MS: [M+H]+1 = 405.3.
Synthesis 183
3'-(4-((1 HA ,2,4-Triazol-1 -yl)methyl)benzylamino)-5-isopropylbiphenyl-2,4-diol
(Compound CC-035)
Prepared using General Procedure 4. Starting material: /V-(4-((1/-/-1 ,2,4-Triazol-1- yl)methyl)benzyl)-5'-isopropyi-2',4'-dimethoxybiphenyl-3-amine. 1H-NMR (DMSO-cfe): δ 9.12 (s, 1H), 8.92 (s, 1 H), 8.63 (s, 1 H), 7.96 (s, 1H), 7.36-7.27 (arom, 3H), 7.11 (m, 1H), 6.98 (t, 1 H), 6.81 (s, 1 H), 6.67 (m, 2H), 6.39 (s, 1H). 6.38 (masked m, 1H)1 6.15 (m, 1H), 5.39 (s, 2H), 4,24 (d, 2H), 3.08 (sβp, 1 H), 1.10 (d, 6H). MS: [M+H]+1 = 415.3.
Synthesis 184 4-lsopropyl-6-(oxazol-5-yl)benzene-1 ,3-diol (Compound AA-004)
Prepared using General Procedure 4. Starting materials: 5-(5-lsopropyl-2,4- dimethoxyphenyl)oxazole. Obtained as 90-95 % pure. 1H-NMR (DMSO-c/6): δ 9.96 (s, 1 H), 9.54 (s, 1 H), 8.25 (s, 1 H), 7.31 (s, 1 H), 7.27 (s, 1 H), 6.49 (s, 1 H), 3.11 (sep, 1 H), 1.15 (d, 6H). MS+: 220.0 (M+1 ). MS-: 218.0 (M-H).
Synthesis 185 4-(5-(4-Ethylphenyl)oxazol-4-yl)-6-isopropylbenzene-1 ,3-diol (Compound AA-001 )
Prepared using General Procedure 4. Starting material: 5-(4-Ethylphenyl)-4-(5-isopropyl- 2,4-dimethoxyphenyl)oxazole. 1H-NMR (DMSO-c/6): δ 9.39 (bs, 1H), 9.24 (bs, 1H), 8.41 (S1 1H), 7.39 (d, 2H), 7.20 (d, 2H), 6.99 (s, 1 H), 6.42 (s, 1 H), 3.09 (sep, 1H), 2.59 (q, 2H), 1.16 (t, 3H), 1.08 (d, 6H).
Synthesis 186 4-(5-(4-Fluorophenyl)oxazol-4-yl)-6-isopropylbenzene-1 ,3-diol (Compound AA-002)
Prepared using General Procedure 4. Starting material: 5-(4-Fluorophenyl)-4-(5- isopropy)-2,4-dimethoxyphenyl)oxazole. 1H-NMR (DMSO-Of6): δ 9.42 (bs, 1H), 9.26 (bs,
1 H), 8.43 (s, 1 H), 7.49 (m, 2H), 7.23 (m, 2H), 7.01 (s, 1 H), 6.45 (s, 1H), 3.10 (sep, 1H), 1.09 (d, 6H).
Synthesis 187 4-lsopropyl-6-(5-(naphthalen-2-yl)oxazol-4-yl)benzene-1 ,3-diol (Compound AA-003)
Prepared using General Procedure 4. Starting material: 4-(5-lsopropyl~2,4- dimethoxyphenyl)-5-(naphthalen-2-yl)oxazole. 1H-NMR (DMSO-c/6): δ 9.45 (s, 1 H), 9.28 (bs, 1H), 8.51 (s, 1H), 8.08 (s, 1H), 7.91-7.82 (m, 3H), 7.57-7 Al (m, 3H), 7.09 (s, 1H), 6.45 (s, 1 H), 3.11 (sep, 1 H), 1.09 (d, 6H).
Synthesis 188 4-lsopropyl-6-(4-phenyloxazol-5-yl)benzene-1 ,3-diol (Compound AA-005)
Prepared using General Procedure 4. Starting material: 5-(5-lsopropyl-2,4- dimethoxyphenylH-phenyloxazole. 1H-NMR (DMSOd6): δ 9.64 (br, 1H), 9.50 (br, 1H), 8.38 (S1 1H), 7.57 (m, 2H), 7.35-7.18 (m, 3H), 6.95 (s, 1 H), 6.49 (s, 1H), 3.09 (sep, 1H), 1.07 (d, 6H). MS: [M+H]+1 = 296.1.
Synthesis 189 4-(4-(4-Fluorophenyl)oxazol-5-yl)-6-isopropylbenzene-1 ,3-diol (Compound AA-006)
Prepared using General Procedure 4. Starting material: 4-(4-Fluorophenyl)-5-(5- isopropy!-2,4-dimethoxyphenyl)oxazole. 1H-NMR (DMSO-αfβ): δ 9.66 (br, 1H), 9.50 (br, 1 H), 8.38 (s, 1 H), 7.57 (m, 2H), 7.16 (m, 2H), 6.96 (s, 1 H), 6.49 (s, 1 H), 3.09 (sep, 1 H), 1.08 (d, 6H). MS: [M+H]+1 = 314.1.
Svnthesis 190 4-(4-(4-Ethylphenyl)oxazol-5-yl)-6-isopropylbenzene-1 ,3-diol (Compound AA-007
Prepared using General Procedure 4. Starting material: 4-(4-Ethylphenyl)-5-(5-isopropyl- 2,4-dimethoxyphenyl)oxazole. 1H-NMR (DMSO-Qf6): δ 9.62 (br, 1H), 9.44 (br, 1H), 8.35 (s, 1 H), 7.48 (d, 2H), 7.14 (d, 2H), 6.95 (s, 1 H), 6.48 (s, 1 H), 3.09 (sep, 1H), 2.56 (masked q, 2H), 1.15 (t, 3H), 1.07 (d, 6H). MS: [M+H]+1 = 322.2.
Synthesis 191 4-lsopropyl-6-(5-phenyloxazol-4-yl)benzene-1 ,3-diol (Compound AA-008)
Prepared using General Procedure 10. Starting material: 4-(2,4-Bis(benzyloxy)-5- isopropylphenyl)-5-phenyloxazole. 1H-NMR (DMSO-c/6): δ 9.42 (s, 1H), 9.26 (s, 1 H), 8.44 (s, 1 H), 7.53-7.22 (arom, 5H), 7.00 (s, 1 H), 6.43 (s, 1 H), 3.09 (sep, 1 H), 1.08 (d, 6H). MS: [M+H]+1 = 296.2.
Synthesis 192 4-(5-(2-Ethylphenyl)oxazol-4-yl)-6-isopropylbenzene-1 ,3-diol (Compound AA-009)
Prepared using General Procedure 10. Starting material: 4-(2,4-Bis(benzyloxy)-5- isopropylphenyl)-5-(2-ethylphenyl)oxazole. 1H-NMR (DMSO-c/6): δ 10.12 (s, 1H), 9.42 (s, 1 H), 8.66 (s, 1 H), 7.53-7.28 (arom, 4H), 6.70 (s, 1H), 6.30 (s, 1H), 2.92 (sep, 1 H), 2.45 (masket q, 2H), 0.99 (t, 3H), 0.80 (d, 6H). MS: [M+H]+1 = 324.2.
Svπthesis 193 4-lsopropyl-6-(5-(4-methoxyphenyl)oxazol-4-yl)benzene-1 ,3-dio! (Compound AA-010)
Prepared using General Procedure 10. Starting material: 4-(2,4-Bis(benzyloxy)-5- isopropylphenyl)-5-(4-methoxyphenyl)oxazole. 1H-NMR (DMSO-Cf6): δ 9.39 (s, 1H), 9.25 (s, 1 H), 8.38 (s, 1 H), 7.40 (d, 2H), 6.98 (s, 1 H), 6.95 (d, 2H), 6.41 (s, 1H), 3.75 (s, 3H), 3.09 (sep, 1 H), 1.08 (d, 6H). MS: [M+H]+1 = 326.2.
Synthesis 194 4-(5-(3,4-dimethoxyphenyl)oxazol-4-yl)-6-isopropylbenzene-1 ,3-diol (Compound AA-011 )
Prepared using General Procedure 10. Starting material: 4-(3,4-Dimethoxyphenyl)-5-(5- isopropyl~2,4-dimethoxyphenyl)oxazole. 1H-NMR (DMSO-Cf6): δ 9.39 (s, 1H), 9.27 (s, 1H), 8.38 (s, 1 H), 7.09-6.93 (arom, 4H), 6.43 (s, 1 H), 3.75 (s, 3H), 3.60 (s, 3H), 3.09 (sep, 1H), 1.08 (d, 6H). MS: [M+H]+1 = 356.2.
Synthesis 195
4-(5-(Benzo[d][1 ,3]dioxol-5-yl)oxazol-4-yl)-6-isopropylbenzene-1 ,3-diol
(Compound AA-012)
Prepared using General Procedure 10. Starting material: 5-(Benzo[d][1 ,3]dioxol-5-yl)-4- (2,4-bis(benzyloxy)-5-isopropylphenyl)oxazole. 1H-NMR (DMSO-Cf6): δ 9.41 (s, 1H), 9.27 (s, 1 H), 8.38 (s, 1 H), 7.04-6.90 (arom, 4H), 6.42 (s, 1 H), 6.02 (s, 2H), 3.09 (sep, 1H), 1.09 (d, 6H). MS: [M+H]+1 = 340.2.
Svnthesis 196 2-(4-(2,4-Dihydroxy-5-isopropylphenyl)oxazol-5-yl)benzonitrile (Compound AA-013)
Prepared using General Procedure 10. Starting material: 2-(4-(2,4-Bis(benzyloxy)-5- isopropylpheny!)oxazol-5-yl)benzonitrile. 1H-NMR (DMSO-d6): δ 9.44 (s, 1H), 9.34 (s, 1 H), 8.63 (s, 1 H), 7.93 (dd, 1 H), 7.70 (dt, 1 H), 7.56 (dt, 1 H), 7.45 (dd, 1H), 7.10 (s, 1H), 6.33 (s, 1 H), 3.06 (sep, 1 H), 1.06 (d, 6H). MS: [M+H]+1 = 321.2.
Synthesis 197
4-isopropyl-6-(5-(4-(morpholinomethyl)phenyl)oxazol-4-yl)benzene-1 ,3-diol
(Compound AA-014)
Prepared using General Procedure 10. Starting material: 4-(4-(4-(2,4-Bis(benzyloxy)-5- isopropylphenyl)oxazol-5-yl)benzyl)morpholine. 1H-NMR (DMSO-Cf5): δ 9.49 (s, 1 H), 9.27 (S1 1 H), 8.49 (S, 1 H), 7.55 (d, 2H), 7.48 (d, 2H), 7.00 (s, 1 H), 6.45 (s, 1 H), 4.33 (br, 2H), 3.96 (br, 2H), 3.6 (masked, 2H), 3.24 (br, 2H), 3.10 (br. masked, 2H), 3.09 (sep, 1H), 1.07 (d, 6H). MS: [M+H]+1 = 395.2.
Synthesis 198
4-(5-(4-((1W-lmidazol-1-yl)methyl)phenyl)oxazol-4-yl)-6-isopropylbenzene-1 ,3-diol
(Compound AA-015)
Prepared using General Procedure 10. Starting material: 5-(4-((1W-lmidazol-1- yl)methyl)phenyl)-4-(2,4-bis(benzyloxy)-5-isopropylphenyl)oxazo!e. 1H-NMR (DMSO-c/6): δ 9.42 (s, 1 H), 9.24 (s, 1 H), 8.43 (s, 1 H), 7.73 (s, 1 H), 7.44 (d, 2H), 7.25 (d, 2H), 7.17 (s,
1 H), 6.99 (s, 1H), 6.90 (s, 1 H), 6.41 (s, 1 H), 5.18 (s, 2H), 3.09 (br. masked, 2H), 3.09 (sep, 1 H), 1.08 (d, 6H). MS: [M+H]+1 = 376.2.
Synthesis 199 4-(5-(4-((1 H- 1 ,2,4-Triazol-1 -yl)methyl)phenyl)oxazol-4-yl)-6-isopropylbenzene-1 ,3-diol
(Compound AA-016)
Prepared using General Procedure 10. Starting material: 5-(4-((1/-/-1 ,2,4-Triazol-1- yl)methyl)phenyl)-4-(2,4-bis(benzyloxy)-5-isopropylphenyl)oxazole. 1H-NMR (DMSO-d6): δ 9.42 (s, 1 H), 9.25 (s, 1 H), 8.65 (s, 1 H), 8.43 (s, 1 H), 7.98 (s, 1H), 7.44 (d, 2H), 7.26 (d, 2H), 7.00 (s, 1 H), 6.41 (s, 1 H), 5.40 (s, 2H), 3.09 (br. masked, 2H), 3.09 (sep, 1H), 1.08 (d, 6H). MS: [M+H]+1 = 377.2.
Synthesis 200 4-lsopropyl-6-(5-(4-(piperidin-1 -ylmethyl)phenyl)oxazol-4-yl)benzene-1 ,3-diol
(Compound AA-017)
Prepared using General Procedure 10. Starting material: 4-(2,4-Bis(benzyloxy)-5- isopropylphenyl)-5-(4-(piperidin-1-ylmethyl)phenyl)oxazole. 1H-NMR (DMSO-c/6): δ 9.42 (s, 1 H), 9.29 (s, 1H), 8.43 (s, 1 H), 7.42 (d, 2H), 7.29 (d, 2H), 6.99 (s, 1 H), 6.42 (s, 1H), 3.40 (br, 2H), 3.09 (sep, 1H), 2.31 (br, 4H), 1.49 (br, 4H), 1.37 (br, 2H), 1.07 (d, 6H). MS: [M+H]+1 = 393.3.
Synthesis 201
4-lsopropyl-6-(5-(4-((4-methylpiperazin-1-yl)methyl)phenyl)oxazol-4-yl)benzene-1 ,3-diol
(Compound AA-018)
Prepared using General Procedure 10. Starting material: 4-(2,4-bis(benzyloxy)-5- isopropylphenyl)-5-(4-((4-methylpiperazin-1-yl)methyl)phenyl)oxazole. 1H-NMR (DMSO- Cf6): δ 9.43 (s, 1 H), 9.24 (s, 1 H), 8.43 (s, 1 H), 7.43 (s, 2H), 7.28 (d, 2H), 6.98 (s, 1 H), 6.42 (S1 1 H)1 3.43 (s, 2H), 3.09 (sep, 1 H), 2.33 (br, 8H), 2.14 (s, 3H), 1.08 (d, 6H). MS: [M+H]+1 = 408.3.
Synthesis 202
4-lsopropyi-6-(5-(4-((4-methyl-1 ,4-diazepan-1-yl)methyl)phenyl)oxazol-4-yl)benzene-1 I3- diol (Compound AA-019)
Prepared using General Procedure 10. Starting material: 4-(2,4-Bis(benzyloxy)-5- isopropylphenyl)-5-(4-((4-methyl-1 ,4-diazepan-1 -yl)methyl)phenyl)oxazole. 1H-NMR (DMSO-Cy6): δ 9.43 (s, 1H), 9.30 (s, 1 H), 8.43 (s, 1 H), 7.43 (s, 2H), 7.30 (d, 2H), 6.98 (s, 1 H), 6.42 (s, 1 H), 3.58 (s, 2H), 3.09 (sep, 1 H), 2.65-2.54 (m, 4H), 2.5 (masked, 4H), 2.26 (s, 3H), 1.70 (m, 1H), 1.08 (d, 6H). MS: [M+H]+1 = 422.3.
Synthesis 203
4-lsopropyl-6-(5-(4-(pyrrolidin-1-ylmethyl)phenyl)oxazol-4-yl)benzene-1 ,3-diol
(Compound AA-020)
Prepared using General Procedure 10. Starting material: 4-(2,4-Bis(benzyloxy)-5- isopropylphenyl)-5-(4~(pyrrolidin-1-ylmethyl)phenyl)oxazoie. 1H-NMR (DMSO-Cf6): δ 9.44
(s, 1 H), 9.29 (s, 1 H), 8.44 (s, 1 H), 7.44 (s, 2H)1 7.33 (d, 2H), 7.00 (s, 1H), 6.44 (s, 1H), 3.67 (br, 2H), 3.09 (sep, 1 H), 1.72 (br, 4H), 1.08 (d, 6H). MS: [M+H]+1 = 379.3.
Synthesis 204
4-lsopropyl-6-(5-(4-(2-morpholinoethylamino)phenyl)oxazol-4-yl)benzene-1 ,3-diol
(Compound AA-021 )
Prepared using General Procedure 10. Starting material: 4-(4-(2,4-Bis(benzyloxy)-5- isopropylphenyl)oxazol-5-yl)-N-(2-morpholinoethyl)aniline. 1H-NMR (DMSO-Ct6): δ 9.36 (s, 1 H), 9.31 (s, 1 H), 8.31 (s, 1 H), 7.22 (s, 2H), 6.98 (s, 1H), 6.57 (d, 2H), 6.39 (s, 1H), 5.77 (br, NH), 3.58 (m, 4H), 3.15 (m, 2H), 3.08 (sep, 1 H), 2.52-2.35 (masked br, 6H), 1.06 (d, 6H). MS: [M+H]+1 = 424.3.
Synthesis 205
4-(5-(3-((1H-lmidazol-1-yl)methyl)phenyl)oxazol-4-yl)-6-isopropylbenzene-1 ,3-diol
(Compound AA-022)
Prepared using General Procedure 10. Starting material: 5-(3-((1H-lmidazol-1- yl)methyl)phenyl)-4-(2,4-bis(benzyloxy)-5-isopropylphenyl)oxazole. 1H-NMR (DMSO-Qf6): δ 9.42 (s, 1 H), 9.23 (s, 1 H), 8.44 (s, 1 H), 7.78 (s, 1 H), 7.45 (s, 1H), 7.32 (m, 2H), 7.17 (m, 2H), 6.99 (s, 1 H), 6.42 (s, 1H), 5.19 (s, 2H), 3.10 (sep, 1H), 1.09 (d, 6H). MS: [M+H]+1 = 376.2.
Svnthesis 206
4-(5-(3-((1 H-1 ,2,4-Triazol-1 -yl)methyi)phenyl)oxazol-4-yl)-6-isopropylbenzene-1 ,3-diol
(Compound AA-023)
Prepared using General Procedure 10. Starting material: 5-(3-((1H-1 ,2,4-Triazol-1- yl)methyl)phenyl)-4-(2,4-bis(benzyloxy)-5-isopropylphenyl)-oxazole. 1H-NMR (DMSO-Cf6): δ 9.42 (s, 1 H), 9.22 (s, 1 H), 8.63 (s, 1 H), 8.44 (s, 1 H), 7.96 (s, 1 H), 7.47 (s, 1 H), 7.32 (m, 2H), 7.19 (m, 1 H), 6.99 (s, 1 H), 6.42 (s, 1 H), 5.42 (s, 2H), 3.10 (sep, 1H), 1.08 (d, 6H). MS: [M+H]+1 = 377.2.
Synthesis 207
4-lsopropyl-6-(5-(3-((4-methylpiperazin-1-yl)methyl)phenyl)oxazol-4-yl)benzene-1 ,3-diol
(Compound AA-024)
Prepared using General Procedure 10. Starting material: 4-(2,4-Bis(benzyloxy)-5- isopropylphenyl)-5-(3-((4-methylpiperazin-1-yl)methyl)phenyl)-oxa2ole. 1H-NMR (DMSO- Cf6): δ 9.39 (s, 1 H), 9.20 (s, 1 H), 8.42 (s, 1 H), 7.48-7.13 (arom, 4H), 6.98 (s, 1 H), 6.41 (s, 1 H), 3.39 (s, 2H), 3.09 (sep, 1 H), 2.27 (br, 8H), 2.13 (s, 3H), 1.08 (d, 6H). MS: [M+H]+1 = 408.3.
Synthesis 208
4-lsopropyl-6-(5-(3-(pyrrolidin-1-ylmethyl)phenyl)oxazol-4-yl)benzene-1 ,3-diol
(Compound AA-025)
Prepared using General Procedure 10. Starting material: 4-(2,4-bis(benzyloxy)-5- isopropylphenyl)-5-(3-(pyrrolidin-1-ylmethyl)phenyl)oxazole. 1H-NMR (DMSO-Cf6): δ 9.39 (s, 1 H), 9.22 (s, 1 H), 8.43 (s, 1 H), 7.45 (s, 1 H), 7.36-7.18 (arom, 3H), 6.98 (s, 1 H), 6.42
(S, 1 H), 3.52 (s, 2H), 3.09 (sep, 1 H), 2.37 (br, 4H), 1.66 (br., 4H)1 1.08 (d, 6H). MS: [M+H]+1 = 379.3.
Synthesis 209 4-lsopropy!-6-(5-(3-(pyridin-3-yl)phenyl)oxazol-4-yl)benzene-1 ,3-diol (Compound AA-026)
Prepared using General Procedure 10. Starting material: 4-(2,4-Bis(benzyloxy)-5- isopropylphenyl)-5-(3-(pyridin-3-yl)phenyl)oxazole. 1H-NMR (DMSO-d6): δ 9.46 (s, 1H), 9.36 (s, 1 H), 8.76 (d, 1 H), 8.57 (dd, 1 H), 8.49 (s, 1 H), 7.96 (m, 1 H), 7.73 (m, 1H), 7.66 (dt, 1 H), 7.59-7.51 (m, 2H), 7.46 (dd, 1 H), 7.05 (s, 1 H), 6.47 (s, 1 H), 3.09 (sep, 1 H), 1.07 (d, 6H). MS: [M+H]+1 = 373.2.
Synthesis 210 4-(2,4-Dihydroxy-5-isopropylphenyl)oxazole-5-carboxylic acid (Compound AA-027)
Prepared using General Procedure 10. Starting material: 4-(5-lsopropyl-2,4- dimethoxyphenyl)oxazole-5-carboxylic acid. 1H-NMR (DMSO-c/6): δ 10.0 (vbr. OH+COOH), 9.52 (s, 1H), 8.57 (s, 1 H), 7.44 (s, 1H), 6.36 (s, 1H), 3.09 (sep, 1H), 1.12 (d, 6H). MS: [M+H]+1 = 264.0.
Synthesis 211
Λ/-Benzyl-4-(2,4-dihydroxy-5-isopropylphenyl)oxazole-5-carboxamide
(Compound AA-028)
Prepared using General Procedure 4. Starting material: Λ/-Benzyl-4-(5-isopropyl-2,4- dimethoxyphenyl)oxazole-5-carboxamide. 1H-NMR (DMSO-c/6): δ 10.12 (bs, 1 H), 9.59 (bs, 1 H), 9.22 (bt, NH), 8.65 (s, 1H), 7.58 (s, 1H), 7.35-7.18 (arom, 5H), 6.37 (s, 1H), 4.45 (d, 2H)1 3.10 (sep, 1 H), 1.13 (d, 6H). MS: [M+H]+1 = 353.1.
Synthesis 212
/V-((1 H-lndol-5-yl)methyl)-4-(2,4-dihydroxy-5-isopropylphenyl)oxazole-5-carboxamide
(Compound AA-029)
Prepared using General Procedure 10. Starting material: Λ/-((1H-indol-5-yl)methyl)-4- (2,4-bis(benzyloxy)-5-isopropylphenyl)oxazole-5-carboxamide. 1H-NMR (DMSO-Cf6)'- δ 11.02 (bs, 1 H), 10.23 (s, 1 H), 9.59 (s, 1 H), 9.21 (bs, 1 H), 8.63 (s, 1 H), 7.56 (s, 1H), 7.45 (s, 1 H), 7.31 (m, 2H), 7.05 (d, 1 H), 6.38 (s, 1 H), 6.38 (masked m, 1H), 4.51 (d, 2H), 3.10 (sep, 1 H), 1.13 (d, 6H). MS: [M+H]+1 = 392.2.
Synthesis 213
4-(2,4-Dihydroxy-5-isopropylphenyl)-Λ/-(4-(/V,Λ/-dimethylamino)benzyl)oxazole-5- carboxamide (Compound AA-030)
Prepared using General Procedure 10. Starting material: 4-(2,4-bis(benzyloxy)-5- isopropyIphenyl)-/V-(4-(/V,/V-dimethylamino)benzyl)oxazole-5-carboxamide. 1H-NMR (DMSO-Cf6): δ 10.2 (s, 1H), 9.59 (s, 1 H), 9.13 (bs, 1 H), 8.63 (s, 1H), 7.54 (s, 1H), 7.13 (d, 2H), 6.65 (s, 2H), 6.38 (s, 1 H), 4.32 (d, 2H), 3.10 (sep, 1 H), 2.84 (s, 6H), 1.13 (d, 6H). MS: [M+H]+1 = 396.1.
Synthesis 214
Rac-4-(2,4-Dihydroxy-5-isopropylphenyl)-N-(4-(1-hydroxyethyl)benzyl)oxazole-5- carboxamide (Compound AA-031)
Prepared using Genera! Procedure 10. Starting material: Λ/-(4-Acetylbenzyl)-4-(2,4- bis(benzyloxy)-5-isopropylphenyl)oxazole-5-carboxamide. 1H-NMR (DMSO-Cf6): δ 10.14 (s, OH), 9.60 (s, OH), 9.22 (t, NH), 8.64 (s, 1 H), 7.57 (s, 1 H), 7.25 (m, 4H), 6.38 (s, 1H), 5.08 (d, OH), 4.67 (m, 1 H), 4.42 (d, 2H), 3.10 (sep, 1 H), 1.28 (d, 3H), 1.13 (d, 6H). MS: [M+Na]+1 = 419.2.
Synthesis 215
/V-(4-(4-(2,4-Dihydroxy-5-isopropylphenyl)oxazol-5-yl)phenyl)-N-(2- morpholinoethyl)acetamide (Compound AA-032)
Prepared using General Procedure 10. Starting material: Λ/-(4-(4-(2,4-Bis(benzyloxy)-5- isopropylphenyl)oxazol-5-yl)phenyl)-Λ/-(2-morpholinoethyl)acetamide. 1H-NMR (DMSO- Cf6): δ 9.46 (s, 1 H), 9.32 (s, 1 H), 8.47 (s, 1 H), 7.53 (d, 2H), 7.34 (m, 3H), 6.99 (s, 1H), 6.45 (S, 1 H), 3.72 (t, 2H), 3.49 (m, 4H), 3.10 (sep, 1H), 2.37-2.23 (m, 6H), 1.74 (bs, 3H), 1.08 (s, 6H). MS: [M+H]+1 = 466.3.
Svnthesis 216
4-lsopropyl-6-(5-(4-(2-morpholinoethoxy)phenyl)oxazol-4-yl)benzene-1,3-diol
(Compound AA-033)
Prepared using General Procedure 10. Starting material: 4-(2-(4-(4-(2,4-Bis(benzyloxy)- 5-isopropylpheny!)oxazol-5-yl)phenoxy)ethyl)morpholine. 1H-NMR (DMSO-Cf6): δ 9.39 (bs, 1 H), 9.25 (bs, 1 H), 8.38 (s, 1 H), 7.39 (d, 2H), 6.98 (s, 1 H), 6.95 (d, 2H), 6.41 (s, 1 H) 4.08 (t, 2H), 3.56 (m, 4H), 3.09 (sep, 1 H), 2.67 (m, 2H), 2.45 (masked m, 4H), 1.08 (d, 6H). MS: [M+H]+1 = 425.3.
Biological Methods
Primary Assay : ATPase Activity
Briefly, this assay relies on the enzymatic hydrolysis of ATP to ADP + Pi (inorganic phosphate) by the yeast homologue of Hsp90, Hsp82. The level of Pi is detected by malachite green reagent. Measurement of Pi formation in the presence and absence of of a test compound provides an indication of that compounds ability to inhibit Hsp82 activity.
Hsp82 was recombinant^ expressed as a GST-tagged protein from E. CoIi. Hsp82 was incubated for 3 hours in assay buffer (50 mM HEPES-KOH, pH 7.5, 150 mM KAc, 8 mM MgAc, 0.25 mg/ml BSA) with 500 mM ATP in the presence of test compound. The extent of Pi formation was determined by addition of 100 μL malachite green solution (0.2% (w/v), ammonium molybdate, 0.7 M HCI, 0.03% (w/v) malachite green, 0.05% (v/v) Triton X-100) followed by 10 μL 37% (w/v) sodium citrate.
Expression/purification of GST-Hsp82
Rossetta pLysS (Novagen Inc) transformed with pGEX6P-Hsp82, were grown in Lennox Broth (supplemented with 100 μ/mL Ampicillin, 30 μg/mL Chloramphenical) at 37°C with agitation. At 0.70D6oo. the cultures were cooled to 300C and induced with 0.5 μM IPTG for 3 hours. The cultures were harvested by centrifugation (Sorvall GS3 rotor, ΘOOOrpm, 10 minutes). Each 1 L pellet was re-suspended in 20 mL ice cold phosphate-buffered saline (PBS) + 1% Tween + 1x complete protease inhibitors (Roche), 200 mM KCI,
10 mM DTT and incubated on ice for 5 minutes. The cell suspensions were sonicated at maximum power 4 x 10 second bursts on ice. Triton was added to a final concentration of 1% (v/v) and the lysates centrifuged (Sorvall SS34 rotor, 20,000 rpm, 20 minutes, 40C). The supematants were recovered and added to 2 mL of 50% v/v GST-Sepharose-4B beads in PBS + 1% Tween (PBST) and incubated on a rotating wheel at 4°C for 1 hour. The GST-beads were washed twice in 25 mL of PBST. Protein was eluted 3 times in 1 mL of 50 mM Tris, pH 8, 10 mM reduced glutathione. Each elution was performed for 5 minutes at 4°C on a rotating wheel.
Assay method
GST-Hsp82 was incubated with 500 mM ATP along with appropriate dilutions of candidate compounds (5 μL) in a total volume of 50 μL of assay buffer in clear 96 well plates (nunc polysorp). The reaction was carried out at 370C for 3 hours, after which 100 μL of malachite green solution (prepared 30 minutes earlier) was added followed by
10 //L of 37% (w/v) sodium citrate. The colour reaction was allowed to develop for 10 minutes and then measured on a scanning multi-well spectrophotometer at 690 nm.
Percent activity (% activity) for each test compound was calculated as:
% activity = { (Sc - B) / (S0 - B) } x 100
wherein Sc denotes signal measured in the presence of enzyme and the compound being tested, S° denotes signal measured in the presence of enzyme but in the absence of the compound being tested, and B denotes the background signal measured in the absence of both enzyme and compound being tested. The IC50 corresponds to the concentration which achieves 50% activity.
Secondary Assays
Compounds with Hsp90 inhibition activity, as determined using the primary assay, were subsequently evaluated using one or more secondary cell-based assays.
Secondary Assay: Her-2 Degradation Assay
Compounds which inhibit intracellular Hsp90 will result in the degradation of Hsp90 client proteins. HER2 is a well characterized client protein of Hsp90 and has been reliably shown to be degraded in response to Hsp90 inhibitors. This assay measures the quantity of extracellular HER2 present on MCF7 breast carcinoma cells by fluorescence.
MCF7 breast carcinoma cells (ATCC) were grown in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS), 100 units/mL penicillin and 0.1 mg/mL streptomycin plated in 6-well plates (400,000 cells/well/2mL). 24 hours later (cells were 65-70% confluent), test compounds were added at appropriate concentrations and the radicicol control at 1 μM and incubated overnight for 16 hours. The wells were washed with 1 mL of PBS, and 500 μL trypsin was added to each well. After trypsinization was complete, 1 mL of Media was added to each well. The cells were transferred to 1.5 mL eppendorf tubes and centrifuged at 6000 rpm (Eppendorf benchtop centrifuge) for 5 minutes. The supernatant was drawn off and discarded, and the cell pellet was washed twice in PBA buffer (PBS + 0.2% w/v BSA and 0.2% w/v sodium azide). The cells were then re-suspended in 100 μL PBA + PE conjugated anti-Her-2/neu antibody (Becton Dickinson, #340552, 1/20, final concentration 0.25 μg/mL) at 4°C on a rotating wheel for 1 hour. The cells were washed twice with 1 mL of PBA buffer, resuspended in 500 μL of FACS flow buffer (BD Biosciences), and transferred to FACSCAN tubes. Samples were analyzed using a FACScan flow cytometer (Becton Dickinson, San Jose, CA) configured to emit 488 nm-light to excite the phycoerythrin
fluorochrome. 30,000 events were collected per sample. A fluorescence histogram was generated and the Geometric mean (GE) of each sample was determined using Cellquest software. Cells were always incubated with DMSO as untreated controls, since the compounds were re-suspended in DMSO and 1 μM radicicol as the positive control.
Compound activity was expressed as the leftwards fold shift in the GE relative to the untreated control:
activity = Sc/ S°
wherein Sc denotes GE measured in the presence of enzyme and the compound being tested, S0 denotes signal measured in the untreated control.
Secondary Assay: HCT116 WST-1 Assay
The following cell line was used: HCT116 - Human colorectal cancer cell line (ATCC CCL-247). Cells were cultured, exposed to candidate compounds, and incubated for a time, and the number of viable cells was then assessed using the Cell Proliferation Reagent WST-1 from Boehringer Mannheim (Cat. No. 1 644 807), described below.
Cells were plated in 96-well plates at 3-10 x 103 cells/well in 100 μl_ of culture medium. The following day, different concentrations of candidate compounds were added and the cells incubated at 370C for 48 hours. Subsequently, 10 μL/well of WST-1 reagent was added and the cells re-incubated for 1 hour. After the incubation time, absorbance was measured.
WST-1 is a tetrazolium salt which is cleaved to formazan dye by cellular enzymes. An expansion in the number of viable cells results in an increase in the overall activity of mitochondrial dehydrogenases in the sample. This augmentation in the enzyme activity leads to an increase in the amount of formazan dye formed, which directly correlates to the number of metabolically active cells in the culture. The formazan dye produced is quantified by a scanning multi-well spectrophotometer by measuring the absorbance of the dye solution at 450 nm wavelength (reference wavelength: 690 nm).
Percent activity (% activity) in reducing the number of viable cells was calculated for each test compound as:
% activity = { (Sc - B) / (S° - B) } x 100
wherein Sc denotes signal measured in the presence of the compound being tested, S0 denotes signal measured in the absence of the compound being tested, and B
denotes the background signal measured in blank wells containing medium only. The IC50 corresponds to the concentration which achieves 50% activity. IC50 values were calculated using the software package Prism 4.0 (GraphPad Software Inc., San Diego, CA).
Biological Data
The following compounds were tested in the "ATPase Activity" assay described above: AA-001 , AA-002, AA-003, AA-004, BB-001 , BB-002, CC-003, CC-012, CC-014, DD-004, DD-009.
The following compounds have a "% inhibition at 100 μM" of at least 5%: AA-001, AA-002, AA-003, BB-001 , BB-002, CC-003, CC-012, CC-014, DD-004, DD-009.
The following compounds have a "% inhibition at 100 μM" of at least 10%: AA-002, AA-003, BB-001 , CC-003, CC-012, CC-014, DD-004, DD-009.
One compound, compound AA-002, has a "% inhibition at 100 μM" of 16.2%. One compound, compound BB-002, has a "% inhibition at 100 μM" of 7.5%. One compound, compound CC-014, has a "% inhibition at 100 μM" of 30.2%. One compound, compound DD-009, has a "% inhibition at 100 μM" of 16.4%.
The following compounds were tested in the Ηer-2 Degradation Assay" assay described above: AA-002, AA-004, AA-009, AA-015, AA-017, BB-002, BB-003, CC-002, CC-011, CC-012, CC-013, CC-014, DD-006, DD-008, EE-001.
The following compounds have a fold-shift of GE, at 1 μM, of at least 5: AA-015, AA-017.
The following compounds have a fold-shift of GE, at 10 μM, of at least 1.3: AA-002, AA-009, BB-002, BB-003, CC-012, CC-013, CC-014. DD-008.
The following compounds have a fold-shift of GE, at 10 μM, of at least 2: AA-002, BB-002, CC-013, CC-014.
The following compounds have a fold-shift of GE, at 50 μM, of at least 1.5: AA-004, CC-002, CC-011 , DD-006, EE-001.
The following compounds have a fold-shift of GE, at 50 μM, of at least 2: AA-004, CC-002, DD-006.
The ability of several compounds to inhibit heat shock protein 90 (HSP90) activity was determined using the "HCT116 WST- 1 Assay" described above.
The following compounds were tested: AA-O01 , AA-005, AA-006, AA-007, AA-008, AA-009, AA-013, AA-015, AA-016, AA-017, AA-018, AA-019, AA-020, AA-021, AA-022, AA-023, AA-024, AA-029, AA-030, AA-031 , AA-032, AA-033, BB-002, BB-005, BB-007, BB-008, CC-002, CC-012, CC-013, CC-014, DD-015, DD-019, DD-020.
All of those compounds have an IC50 of less than 50 μM.
The following compounds have an IC50 of 10 μM or more, and less than 50 μM: AA-001 , AA-009, AA-022, AA-029, AA-030, AA-031 , CC-002, CC-013, DD-015, DD-019, DD-020.
The following compounds have an IC50 of less than 10 μM: BB-002, CC-012, CC-014.
The following compounds have an IC50of 1 μM or more, and of less than 10 μM: AA-005, AA-006, AA-007, AA-008, AA-013, AA-018, AA-019, AA-021 , AA-023, AA-024, AA-033, BB-002, BB-007, BB-008, CC-012, CC-014.
The following compounds have an IC50 of less than 1 μM: AA-015, AA-016, AA-017, AA-020, AA-032, BB-005.
One compound, compound AA-001 , has an IC50 value of 24.0 μM. One compound, compound AA-005, has an IC50 value of 1.6 μM
One compound, compound BB-002, has an IC50 value of 5.3 μM.
One compound, compound BB-007, has an IC50 value of 3.8 μM.
One compound, compound CC-012, has an 1C50 value of 3.5 μM.
One compound, compound CC-014, has an IC50 value of 5.9 μM. One compound, compound DD-015, has an IC50 value of 46.1 μM.
The foregoing has described the principles, preferred embodiments, and modes of operation of the present invention. However, the invention should not be construed as limited to the particular embodiments discussed. Instead, the above-described embodiments should be regarded as illustrative rather than restrictive, and it should be appreciated that variations may be made in those embodiments by workers skilled in the art without departing from the scope of the present invention.
REFERENCES
A number of patents and publications are cited above in order to more fully describe and disclose the invention and the state of the art to which the invention pertains. Full citations for these references are provided below. Each of these references is incorporated herein by reference in its entirety into the present disclosure, to the same extent as if each individual reference was specifically and individually indicated to be incorporated by reference.
Buchner J., 1999, "Hsp90 & Co. - a holding for folding", Trends Biochem. Sd., Vol. 24,
No. 4, pp. 136-141.
Caplan A. J., 1999, "HspθO's secrets unfold: new insights from structural and functional studies", Trends Cell Biol., Vol. 9, No. 7, pp. 262-268.
Chessari, G., et al., 2006, "Pharmaceutical compounds", published international (PCT) patent application publication number WO 2006/109075, published 19 October 2006.
CS 159525, patent application filed 03 November 1972, published 31 January 1975. Dai K et al, 1996, "Physical interaction of mammalian CDC37 with CDK4" J. Biol. Chem.
Vol. 27 No. 36 pp 22030-22034.
DeFranco D.B., et al., 1999, "Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke," published international (PCT) patent application number WO99/51223, published 14 October 1999. Drysdale, MJ. , et al., 2004, "Isoxazole compounds as inhibitors of heat shock proteins", published international (PCT) patent application publication number WO 2004/072051, published 26 August 2004. Gold, B. G., 2001 , "Compositions and methods for promoting nerve regeneration",
US Patent No. 6,210,974 issued 03 April 2001. Greenert J. P., et al., 1997, "The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation", J. Biol. Chem., Vol. 272, No. 38, pp. 23843-23850. Hartmann, F., et al., 1997, "Effects of the tyrosine-kinase inhibitor geldanamycin on ligand induced Her-2/neu activation, receptor expression and proliferation of Her-2- positive malignant cell lines", Int. J. Cancer. Vol. 70, No. 2, pp. 221-229.
Kuramochi, H., et al., 2006, "Novel HSP90 inhibitor", published international (PCT) patent application publication number WO 2006/095783, published 14 September 2006. Lapkin et al., 1974, Izvestiva Vvsshikh Uchebnvkh Zavedenii, Khimiva I Khimicheskava
Tekhnoloαiva. Vol. 17(5), pp. 713-716. Lee, C-W., et al., 2008, "Compounds that modulate HSP90 activity", published international (PCT) patent application publication number WO 2008/118391 A2, published 02 October 2008. Miller, P., et al., 1994, "Depletion of the erbB-2 gene product p185 by benzoquinoid ansamvcins" Cancer Res.. Vol. 54, No. 10, pp. 2724-2730. Mimnaugh, E.G., et al., 1996, "Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin", J. Biol.
Chem.. Vol. 271 , No. 37, pp. 22796-22801. Muise-Helmericks, R. C, et al., 1998, "Cyclin D expression is controlled post- transcriptionally via a phosphatidyl! nositol 3-kinase/Akt-dependent pathway", J. Biol. Chem., Vol. 273, No. 45, pp. 29864-29872.
Nakatani, N., et al, 1990, "Biphenyl compounds, anti-oxidant composition and deodorant composition containing same compounds", Japanese patent application number
02-160737, published 20 June 1990.
Panaretou, B., et al., 1998, "ATP binding and hydrolysis are essential to the function of the Hsp90 molecular chaperone in vivo", EMBO J., Vol. 17, No. 16, pp. 4829-4836. Prodromou, C, et al., 1997, "Identification and structural characterization of the
ATP/ADP-binding site in the Hsp90 molecular chaperone", CeH, Vol. 90, No. 1, pp. 65-75. Rosen, N., et al., 2002, "Methods for treating cell proliferative disorders and viral infections," published international (PCT) patent application number
WO 02/09696, published 07 February 2002. Scheibel, T., et al., 1999, "The charged region of Hsp90 modulates the function of the
N-terminal domain", Proc. Natl. Acad. Sd. U.S.A., Vol. 96, No. 4, pp. 1297-1302. Schneider, C1 et al., 1996 "Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90", Proc. Natl. Acad. Sci. U.S.A.. Vol. 93,
No. 25, pp. 14536-14541. Schnur, R.C, et al, 1995, "Inhibition of the oncogene product p185erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives", J. Med. Chem., Vol. 38, No. 19, pp. 3806-3812.
Schulte, T.W., et al., 1995, "Disruption of the Raf-1-Hsp90 molecular complex results in destabilization of Raf-1 and loss of Raf-1-Ras association", J. Biol. Chem.,
Vol. 270, No. 41 , pp. 24585-24588.
Schulte, T.W., et al., 1997, "Geldanamycin-induced destabilization of Raf-1 involves the proteasome", Biochem. Biophvs. Res. Commun.. Vol. 239, No. 3, pp. 655-659.
Segnitz, B., et al., 1997, "The function of steroid hormone receptors is inhibited by the hsp90 specific compound geldananmycin", J. Biol. Chem., Vol. 272, No. 30, pp. 18694-18701.
Sepp-Lorenzino, L., et al., 1995, "Herbimycin A induces the 2OS proteasome- and ubiquitin-dependent degradation of receptor tyrosine kinases", J. Biol. Chem.,
Vol. 270, No. 28, pp. 16580-16587. Smith, D. F., et al., 1995, "Progesterone receptor structure and function altered by geldanamycin, an hsp90-binding agent", MoI. Cell. Biol., Vol. 15, No. 12, pp. 6804-6812. Stebbins, C, et al, 1997, "Crystal structure of an HSP90-geldanamycin complex: targeting of a protein chaperone by an anti-tumour agent", Cell, Vol. 89, No. 2, pp. 239-250. Stepanova, L., et al, 1996, "Mammalian p50Cdc37 is a protein kinase-targeting subunit of
Hsp90 that binds and stabilizes Cdk4", Genes Dev.. Vol. 10, No. 12, pp. 1491-1502.
Strehlow, D., 2002, "Use of geldanamycin and related compounds for prophylaxis or treatment of fibrogenic disorders", published international (PCT) application number WO 01/02123, published 10 January 2002.
Vasilevskaya, I. A., et al., 1999, "Effects of geldanamycin on signalling through activator- protein 1 in hypoxic HT29 human colon adenocarcinoma cells", Cancer Res.,
Vol. 59, No. 16, pp. 3935-3940. Whitesell, L., et al., 1994, "Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation", Proc. Natl. Acad. Sci. U.S.A., Vol. 91 , No. 18, pp. 8324-8328.
Ying, W., et al., 2006, "Triazole compounds that modulate HSP90 Activity", published international (PCT) patent application publication number WO 2006/055760, published 26 May 2006.
Ying, W., et al., 2007, "Imidazole compounds that modulate HSP90 Activity", published international (PCT) patent application publication number WO 2007/021877, published 22 February 2007. Ying, W., et al., 2007, "Pyrazole compounds that modulate HSP90 Activity", published international (PCT) patent application publication number WO 2007/021966, published 22 February 2007.
Claims
1. A compound selected from compounds of the following formula, and pharmaceutically acceptable salts, hydrates, and solvates thereof:
-X1- is independently a covalent single bond or -X1L-; -X2- is independently a covalent single bond or -X2L-;
-A1- is independently -A1A-;
-A2 is independently -A2A, -H, or -F; except that if: -X2- is -X2L-, then: -A2 is -A2A;
each of -X1L- and -X2L- is independently:
-RL-,
-C(=O)-, -RL-C(=O)-,
-C(=O)-RL-, -RL-C(=O)-RL-,
-O-RL-C(=O)-, -C(=O)-RL-O-,
-C(=O)-RL-S-, -O-RL-C(=O)-RL-O,
-NH-S(=O)2-, -NRA-S(=O)2-, -RL-NH-S(=O)2-, -RL-NRA-S(=O)2-,
-NH-S(=O)2-RL-, -NRA-S(=O)2-RL-, -RL-NH-S(=O)2-RL-, -RL-NRA-S(=O)2-RL-,
-S(=O)2-NH-, -S(=O)2-NRA-, -RL-S(=O)2-NH-, -RL-S(=O)2-NRA-,
-C(=O)-NH-RL-, -C(=O)-NRA-RL-, -RL-S(=O)2-NH-RL-, -RL-S(=O)2-NRA-RL-, -O-, -RL-O-, -O-RL-, -RL-O-RL-,
-NH-C(=O)-, -NRA-C(=O)-, -RL-NH-C(=O)-, -RL-NRA-C(=O)-, -NH-C(=O)-RL-, -NRA-C(=O)-RL-, -RL-NH-C(=O)-RL-, -RL-NRA-C(=O)-RL-,
-C(=O)-NH-, -C(=O)-NRA-, -RL-C(=O)-NH-, -RL-C(=O)-NRA-, -C(=O)-NH-RL-, -C(=O)-NRA-RL-, -RL-C(=O)-NH-RL-, -RL-C(=O)-NRA-RL-,
-NH-C(=O)-NH-, -NRA-C(=O)-NH-, -NH-C(=O)-NRA-, -NRA-C(=O)-NRA-,
-RL-NH-C(=O)-NH-, -RL-NRA-C(=O)-NH-,
-RL-NH-C(=O)-NRA-, -RL-NRA-C(=O)-NRA-,
-NH-C(=O)-NH-RL-, -NRA-C(=O)-NH-RL-, -NH-C(=O)-NRA-RL-, -NRA-C(=O)-NRA-RL-,
-RL-NH-C(=O)-NH-RL-, -RL-NRA-C(=O)-NH-RL-, -RL-NH-C(=O)-NRA-RL-, -RL-NRA-C(=O)-NRA-RL-,
-NH-, -NR\ -RL-NH-, -RL-NRA-,
-NH-R1-, -NRA-RL-, -RL-NH-RL-, -RL-NRA-RL-,
-C(=O)-O- -RL-C(=O)-O-,
-C(=O)-O-RL-, -RL-C(=O)-O-RL-,
-O-C(=O)-, -RL-O-C(=O)-,
-O-C(=O)-RL-, -RL-O-C(=O)-RL-,
-S(=O)-, -RL-S(=O)-, -S(=O)-RL-,
-RL-S(=O)-RL-,
-S(=O)2-, -RL-S(=O)2-, -S(=O) 2-RL-, or
-RL-S(=O)2-RL-;
except that -X1L- is not:
-C(=O)-NH-, -C(=O)-NRA-, -C(=O)-NH-RL-, or -C(=O)-NRA-RL-;
wherein:
each -RA is independently -RM, -RAB, or -RAC; each -RM is independently saturated aliphatic C1-6alkyl; each -RAB is independently aliphatic C2-6alkenyl; each -RAC is independently saturated C3-6cycloalkyl; and each -RM, -RAB, and -RAC is independently unsubstituted or substituted with one or more substituents selected from -F1 -Cl, -Br, -I, -OH, -OR, -NH2, -NHR, -NR2,
-NHC(=O)R, -NRC(=O)R, -C(=O)OR, -OC(=O)R, -C(=O)NH2) -C(=O)NHR, and -C(=O)NR2, wherein each R is independently saturated aliphatic C^alkyl, phenyl, or benzyl;
each -RL- is independently -Ru-, -RLB-, -RLC-, -RLA-RLC-, -R^-R^-, or
each -RLA is independently saturated aliphatic Ci-βalkylene; each -RLB is independently aliphatic C2_6alkenylene; each -RLC is independently saturated C3-6cycloalkylene; and each -RLA, -RLB, and -RLC is independently unsubstituted or substituted with one or more substituents selected from -F, -Cl, -Br, -I, -OH, -OR, -NH2, -NHR, -NR2, -NHC(=O)R, -NRC(=O)R, -C(=O)OR, -OC(=O)R, -C(=O)NH2, -C(=O)NHR, and
-C(=O)NR2, wherein each R is independently saturated aliphatic C1-4alkyl, phenyl, or benzyl;
and wherein:
-A1A- is independently -A1AC- or -A1AH-; -A1AC- is independently C6.10carboarylene; -A1AH- is independently C5-12heteroarylene; and each -A1AG- and each -A1AH- is independently unsubstituted or substituted with one or more substituents -Q1;
-A2A is independently -A2^ or -A2AH; -A2AC is independently C6-iocarboaryl; -A2AH is independently C5-12heteroaryl; and each -A2AC and each -A2AH is independently unsubstituted or substituted with one or more substituents -Q2;
wherein:
each -Q1 and each -Q2 is independently:
-F, -Cl, -Br, -I,
-R1A1,
-CF3, -OCF3,
-OH, -L1A-OH, -O-L1A-OH, -OR1A1, -L1A-OR1A1, -O-L1A-OR1A1,
-SH, -SR1A1,
-CN,
-NO2,
-NH2, -NHR1A1, -NR1A1 2, -NR1A2R1A3, -L1A-NH2, -L1A-NHR1A1 , -L1A-NR1A1 2, -L1 A-NR1 A2R1A3,
-O-L1A-NH2, -O-L1A-NHR1A1, -O-L1A-NR1A1 2, -O-L1A-NR1A2R1A3,
-NH-L1A-NH2, -NH-L1A-NHR1A1, -NH-L1A-NR1A1 2, -NH-L1A-NR1A2R1A3,
-NR1A1-L1A-NH2, -NR1A1-L1A-NHR1A1, -NR1A1-L1A-NR1A1 2, -NR1A1-L1A-NR1A2R1A3,
-C(=O)OH, -C(=O)OR1A1, -OC(=O)R1A1, -C(O)NH2, -C(=O)NHR1A1, -C(=O)NR1A1 2, -C(=O)NR1A2R1A3,
-NHC(=O)R1A1, -NR1A1C(=O)R1A1,
-C(=O)NHOR1A\ -C(=O)NR1A1OR1A1,
-NHC(=O)R1A1 , -NR1A1C(=O)R1A1 ,
-NHC(=O)OR1A1, -NR1A1C(=O)OR1A1, -OC(=O)NH2, -OC(=O)NHR1A1, -OC(=O)NR1A1 2, -OC(=O)NR1A2R1A3,
-C(=O)R1A1,
-NHC(=O)NH2, -NHC(=O)NHR1A1,
-NHC(=O)NR1A1 2, -NHC(=O)NR1A2R1A3,
-NR1A1C(=O)NH2, -NR1A1C(=O)NHR1A1, -NR1A1C(=O)NR1A1 2, -NR1A1C(=O)NR1A2R1A3,
-NHS(=O)2R1A1, -NR1A1S(=O)2R1A1, -S(=O)2NH2, -S(=O)2NHR1A1, -S(=O)2NR1A1 2, -S(=O)2NR1A2R1A3, -S(=O)R1A1, -S(=O)2R1A1, -OS(=O)2R1A1, or -S(=O)2OR1A1;
wherein:
each -L1A- is independently saturated aliphatic C^alkylene; in each group -NR1A2R1A3, -R1A2 and -R1A3, taken together with the nitrogen atom to which they are attached, form a 4-, 5-, 6-, or 7-membered non-aromatic ring having exactly 1 ring heteroatom or exactly 2 ring heteroatoms, wherein one of said exactly 2 ring heteroatoms is N, and the other of said exactly 2 ring heteroatoms is independently N, O, or S;
each -R1A1 is independently:
-RiEi1 _p1B2 _p1B3 _p1β4 -P1 B5 -R1 B6 -R1 B7 -R1B8 -L1B-R1B4, -L1B-R1B5, -L1B-R1B6, -L1B-R1B7, or -L1B-R1B8; wherein: each -R1B1 is independently saturated aliphatic C1-6alkyl; each -R1B2 is independently aliphatic C2-6alkenyl; each -R183 is independently aliphatic C2.6alkynyl; each -RtB4 is independently saturated C3.6cycloalkyl; each -R1B5 is independently C3-6cycloalkenyl; each -R1B6 is independently non-aromatic C3-7heterocyclyl; each -R1B7 is independently C6-iocarboaryl; each -R1B8 is independently C5-ioheteroaryl; each -L1B- is independently saturated aliphatic C1-3alkylene; and wherein: each -R1B4, -R1B5, -R1B6, -R1B7, and -R1B8 is optionally substituted, for example, with one or more substituents -R1C1 and/or one or more substituents -R1C2, and each -R1B1, -R1B2, -R1B3, and -L1B- is optionally substituted, for example, with one or more substituents -R1C2, wherein: each -R1C1 is independently saturated aliphatic d^alkyl, phenyl, or benzyl; each -R1C2 is independently:
-F, -Cl, -Br, -I, -CF3, -OCF3,
-OH, -L1D-OH, -O-L1D-OH, -OR1D1, -L1D-OR1D1, -O-L1D-OR1D1, -SH, -SR1D1, -CN, -NO2,
-NH2, -NHR1D1, -NR1D12, -NR102R103, -L1D-NH2, -L1D-NHR1D1, -L1D-NR1D1 2l or -L1D-NR1D2R1D3,
-O-L1D-NH2, -O-L1D-NHR1D1, -O-L1D-NR1D1 2| -O-L1D-NR1D2R1D3,
-NH-L1D-NH2, -NH-L1D-NHR1D1, -NH-L1D-NR1D1 2, -NH-L1D-NR1D2R1D3,
-NR1D1-L1D-NH2, -NR1D1-L1D-NHR1D1, -NR1D1-L1D-NR1D1 2, -NR1D1-L1D-NR1D2R1D3,
-C(=O)OH, -C(=O)OR1D1, -OC(=O)R101,
-C(=O)R1D1,
-C(=O)NH2, -C(=O)NHR1D1, -C(=O)NR1D1 2, -C(=O)NR1D2R1D3,
-NHC(=O)R1D1, -NR1D1C(=O)R1D1, -S(=O)2NH2, -S(=O)2NHR1A1 , -S(=O)2NR1A1 2, -S(=O)2NR1A2R1A3, or
-S(=O)2R1A1; wherein: each -R1D1 is independently saturated aliphatic C^alkyl, phenyl, or benzyl; each -L1D- is independently saturated aliphatic C1-5alkylene; and in each group -NR102R103, -R102 and -R103, taken together with the nitrogen atom to which they are attached, form a 4-, 5-, 6-, or 7-membered non-aromatic ring having exactly 1 ring heteroatom or exactly 2 ring heteroatoms, wherein one of said exactly 2 ring heteroatoms is N, and the other of said exactly 2 ring heteroatoms is independently N, O, or S;
and additionally, two adjacent -Q1 groups, if present, may together form -0-CH2-O- or -0-CH2CH2-O-; and additionally, two adjacent -Q2 groups, if present, may together form -0-CH2-O- or -0-CH2CH2-O-.
except that:
if -X1- is a covalent single bond, then -A1- is not:
1 ,2,4-triazine-6-one, substituted 1 ,2,4-triazine 6-one, 1 ,2,4-triazine-6-thione, or substituted 1 ,2,4-triazine-6~thione;
2-0X0-1 ,2,3,4-tetrahydropyrimidine or substituted 2-oxo-1, 2,3,4- tetrahydropyrimidine;
2-amino-1 ,2,3,4-tetrahydropyrimidine or substituted 2-amino-1 ,2,3,4- tetrahydropyrimidine; pyrazol-diyl or substituted pyrazol-diyl;
1 ,3-dihydro-imidazol-2-one-diyl or substituted 1 ,3-dihydro-imidazol-2-one-diyl;
1 ,3-dihydro-imidazol-2-thione-diyl or substituted 1 ,3-dihydro-imidazol-2-thione-diyl;
1 ,2,4-triazol-diyl or substituted 1 ,2,4-triazol-diyl;
2,4-dihydro-[1 ,2,4]triazol-3-one-diyl or substituted 2,4-dihydro- [1 ,2,4]triazol-3-one-diyl; 2l4-dihydro-[1 ,2,4]triazol-3-thione-diyl or substituted 2,4-dihydro- [1 ,2,4]triazol-3-thione-diyl; or isoxazol-diyl or substituted isoxazol-diyl;
and with the proviso that the compound is not a compound selected from the following compounds, and salts, hydrates, and solvates thereof: (P-001) 4-(2,4-Dihydroxy-5-isopropyl-phenyl)-6-isopropyl-3-methyl- [1 ,2]benzoquinone;
(P-002) (2,4-Dihydroxy-5-isopropyl-phenyl)-phenyl-methanone; and (P-003) 4-[1 -(3-Bromo-phenyl)-ethyl]-6-isopropyl-benzene-1 ,3-diol.
2. A compound according to claim 1 , wherein -X1- is independently a covalent single bond.
3. A compound according to claim 1 , wherein -X1- is independently -X1L-.
4. A compound according to any one of claims 1 to 3, wherein -X2- is independently a covalent single bond.
5. A compound according to any one of claims 1 to 3, wherein -X2- is independently -X2L-.
6. A compound according to any one of claims 1 to 5, wherein -A2 is independently -A2A or -H.
7. A compound according to any one of claims 1 to 5, wherein -A2 is independently -A2A.
8. A compound according to any one of claims 1 to 5, wherein -A2 is independently -H or -F.
9. A compound according to any one of claims 1 to 5, wherein -A2 is independently -H.
10. A compound according to claim 1 , wherein the group -X1-A1-X2-A2 is independently:
_X1L-A1A-X2L-A2A, 5 _χiL_A1A-A2A,
_χ1L-A 1A-H, -X1L-A1A-F, -A1A-X2L-A2A, -A1A-A2A, 0 -A1A-H, or
-A1A-F.
1 1. A compound according to claim 1 , wherein the group -X1-A1-X2-A2 is independently: 5 -X1L-A1A-H,
_X 1L-A1A-F,
_A1A_χ2L_A2A
-A1A-A2A, -A1A-H, or 0 -A1A-F.
12. A compound according to claim 1 , wherein the group -X1-A1-X2-A2 is independently -X1L-A1A-H or -X1L-A1A-F. 5
13. A compound according to claim 1 , wherein the group -X1-A1-X2-A2 is independently -X1L-A1A-H.
14. A compound according to claim 1 , wherein the group -X1-A1-X2-A2 is independently -A1A-X2L-A2A. 0
15. A compound according to claim 1 , wherein the group -X1-A1-X2-A2 is independently -A1A-A2A.
16. A compound according to claim 1 , wherein the group -X1-A1-X2-A2 is5 independently -A1A-H or -A1A-F.
17. A compound according to claim 1 , wherein the group -X1-A1-X2-A2 is independently -A1A-H. Q * * *
18. A compound according to any one of claims 1 to 17, wherein -X1L-, if present, is independently:
-RL-, -C(=O)-,
5 -RL-C(=O)-,
-C(=O)-RL-, -RL-C(=O)-RL-, -O-RL-C(=O)-, -C(=O)-RL-O-, 0 -C(=O)-RL-S-, or
-O-RL-C(=O)-RL-O,
19. A compound according to any one of claims 1 to 17, wherein -X1L-, if present, is independently: 5 -RL-,
-C(=O)-,
-C(=O)-RL-,
-C(=O)-RL-S-, or
-C(=O)-RL-O-. 0
20. A compound according to any one of claims 1 to 17, wherein -X1L-, if present, is independently:
-C(=O)-, -C(=O)-RL-, 5 -C(=O)-RL-S-, or
-C(=O)-RL-O-.
21. A compound according to any one of claims 1 to 17, wherein -X1L-, if present, is independently -C(=O)-. 0
22. A compound according to any one of claims 1 to 17, wherein -X1L-, if present, is independently -C(=O)-RL-.
23. A compound according to any one of claims 1 to 17, wherein -X1L-, if present,5 is independently -C(=O)-RL-O-.
24. A compound according to any one of claims 1 to 17, wherein -X1L-, if present, is independently -RL-. Q * * *
25. A compound according to any one of claims 1 to 24, wherein -X2L-, if present, is independently:
-RL-,
-NH-S(=O)2-, -NRA-S(=O)2-,
-RL-NH-S(=O)2-, -RL-NRA-S(=O)2-,
-NH-S(=O)2-RL-, -NRA-S(=O)2-RL-,
-RL-NH-S(=O)2-RL-, -RL-NRA-S(=O)2-RU-,
-SC=O)2-NH-, -S(=O)2-NRA-,
-RL-S(=O)2-NH-, -RL-S(=O)2-NRA-,
-C(=O)-NH-RL-, -C(=O)-NRA-RL-,
-RL-S(=O)2-NH-RL-, -RL-S(=O)2-NRA-RL-,
-O-,
-RL-O-,
-O-RL-,
-RL-O-RL-,
-NH-C(=O)-, -NRA-C(=O)-,
-RL-NH-C(=O)-, -RL-NRA-C(=O)-,
-NH-C(=O)-RL-, -NRA-C(=O)-RL-,
-RL-NH-C(=O)-RL-, -RL-NRA-C(=O)-RL-,
-C(=O)-NH-, -C(=O)-NRA-,
-RL-C(=O)-NH-, -RL-C(=O)-NRA-,
-C(=O)-NH-RL-, -C(=O)-NRA-RL-,
-RL-C(=O)-NH-RL-, or -RL-C(=O)-NRA-RL-.
26. A compound according to any one of claims 1 to 24, wherein -X2L-, if present, is independently:
-RL-,
-NH-S(=O)2-, -NRA-S(=O)2-,
-RL-NH-S(=O)2-, -RL-NRA-S(=O)2~,
-NH-S(=O)2-RL-, -NRA-S(=O)2-RL-,
-RL-NH-S(=O)2-RL-, -RU-NRA-S(=O)2-RL-,
-O-, -RL-O-, -O-RL-, -RL-O-RL-,
-C(=O)-NH-, -C(=O)-NRA-,
-RL-C(=O)-NH-, -RL-C(=O)-NRA-, -C(=O)-NH-RL-, -C(=O)-NRA-RL-, -RL-C(=O)-NH-RL-, or -RL-C(=O)-NRA-RL-.
27. A compound according to any one of claims 1 to 24, wherein -X2L-, if present, is independently:
-RL-,
-NH-S(=O)2-, -NRA-S(=O)2-, -NH-S(=O)2-RL-, -NRA-S(=O)2-RL-, -RL-O-,
-C(=O)-NH-, -C(=O)-NRA-, -C(=O)-NH-RL-, or -C(=O)-NRA-RL-.
28. A compound according to any one of claims 1 to 24, wherein -X2L-, if present, is independently -RL-.
29. A compound according to any one of claims 1 to 24, wherein -X2L-, if present, is independently -NH-S(=O)2-, -NRA-S(=O)2-, NH-S(=O)2-RL- or -NRA-S(=O)2-RL-.
30. A compound according to any one of claims 1 to 24, wherein -X2L-, if present, is independently -NH-S(=O)2- or -NRA-S(=O)2-.
31. A compound according to any one of claims 1 to 24, wherein -X2L-, if present, is independently -NH-S(=O)2-RL- or -NRA-S(=O)2-RL-.
32. A compound according to any one of claims 1 to 24, wherein -X2L-, if present, is independently -RL-O-.
33. A compound according to any one of claims 1 to 24, wherein -X2L-, if present, is independently -C(=O)-NH- or -C(=O)-NRA-.
34. A compound according to any one of claims 1 to 24, wherein -X2L-, if present, is independently -C(=O)-NH-RL- or -C(=O)-NRA-RL-.
* * *
35. A compound according to any one of claims 1 to 34, wherein each -RL-, if present, is independently -RLA-, -RLB-, or -RLC-.
36. A compound according to any one of claims 1 to 34, wherein each -RL-, if present, is independently -RUA-.
37. A compound according to any one of claims 1 to 39, wherein each -RL-, if present, is independently unsubstituted.
38. A compound according to any one of claims 1 to 36, wherein each -R1A if present, is independently saturated aliphatic Ci.4alkylene.
39. A compound according to any one of claims 1 to 36, wherein each -R1A if present, is independently saturated aliphatic Ci-3alkylene.
40. A compound according to any one of claims 1 to 36, wherein each -R1A if present, is independently saturated aliphatic Ci.2alkylene.
41. A compound according to any one of claims 1 to 34, wherein each -RL-, if present, is independently -CH2- or -CH2CH2-.
42. A compound according to any one of claims 1 to 34, wherein each -RL-, if present, is independently -CH2-.
* * *
43. A compound according to any one of claims 1 to 42, wherein each -RΛ, if present, is independently -RM or -RAB.
44. A compound according to any one of claims 1 to 42, wherein each -RA, if present, is independently -RM.
45. A compound according to any one of claims 1 to 42 wherein each -RA, if present, is independently saturated aliphatic C^alkyl.
46. A compound according to any one of claims 1 to 42, wherein each -RA, if present, is independently -Me or -Et.
47. A compound according to any one of claims 1 to 42, wherein each -RA, if present, is independently -Me.
48. A compound according to any one of claims 1 to 47, wherein -A1A-, if present, is independently -A1AC-.
49. A compound according to any one of claims 1 to 48, wherein -A1AG-, if present, is independently phenyfene or naphth-diyl, and is optionally substituted.
50. A compound according to any one of claims 1 to 48, wherein -A1AC-, if present, is independently phenylene, and is optionally substituted.
51. A compound according to any one of claims 1 to 48, wherein -A1AC-, if present, is independently phenyl-1 ,2-diyl, and is optionally substituted.
52. A compound according to any one of claims 1 to 48, wherein -A1AC-, if present, is independently phenyl-1 ,3-diyl, and is optionally substituted.
53. A compound according to any one of claims 1 to 48, wherein -A1AC-, if present, is independently phenyl-1 , 4-diyl, and is optionally substituted.
54. A compound according to any one of claims 1 to 48, wherein -A1AC-, if present, is independently naphth-diyl, and is optionally substituted.
55. A compound according to any one of claims 1 to 48, wherein -A1AC-, if present, is independently naphth-1 ,2-diyl, and is optionally substituted.
56. A compound according to any one of claims 1 to 48, wherein -A1AC-, if present, is independently naphth-1 ,4-diyi, and is optionally substituted.
* * *
57. A compound according to any one of claims 1 to 47, wherein -A1A-, if present, is independently -A1AH-.
58. A compound according to any one of claims 1 to 47 and 57, wherein -A1AH-, if present, is independently C5.6heteroarylene, and is optionally substituted.
59. A compound according to any one of claims 1 to 47 and 57, wherein -A1AH-, if present, is independently C7-10heteroarylene, and is optionally substituted.
60. A compound according to any one of claims 1 to 47 and 57, wherein -A1AH-, if present, is independently furan-diyl, thien-diyl, pyrrol-diyl, 1 ,2,3-triazol-diyl, tetrazol-diyl, oxazol-diyl, thiazol-diyl, isothiazoi-diyl, pyridin-diyl, pyrimidin-diyl, pyrazin-diyl, or pyridazin-diyl, and is optionally substituted.
61. A compound according to any one of claims 1 to 47 and 57, -A1AH-, if present, is independently furan-diyl, thien-diyl, 1 ,2,3-triazol-diyl, oxazol-diyl, thiazol-diyl, or pyridin-diyl, and is optionally substituted.
62. A compound according to any one of claims 1 to 47 and 57, -A1AH-, if present, is independently triazol-diyl, and is optionally substituted.
63. A compound according to any one of claims 1 to 47 and 57, -A1AH-, if present, is independently 1 ,2,3-triazol-diyl, and is optionally substituted.
64. A compound according to any one of claims 1 to 47 and 57, -A1AH-, if present, is independently 1 ,2,3-triazol-1 ,4-diyl, and is optionally substituted.
65. A compound according to any one of claims 1 to 47 and 57, -A1AH-, if present, is independently 1 ,2,3-triazol-1 ,5-diyl, and is optionally substituted.
66. A compound according to any one of claims 1 to 47 and 57, -A1AH-, if present, is independently 1 ,2,3-triazol-1 ,4-diyl, and is optionally substituted, wherein -X1- is attached at the 1 -position of the 1 ,2,3-triazol-1 ,4-diyl.
67. A compound according to any one of claims 1 to 47 and 57, -A1AH-, if present, is independently 1 ,2,3-triazol-1 ,4-diyl, and is optionally substituted, wherein -X1- is attached at the 4-position of the 1 ,2,3-triazoM ,4-diyl.
68. A compound according to any one of claims 1 to 47 and 57, -A1AH-, if present, is independently 1 ,2,3-triazol-1 ,5-diyl, and is optionally substituted, wherein -X1- is attached at the 1 -position of the 1 ,2, 3-triazol-1 ,4-diyl.
69. A compound according to any one of claims 1 to 47 and 57, -A1AH-, if present, is independently 1 ,2,3-triazoM ,5-diyl, and is optionally substituted, wherein -X1- is attached at the 5-position of the 1 ,2,3-triazoM ,4-diyl.
70. A compound according to any one of claims 1 to 47 and 57, -A1AH-, if present, is independently oxazol-diyl, and is optionally substituted.
71. A compound according to any one of claims 1 to 47 and 57, -A1AH-, if present, is independently oxazol-4,5-diyl, and is optionally substituted.
72. A compound according to any one of claims 1 to 47 and 57, -A1AH-, if present, is independently oxazol-2,4-diyl, and is optionally substituted.
73. A compound according to any one of claims 1 to 47 and 57, -A1AH-, if present, is independently oxazol-2,5-diyl, and is optionally substituted.
74. A compound according to any one of claims 1 to 47 and 57, -A1AH-, if present, is independently oxazol-4,5-diyl, and is optionally substituted, wherein -X1- is attached at the 4-position of the oxazol-4,5-diyl.
75. A compound according to any one of claims 1 to 47 and 57, -A1AH-, if present, is independently oxazol-4,5-diyl, and is optionally substituted, wherein -X1- is attached at the 5-position of the oxazol-4,5-diyl.
76. A compound according to any one of claims 1 to 47 and 57, -A1AH-, if present, is independently furan-diyl, and is optionally substituted.
77. A compound according to any one of claims 1 to 47 and 57, -A1AH-, if present, is independently thien-diyl, and is optionally substituted.
78. A compound according to any one of claims 1 to 47 and 57, -A1AH-, if present, is independently pyridin-diyl, and is optionally substituted.
79. A compound according to any one of claims 1 to 47 and 57, -A1AH-, if present, is independently quinolin-diyl, and is optionally substituted.
80. A compound according to any one of claims 1 to 47 and 57, -A1AH-, if present, is independently isoquinolin-diyl, and is optionally substituted.
81. A compound according to any one of claims 1 to 80, wherein -A2A, if present, is independently -A2AC.
82. A compound according to any one of claims 1 to 81 , -A2AC, if present, is independently phenyl or naphthyl, and is optionally substituted.
83. A compound according to any one of claims 1 to 81 , -A2AG, if present, is independently phenyl, and is optionally substituted.
84. A compound according to any one of claims 1 to 81 , -A2^1 if present, is independently phenyl, and is optionally substituted at the para-position.
85. A compound according to any one of claims 1 to 81 , -A2AC, if present, is independently naphthyl, and is optionally substituted.
86. A compound according to any one of claims 1 to 81 , -A2AC, if present, is independently naphth-1-yl, and is optionally substituted.
87. A compound according to any one of claims 1 to 81 , -A2AC, if present, is independently naphth-2-yl, and is optionally substituted.
88. A compound according to any one of claims 1 to 80, wherein -A2A, if present, is independently -A2AH.
89. A compound according to any one of claims 1 to 80 and 88, wherein -A2AH, if present, is independently C5.6 heteroaryl, and is optionally substituted.
90. A compound according to any one of claims 1 to 80 and 88, wherein -A2AH, if present, is independently C7--I0 heteroary I, and is optionally substituted.
91. A compound according to any one of claims 1 to 80 and 88, wherein -A2AH, if present, is independently furanyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, or pyridazinyl, and is optionally substituted.
92. A compound according to any one of claims 1 to 80 and 88, wherein -A2AH, if present, is independently pyridinyl, thiazolyl, or furanyl, and is optionally substituted.
93. A compound according to any one of claims 1 to 80 and 88, wherein -A2AH, if present, is independently pyridinyl, and is optionally substituted.
94. A compound according to any one of claims 1 to 80 and 88, wherein -A2AH, if present, is independently pyridin-2-yl, and is optionally substituted.
95. A compound according to any one of claims 1 to 80 and 88, wherein -A2AH, if present, is independently pyridin-3-yl, and is optionally substituted.
96. A compound according to any one of claims 1 to 80 and 88, wherein -A2AH, if present, is independently pyridin-4-yl, and is optionally substituted.
97. A compound according to any one of claims 1 to 80 and 88, wherein -A2AH, if present, is independently thiazolyl, and is optionally substituted.
98. A compound according to any one of claims 1 to 80 and 88, wherein -A2AH, if present, is independently thiazol-4-yl, and is optionally substituted.
99. A compound according to any one of claims 1 to 80 and 88, wherein -A2AH, if present, is independently furanyl, and is optionally substituted.
100. A compound according to any one of claims 1 to 80 and 88, wherein -A2AH, if present, is independently furan-5-yl, and is optionally substituted.
101. A compound according to any one of claims 1 to 80 and 88, wherein -A2AH, if present, is independently imidazolyl, and is optionally substituted.
102. A compound according to any one of claims 1 to 80 and 88, wherein -A2'*'1"1, if present, is independently imidazol-1-yl, and is optionally substituted.
103. A compound according to any one of claims 1 to 80 and 88, wherein -A2AH, if present, is independently quinolinyl, and is optionally substituted.
104. A compound according to any one of claims 1 to 80 and 88, wherein -A2AH, if present, is independently quinolin-6-yl, and is optionally substituted.
105. A compound according to any one of claims 1 to 80 and 88, wherein -A2AH, if present, is independently indolyl, and is optionally substituted.
106. A compound according to any one of claims 1 to 80 and 88, wherein -A2AH, if present, is independently indol-5-yl, and is optionally substituted.
107. A compound according to claim 1, wherein: the group -X1-A1-X2-A2 is independently -A^-A2*; -A1A- is independently oxazol-4,5-diyl; and -A2A is independently phenyl, and is optionally substituted.
108. A compound according to claim 1 , wherein: the group -X1-A1-X2-A2 is independently -A1A-A2A; -A1A- is independently oxazol-4,5-diyl; wherein -A2A- is attached at the 5-position of the oxazol-4,5-diyl; and -A2A is independently phenyl, and is optionally substituted.
109. A compound according to claim 1 , selected from compounds of the following formula, and pharmaceutically acceptable salts, hydrates, and solvates thereof:
110. A compound according to claim 1, wherein: the group -X1-A1-X2-A2 is independently -A1A-A2A; -A1A- is independently oxazol-4,5-diyl; and -A2A is independently -A2AH; and ~A2AH is independently C5.6heteroaryl, and is optionally substituted.
111. A compound according to claim 1 , wherein: the group -X1-A1-X2-A2 is independently -A1A-A2A; -A1A- is independently oxazol-4,5-diyl; and wherein -A2A- is attached at the 5-position of the oxazol-4,5-diyl; and
-A2A is independently -A2AH; and -A2AH is independently C5.6heteroaryl, and is optionally substituted.
1 12. A compound according to claim 1 , wherein: the group -X1-A1-X2-A2 is independently -A1A-A2A;
-A1A- is independently oxazol-2,5-diyl; and -A2A is independently phenyl, and is optionally substituted.
113. A compound according to claim 1 , wherein: the group -X1-A1-X2-A2 is independently -A1A-A2A; -A1A- is independently oxazol-2,5-diyl; and -A2A is independently -A2AH; and -A2AH is independently Cs^heteroaryl, and is optionally substituted.
114. A compound according to claim 1 , wherein: the group -X1-A1-X2-A2 is independently -A^-A2*; -A1A- is independently 1 ,2,3-triazol-1 ,4-diyl or 1 ,2,3-triazol-1 ,5-diyl; -A2A is independently phenyl, and is optionally substituted.
115. A compound according to claim 1 , wherein: the group -X1-A1-X2-A2 is independently -A1A-A2*; -A1A- is independently 1 ,2,3-triazol-i ,4-diyl; and -A2A is independently phenyl, and is optionally substituted.
1 16. A compound according to claim 1 , wherein: the group -X1-A1-X2-A2 is independently -A1A-A2A; -A1A- is independently 1 ,2,3-triazol-1 ,5-diyl; and -A2A is independently phenyl, and is optionally substituted.
1 17. A compound according to claim 1 , wherein: the group -X1-A1-X2-A2 is independently -X1L-A1A-H or -X1L-A1A-F; -X1L- is independently -C(=O)-, -C(=O)-CH2-, -C(=O)-CH2-O-, or -C(=O)-RL-S-, or; and
-A1A- is independently phenyl, and is optionally substituted.
1 18. A compound according to claim 1 , wherein: the group -X1-A1-X2-A2 is independently -X1L-A1A-H or -X1U-A1A-F; -X1L- is independently -C(O)-CH2-; and
-A1A- is independently phenyl, and is optionally substituted.
1 19. A compound according to claim 1 , wherein: the group -X1-A1-X2-A2 is independently -X1L-A1A-H; -X1L- is independently -C(O)-CH2-; and
-A1A- is independently phenyl, and is optionally substituted.
120. A compound according to claim 1 , wherein: the group -X1-A1-X2-A2 is independently -X1L-A1A-H or -X1L-A1A-F; -X1L- is independently -C(O)-; and
-A1A- is independently phenyl, and is optionally substituted.
121. A compound according to claim 1 , wherein: the group -X1-A1-X2-A2 is independently -X1L-A1A-H; -X1L- is independently -C(=O)-; and -A1A- is independently phenyl, and is optionally substituted.
122. A compound according to claim 1 , wherein: the group -X1-A1-X2-A2 is independently -A1A-H;
.-A1A- is independently phenyl and bears at least one substituent, -Q1, which is independently:
-NHS(=O)2R1A1, -NR1A1S(=O)2R1A1,
-S(O)2NH2, -S(=O)2NHR1A1, -S(=O)2NR1A1 2l or -S(=O)2NR1A2R1A3.
123. A compound according to claim 1 , wherein: the group -X1~A1-X2-A2 is independently -A1A-H;
-A1A- is independently phenyl and bears at least one substituent, -Q1, which is independently:
-NHS(=O)2R1A1 or -NR1A1S(=O)2R1A1.
124. A compound according to claim 1 , wherein: the group -X1-A1-X2-A2 is independently -A1A-X2L-A2A;
-A1A- is independently 1 ,2,3-triazol-i ,4-diyl or 1 ,2,3-triazol-1 ,5-diyl;
-X2L- is independently -CH2-; and
-A2A is independently phenyl, and is optionally substituted.
125. A compound according to claim 1 , wherein: the group -X1-A1-X2-A2 is independently -A1A-X2L-A2A; -A1A- is independently 1 , 2, 3-triazol-1 ,4-diyl; -X2L- is independently -CH2-; and -A2A is independently phenyl, and is optionally substituted.
126. A compound according to claim 1 , wherein: the group -X1-A1-X2-A2 is independently -A1A-X2L-A2A; -A1A- is independently 1,2,3-triazol-1 ,5-diyl; -X2L- is independently -CH2-; and
-A2A is independently phenyl, and is optionally substituted.
127. A compound according to claim 1 , wherein: the group -X1-A1-X2-A2 is independently -A1A-X2L-A2A; -A1A- is independently oxazol-2,5-diyl; -X2L- is independently -CH2-; and -A2A is independently phenyl, and is optionally substituted.
128. A compound according to claim 1 , wherein: the group -X1-A1-X2-A2 is independently -A2A;
-A2A is independently phenyl, and is optionally substituted.
129. A compound according to any one of claims 1 to 128, wherein each -Q1, if present, is independently: -F1 -Cl1 -Br1 -I,
-R1A1,
-CF3, -OCF3,
-OH, -L1A-OH, -O-L1A-OH,
-OR1A1, -L1A-OR1A1, -O-L1A-OR1A1, -NO2,
-NH2, -NHR1A1, -NR1A1 2, -NR1A2R1A3,
-C(=O)OH, -C(=O)OR1A1,
-C(=O)NH2, -C(=O)NHR1A1, -C(=O)NR1A1 2, -C(=O)NR1A2R1A3,
-NHC(=O)R1A1, -NR1A1C(=O)R1A1, -NHS(=O)2R1A1, -NR1A1S(=O)2R1A\
-S(=O)2NH2, -S(=O)2NHR1A1, -S(=O)2NR1A1 2, or -S(=O)2NR1A2R1A3; and additionally, two adjacent -Q1 groups, if present, may together form
-0-CH2-O- or -0-CH2CH2-O-.
130. A compound according to any one of claims 1 to 128, wherein each -Q1, if present, is independently:
-F, -Cl, -Br, -I, -R1A1, -OH, -OR1A1,
-NHS(=O)2R1A1, -NR1A1S(=O)2R1A\
-S(=O)2NH2, -S(=O)2NHR1A1, -S(=O)2NR1A1 2, or -S(=O)2NR1A2R1A3.
131. A compound according to any one of claims 1 to 128, wherein each -Q1, if present, is independently: -F, -Cl, -Br, -I, -R1A1, -OH, or -OR1A1.
132. A compound according to any one of claims 1 to 128, wherein each -Q1, if present, is independently: -R1A1.
133. A compound according to any one of claims 1 to 128, wherein at least one -Q1 is present, and is independently:
-NHS(=O)2R1A\ -NR1A1S(=O)2R1A1,
-S(=O)2NH2) -S(=O)2NHR1A\ -S(=O)2NR1A1 2, or -S(=O)2NR1A2R1A3.
134. A compound according to any one of claims 1 to 128, wherein at least one -Q1 is present, and is independently: -NHS(=O)2R1A1 or -NR1A1S(=O)2R1A1.
135. A compound according to any one of claims 1 to 128, wherein each -Q2, if present, is independently:
-F, -Cl, -Br, -I,
-R1A1, -CF31 -OCF3,
-OH, -L1A-OH, -O-L1A-OH,
-OR1A1, -L1A-OR1A1, -O-L1A-OR1A1,
-NO2,
-NH2, -NHR1A1, -NR1A1 2, -NR1A2R1A3, -C(=O)OH, -C(=O)OR1A1,
-C(=O)NH2, -C(=O)NHR1A1, -C(=O)NR1A1 2, -C(=O)NR1A2R1A3,
-NHC(=O)R1A1, -NR1A1C(=O)R1A1,
-NHS(=O)2R1A1, -NR1A1S(=O)2R1A1,
-S(=O)2NH2, -S(=O)2NHR1A1, -S(=O)2NR1A1 2, or -S(=O)2NR1A2R1A3; and additionally, two adjacent -Q1 groups, if present, may together form
-0-CH2-O- or -0-CH2CH2-O-.
136. A compound according to any one of claims 1 to 128, wherein each -Q2, if present, is independently: -F, -Cl, -Br, -I, -R1A1, -OH, -OR1A1,
-NHS(=O)2R1A\ -NR1A1S(=O)2R1A1, -S(O)2NH2, -S(=O)2NHR1A1, -S(=O)2NR1A1 2, or -S(=O)2NR1A2R1A3.
137. A compound according to any one of claims 1 to 128, wherein each -Q2, if present, is independently: -F, -Cl, -Br, -I, -R1A1, -OH, or -OR1A1.
138. A compound according to any one of claims 1 to 128, wherein each -Q2, if present, is independently: -R1A1.
* * *
139. A compound according to any one of claims 1 to 138, wherein each -NR1A2R1A3, if present, is independently azetidino, pyrrolidino, imidazolidino, pyrazolidino, piperidino, piperazino, morpholino, thiomorpholino, thiomorpholine-1,1 -dioxide, azepino, or diazepino, and is optionally substituted with one or more groups selected from saturated aliphatic Ci.3alkyl.
140. A compound according to any one of claims 1 to 138, wherein each -NR1A2R1A3, if present, is independently pyrrolidino, piperidino, piperazino, morpholino, thiomorpholino, or thiomorpholine-1 ,1-dioxide, and is optionally substituted with one or more groups selected from saturated aliphatic C1-3alkyl.
141. A compound according to any one of claims 1 to 140, wherein each -R1A1, if present, is independently:
_p1B1 _p1B4 _p1B6 _Q1 B7 _D1B8 -L1B-R1B4, -L1B-R1B6, -L1B-R1B7, or -L1B-R1B8.
143. A compound according to any one of claims 1 to 140, wherein each -R1A1, if present, is independently -L1B-R1B6, -L1B-R1B7, or -L1B-R1B8.
144. A compound according to any one of claims 1 to 140, wherein each -R1A1, if present, is independently -L1B-R1B6 or -L1B-R1B8.
145. A compound according to any one of claims 1 to 140, wherein each -R1A1, if present, is independently - R1B1.
146. A compound according to any one of claims 1 to 145, wherein each -R1B6, if present, is independently azetidinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidinyl, piperazinyl, morpholinyl, azepinyl, diazepinyl, tetrahydrofuranyl, tetrahydropyranyl, or dioxanyl, and is optionally substituted.
147. A compound according to any one of claims 1 to 145, wherein each -R1BΘ, if present, is independently pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, tetrahydrofuranyl, tetrahydropyranyl, or dioxanyl, and is optionally substituted.
148. A compound according to any one of claims 1 to 147, wherein each -R1B7, if present, is independently phenyl, and is optionally substituted.
149. A compound according to any one of claims 1 to 148, wherein each -R1B8, if present, is independently C5.6heteroaryl, and is optionally substituted.
150. A compound according to any one of claims 1 to 148, wherein each -R1B8, if present, is independently furanyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, oxazolyi, isoxazolyl, thiazolyl, isothiazolyl, pyridyl, pyrimidinyl, or pyridazinyl, and is optionally substituted.
151. A compound according to any one of claims 1 to 150, wherein each -L1B-, if present, is independently -CH2-.
152. A compound according to any one of claims 1 to 151 , wherein each -R1C1, if present, is independently saturated aliphatic C^alkyl.
153. A compound according to any one of claims 1 to 152, wherein each -R1C2, if present, is independently:
-F, -Cl, -Br, -I,
-CF3, -OCF3, -OH,
-OR1D1,
-SH, -SR101,
-CN,
-NO2, -NH2, -NHR1D1, -NR1D1 2, -NR102R103,
-C(=O)OH, -C(=O)OR1D1, -OC(=O)R1D\
-C(=O)R1D1,
-C(=O)NH2, -C(=O)NHR1D1, -C(=O)NR1D1 2, -C(=O)NR1D2R103,
-NHC(=O)R1D1, -NR1D1C(=O)R1D1, -S(O)2NH2, -S(=O)2NHR1A1, -S(=O)2NR1A1 2, -S(=O)2NR1A2R1A3, or
-S(=O)2R1A1.
154. A compound according to any one of claims 1 to 152, wherein each -R1C2, if present, is independently: -F, -Cl, -Br, -I,
-CF3, -OCF3,
-OH,
-OR101,
-NH2, -NHR1D1, -NR1D1 2, -NR102R103, -C(=O)OH, -C(=O)OR101, -OC(=O)R1D1,
-C(=O)R1D1, -C(O)NH2, -C(=O)NHR1D1, -C(=0)NR1D1 2, -C(=O)NR1D2R1D3,
-NHC(=O)R1D1, -NR1D1C(=O)R1D1,
-S(=O)2NH2, -S(=O)2NHR1A\ -S(=O)2NR1A1 2, or -S(=O)2NR1A2R1A3.
155. A compound according to any one of claims 1 to 154, wherein each -R1D\ if present, is independently saturated aliphatic Ci-4alkyl.
156. A compound according to any one of claims 1 to 155, wherein each -NR102R103, if present, is independently azetidino, pyrrolidino, imidazoiidino, pyrazolidino, piperidino, piperazino, morpholino, thiomorpholino, thiomorpholine-1 ,1-dioxide, azepino, or diazepino, and is optionally substituted with one or more groups selected from saturated aliphatic C^alkyl.
157. A compound according to any one of claims 1 to 155, wherein each -NR102R103, if present, is independently pyrrolidino, piperidino, piperazino, morpholino, thiomorpholino, or thiomorpholine-1 ,1 -dioxide, and is optionally substituted with one or more groups selected from saturated aliphatic C^alkyl.
158. A compound selected from the following compounds, and pharmaceutically acceptable salts, hydrates, and solvates thereof: Compound Nos. AA-001 through AA-004.
159. A compound selected from the following compounds, and pharmaceutically acceptable salts, hydrates, and solvates thereof: Compound Nos. BB-001 through BB-004.
160. A compound selected from the following compounds, and pharmaceutically acceptable salts, hydrates, and solvates thereof: Compound Nos. CC-001 through CC-014.
161. A compound selected from the following compounds, and pharmaceutically acceptable salts, hydrates, and solvates thereof: Compound Nos. DD-001 through DD-015.
162. A compound selected from the following compounds, and pharmaceutically acceptable salts, hydrates, and solvates thereof: Compound Nos. EE-001 through EE-004.
163. A pharmaceutical composition comprising a compound according to any one of claims 1 to 162, and a pharmaceutically acceptable carrier or diluent.
164. A method of preparing a pharmaceutical composition comprising the step of admixing a compound according to any one of claims 1 to 162, and a pharmaceutically acceptable carrier or diluent.
165. A compound according to any one of claims 1 to 162, without the proviso regarding P-O01 through P-003, for use in a method of treatment of the human or animal body by therapy.
166. A compound according to any one of claims 1 to 162, without the proviso regarding P-001 through P-003, for use in a method of treatment of a disease or condition that is mediated by heat shock protein 90 (HSP90).
167. A compound according to any one of claims 1 to 162, without the proviso regarding P-001 through P-003, for use in a method of treatment of a disease or condition that is ameliorated by the inhibition of heat shock protein 90 (HSP90) function.
168. A compound according to any one of claims 1 to 162, without the proviso regarding P-001 through P-003, for use in a method of treatment of a disease or condition that is known to be treated by heat shock protein 90 (HSP90) inhibitors.
169. A compound according to any one of claims 1 to 162, without the proviso regarding P-001 through P-003, for use in a method of treatment of a proliferative condition.
170. A compound according to any one of claims 1 to 162, without the proviso regarding P-001 through P-003, for use in a method of treatment of cancer.
* * *
171. Use of a compound according to any one of claims 1 to 162, without the proviso regarding P-001 through P-003, in the manufacture of a medicament for the treatment of a disease or condition that is mediated by heat shock protein 90 (HSP90).
172. Use of a compound according to any one of claims 1 to 162, without the proviso regarding P-001 through P-003, in the manufacture of a medicament for the treatment of a disease or condition that is ameliorated by the inhibition of heat shock protein 90 (HSP90) function.
173. Use of a compound according to any one of claims 1 to 162, without the proviso regarding P-001 through P-003, in the manufacture of a medicament for the treatment of a disease or condition that is known to be treated by heat shock protein 90 (HSP90) inhibitors.
174. Use of a compound according to any one of claims 1 to 162, without the proviso regarding P-001 through P-003, in the manufacture of a medicament for the treatment of a proliferative condition.
175. Use of a compound according to any one of claims 1 to 162, without the proviso regarding P-001 through P-003, in the manufacture of a medicament for the treatment of cancer.
176. A method of treatment of a disease or condition that is mediated by heat shock protein 90 (HSP90) comprising administering to a subject in need of treatment a therapeutically-effective amount of a compound according to any one of claims 1 to 162, without the proviso regarding P-001 through P-003.
177. A method of treatment of a disease or condition that is ameliorated by the inhibition of heat shock protein 90 (HSP90) function comprising administering to a subject in need of treatment a therapeutically-effective amount of a compound according to any one of claims 1 to 162, without the proviso regarding P-001 through P-003.
178. A method of treatment of a disease or condition that is known to be treated by heat shock protein 90 (HSP90) inhibitors comprising administering to a subject in need of treatment a therapeutically-effective amount of a compound according to any one of claims 1 to 162, without the proviso regarding P-001 through P-003.
179. A method of treatment of a proliferative condition comprising administering to a subject in need of treatment a therapeutically-effective amount of a compound according to any one of claims 1 to 162, without the proviso regarding P-001 through P-003.
180. A method of treatment of cancer comprising administering to a subject in need of treatment a therapeutically-effective amount of a compound according to any one of claims 1 to 162, without the proviso regarding P-001 through P-003.
181. A method of inhibiting heat shock protein 90 (HSP90) function, in vitro or in vivo, comprising contacting a HSP90 with an effective amount of a compound according to any one of claims 1 to 162, without the proviso regarding P-001 through P-003.
182. A method of inhibiting heat shock protein 90 (HSP90) function in a cell, in vitro or in vivo, comprising contacting the cell with an effective amount of a compound according to any one of claims 1 to 162, without the proviso regarding P-001 through P-003.
183. A method of inhibiting cell proliferation, inhibiting cell cycle progression, promoting apoptosis, or a combination of one or more these, in vitro or in vivo, comprising contacting the cell with an effective amount of a compound according to any one of claims 1 to 162, without the proviso regarding P-001 through P-003.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US98891507P | 2007-11-19 | 2007-11-19 | |
GB0722680.6 | 2007-11-19 | ||
GBGB0722680.6A GB0722680D0 (en) | 2007-11-19 | 2007-11-19 | Therapeutic compounds and their use |
US60/988,915 | 2007-11-19 | ||
US5495308P | 2008-05-21 | 2008-05-21 | |
US61/054,953 | 2008-05-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009066060A2 true WO2009066060A2 (en) | 2009-05-28 |
WO2009066060A3 WO2009066060A3 (en) | 2009-12-23 |
Family
ID=38896559
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2008/003871 WO2009066060A2 (en) | 2007-11-19 | 2008-11-18 | 4-substituted-6-isopropyl-benzene-1,3-diol compounds and their use |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB0722680D0 (en) |
WO (1) | WO2009066060A2 (en) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010015583A1 (en) * | 2008-08-08 | 2010-02-11 | Neurosearch A/S | Novel diphenyl 1,2,3-triazole derivatives useful as modulators of nicotinic acetylcholine receptors |
WO2011027081A2 (en) | 2009-09-03 | 2011-03-10 | Sanofi-Aventis | Novel derivatives of 5,6,7,8-tetrahydroindolizine inhibiting hsp90, compositions containing same, and use thereof |
US7994185B2 (en) | 2008-05-06 | 2011-08-09 | Glaxo Smith Kline LLC | Benzene sulfonamide thiazole and oxazole compounds |
JP2012025686A (en) * | 2010-07-21 | 2012-02-09 | National Agriculture & Food Research Organization | New biphenyl compound |
US20120046266A1 (en) * | 2009-04-21 | 2012-02-23 | Nerviano Medical Sciences S.R.L. | Resorcinol derivatives as hsp90 inhibitors |
WO2012087289A1 (en) * | 2010-12-21 | 2012-06-28 | Colgate-Palmolive Company | Halogenated biphenols as antibacterial agents |
US8778939B2 (en) | 2009-09-29 | 2014-07-15 | Glaxo Group Limited | Compounds |
US8835449B2 (en) | 2011-11-11 | 2014-09-16 | Pfizer Inc. | 2-thiopyrimidinones |
CN104059055A (en) * | 2013-12-10 | 2014-09-24 | 常州大学 | 1, 2, 3-triazole compounds and preparation method and use thereof |
US9073875B2 (en) | 2012-11-20 | 2015-07-07 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase |
US9771332B2 (en) | 2015-05-05 | 2017-09-26 | Pfizer Inc. | 2-thiopyrimidinones |
JP2020512327A (en) * | 2017-03-20 | 2020-04-23 | タイペイ メディカル ユニバーシティ | Heat shock protein 90 inhibitor |
CN113651806A (en) * | 2021-06-09 | 2021-11-16 | 福建医科大学 | A kind of preparation method of 4,5-diaryl oxazole compounds |
CN114014849A (en) * | 2021-06-09 | 2022-02-08 | 福建医科大学 | 4, 5-diaryl oxazole compound and application thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4921162B2 (en) * | 2003-02-11 | 2012-04-25 | ヴァーナリス(ケンブリッジ)リミテッド | Isoxazole compounds as inhibitors of heat shock proteins |
GB0315111D0 (en) * | 2003-06-27 | 2003-07-30 | Cancer Rec Tech Ltd | Substituted 5-membered ring compounds and their use |
WO2006055760A1 (en) * | 2004-11-18 | 2006-05-26 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
DE102005022977A1 (en) * | 2005-05-19 | 2006-12-07 | Merck Patent Gmbh | Phenylchinazolinderivate |
JP5178515B2 (en) * | 2005-08-12 | 2013-04-10 | シンタ ファーマシューティカルズ コーポレーション | Pyrazole compounds that modulate Hsp90 activity |
CA2618724A1 (en) * | 2005-08-18 | 2007-02-22 | Synta Pharmaceuticals Corp. | Imidazole compounds that modulate hsp90 activity |
-
2007
- 2007-11-19 GB GBGB0722680.6A patent/GB0722680D0/en not_active Ceased
-
2008
- 2008-11-18 WO PCT/GB2008/003871 patent/WO2009066060A2/en active Application Filing
Cited By (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9233956B2 (en) | 2008-05-06 | 2016-01-12 | Novartis Ag | Benzene sulfonamide thiazole and oxazole compounds |
US8642759B2 (en) | 2008-05-06 | 2014-02-04 | Glaxosmithkline Llc | Benzene sulfonamide thiazole and oxazole compounds |
US7994185B2 (en) | 2008-05-06 | 2011-08-09 | Glaxo Smith Kline LLC | Benzene sulfonamide thiazole and oxazole compounds |
US8415345B2 (en) | 2008-05-06 | 2013-04-09 | Glaxo SmithKline LLC | Benzene sulfonamide thiazole and oxazole compounds |
WO2010015583A1 (en) * | 2008-08-08 | 2010-02-11 | Neurosearch A/S | Novel diphenyl 1,2,3-triazole derivatives useful as modulators of nicotinic acetylcholine receptors |
US20120046266A1 (en) * | 2009-04-21 | 2012-02-23 | Nerviano Medical Sciences S.R.L. | Resorcinol derivatives as hsp90 inhibitors |
US8993556B2 (en) * | 2009-04-21 | 2015-03-31 | Nerviano Medical Sciences S.R.L. | Resorcinol derivatives as HSP90 inhibitors |
WO2011027081A2 (en) | 2009-09-03 | 2011-03-10 | Sanofi-Aventis | Novel derivatives of 5,6,7,8-tetrahydroindolizine inhibiting hsp90, compositions containing same, and use thereof |
US8778939B2 (en) | 2009-09-29 | 2014-07-15 | Glaxo Group Limited | Compounds |
JP2012025686A (en) * | 2010-07-21 | 2012-02-09 | National Agriculture & Food Research Organization | New biphenyl compound |
CN103261138A (en) * | 2010-12-21 | 2013-08-21 | 高露洁-棕榄公司 | Halogenated biphenols as antibacterial agents |
RU2549543C2 (en) * | 2010-12-21 | 2015-04-27 | Колгейт-Палмолив Компани | Halogenated biphenols as antibacterial agents |
WO2012087289A1 (en) * | 2010-12-21 | 2012-06-28 | Colgate-Palmolive Company | Halogenated biphenols as antibacterial agents |
US9334212B2 (en) | 2010-12-21 | 2016-05-10 | Colgate-Palmolive Company | Compounds and compositions |
US8835449B2 (en) | 2011-11-11 | 2014-09-16 | Pfizer Inc. | 2-thiopyrimidinones |
US8841314B2 (en) | 2011-11-11 | 2014-09-23 | Pfizer Inc. | 2-Thiopyrimidinones |
US9873673B2 (en) | 2011-11-11 | 2018-01-23 | Pfizer Inc. | 2-thiopyrimidinones |
US9399626B2 (en) | 2011-11-11 | 2016-07-26 | Pfizer Inc. | 2-thiopyrimidinones |
US9499497B2 (en) | 2012-11-20 | 2016-11-22 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase |
US9073875B2 (en) | 2012-11-20 | 2015-07-07 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase |
CN105440020A (en) * | 2013-12-10 | 2016-03-30 | 常州大学 | 1,2,3-triazole compounds with antitumor activity and preparation method for 1,2,3-triazole compounds |
CN104059055B (en) * | 2013-12-10 | 2016-08-31 | 常州大学 | 1,2,3-triazole class compounds and its production and use |
CN104059055A (en) * | 2013-12-10 | 2014-09-24 | 常州大学 | 1, 2, 3-triazole compounds and preparation method and use thereof |
CN105440020B (en) * | 2013-12-10 | 2018-12-18 | 常州大学 | 1,2,3- triazole class compounds with anti-tumor activity and preparation method thereof |
US9771332B2 (en) | 2015-05-05 | 2017-09-26 | Pfizer Inc. | 2-thiopyrimidinones |
JP2020512327A (en) * | 2017-03-20 | 2020-04-23 | タイペイ メディカル ユニバーシティ | Heat shock protein 90 inhibitor |
CN111164074A (en) * | 2017-03-20 | 2020-05-15 | 台北医学大学 | Heat shock protein 90 inhibitor |
EP3601226A4 (en) * | 2017-03-20 | 2021-03-03 | Taipei Medical University | INHIBITORS OF THE HEAT SHOCK PROTEIN 90 |
JP7157462B2 (en) | 2017-03-20 | 2022-10-20 | タイペイ メディカル ユニバーシティ | heat shock protein 90 inhibitor |
US11479528B2 (en) | 2017-03-20 | 2022-10-25 | Taipei Medical University | Heat shock protein 90 inhibitors |
CN111164074B (en) * | 2017-03-20 | 2024-02-02 | 台北医学大学 | Heat shock protein 90 inhibitors |
CN113651806A (en) * | 2021-06-09 | 2021-11-16 | 福建医科大学 | A kind of preparation method of 4,5-diaryl oxazole compounds |
CN114014849A (en) * | 2021-06-09 | 2022-02-08 | 福建医科大学 | 4, 5-diaryl oxazole compound and application thereof |
Also Published As
Publication number | Publication date |
---|---|
GB0722680D0 (en) | 2007-12-27 |
WO2009066060A3 (en) | 2009-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009066060A2 (en) | 4-substituted-6-isopropyl-benzene-1,3-diol compounds and their use | |
JP6082409B2 (en) | 3-Aryl-5-substituted isoquinolin-1-one compounds and therapeutic uses thereof | |
US6664269B2 (en) | Isoquinolinone derivatives | |
AU2001295789B2 (en) | Phthalazinone derivatives | |
EP1417196B1 (en) | Dna-pk inhibitors | |
WO2007029021A1 (en) | 1,5-substituted tetrazoles as therapeutic compounds | |
WO2012117216A1 (en) | N- (arylalkyl) - 1h- indole- 2 - sulfonic acid amide compounds and their therapeutic use as cannabinoid allosteric modulators | |
EP0757682A1 (en) | Benzofuran derivatives useful as inhibitors of bone resorption | |
CA2922469A1 (en) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use | |
WO2009077741A2 (en) | 3-substituted-4-oxo-3,4-dihydro-imidazo-[5,1-d][1,2,3,5-tetrazine-8-carboxylic acid amides and their use | |
WO2016034512A1 (en) | Quinolones as inhibitors of class iv bromodomain proteins | |
EP2041110A1 (en) | 2 -oxyheteroarylamide derivatives as parp inhibitors | |
JP3990061B2 (en) | Purine derivatives and adenosine A2 receptor antagonists as preventive and therapeutic agents for diabetes | |
EP2445915B1 (en) | 3-substituted-8-substituted-3h imidazo[5,1-d][1,2,3,5-tetrazin-4-one compounds and their use | |
WO2006032869A1 (en) | Dna-pk inhibitors | |
EP2155703A1 (en) | Bicyclosulfonyl acid (bcsa) compounds and their use as therapeutic agents | |
WO2009153566A1 (en) | Cyp26 inhibitors | |
EP2443113A1 (en) | Amido-isothiazole compounds and their use as inhibitors of 11beta-hsd1 for the treatment of metabolic syndrome and related disorders | |
EP2888254B1 (en) | Fused heterocyclic compounds and their use | |
WO2018054304A1 (en) | Furoquinolinedione compound and medicinal use thereof | |
EP1416936B1 (en) | Thiopyrane-4-ones as dna protein kinase inhibitors | |
WO2010007389A1 (en) | 5 -amidothiazole derivatives and their use as checkpoint kinase inhibitors | |
WO2014041349A1 (en) | Tetrahydropyran-4-ylethylamino- or tetrahydropyranyl-4-ethyloxy-pyrimidines or -pyridazines as isoprenylcysteincarboxymethyl transferase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08851162 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08851162 Country of ref document: EP Kind code of ref document: A2 |